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Abstract
I In the first part, a brief overview about synthetic organic chemistry is given followed
by a short debate why synthetic organic chemistry is still very important and why the
profession of the synthetic chemist will not be supplanted by the field of synthetic biology.
II The second and main part of this work deals with the asymmetric construction of cyclo-
hepta[b]indoles. Compounds exhibiting this structure motif display a broad spectrum
of biological activities and are found in several natural products but have also attracted
considerable interest from the pharmaceutical industry as potential therapeutics in recent
years. The e￿cient preparation of highly functionalized and unsymmetrically substituted
cyclohepta[b]indoles has become of central interest and, prior to this project, no enantiose-
lective and comprehensive methodology to synthesize this structural motif was published
in the literature.
This work presents several attempts to the synthesis of cyclohepta[b]indoles and the
final strategy which utilizes the divinylcyclopropane-cycloheptadiene rearrangement in
conjunction with the indole nucleus. Syntheses of numerous asymmetric indolylvinyl-
cyclopropane derivatives and their transformation into cyclohepta[b]indoles are discussed,
and the successful application of the developed methodology to the synthesis of (S)-SIRT￿-
inhibitor IV is presented.
With the methodology in hands, attention next turns to the synthesis of Ervatamia
alkaloids. Several approaches to the total synthesis of ￿￿-epimethuenine are discussed
and their advantages and drawbacks are revealed. The final approach presents a robust,
optimized, high-yielding and scalable asymmetric total synthesis of ￿￿-epimethuenine.
III The transformation of ￿￿-epimethuenine into several other natural products is presented
thus underlining the optimized and asymmetric synthesis of diverse Ervatamia alkaloids.
In addition, three compounds were evaluated in a bioassay in close collaboration with the
Helmholtz Zentrum für Infektionsforschung in Braunschweig.
IV A minor part of this work deals with the approaches towards the synthesis of iso-
schizogamine. A general strategy is presented and syntheses of a precursor with a
￿,￿-dihydropyridin-￿-one moiety for the synthesis of isoschizogamine are discussed. A
final approach shows the synthesis of chiral g-butenolides which are converted into the
desired motif.
IV The last part covers a brief introduction into both marine dimeric bisindole alkaloids
and bisindolylmaleimide alkaloids. General strategies for the synthesis of both cyclo-
aplysinopsin A and dihydroarcyriacyanin A are discussed.
Keywords: total synthesis, divinylcyclopropane-cycloheptadiene rearrangement, Ervatamia alkaloids
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Zusammenfassung
I Im ersten Teil wird ein kurzer allgemeiner Überblick über das Feld der synthetischen
organischen Chemie gegeben, gefolgt von einer kurzen Erörterung, warum dieses Gebiet
auch heutzutage noch einen hohen Stellwert besitzt und auch in naher Zukunft nicht
vom Gebiet der synthetischen Biologie verdrängt werden wird.
II Der zweite und größte Teil dieser Arbeit beschäftigt sichmit der asymmetrischen Synthese
von Cyclohepta[b]indolen. Zahlreiche Verbindungen mit diesem Motiv zeigen diverse
biologische Aktivitäten und werden in zahlreichen Natursto￿en gefunden, doch auch
von der pharmazeutischen Industrie wird dieses Motiv gerne benutzt. Eine e￿ziente
und asymmetrische Synthese dieses Motivs ist von allgemein großer Bedeutung und war
zu Beginn dieser Arbeit nicht literaturbekannt.
Diese Arbeit zeigt verschiedene Ansätze für die Synthese von Cyclohepta[b]indolen. Die
finale Strategie beruht auf der Divinylcyclopropan-Umlagerung, welche den Indolkern
inkludiert. Synthesen von zahlreichen asymmetrischen Indolylvinylcyclopropanderivaten
und deren Transformationen in die zugehörigen Cyclohepta[b]indole werden diskutiert.
Eine erste Anwendung der Methode wurde anhand der Syntheses des (S)-SIRT￿ In-
hibitors IV demonstriert.
Mit der Etablierung der Methode beginnt die Anwendung für die Synthese von Er-
vatamia Alkaloiden. Etliche Ansätze einer möglichen Synthese von ￿￿-Epimethuenin wer-
den auf ihre Vor- und Nachteile diskutiert. Der finale Weg zeigt eine robuste, optimierte
und skalierbare Totalsynthese von ￿￿-Epimethuenin mit durchweg hohen Ausbeuten.
III Die Transformation von ￿￿-Epimethuenin in diverse andere Natursto￿e wird gezeigt.
Dies unterstreicht die E￿zienz und Durchführbarkeit der Methode in Hinblick auf die
Synthese von Ervatamia Alkaloiden. Weiterhin wurden drei Verbindungen in biologi-
schen Tests evaluiert; dies geschah in Kooperation mit dem Helmholtz Zentrum für
Infektionsforschung in Braunschweig.
IV Ein kleiner Teil dieser Arbeit beschäftigt sich mit Ansätzen für die Synthese von
Isoschizogamin. Eine allgemeine Strategie für die Synthese eines Vorläufers basierend
auf ￿,￿-Dihydropyridin-￿-on für die Synthese von Isoschizogamin wird aufgezeigt. Ein
finaler Weg zeigt die Synthese chiraler g-Butenolide, die in das gewünschte Motiv trans-
formiert werden.
IV Der letzte Teil dieser Arbeit beschreibt sowohl eine kurze Einführung in marine dimere
Bisindol-Alkaloide als auch Bisindolylmaleimid-Alkaloide. Allgemeine Strategien für die
Synthesen von Cycloaplysinopsin A und Dihydroarcyriacyanin A werden diskutiert.
Stichworte: Totalsynthese, Divinylcyclopropan-Umlagerung, Ervatamia Alkaloide
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General Remarks
Within this dissertation numbering of the compounds relates to that reported for the ervitsine–
ervatamine natural products (see below). In many cases for clarity, any atom mentioned in the
text is numbered on the corresponding scheme, figure or table.
With regards to stereochemistry use of bold or dashed wedges indicates a single enantiomer,
while bold or dashes lines indicates relative stereochemistry of a racemate. In case of plain
drawn lines the configuration is unknown.
single enantiomer /
absolute configuration
racemate /
relative configuration
unknown configuration
N
H
Me
N
MeO2C
H
O
5
20
19
21
16
15
14
32
6
18
78
9
10
11
12
13
ervatamine
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Part I
Introduction

￿Constructing Nature’s Molecules
The world is made of two parts, the full (pleres, stereon) and the empty, the
vacuum (cenon, manon). The fullness is divided into small particles called
atoms (atomon, that cannot be cut, indivisible). The atoms are infinite in
number, eternal, absolutely simple; they are all alike in quality but di￿er in
shape, order, and position. Every substance, every single object, is made up of
those atoms, the possible combinations of which are infinite in an infinity of
ways. The objects exist as long as the atoms constituting them remain together;
they cease to exist when their atoms move away from one another. The endless
changes of reality are due to the continual aggregation and disaggregation of
atoms.
– Democritus, ￿th century BC
Synthetic organic chemistry is the science of constructing complex molecules from more basic
starting materials and reagents through formation and breaking of covalent bonds. It has
developed to one of the most important branches of organic chemistry and can also be seen as
powerful tool for other areas, that is biology, physics, materials science and medicine.
The field of organic synthesis can be divided intomethod oriented synthesis and target oriented
synthesis(Chart ￿-￿).[￿] The latter one is commonly referred to as total synthesis; a chemical
synthesis of a target molecule—originally natural products—from relatively simple starting
materials and reagents via a sequence of consecutive reactions in the most e￿cient way. The
synthesis is based on a synthetic strategy which relies on the development of suitable synthetic
methods and reagents. The field of method oriented synthesis is devoted to the development of
new reagents, new catalysts, new bond forming strategies, new reaction and work-up procedures,
in general to any innovation that can improve a synthetic procedure. The term total synthesis
has evolved and target oriented synthesis also incorporates the field of designed molecules.
Apart from natural bioactive compounds, target oriented synthesis covers also compounds
￿
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Chart ￿-￿. Organic synthesis in perspective.[￿]
derived from rational design as potentially bioactive, compounds of commercial relevance,
compounds with special physical or mechanical properties, or even compounds of theoretical
interest. Examples for common and interesting targets are drugs, flavors, nutraceuticals, and
new materials.
The field of organic synthesis can be traced back to ancient times, although it was not recognized
as such. Most general chemistry and organic chemistry textbooks describe Friedrich Wöhler’s
synthesis of urea as the moment when modern organic chemistry was born.[￿] It was ￿￿￿￿, when
he obtained artificial urea (￿) by treating silver cyanate with ammonium chloride.[￿]
AgNCO+NH￿Cl     (NH￿)￿CO+AgCl (￿-￿)
This was a rather uncomplex synthesis but is seen as landmark. It was the first instance in
which an inorganic substance was converted into an organic substance. This synthesis was
followed by other milestones (Fig. ￿-￿). In ￿￿￿￿, Hermann Kolbe carried out the first organic
compound synthesis, involving the formation of carbon-carbon and carbon-hydrogen bonds,
using inorganic compounds. Pure carbon was transformed into carbon disulfide with iron
sulphide which was transformed into carbon tetrachloride via chlorination, followed by pyrolysis
to tetrachloroethylene and aqueous chlorination to trichloroacetic acid, and concluded with
electrolytic reduction to acetic acid (￿).[￿] From today’s perspective it was a rather complex
synthesis for such a simple compound. It is noteworthy, that Kolbe used the word synthesis for
the first time to describe the process of the construction of a compound from other substances.[￿]
After syntheses of alizarin (￿, ￿￿￿￿) by Carl Graebe and Carl Liebermann,[￿] and indigo
(￿, ￿￿￿￿) by Adolf Baeyer[￿] the probably most impressive total synthesis of the nineteenth
century was that of (￿)-glucose (￿) by Emil Fischer in ￿￿￿￿.[￿] It was the first molecule which
￿
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Figure ￿-￿. Selected milestones of early natural product total syntheses (￿￿￿￿–￿￿￿￿).[￿]
contained stereochemical elements and the synthesis was remarkable for the complexity of
the target. Emil Fischer was honored by the Nobel Prize for chemistry (￿￿￿￿) for “his work
on sugar and purine syntheses”. Other early landmark total syntheses of natural products
were the synthesis of (±)-a-terpineol (￿, W.H. Perkin, ￿￿￿￿),[￿] camphor (￿, G. Komppa, ￿￿￿￿;
W.H. Perkin, ￿￿￿￿),[￿￿] tropinone (￿, R. Robinson, ￿￿￿￿),[￿￿] haemin (￿, H. Fischer, ￿￿￿￿),[￿￿]
equilenin (￿￿, W. E. Bachmann, ￿￿￿￿),[￿￿] and pyridoxine hydrochloride (￿￿, K. Folkers, ￿￿￿￿).[￿￿]
Although great achievements were gained, the field of total synthesis began flourishing
after World War II and rapid development could be observed. It is due to two personalities
who characterized the post World War II era that organic synthesis evolved so fast. It was in
￿￿￿￿ when R. B. Woodward became an assistant professor in the Department of Chemistry at
Harvard University and the term total synthesis became a new meaning. One after another,
several complex structures were synthesized and total synthesis progressed enormously. In ￿￿￿￿,
Woodward said: “Erythromycin, with all our advantages, looks at present quite hopelessly complex,
particularly in view of its plethora of asymmetric centers.”[￿￿] However, ￿￿ years later, Woodward
reported the first total synthesis of erythromycin A.[￿￿] It was ￿￿￿￿, when young E. J. Corey
took a sabbatical with the aid of a Guggenheim fellowship and went to Harvard University
￿
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Figure ￿-￿. A couple of the most complex natural compounds which have been synthesized.
￿
at the invitation of the world’s best synthetic chemist at this time, R. B. Woodward.[￿￿] Two
years later, E. J. Corey himself became a full professor of chemistry at Harvard University. He
introduced the concept of retrosynthetic analysis in ￿￿￿￿ with his synthesis of longifolene.[￿￿]
Combining his systematic approaches to total synthesis with the new tools of organic synthesis
and analytical chemistry, E. J. Corey synthesized hundreds of natural and designed products.[￿]
R. B. Woodward won the Nobel Prize for chemistry in ￿￿￿￿ (“for his outstanding achievements in
the art of organic synthesis”), E. J. Corey in ￿￿￿￿ (“for his development of the theory and methodology
of organic synthesis”). Both personalities made organic synthesis to a powerful science and a fine
art. A science and art which was carried on by numerous other chemists, and it was around
￿￿￿￿, when a new era began to rise and became apparent at the ￿th International Symposium:
“Synthesis in Organic Chemistry” (Cambridge, ￿￿￿￿).[￿￿] R. B. Woodward was supposed to give a
talk on his synthesis of erythronolide A (￿￿, Fig. ￿-￿) but was struck down by a heart attack two
weeks before and died prior to the arrival of medical help.[￿￿] Over ￿￿ co-workers contributed to
the synthesis of ￿￿.[￿￿] W. C. Still took his place and presented his synthesis of monensin (￿￿,
Fig. ￿-￿)—a compound, which exceeds erythronolide A in complexity but was completed by only
two co-workers.[￿￿] The audience became silent during this lecture. Everybody realized, that a
new era has begun and from this point on, “only highly focused syntheses of complex natural
products would make an impact on the organic chemistry community”.[￿￿]
Natural products provide the ultimate challenge to synthetic chemists and syntheses of
numerous complex natural compounds have been accomplished (Fig. ￿-￿). The field of organic
synthesis is nowadays advanced in such a way that it seems that the chemical synthesis of every
natural product can be accomplished. The question is whether it can be made in a nice and
practical way.
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Figure ￿-￿. Structures of erythronolide A (￿￿) and monensin (￿￿).
The field of synthetic organic chemistry has evolved rapidly. For a long time, this powerful
science has been used to construct compounds, most notably compounds from natural sources
which are hard to obtain. But also the field of synthetic biology has evolved even faster than the
field of organic chemistry and emerged as an alternative for the synthesis of organic molecules.
In ￿￿￿￿, R. McDaniel and R. Weiss were even keen in such a way that they stated synthetic
biology will replace chemical synthesis in the foreseeable future.[￿￿]
￿
￿ Constructing Nature’s Molecules
This leads to the simple question: “Why synthesize?”.￿ There is no doubt, that synthetic biology
enriches the syntheses of molecules and has the potential to shorten synthetic routes and reduce
waste. However, there are more than enough reasons that synthetic chemistry will continue to
dominate and that the demand for the profession of the synthetic chemist will not be supplanted
by the field of synthetic biology.[￿￿,￿￿]
Total synthesis has long been seen as the epitome of the art. In the classical era, the reason
to make complex molecules by total synthesis was often to confirm the molecular structure
of a natural product. That motive have vanished thanks to powerful analytical techniques,
especially X-ray crystallography and NMR spectroscopy. Another reason was because of the
useful properties of quite a few natural products. Very often, it was cheaper to synthesize a
natural product than to extract it from rare organisms. However, this purpose has changed
nowadays. Today synthetic routes for advanced natural products are too complex to be used by the
pharmaceutical industry. These compounds are basically the only ones which synthetic biology
can compete with since evolution has optimized the biosynthesis of those products over time.[￿￿]
But total synthesis gives access to non-natural derivatives that also can have useful properties
and helps in the discovery of new pharmaceutical relative compounds. Most of the relevant
compounds for the pharmaceutical industry are based on non-natural molecular structures,
ergo, enzymatic processes cannot be used for their synthesis; supposably, these compounds are
even toxic to the organisms used in synthetic biology. The optimization of structures for superior
properties is still carried out best by synthetic chemistry. Numerous chemical methods can do
this in many di￿erent cases, and, in contrast to synthetic biology, these syntheses can often
be developed and implemented in a competitive and short amount of time. But not only the
pharmaceutical industry relies on synthetic chemistry. The global market demands molecules
with particular physical properties which requires modern chemical branches like chemical
biology or nanotechnology. However, these fields still depend on synthetic chemists since the
required molecules contain motifs that are anything but natural. Once again, an enzymatic
processes cannot necessarily be used for their whole synthesis. In summary, the demand for
a complete total synthesis of a natural product is not given anymore. These compounds are
basically the only ones which synthetic biology can compete. However, total syntheses of non-
natural compounds or derivatives are still in demand; the field is as lively as ever and the supply
of these molecules is best addressed by synthetic chemistry.
But there are far more reasons to decide to do synthetic chemistry and total synthesis of natural
compounds. R. B. Woodward and E. J. Corey not only made synthetic chemistry to a powerful
science, they also made an art out of it. To express it in Ball’s words: “Like architecture, chemistry
deals in elegance in both design and execution.”[￿￿] Natural products provide the ultimate challenge
to synthetic chemists. Whereas non-natural compounds can be designed in a particular facile
way to avoid synthetic di￿culties, nature has no mercy on the synthetic chemist.[￿] A good
￿ This paragraph relies on the essays of P. Ball (Nature ￿￿￿￿, ￿￿￿, ￿￿￿–￿￿￿) and P. Baran (Nature ￿￿￿￿, ￿￿￿, ￿￿￿–￿￿￿.),
further reading is recommended. My opinion does not necessarily represent the general opinion of the synthetic
community.
￿
synthetic chemist values the challenge of synthesizing a naturally occurring substance and
developing new synthetic chemistry which is required to solve the occurring synthetic problems.
A great feeling arises, once a total synthesis of a natural product is conquered. However, this
happens only rarely and most of the time, synthetic chemists have to cope with the inevitable
disappointments. But after all, dealing with this disappointments and solving new problems
day-to-day belongs to the process of the formation of a qualified synthetic chemist. Total synthesis
of natural products is still ideal and will be for a long time to equip students with the practical
skills that industry requires. The skill of synthesizing molecules remains the essential training
for the next generation of chemists—combined with the sheer excitement of the endeavor.[￿]
However, total synthesis of natural products also became a contest. It is not unusual, that
natural products are synthesized, “just because they are there”.[￿￿] Derek Lowe at Vertex Pharma-
ceuticals in Boston, Massachusetts, argues, that some groups pursue the goal of making gigantic
natural products just for a publication in the end no one much cares about, often by utilizing
chemistry everybody already knows, and by using a synthetic strategy which has been used
several times before. Some people forgot about the art in total synthesis and often elegance is
sacrificed for speed. In this day and age, statements like the one from S. Ley are very appreciated:
“I don’t have to be first, the elegance of the approach is what interests me.”[￿￿] As already mentioned
before, the field of organic synthesis is nowadays advanced in such a way that the chemical
synthesis of every natural product can be accomplished. The question is whether it can be made
in a nice and practical way.
Figure ￿-￿. Modern synthetic chemistry? An illustration by David Parkins. (Reprinted by permission from Macmillan Publishers
Ltd: Nature ￿￿￿￿, ￿￿￿, ￿￿￿–￿￿￿, © ￿￿￿￿, license number: ￿￿￿￿￿￿￿￿￿￿￿￿￿).
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This discussion shall find some closing remarks from R. B. Woodward and E. J. Corey:
“Chemical synthesis always has some element of planning in it. But, the planning
should never be too rigid. Because, in fact, the specific objective which the synthetic
chemist uses as the excuse for his activity is often not of special importance in the
general sense; rather, the important things are those that he finds out in the course
of attempting to reach his objective.”
R. B. Woodward, Proc. Robert A. Welch Found. Conf. Chem. Res. ￿￿￿￿, ￿￿, ￿.
“I believe that chemical synthesis will make enormous contributions to human
progress in the next century […] However, those developments will not be fully
realizedwithout great and continuing advances in the central disciplines of chemistry.
There is so much that remains to be discovered […] that today’s chemistry will seem
archaic to a ￿￿nd century chemist. I envy the young people in chemistry who will
experience the excitement and pleasure of making the many discoveries of the next
century of chemical research. Yet, at the same time, I worry about whether the
younger generations of this country and the world will aspire to high creativity and
persevere to achieve their impossible dreams.”
E. J. Corey, J. Org. Chem. ￿￿￿￿, ￿￿, ￿￿￿￿–￿￿￿￿.
￿.￿ Natural Products and Pharmaceutical Industry
A lot of commercially available drugs against various diseases have been developed from isolated
natural products. According to D. J. Newman and G.M. Cragg, one third of all small-molecule
approved drugs from ￿￿￿￿–￿￿￿￿ are either pure natural products or natural product derivatives
(Chart ￿-￿a).[￿￿] Additional ￿% are synthetic drugs which contain a pharmacophore from a
natural product. One third of all all small-molecule approved drugs from ￿￿￿￿–￿￿￿￿ are absolute
synthetic drugs. The remaining percentage are combinations of this classes which mimic a
natural product. The whole database contains ￿￿￿￿ new approved drugs from ￿￿￿￿–￿￿￿￿, of
which ￿￿￿￿ were small-molecule drugs.
“The simplest definition for a natural product is a small molecule that is produced by a
biological source.”[￿￿] Natural products can be classified based on the chemical structure, on
physiological activity, on taxonomy, or on biogenesis. In terms of synthetic chemistry, the classi-
fication occurs according to shared sca￿olding elements. This leads to several structural classes,
such as polyketides, peptides, terpenoids, and alkaloids. Natural products are derived from small
monomeric building blocks of primary and secondary metabolic pathways. Organisms have
evolved the ability to biosynthesize secondary metabolites although they are not essential for
survival. This is argued to be due to the selectional advantages they obtain as a result of the
functions of these compounds.[￿￿]
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Chart ￿-￿. a) All small-molecule approved drugs ￿￿￿￿–￿￿￿￿, n = ￿￿￿￿. S = absolute synthetic drug, S/NM = absolute synthetic
drug, but mimic of natural product, S* = synthetic drug with a pharmacophore from a natural product, S*/NM
= synthetic drug with a pharmacophore from a natural product, mimic of natural product, N = unaltered natural
product, NB = botanical drug, ND = natural product derivative. b) Source of pharmaceutical related or biological
active natural products. A = alkaloid, DNP = other natural product class.
The term alkaloid originally derives from the concept of a compound being “alkali-like”. These
compounds contain at least one nitrogen atom and have a plant origin. As time went by, analytical
techniques have developed enormously and structures became clearer thus requiring a more
detailed definition of the the term alkaloid. The concept of being derived from amino acids
together with the idea that the nitrogen should be in a heterocyclic ring were added. However,
several alkaloids are known which do not fulfill this definition completely. Definitions for an
alkaloid are proposed regularly, but none of these definitions is totally embracing.[￿￿] Although
the first alkaloid was isolated fromman, (spermine phosphate in ￿￿￿￿ by van Leeuwenhoek), the
best known sources of alkaloids are plants, fungi, bacteria, marine animals, andmicroorganisms.
In ￿￿￿￿, G. A. Cordell and co-workers analyzed the NAPRALERT® database￿ and reported, that
￿￿% of the natural products derived drugs were based on alkaloids (Chart ￿-￿b).[￿￿] On the
contrary, this analysis indicated only ￿￿ ￿￿￿ known alkaloid structures out of about ￿￿￿ ￿￿￿
characterized natural products, which is only ￿￿% (Chart ￿-￿a). As a result of this, alkaloids play
an important role in drugs and drug design. In addition, of the ￿￿ ￿￿￿ alkaloids from higher
plants, ￿￿￿￿ have been evaluated in a single bioassay (Chart ￿-￿b). ￿￿￿￿ have been evaluated in
between two and ten bioassays. Only ￿￿￿ alkaloids have been tested in more than ￿￿ bioassays
and one third of these alkaloids is pharmaceutically significant. More then three quarter of
all alkaloids have never been subjected to any bioactivity study. As a result, only on very little
amount of all alkaloids have contributed largely to the list of new chemical entities.
￿ NAPRALERT® is a relational database of natural products, including ethnomedical information, pharmacologi-
cal/biochemical information on extracts of organisms in vitro, in situ, in vivo, in human (case reports, non-clinical
trials) and clinical studies. Similar information is available for secondary metabolites from natural sources. At
the date of Cordell’s analysis, ￿￿￿ ￿￿￿ scientific papers and reviews were included in NAPRALERT, representing
organisms from all countries of the world, including marine and microorganisms.
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Chart ￿-￿. a) Classes of known natural products, n =￿￿￿ ￿￿￿. DNP = other natural product class, A = alkaloid. b) The
biological evaluation of alkaloids from higher plants (number of biological tests). ￿ biological tests, ￿ biological
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In summary, alkaloids have contributed in a significant way to the development of new drugs.
By seeking for new bioactive molecules, alkaloids seem to be an ideal starting point. Of all
known alkaloids, only a quarter has been evaluated at least once in a bioassay. Only a very small
percentage of all known alkaloids have been seriously evaluated and one third of these alkaloids
is pharmaceutically significant. Chances are very high to find new bioactive molecules by
investigating unevaluated alkaloid natural products. The task for a synthetic chemist is therefore
the ongoing investigation of total syntheses, but not only of alkaloids and their derivatives but all
classes of natural products. This field equips chemists with the practical skills and the knowledge
that industry requires.￿
￿ Note: The analysis of G. A. Cordell dates back to ￿￿￿￿. In the meantime, the database contains over ￿￿￿ ￿￿￿ entries.
However, it is very likely, that the general conclusion of this paragraph has not changed.
￿￿
Part II
Cyclohepta[b]indoles

￿The Cyclohepta[b]indole Motif
￿.￿ Introduction￿
Seven-membered rings fused with an indole are termed cyclohepta[b]indoles. Compounds
exhibiting this structure motif display a broad spectrum of biological activities, ranging from
inhibition of adipocyte fatty-acid-binding protein (A-FABP), deacetylation of histones, inhibi-
tion of leukotriene production p￿￿, anti-tuberculosis activities, and anti-HIV activities. These
biological profiles are found in natural products containing the cyclohepta[b]indole motif, as
well as in pharmaceuticals that contain this structure motif. Therefore, the biology of molecules
derived from the skeleton of cyclohepta[b]indoles, as well as cyclopenta- and cyclohexa[b]indoles,
has attracted considerable interest from the pharmaceutical industry as potential therapeutics
in recent years. This is reflected by more than two dozen patents that have been issued in the
last decade, solely based on the cyclohepta[b]indole structure motif. The e￿cient preparation
of highly functionalized and unsymmetrically substituted cyclohepta[b]indoles has therefore
become of central interest for synthetic organic chemists. Historically, this structure motif
most often has been prepared by means of a Fischer indole synthesis. Although very robust
and useful, this reaction poses certain limitations. Especially unsymmetrically functionalized
cyclohepta[b]indoles are not suitable for a Fischer indole type synthesis, since product mixtures
are inevitable. Therefore, novel methodologies to overcome these synthetic obstacles have been
developed in recent years.
This chapter introduces all natural products and some pharmaceutical compounds exhibiting
the cyclohepta[b]indole motif. The structural variability within cyclohepta[b]indole alkaloids
in combination with the broad range of organisms where these alkaloids have been isolated
￿ Parts of this chapter have already been published as a review with the title “Cyclohepta[b]indoles: A Privileged
Structure Motif in Natural Products and Drug Design” (E. Stempel, T. Gaich, Acc. Chem. Res. ￿￿￿￿, ￿￿, ￿￿￿￿–￿￿￿￿.
© ￿￿￿￿ American Chemical Society).[￿￿] The content of the published review is not as thoroughly as this chapter:
due to a word limitation some parts of this chapter are not part of the review or passages have been shortened.
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from, strongly suggests that the cyclohepta[b]indole is somehow a “privileged” structure motif.
The organisms producing these compounds range from evergreen trees (actinophyllic acid)
to cyanobacteria (ambiguinines). The synthetic methodologies to construct these molecular
sca￿olds (natural and unnatural in origin) are in turn highlighted and discussed with regard
to their potential to access highly functionalized and unsymmetrical cyclohepta[b]indoles, for
which they specifically have been designed. The methods are classified with respect to reaction
type and whether or not they are enantioselective. Finally, the syntheses of cyclohepta[b]indole
natural products are presented, focusing on the construction of this structure motif in the course
of the respective total synthesis.
￿.￿ Natural Products
￿.￿.￿ Alkaloids
Several indole alkaloids exhibiting a cyclohepta[b]indole core are known (Fig. ￿-￿). Probably
the best known natural product of this category is actinophyllic acid (￿￿) which was isolated
in ￿￿￿￿ by Carroll and co-workers[￿￿] from the leaves of Alstonia actinophylla and possesses a
complex unique skeleton which drew the attention of several synthetic groups. The alkaloid is
an inhibitor of carboxypeptidase U/hippuricase.Three total syntheses have been accomplished
to this day by Overman, Martin, and Kwon.[￿￿–￿￿]
Arcyriacyanin A (￿￿) is a pigment from Arcyria nutans. It is a cytotoxic compound and inhibits
protein kinase C and protein tyrosine kinase.[￿￿,￿￿] The green-blue bisindolylmaleimide is not
only a cyclohepta[b]indole but also a cyclohepta[cd]indole and so far has been synthesized by
two groups in the late ￿￿￿￿s.[￿￿,￿￿] The cis-dihydro modification dihydroarcyriacyanin A (￿￿) has
been found in the yellow sporangia of Arcyria nutans[￿￿] and recently in the fruiting bodies of
Arcyria denudate and Arcyria obvelata.[￿￿] The bisindole caulersin (￿￿) has been isolated from
the alga Caulerpa serrulata which naturally exists in the ocean around the Paracel Islands.[￿￿]
Compound ￿￿ is an inhibitor of the multixenobiotic resistance (MXR) pump in algae and has
been shown to act as plant growth regulator. Several syntheses have been published.[￿￿–￿￿]
The most recent found natural products are exotines A (￿￿) and B (￿￿), two heterodimers of
isopentenyl-substituted indoles and coumarin derivatives from Murraya exotica. Inhibitory
e￿ects on lipopoly-saccharide induced nitric oxide production in BV-￿microglial cells has been
reported.[￿￿] Aristolasol (￿￿) and aristolasene (￿￿) are two minor alkaloids from the aerial parts
of Aristotelia australasica (Elaeocarpaceae).[￿￿] These molecules have found very little attention
up to now, no biological activities are known and one total synthesis of aristolasene (￿￿) starting
from ￿￿-hydroxyhobartine has been published.[￿￿]
A large group containing many alkaloids with a cyclohepta[b]indole skeleton can be found in
the ambiguines which are structurally related to the hapalindoles.[￿￿] To this date ￿￿ di￿erent
marine alkaloids have been found (ambiguines A–Q) of which ￿￿ contain the cyclohepta[b]indole
motif (ambiguines D–G and ambiguines I–Q, see Fig. ￿-￿). The earliest found marine alkaloids
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Figure ￿-￿. Natural products containing the cyclohepta[b]indole motif.
are ambiguine D isonitrile (￿￿) from the terrestrial blue-green algae Fischerella ambigua and
Westiellopsis prolifica, ambiguine E isonitrile (￿￿) from terrestrial blue-green algae Fischerella
ambigua, Hapalosiphon hibernicus and Westiellopsis prolifica, and ambiguine F isonitrile (￿￿)
from the terrestrial blue-green alga Fischerella ambigua.[￿￿] All three alkaloids have antibiotic
characteristics. The dechlorinated forms of ambiguines D and E (ambiguine J isonitrile (￿￿)
and ambiguine I isonitrile (￿￿) have been extracted from cultured cyanobacterium Fischerella
sp. but no biological activites are known.[￿￿] Ambiguine G nitrile (￿￿) has been isolated from
the blue-green algaHapalosiphon delicatulus.[￿￿] No biological activities have been reported. In
contrast to the other ambiguines, ￿￿ possesses a nitrile instead of an isonitrile group. Ambigu-
ines isonitriles K–O (￿￿–￿￿) were isolated from cultured cyanobacterium Fischerella ambigua.
Ambiguine K isonitrile and ambiguine M isonitrile showed antibacterial activities againstM.
tuberculosis.[￿￿] In ￿￿￿￿, two more alkaloids have been isolated from cultured cyanobacterium
Fischerella ambigua.[￿￿] Ambiguine P (￿￿) is the first ambiguine which lacks an isonitrile or nitrile
group and is also the only derivative bearing a hydroxyl group at C-￿￿. Ambiguine Q nitrile (￿￿)
is the second congener with a nitrile instead of an isonitrile group. No noteworthy biological
activities have been found. Although many derivatives of ambiguines with a cyclohepta[b]indole
motif have been isolated, no total synthesis of ambiguines has been reported so far.
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Figure ￿-￿. Ambiguines, a large group containing alkaloids with a cyclohepta[b]indole skeleton.
Another large group of alkaloids with a cyclohepta[b]indole skeleton are the ervitsine–er-
vatamine alkaloids (Fig. ￿-￿). Ervatamine (￿￿) is the main alkaloid of the Ervatamia alkaloids
which are corynanthean-type ￿-acylindole alkaloids, but the side chain from the indole C-￿
positions contains three linearly disposed carbon atoms and therefore lacks the characteristic
tryptamine moiety.[￿￿] Compound ￿￿ was isolated from Ervatamia orientalis and Ervatamia li-
fuana (Apocynaceae),[￿￿,￿￿] and is a sodium channel blocker in nerve fibers and a local anesthetic
blocker.[￿￿] From the same sources ￿￿-epiervatamine (￿￿) and ￿￿,￿￿-didehydroervatamine (￿￿)
have been isolated.[￿￿,￿￿] ￿￿,￿￿-didehydro-N￿-methoxyervatamine (￿￿) is an alkaloid from Er-
vatamia malaccensis (Apocynaceae),[￿￿] ￿￿,￿￿-didehydro-￿-oxoervatamine (￿￿) has been isolated
from leaves of Tabernaemontana corymbosa (Apocynaceae),[￿￿] ￿￿,￿￿ didehydro-￿a-hydroxyervat-
amine (￿￿) and dehydroxyervataminol (￿￿) are alkaloids from Ervatamia divaricate.[￿￿] Decar-
boxylation of the ester at C-￿￿ leads to the series of the methuenine–silicine alkaloids. Methue-
nine (￿￿) is an alkaloid from Ervatamia o￿cinalis,Hazunta spp., Pterotaberna inconspicua, and
can also be isolated from the leaves and stem bark of Ervatamia malaccensis. It is an anti-
cholinergic agent.[￿￿,￿￿–￿￿] Also known is its ￿￿-epimer (￿￿),[￿￿,￿￿,￿￿,￿￿] its N-oxide (￿￿),[￿￿] its ￿￿-
epimer-N-oxide (￿￿),[￿￿] the ￿-oxo derivative (￿￿),[￿￿,￿￿,￿￿] and the N￿-methoxy derivative (￿￿).[￿￿]
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Figure ￿-￿. Ervitsine–ervatamine alkaloids.
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Silicine (￿￿) possesses an ethyl group at C-￿￿ instead of an ethylidene function.[￿￿,￿￿–￿￿] Seven
further derivatives of ￿￿ have been isolated: ￿￿-episilicine (￿￿),[￿￿] ￿￿-episilicine (￿￿),[￿￿,￿￿]
￿￿,￿￿-episilicine (￿￿),[￿￿] ￿-oxosilicine (￿￿),[￿￿,￿￿,￿￿] ￿-oxo-￿￿-episilicine (￿￿),[￿￿] ￿-oxo-￿￿,￿￿-epi-
silicine (￿￿),[￿￿] and ￿,￿￿-didehydro-￿￿-episilicine (￿￿).[￿￿] Ervitsine (￿￿) is a minor alkaloid from
the root bark of Pandaca boiteaui (Apocynaceae).[￿￿,￿￿] It is the only member of this alkaloid
family which has an additional link between C-￿ and the C-￿ and is therefore the only bridged
alkaloid. Total syntheses of several members of the ervitsine–ervatamine alkaloids have been
published.[￿￿–￿￿]
￿.￿.￿ Non-natural Products with Biological Activities
Besides their widespread occurrence in natural products, cyclohepta[b]indoles exhibit a broad
spectrum of biological activity and have attracted considerable interest from the pharmaceutical
industry as potential therapeutics. Indole ￿￿ is an active and selective compound (IC￿￿ = ￿￿￿ n￿)
for the inhibition of leukotriene B￿ (LTB￿) production which is implicated in numerous inflam-
matory and allergic diseases (Fig. ￿-￿).[￿￿]
Compound ￿￿ is a selective inhibitor of adipocyte fatty-acid binding protein (A-FABP, IC￿￿ =
￿￿￿ ￿￿).[￿￿] Consequences of the inhibition of A-FABP are a lower risk for hypertriglyceridemia,
type ￿ diabetes and coronary heart disease. The corresponding similar derivative based on a
cyclohexa[b]indole core has shown lower activity.
Indole ￿￿ shows large activity against Gram positive bacteria and good activity against Gram
negative bacteria and high anti-tuberculosis activity with a minimum inhibitory concentration
of ￿.￿￿ ￿g ml-￿. Similar compounds bearing a pyrazole or pyrimidine moiety instead of the
isoxazole moiety have shown similar activities. In addition, it has been shown that the chlorine
at the C-￿ position of the indole is crucial for the activity.[￿￿]
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The SIRT￿-inhibitor IV (￿￿) shows outstanding biological activity and is therefore heavily
investigated. It belongs to a new class of histone deacetylase (HDAC) inhibitors and is involved
in gene silencing via a new mode of action. Data shows that inhibition of SIRT￿ enhances
acetylation of p￿￿. Compound ￿￿ is one of the most potent compounds described (IC￿￿ = ￿￿ n￿)
representing a ￿￿￿-fold improvement over previously reported inhibitors.[￿￿] Enantioselective
gram-scale synthesis of (S)-￿￿ has been reported.[￿￿]
Furthermore, it has been shown that N-substituted ￿,￿-dihydrobenzo-[￿,￿]cyclohepta[b]indol-
￿-one derivatives like compound ￿￿ are an interesting class of cytotoxic compounds and show
activities against L￿￿￿￿murine leukemia andHT￿￿ cell lines.[￿￿] Indole ￿￿ is a novel opioid ligand
with a C-homomorphinan skeleton and shows strong binding a￿nities for the d receptor.[￿￿]
￿.￿ Methodologies for Construction of Cyclohepta[b]indoles
Cyclohepta[b]indoles are often prepared by means of the Fischer indoles synthesis. Although
this reaction can be quite useful and satisfies the requirements of a modern indole synthesis, it
possesses certain limitations.[￿￿,￿￿] Hence quite a few methodologies have been published for the
construction of cyclohepta[b]indoles or derivatives respectively. In most cases pericyclic reactions
have been used. Only publications with the aim of generation of this motif are covered. For
more methodologies for general syntheses of carbocycle-fused indoles which are also suitable
for the generation of cyclohepta[b]indoles further literature is recommended.[￿￿–￿￿￿]
￿.￿.￿ Via Cycloaddition Reactions
￿.￿.￿.￿ [￿+￿] Cycloaddition
One possibility for the formation of cyclohepta[b]indoles are [￿+￿] cycloaddition reactions, first
published by J. Wu[￿￿] and later in ￿￿￿￿ by Y. Li[￿￿￿] and co-workers. In the work of J. Wu indole
￿￿ reacts with an aldehyde or ketone to form indolyl alcohol ￿￿ which generates corresponding
indolyl cation ￿￿ in the presence of a Lewis acid (Scheme ￿-￿). It was observed that especially
gallium(III) bromide and gallium(III) triflate were e￿ectively promoting this desired reaction.
In addition, most gallium(III) salts—especially Ga(OTf)￿—are bench stable and therefore easy
to handle. Once indolyl cation ￿￿ is formed it reacts with diene ￿￿ in a [￿+￿] cycloaddition
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furnishing cyclohepta[b]indole ￿￿. It was the first time a [￿+￿] cycloaddition reaction has been
described in which the ￿p component is derived from indole. The scope of this gallium(III)
mediated regio- and diastereoselective three-component [￿+￿] cycloaddition is quite broad and
allows the access to several cyclohepta[b]indoles with di￿erent substitution patterns in one single
step. Nevertheless, a major drawback is the formation of racemic products.
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Scheme ￿-￿. Synthesis of cyclohepta[b]indoles via one pot hydroamination/[￿+￿] cycloaddition by Y. Li and co-workers (R = alkyl,
aryl; R￿ = H, Me).[￿￿￿]
Y. Li’s strategy is also based on a [￿+￿] cycloaddition reaction but instead of using an indole,
cyclohepta[b]indoles are furnished by means of Fischer base derivative ￿￿ and various dienes
(Scheme ￿-￿). For this purpose, ￿￿ derives from silver(I) catalyzed intramolecular hydroamina-
tion reaction of N-tosyl protected hydroxypropynylaniline ￿￿. The ￿-exo-dig ring closure was
only e￿ectively promoted by silver(I) triflate, neither Pd(OAc)￿ or AuCl were able to promote this
cyclization. Next in line is the generation of cationic species ￿￿ which was found to be promoted
by ZnCl￿ in high yield. The N-tosyl protection seems to be crucial, using Boc or Bn protecting
groups instead leads to complete recovery of starting material. By adding ￿.￿ equivalents of a
diene, cationic species ￿￿ undergoes [￿+￿] cycloaddition to furnish cyclohepta[b]indole ￿￿. In
general, electron-rich dienes show better reactivity. Many substituents at the indole are tolerated,
too. In conclusion, racemic cyclohepta[b]indoles are furnished via one pot tandem reaction
containing hydroamination/[￿+￿].
R. P. Hsung and co-workers developed a di￿erent [￿+￿] cycloaddition strategy for the gener-
ation of aforesaid structure motif.[￿￿￿] This approach starts with N-arylallenamides ￿￿ which
are subjected to Murray’s reagent, zinc chloride and furan. This results in the formation of
oxyallyl cation ￿￿ which undergoes [￿+￿] cycloaddition with furan to a￿ord cycloadduct ￿￿ as
a single diastereomer (Scheme ￿-￿). The yields for this transformation vary between ￿￿% and
￿￿%. With cycloadduct ￿￿ in hand, indoline formation is accomplished via intramolecular
Grignard reaction using iPrMgCl   LiCl which yields in the generation of tertiary alcohol ￿￿.
Transformation of the alcohol into the corresponding xanthate anion followed by elimination
furnishes tetracyclic cyclohepta[b]indoles ￿￿ in good yields. The required syn-relationship for
the Chugaev elimination is given due to the diastereoselective attack of the Grignard reagent. In
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Scheme ￿-￿. Synthesis of cyclohepta[b]indoles via [￿+￿] cycloaddition–cyclization–elimination sequence by R. P. Hsung and co-
workers (R = CO￿Me, halide).
[￿￿￿]
summary, this protocol allows rapid formation of racemic tetracyclic cyclohepta[b]indoles via a
[￿+￿] cycloaddition reaction followed by intramolecular cyclization and Chugaev syn-elimination.
￿.￿.￿.￿ Formal [￿+￿] Cycloaddition
In ￿￿￿￿ the groups of W. Tang and N. Iwasawa published independently an almost identical
protocol for the synthesis of cyclohepta[b]indoles using a metal-catalyzed intermolecular formal
[￿+￿] cycloaddition reaction of vinyl Fischer carbenes with silyloxydienes.[￿￿￿,￿￿￿] Although the
same type of reaction is described, di￿erent reaction mechanisms have been proposed. The
protocol of W. Tang uses catalytic amounts of platinum(II) chloride whose reactivity is enhanced
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Scheme ￿-￿. Syntheses of cyclohepta[b]indoles via a formal [￿+￿] cycloaddition reaction of vinyl Fischer carbenes and silyloxydienes.
a) Protocol by W. Tang and co-workers (R = alkyl, aryl).[￿￿￿] b) Protocol by N. Iwasawa and co-workers (R = alkyl,
aryl).[￿￿￿]
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by the addition of electron-deficient tris(pentafluorophenyl)phosphine ligand in the presence of
sodium carbonate in absolute ￿,￿-dioxane at ￿￿ °C. Typical reaction times with ￿.￿ equivalents
of silyloxydiene ￿￿ are ￿￿ hours (Scheme ￿-￿a). In some cases, the metal catalyst has been
substituted with [Rh(CO)￿Cl￿] in combination with P[OCH(CF￿)￿]￿ as ligand. The protocol
of N. Iwasawa is quite similar, but di￿ers in the amount of diene ￿￿ (￿.￿–￿.￿ equivalents).
Furthermore a slightly di￿erent platinum(II) catalyst is used ([PtCl￿(C￿H￿)]￿) and addition of
￿ Å molecular sieves reduces the reaction time and temperature drastically compared to the
methodology of W. Tang (￿ h vs. ￿￿ h, room temperature vs. ￿￿￿ °C, see Scheme ￿-￿b).
Albeit it is a formal [￿+￿] cycloaddition reaction, di￿erent reaction mechanisms are proposed
by the authors. Vinyl Fischer carbene ￿￿ is formed in a metal catalyzed ￿-endo-dig cyclization
followed by elimination of methanol (Scheme ￿-￿a)[￿￿￿] and several potential pathways for
the cycloaddition with silyloxydiene ￿￿ are proposed by the group of Tang. Cyclopropanation
can a￿ord Fischer base derivative ￿￿ which undergoes divinylcyclopropane rearrangement
to directly furnish cyclohepta[b]indole ￿￿, although there is no plausible justification for the
divinylcyclopropane intermediate since di￿erent regioselectivity for the cyclopropanation had
been reported before.[￿￿￿,￿￿￿] In addition, exclusive formation of cis-divinylcyclopropane ￿￿ is
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required for the sigmatropic rearrangement since trans-cis-isomerization usually occurs above
￿￿￿ °C.[￿￿￿] Furthermore the vinyl Fischer carbene can be attacked nucleophilicly by silyl enol
ether ￿￿ in a ￿,￿-manner followed by formation of metallacycle ￿￿. This metallacycle can also
be furnished via concerted [￿+￿] cycloaddition reaction between ￿￿ and silyl enol ether ￿￿.
Reductive elimination gives cyclohepta[b]indole ￿￿. It can also be formed via concerted [￿+￿]
cycloaddition reaction between ￿￿￿ and silyloxydiene ￿￿ and concomitant elimination of the
metal (Scheme ￿-￿b).
Iwasawa et al. proposed a di￿erent mechanistic pathway due to the observation of the forma-
tion of a minor product (Scheme ￿-￿). Like the proposal of Tang it is assumed that vinyl Fischer
carbene ￿￿ is attacked nucleophilicly by silyl enol ether ￿￿ in a ￿,￿-manner but ring closure
occurs at the b-position of the metal to yield six-membered spiro-cyclic carbene intermediate ￿￿￿.
Formation of ￿￿￿ is also conceivable via [￿+￿] cycloaddition reaction between carbene ￿￿ and
silyloxydiene ￿￿. With electron donation from the nitrogen in mind ￿,￿-alkyl shift occurs at
the carbene moiety forming N-acyliminium ion ￿￿￿. Regeneration of the metal catalyst fur-
nishes cyclohepta[b]indole ￿￿. When using less electron-deficient phosphine ligands tetracyclic
compound ￿￿￿ has been observed as byproduct which is formed via insertion of the carbene
intermediate ￿￿￿ into the C–H bond. Further mechanistic studies have been carried out which
support that the reaction proceeds through described mechanism.
In conclusion, a unique method for an indole annulation/[￿+￿] cycloaddition sequence has
been developed independently by the groups of Tang and Iwasawa. In both cases a highly
regioselective formation of achiral cyclohepta[b]indoles viametal-catalyzed reaction of propargylic
aniline derivatives and electron-rich dienes is described.
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￿.￿.￿.￿ [￿+￿] Cycloaddition
C.C. Li and co-workers elaborated a protocol for the construction of highly functionalized oxa-
cyclohepta[b]indoles using a dearomative indole [￿+￿] cycloaddition reaction.[￿￿￿] This work is
inspired by the work of P. Wender’s synthesis of seven-membered rings based on the generation
and cycloaddition of ￿-methoxy-￿-oxidopyrylium intermediates.Wender:￿￿￿￿kx g-Pyrone ￿￿￿
is treated with a strong methylating reagent to form the methoxy pyrylium salt of kojic acid
derivative ￿￿￿ (Scheme ￿-￿). In accordance with P. Wender methyl triflate in dichloromethane
is used in this case. When this salt in CH￿Cl￿/DMF is exposed to anhydrous caesium fluoride,
generation of oxidopyrylium ylide ￿￿￿ occurs and [￿+￿] cycloaddition proceeds smoothly at ambi-
ent temperature to give cycloadduct ￿￿￿. Exclusive production of the endo cycloaddition product
is observed which has also been fortified by DFT calculations. The protocol allows the formation
of a variety of indole systems with electron-withdrawing or electron-donating substituents at the
indole-N￿ or the indole-C￿ positions. Electronically mismatched oxidopyrylium ylides are also
suitable. In summary, racemic oxacyclohepta[b]indoles are furnished via a novel dearomative
intramolecular indole [￿+￿] cycloaddition using an oxidopyrylium ylide as ￿p component and
the indole C￿–C￿ bond as ￿p unit with exclusive endo selectivity.
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Scheme ￿-￿. Synthesis of cyclohepta[b]indoles via dearomative indole [￿+￿] cycloaddition reaction by C. C. Li and co-workers (R= H,
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￿.￿.￿ Via Sigmatropic Rearrangements
For more than ￿￿ years the divinylcyclopropane rearrangement has been known for the gener-
ation of seven-membered rings and by the end of the ￿￿￿￿s the rearrangement has achieved
synthetic utility and has been extensively applied to a number of syntheses of natural prod-
ucts.[￿￿￿] Hence, it is not surprising that this variation of the Cope rearrangement has also been
applied to syntheses of cyclohepta[b]indoles. The group of S. Sinha and co-workers developed a
protocol using in situ generated Fischer base derivatives which undergo aforesaid rearrange-
ment.[￿￿￿] Alkynylaniline ￿￿￿ is transformed into ￿,￿-disubsituted indole ￿￿￿with ￿.￿ equivalents
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Scheme ￿-￿. Synthesis of cyclohepta[b]indoles via in situ generated divinylcyclopropyl Fischer base derivatives by S.Sinha and
co-workers (R = H, halide, CF￿; R
￿ = alkyl, aryl; R￿ = alkyl).[￿￿￿]
of ￿,￿-dichloro-￿-butene (￿￿￿) in the presence of ￿mol % bis(acetonitrile)palladium(II) chloride
and propylene oxide (Scheme ￿-￿). Treatment with sodium hydroxide leads to decarboxylation
followed by intramolecular allylic alkylation in SN￿’ manner to give ￿￿￿. Depending on the rest
at the indole C-￿ position di￿erent pathways are possible. If R￿ = aryl then vinylcyclopropane
rearrangement takes place and spiroindole ￿￿￿ is formed. In the case of R￿ = alkyl isomerization
occurs forming divinylcyclopropane ￿￿￿which undergoes divinylcyclopropane rearrangement to
furnish directly cyclohepta[b]indole ￿￿￿. This methodology allows simple formation of racemic
cyclohepta[b]indoles bearing an alkyl rest at C-￿ position.
￿.￿.￿ Via Palladium-Catalyzed Cyclization
Ishikura et al. developed a methodology for the synthesis of di￿erent cycloalka[b]indoles using
several known concepts: the indole C-￿ nucleophilicity, the ￿,￿-alkyl migration from boron
to carbon, and the Tsuji-Trost allylic alkylation.[￿￿￿] C-￿ lithiated indole ￿￿￿ is added to boron
species ￿￿￿ forming indolylborate ￿￿￿ which is treated with a palladium(￿) species. This leads to
p-allyl cation ￿￿￿which is attacked by the indole core forming cycloalka[b]indoles ￿￿￿ after reduc-
tive elimination and oxidative work-up whereupon rearomatization takes place (Scheme ￿-￿). In
summary, this protocol describes the one-pot intramolecular cyclization for cycloalka[b]indoles
via an intramolecular alkyl migration reaction using indolylborates.
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Scheme ￿-￿. Pd-catalyzed intramolecular cyclization via alkyl migration process in indolylborates for the generation of cy-
cloalka[b]indoles (R = H, Me; R￿ = H, alkyl).[￿￿￿]
Widenhoefer and co workers published a protocol for a palladium(II)-catalyzed tandem cycliza-
tion/carboalkoxylation of alkenyl indoles.[￿￿￿] Alkenyl indole ￿￿￿ reacts with palladium(II) to fur-
nish palladium-complexed olefin ￿￿￿ which in turn undergoes carbopalladation (Scheme ￿-￿￿).
This leads to the formation of halo acylpalladium species ￿￿￿ which is transferred into methyl
ester ￿￿￿ with methanol. Regeneration of the catalyst is e￿ected by copper(II) chloride. The
use of palladium(II) catalysts is beneficial due to the reactivity of palladium(II) alkyl complexes
towards carbon monoxide. Furthermore, B. Stoltz had already demonstrated the oxidative cy-
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Scheme ￿-￿￿. Pd-catalyzed synthesis of cycloalka[b]indoles by Widenhoefer and co-workers..[￿￿￿]
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clization of alkenyl indoles catalyzed by palladium(II).[￿￿￿] To sum up, this protocol allows an
e￿cient palladium(II)-catalyzed formation of functionalized polycyclic indole derivatives.
￿.￿.￿ Enantioselective Approaches
The methodologies presented so far furnish inherently racemic products or have not yet been
developed in enantioselective manner. A combination of organo- and gold-based catalysis was
the first enantioselective method published in ￿￿￿￿ by D. Enders and co-workers.[￿￿￿] Indoles ￿￿￿
react with ortho-alkyne substituted nitrostyrenes ￿￿￿ in an organocatalytic Friedel-Crafts-type
reaction catalyzed by thioamide-based organocatalyst ￿￿￿ to form chiral C-￿ substituted in-
doles which undergo concomitant gold-catalyzed cyclization yielding cyclohepta[b]indoles ￿￿￿
(Scheme ￿-￿￿a). This protocol has two major drawbacks. In the first place only the formation
of benzocyclohepta[b]indoles can be accomplished. Furthermore, it is limited to a nitromethyl
group at C-￿￿ of the cyclohepta[b]indoles albeit this group defines the stereochemistry. Neverthe-
less, this methodology provides rapid access to enantioenriched tetracyclic indole derivatives with
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Scheme ￿-￿￿. a) Synthesis of cyclohepta[b]indoles via organo- and gold-based catalysis by D. Enders and co-workers. b)Mechanistic
explanation for the stereochemical outcome (R= H, Me, OMe; R￿ = Ph, ￿-tolyl; R￿ = H, F).[￿￿￿]
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Scheme ￿-￿￿. Organocatalytic synthesis of chiral cyclohepta[b]indoles by B.-C. Hong and co-workers (R = H, OMe, Br; R￿ = alkyl;
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an enantiomeric excess of up to ￿￿%. The stereochemical outcome is explained in Scheme ￿-￿￿b.
Bifunctional organocatalyst ￿￿￿ forms hydrogen-bonding interactions with indole ￿￿￿ and
nitroolefin ￿￿￿. As a result, both reactions partners are preconfigured favoring Si-attack of
indole ￿￿￿ to give C-￿ substituted indole ￿￿￿. Concomitant addition of p-acidic [Au(PPh￿)]NTf￿
activates the alkyne moiety favoring a second Friedel-Crafts-type ￿-endo-dig cyclization to form
spirocycle ￿￿￿. Indolenine–indole rearrangement furnishes cyclohepta[b]indole ￿￿￿.
B.-C. Hong et al. developed an analog protocol for the synthesis of cyclohepta[b]indoles.[￿￿￿]
Thus, a, b-unsaturated aldehyde ￿￿￿ is activated by conversion into the corresponding Schi￿ base
with ￿-proline derivative ￿￿￿ and is attacked in a ￿,￿-manner by indolylalkyl malononitrile ￿￿￿
from the Re-face (Scheme ￿-￿￿). The Si-face is shielded e￿ciently due to catalyst control which
yields in an enantiomeric excess of ca. ￿￿%. The resulting chiral aldehyde ￿￿￿ subsequently
reacts with Bn-protected indole ￿￿￿ under Brønstedt-acidic conditions (￿￿mol % (+)-CSA) to
give an iminium-activated cation which in turn is trapped by the unprotected indole in a Friedel-
Crafts-type reaction. This results in the generation of cyclohepta[b]indoles ￿￿￿ in moderate yields
(ca. ￿￿%) and diastereoselectivity (ca. ￿￿:￿￿ syn/anti). In summary, this one-pot strategy a￿ords
enantioenriched cyclohepta[b]indoles via tandem organocatalytic Michael addition/Friedel-Crafts
alkylation reations. The reaction is indeed highly stereoselective; however, the diastereoselectivity
is only moderate.
￿.￿.￿ Brief Delineation of Other Methodologies
In the previous paragraphs, eleven methodologies for the synthesis of cyclohepta[b]indoles
were discussed in detail. However, there are numerous more published methodologies which
are going to be discussed very briefly. The reason for this parting is, that most of them are
general syntheses of carbocycle-fused indoles which are also suitable for the generation of
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cyclohepta[b]indoles, or are not as sophisticated as the aforementioned methodologies. At the
very end, methodologies for the preparation of benzocyclohepta[b]indoles are delineated.￿
In ￿￿￿￿, the group of Andrieux published an interesting approach for a hitherto unknown
indole synthesis (Scheme ￿-￿￿).[￿￿￿] Treatment of benzocyclobutenols (￿￿￿) with hydrazoic acid
in the presence of a Lewis acid leads to the corresponding benzocyclobutylazides (￿￿￿). Acid-
catalyzed rearrangement furnishes ￿-substituted or cycloalka[b]indoles (￿￿￿) in good yields.
Although Andrieux described a very elegant indole synthesis, it has found practically no applica-
tion. Only one publication from the group of U. Burger has made use of this approach.[￿￿￿]
The group of Banwell published a Pd(￿)-mediated Ullmann cross-coupling of o-halonitro-
arenes with a-haloenones. The cross-coupling products are converted into the corresponding
cycloalka[b]indoles with hydrogen in the presence of palladium on charcoal (Scheme ￿-￿￿).[￿￿￿]
The group of Arcadi published a double gold-catalyzed conjugate addition type reaction of
indoles with a,b-enones (Scheme ￿-￿￿).[￿￿￿] However, this gold-catalyzed reaction is not streose-
lective and furnishes a diastereomeric mixture of products. The group of Carbery published
a very similar methodology but using an acid-mediated double Friedel-Crafts reaction to yield
diastereomerically pure single products (Scheme ￿-￿￿).[￿￿￿]
Willis et al. developed a new palladium-catalyzed route to N-functionalized indoles, in which
the N fragments are introduced in a single-step cascade sequence onto an acyclic carbon frame-
work (Scheme ￿-￿￿).[￿￿￿]
Liu et al. published a methodology for the generation of ￿,￿-disubstituted indolenines starting
from phenylhydrazine and a variety of a-branched aldehydes. Acid-mediated Wagner–Meerwein-
type rearrangement yields ￿,￿-substituted indoles (Scheme ￿-￿￿).[￿￿￿]
The group of Eilbracht published an interesting approach for the synthesis of a-branched
aldehydes from olefins via Rh-catalyzed hydroformylation. The aldehydes are condensed with
phenylhydrazine to give hydrazones in a one-pot procedure. Acid-promoted [￿,￿]-sigmatropic
rearrangement yields ￿,￿-disubstituted indolenines, which in turn undergo a Wagner–Meerwein-
type rearrangement to furnish ￿,￿-substituted indoles (Scheme ￿-￿￿).[￿￿￿]
Barluenga et al. published a novel method for the construction of indole heterocycles using
readily available starting materials, such as o-dihaloarenes and imines (Scheme ￿-￿￿).[￿￿￿]
Kunick and König published syntheses of cycloalka[b]indoles via a modified Fischer indole
synthesis (Schemes ￿-￿￿ and ￿-￿￿).[￿￿￿,￿￿￿]
Driver and co-workers published a methodology which shows that rhodium carboxylate
complexes, such as [Rh￿(O￿CC￿H￿￿)￿], can catalyze cascade reactions of b,b-disubstituted
styryl azides to selectively produce ￿,￿-disubstituted indoles (Scheme ￿-￿￿). The formation
of both cycloalka[b]indoles and benzo[m,n]cycloalka[b]indoles is described.[￿￿￿] Two years later
the same group demonstrated that iron(II) bromide promotes the tandem transformation of
ortho-substituted aryl azides by C–H bond amination ￿,￿-migration reactions which furnishes
both ￿,￿-disubstituted and cycloalka[b]indoles (Scheme ￿-￿￿).[￿￿￿]
￿ In most cases, the schemes are labeled with the title of the particular publication in this subsection.
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Novak et al. described an aza-Claisen rearrangement of (cycloalkylmethyl)benzeneamines
(￿￿￿, Scheme ￿-￿￿).[￿￿￿] Aza–Claisen rearrangements usually require more harsh conditions
than those required for the classic Claisen rearrangement of oxygenated substrates; this re-
arrangement usually occurs at ￿￿￿–￿￿￿ °C.[￿￿￿] The process describes a Lewis acid catalyzed
aza-Claisen rearrangement followed by an intramolecular aza–Alder–ene reaction to obtain
cyclohepta[b]indoles (￿￿￿).
The group of Messerle prepared a series of new pyrazolyl-￿,￿,￿-triazolyl N–N’ bidentate
donor ligands. This ligands and their rhodium or iridium complexes were then applied to
the synthesis of tricyclic indoles via tandem C–N and C–C bond formation reactions from
hydroxyalkynylanilines (Scheme ￿-￿￿).[￿￿￿]
Cho et al. described a methodology for the preparation of ene-hydrazides (￿￿￿) from enol
triflates. This compounds undergo ZnCl￿-mediated Fischer indolization reaction to yield various
cycloalka[b]indoles (Scheme ￿-￿￿).[￿￿￿]
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Scheme ￿-￿￿. Acid-catalyzed transformation of tertiary benzocyclobutylazides into cycloalka[b]indoles (Andrieux, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Gold-catalyzed conjugate addition type reaction of indoles with a,b-enones (Arcadi, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Palladium-catalyzed tandem alkenyl and aryl C-N bond formation (Willis, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Rearrangement of ￿,￿-disubstituted indolenines and synthesis of ￿,￿-substituted indoles (Liu, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Cyclohepta[b]indoles from olefins and hydrazines via tandem hydroformylation–Fischer indole synthesis and skeletal
rearrangement (Eilbracht, ￿￿￿￿).[￿￿￿]
Pd2(dba)3 (2 mol %), Xphos (4 mol %),
NaO tBu (2.8 eq.), dioxane, 110 °C
87%
Br
I
PhN
N
Ph
￿￿￿ ￿￿￿ ￿￿￿
Scheme ￿-￿￿. The azaallylic anion as a synthon for Pd-catalyzed synthesis of heterocycles (Barluenga, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Stereoselective double Friedel–Crafts alkylation of indoles with divinyl ketones (Carbery, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Synthesis of ￿-tert-butyl-￿,￿,￿,￿,￿,￿￿-hexahydrocyclohepta[b]indole (Kunick, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Rhodium-catalyzed synthesis of cyclohepta[b]indoles from b,b-disubstituted stryryl azides (Driver, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Fischer indole synthesis of cyclohepta[b]indoles in low melting mixtures (König, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Preparation of cycloheptano-indole derivatives (Novak, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Catalyzed tandem C–N/C–C bond formation for the synthesis of tricyclic indoles using Ir(III) pyrazolyl-￿,￿,￿-triazolyl
complexes (Messerle, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. FeBr￿-catalyzed synthesis of cycloalka[b]indoles from aryl azides (Driver, ￿￿￿￿).
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Scheme ￿-￿￿. Ene-hydrazide from enol triflate for the regioselective Fischer indole synthesis (Cho, ￿￿￿￿).[￿￿￿]
￿.￿.￿.￿ Benzocyclohepta[b]indoles
Almost all publications which deal with the formation of benzo[m,n]cyclohepta[b]indoles are
using an indolyl aryl halide which is subjected to Heck reaction conditions to undergo an
intramolecular ring closure (Schemes ￿-￿￿, ￿-￿￿, and ￿-￿￿).[￿￿￿–￿￿￿] J.-Y. Mérour used an indolyl
benzoic acid derivative which undergoes intramolecular cyclization in the presence of a large
excess of polyphosphoric acid and phosphorus pentoxide (Scheme ￿-￿￿).[￿￿,￿￿￿]
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Scheme ￿-￿￿. Synthesis of benzo[￿,￿]cyclohepta[b]indole derivatives (Mérour, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. Synthesis of benzo[￿,￿]cyclohepta[b]indole derivatives (Mérour, ￿￿￿￿, ￿￿￿￿).[￿￿,￿￿￿]
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Scheme ￿-￿￿. Controlled gold-catalyzed reaction of propargylic hydroperoxides with phenols and palladium-catalyzed cyclization of
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Scheme ￿-￿￿. Intramolecular Heck cyclization of aryl bromide ￿￿￿ to synthesize benzo[￿,￿]cylohepta[b]indole ￿￿￿ (Phukan, ￿￿￿￿).[￿￿￿]
￿.￿ Syntheses of Natural Products
Total syntheses of several aforementioned natural products have been published (cf. Section ￿.￿).
Hitherto actinophyllic acid (￿￿) and ervitsine–ervatamine alkaloids have received the most
attention from synthetic groups although the more readily accessible alkaloids arcyriacyanin A
(￿￿) and caulersin (￿￿) have also been synthesized several times by di￿erent groups. Aristolasene
(￿￿) has been synthesized once starting from ￿￿-hydroxyhobartine. No syntheses of aristolasol
(￿￿), exotines or ambiguines have been published to this day.
￿.￿.￿ Synthesis of Ervatamia Alkaloids (J. Bosch)
￿.￿.￿.￿ Synthesis of (±)-Ervitsine
J. Bosch and co-workers published various syntheses of alkaloids of the ervitsine–ervatamine
family. The first total synthesis of (±)-ervitsine was published in ￿￿￿￿ and was revised four years
later.[￿￿,￿￿￿] It is a biomimetic synthesis utilizing ￿,￿-dihydropyridine and uses N￿-SEM protected
￿-acetylindole (￿￿￿) as starting material (Scheme ￿-￿￿). Its enolate reacts with pyridinium
salt ￿￿￿ and forms ￿,￿-dihydropyridine ￿￿￿ followed by treatment with Eschenmoser’s salt.
This leads to iminium ion ￿￿￿ which is trapped intramolecularly by the indole core yielding
bridged system ￿￿￿ in a one-pot three-step sequence with ￿￿% overall yield. Although the
yield of this sequence is poor it allows a rapid construction of the core structure. Oxidation
of the dimethylamino moiety, followed by heating induced Cope elimination produces the
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Scheme ￿-￿￿. Synthesis of (±)-ervitsine (￿￿) by J.Bosch and co-workers.[￿￿,￿￿￿]
exomethylene group at C-￿￿ in ￿￿% yield. Subsequently, the tetracyclic product is subjected to
acid-mediated decarboxylation followed by reduction with sodium borohydride. Under these
conditions the protecting group is also cleaved to form (±)-ervitsine (￿￿) in ￿￿% yield. In this
route, the construction of the cyclohepta[b]indole core is achieved via a Mannich reaction. An
enantioselective approach of this route was used in the synthesis of (–)-N￿-methylervitsine
employing a chiral N-methylpyridinium salt derived from (S)-O-methylprolinol.[￿￿￿]
The total synthesis of (±)-ervatamine (￿￿) was published by J. Bosch in ￿￿￿￿.[￿￿] It profits from
the same strategy as used in the total synthesis of (±)-ervitsine and is therefore also a biomimetic
synthesis via a ￿,￿-dihydropyridine. The synthesis commences with the nucleophilic addition
of the enolate of N￿-benzyl protected ￿-acetylindole (￿￿￿, Scheme ￿-￿￿) to ￿-acylpyridinium
salt ￿￿￿ and trapping of the formed ￿,￿-dihydropyridine with trichloroacetic anhydride to give
￿-acylindole ￿￿￿ in moderate yield. The trichloroacetyl group is converted to the corresponding
methyl ester and the ￿,￿-dihydropyridine moiety is reduced to the ￿,￿,￿,￿-tetrahydropyridine
using H￿ and Adams’s catalyst. Having the precognition that the benzyl group will cause
problems at the end of the synthesis, the protecting group is cleaved using aluminium chloride
in absolute benzene.[￿￿￿] Prior to the biomimetic cyclization, reduction of the ￿-acylindole
carbonyl group is necessary as this moiety prevents successful aminoalkylation at the indole C-￿
position. The resulting diol ￿￿￿ is then treated with Eschenmoser’s salt. After transformation of
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Scheme ￿-￿￿. Synthesis of (±)-ervatamine (￿￿) by J. Bosch and co-workers.[￿￿]
the gramine moiety into the corresponding methiodide under elevated temperatures, Hofmann
elimination takes place and the systemundergoes biomimetic cyclization. The resulting iminium
salt is reduced using NaCNBH￿ and the tetracycle is chemoselectively oxidized to the ervatamine-
type tetracyclic ￿-acylindole ￿￿￿ using MnO￿. Since the hydroxyethyl substituent at C-￿￿ has
to be syn to the adjacent proton at C-￿￿, the alcohol moiety at C-￿￿ is transferred into the
corresponding mesylate followed by an anti elimination for the formation of an E-ethylidene
double bond yielding (±)-￿￿,￿￿-didehydroervatmine (￿￿), which is known to be convertible to
(±)-ervatamine (￿￿) via hydrogenation in the presence of Adams’s catalyst.[￿￿￿] In this synthesis,
the formation of the cyclohepta[b]indole was achieved by gramine-type fragmentation reaction
followed by intramolecular trapping of the putative iminium ion yielding the ervatamine-type
tetracycle.
￿.￿.￿ Synthesis of Actinophyllic Acid
￿.￿.￿.￿ Overman (￿￿￿￿)
The first total synthesis of (±)-actinophyllic acid (￿￿) was published by L. Overman and co-workers
in ￿￿￿￿ employing a concise sequence starting form di-tert-butyl malonate (￿￿￿) which would
allow production of gram quantities of the natural product.[￿￿￿] The magnesium enolate of ￿￿￿
reacts with o-nitrophenylacetyl chloride forming keto diester ￿￿￿, which in turn undergoes
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Scheme ￿-￿￿. Synthesis of (±)-actinophyllic acid hydrochloride (￿￿) by Overman and co-workers.[￿￿￿]
reductive cyclization to furnish an indole-￿-malonate. Installation of a piperidin-￿-one fragment
at the C-￿ position of the indole is simply achieved by the reaction of this indole with N-Boc-￿-
bromopiperidin-￿-one in DMF obtaining indole ￿￿￿. Intramolecular oxidative coupling gives
access to hexahydroazocino[￿,￿-b]indole ￿￿￿, the best results are obtained with a combination of
LDA and [Fe(DMF)￿Cl￿][FeCl￿], an easy prepared iron(III) chloride–dimethylformamide com-
plex which has been elaborated for oxidative couplings of phenols and ketone enolates.[￿￿￿,￿￿￿]
Although the yield is moderate, this optimized procedure allows formation of tetracyclic ke-
tone ￿￿￿ on scales up to ￿￿ g in the presence of an unprotected indole. A vinyl rest is introduced
by attack of the bridged ketone on the Re face followed by removal of the Boc protecting group.
The liberated secondary amine reacts with paraformaldehyde at elevated temperatures to form
iminium ion ￿￿￿which in turn undergoes a cationic ￿-aza-Cope rearrangement and concomitant
Mannich-type attack of the newly formed enol ether to iminium ion ￿￿￿ to form pentacycle ￿￿￿.
A similar aza-Cope/Mannich cascade has been carried out by L. Overman in the synthesis of
strychnine and is a commonly used strategy.[￿￿￿] Treatment of the crude product of this cascade
￿￿
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reaction with neat TFA gives (±)-actinophyllic acid precursor ￿￿￿ in an overall yield of ￿￿%
from hexahydroazocino[￿,￿-b]indole ￿￿￿. Fischer esterification of the carboxylic acid to methyl
ester ￿￿￿ followed by treatment of its enolate with formaldehyde forms the tetrahydrofuran ring
and gives (±)-actinophyllic acid methyl ester which is converted into the natural product ￿￿ via
acidic hydrolysis in ￿￿% overall yield.
￿.￿.￿.￿ Martin (￿￿￿￿)
Five years after the first total synthesis of (±)-actinophyllic acid (￿￿) by L. Overman and co-
workers S. F. Martin and co-workers published a second synthesis using a cascade reaction of
N-stabilized carbocations with p-nucleophiles to yield the tetracyclic skeleton of (±)-actinophyllic
acid in one single step.[￿￿] The required building blocks used in this cascade reaction are acces-
sible in few steps from known compounds. For this purpose N-vinyl-￿-pyrrolidinone (￿￿￿) is
converted into tetrahydroazepinone ￿￿￿ viaNorrish type I photorearrangement.[￿￿￿]The enamine
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Scheme ￿-￿￿. Synthesis of (±)-actinophyllic acid hydrochloride (￿￿) by S. F. Martin and co-workers.[￿￿]
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is protected with an Alloc group followed by formation of the corresponsding TIPS enol ether
yielding dihydroazepinone ￿￿￿ which is one building block for the cascade reaction. Indolyl
acetate ￿￿￿ is formed in a one-pot five-step sequence from indole (￿￿￿) and is then treated with
a Lewis acid to induce ionization of the tertiary acetate which is trapped by enamide ￿￿￿. The
resulting N-acyliminium ion ￿￿￿ is in turn trapped in a Mannich-type reaction by the indole
core, furnishing the tetracyclic core of (±)-actinophyllic acid (￿￿) in excellent yield. To avoid
fragmentation by carbon-nitrogen scission, the indole nitrogen is protected with a Boc group.
The Alloc protecting group is removed under palladium-catalyzed conditions in the presence of
N,N-dimethylbarbituric acid to furnish the free amine ￿￿￿ which in turn undergoes reductive
amination with ￿-chloroacetaldehyde. Treatment with base leads to displacement of the chloride
and formation of bridged pyrrolidine ￿￿￿. Removal of all protecting groups leads to a sponta-
neous cyclization and formation of a hemiacetal. The remaining primary alcohol is oxidized to
the corresponding carboxylic acid completing the synthesis of (±)-actinophyllic acid (￿￿) in only
ten steps from readily available compounds. The formation of the cyclohepta[b]indole core is
achieved via the remarkable cyclization cascade of diene ￿￿￿ and tertiary indolyl acetate ￿￿￿.
￿.￿.￿.￿ Kwon (￿￿￿￿)
Very recently, a third synthesis of (–)-actinophyllic acid (￿￿) has been published by the group of
O. Kwon.[￿￿] The synthesis starts with a chiral phosphine-catalyzed [￿+￿] annulation between
allenoate ￿￿￿ and an indole sulfonylimine ￿￿￿ (Scheme ￿-￿￿).[￿￿￿,￿￿￿] This reaction furnishes
indole dihydropyrrole ￿￿￿ in an almost quantitative yield and very good enantiomeric excess
(￿￿%). Mercury mediated installation of an iodine at the indole C-￿ position, followed by the
removal of the nosyl protecting group and direct alkylation of the generated secondary amine
with ethyl ￿-oxopent-￿-enoate yields iodoketoester ￿￿￿. Subjecting the iodoketoester ￿￿￿ to CuI
in DMSO at ambient temperature furnishes azocane ￿￿￿. Simultaneous removal of the benzyl
protecting group and cis hydrogenation is achieved with a high pressure of H￿ gas over Pd/C.
Esterification of the resulting carboxylic acid with chloroiodomethane furnishes pyrrolidine ￿￿￿.
Next in line is the formation of the tetrahydrooxocine moiety of the natural product; this is
achieved via a modestly yielding alkylative lactonization. A SmI￿ mediated pinacol coupling
furnishes the crucial cyclohepta[b]indole moiety and yields tetrahydrofuran ￿￿￿ in an excellent
yield. Radical dehydroxylation,[￿￿￿] followed by global deprotection through the e￿ect of aqueous
HCl under microwave heating finally furnishes (–)-actinophyllic acid (￿￿) in very good yield. The
Kwon group constructed the cyclohepta[b]indole core of (–)-￿￿ via SmI￿ mediated intramolecular
pinacol coupling between ketone and lactone subunits.
￿.￿.￿.￿ Partial Syntheses
Actinophyllic acid (￿￿) has gained a lot of attention from the synthetic community. Since
its isolation in ￿￿￿￿ by Carroll and co-workers[￿￿] many groups have tried to synthesize this
compound with its unprecedented architecture and great biomedical potential. Three total
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Scheme ￿-￿￿. Synthesis of (–)-actinophyllic acid hydrochloride (￿￿) by O. Kwon and co-workers.[￿￿]
syntheses have been published until today. Nevertheless, several other unfinished endeavors
have been published by the groups of Coldham,[￿￿￿] Maldonado,[￿￿￿] Taniguchi,[￿￿￿] Wood,[￿￿￿]
and Weinreb.[￿￿￿] Our working group has also done some studies concerning the synthesis of
(±)-￿￿.[￿￿￿] Due to incompleteness, these partial syntheses are not part of this dissertation.
￿.￿.￿ Aristolasene (Borschberg, ￿￿￿￿)
H.-J. Borschberg published a synthesis of (+)-aristolasene (￿￿) in ￿￿￿￿, among many other
syntheses of Aristotelia-type alkaloids (Scheme ￿-￿￿).[￿￿] All attemps to convert thiophenyl
ether ￿￿￿—accessible in ￿ steps from perillyl acohol[￿￿￿]—into its corresponding aldehyde
via a Pummerer reaction failed; instead the major product was indole-protected ￿￿-endo-hydroxy-
makomakine (￿￿￿). This alcohol is treated with thionyl chloride which furnishes the rearranged
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allyl chloride which in turn is transformed into its corresponding alcohol ￿￿￿ in two steps.
Removal of the indole protecting group yields (–)-￿￿-hydroxyboartine, which is transformed into
(+)-aristolasene (￿￿) in two additional steps in moderate yield. The cyclohepta[b]indole formation
is achieved via a Pictet-Spengler-type reaction.
￿.￿.￿ Caulersin
￿.￿.￿.￿ Fresneda (￿￿￿￿)
The first total synthesis of caulersin (￿￿) was published by the group of Fresneda in ￿￿￿￿
(Scheme ￿-￿￿).[￿￿] Aldol condensation between ￿-azidobenzaldehyde (￿￿￿) and N-protected
￿-acetyl-￿-chloroindole (￿￿￿) in the absence of solvent yields chalcone ￿￿￿. The aryl azide is
refluxed in o-xylene which furnishes bis(indole) ￿￿￿. Although the authors do not comment on
this transformation, this reaction is a variant of the Hemetsberger-Knittel indole synthesis.[￿￿￿]
The mechanism of this indole synthesis is not entirely clear; the reaction is postulated to proceed
via a highly electrophilic singlet nitrene species.[￿￿￿] Lewis acid catalyzed Michael-type addition
of bis(indolyl)ketone ￿￿￿ to methyl vinyl ketone furnishes ￿-oxoalkylated product ￿￿￿ which is
subjected to basic conditions and undergoes an intramolecular nucleophilic displacement of
the chlorine atom via addition/elimination reaction to obtain ￿￿￿. Dehydrogenation with DDQ,
followed by haloform reaction of the methyl ketone with potassium hypochlorite in methanol
and removal of the indole protecting group under acidic conditions yields caulersin (￿￿) in seven
steps and ￿￿% overall yield. The construction of the central seven-membered ring is based on
an intramolecular nucleophilic substitution of ￿-oxoalkylated product ￿￿￿.
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Scheme ￿-￿￿. The first total synthesis of bis(indole) marine alkaloid caulersin (￿￿) by Fresneda.[￿￿]
￿.￿.￿.￿ Miki (￿￿￿￿)
The second total synthesis of caulersin (￿￿) was published by the group of Miki in ￿￿￿￿.[￿￿]
Lewis acid catalyzed reaction of N-protected indole-￿,￿-dicarboxylic anhydride ￿￿￿ and methyl
indolylacetate ￿￿￿ a￿ords ￿-acylindole-￿-carboxylic acid ￿￿￿ in quantitative yield. The carboxylic
acid is reduced to the corresponding aldehyde ￿￿￿ in the presence of an ester and a ketone
by converting the carboxylic acid to its acid chloride followed by tetrabutyltin hydride in the
presence of Pd(PPh￿)￿. The construction of the central seven-membered ring is based on an
intramolecular aldol condensation reaction. Final global deprotection a￿ords caulersin (￿￿) in
five steps and ￿￿% overall yield.
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Scheme ￿-￿￿. Second total synthesis of bis(indole) marine alkaloid caulersin (￿￿) by Miki.[￿￿]
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￿.￿.￿ Arcyriacyanin A
Arcyriacyanin A (￿￿) has been synthesized twice in the late ￿￿￿￿s by the groups of Steglich and
Tobinaga, respectively.[￿￿,￿￿] Both strategies rely on palladium catalyzed cross-coupling reactions.
Detailed information can be found in Section ￿￿.￿.
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Scheme ￿-￿￿. Synthesis of arcyriacyanin A (Steglich, ￿￿￿￿).[￿￿] Reagents and conditions: a) LDA, THF, –￿￿ °C, ￿ h, then Me￿SnCl,
–￿￿ °C  rt, ￿￿%. b) N-tosyl-￿-bromoindole, PhMe, ￿￿ °C, Pd(PPh￿)￿, ￿￿ h, ￿￿% c) EtOH, ￿￿ °C, ￿￿% NaOH, ￿ h,
￿￿%. d) EtMgBr (￿.￿ eq.), THF, rt., then PhMe, ￿￿￿ °C, ￿,￿-dibromomaleimide, ￿ h, ￿￿%.
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Scheme ￿-￿￿. Synthesis of arcyriacyanin A (Tobinaga, ￿￿￿￿).[￿￿] Reagents and conditions: a) nBuLi, THF, –￿￿ °C, ￿￿min, then Et￿B,
–￿￿ °C, ￿￿ min, then PdCl￿(PPh￿)￿ (￿ mol %), N-(tert-butyldimethylsilyl)-￿-iodoindole, D, ￿ h, ￿￿%. b) TBAF, THF,
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￿.￿ Conclusion
By far the biggest progress in methodology development has been made within the last decade.
This coincides with the enhanced attention of pharmaceutical industry towards compounds
exhibiting the cyclohepta[b]indole motif. However, up to date methods for enantioselective
construction of cyclohepta[b]indoles are scarce. Among the completed ten total syntheses
containing this structural motif, most of them—ervatamine (￿￿), ervitsine (￿￿), aristolasene (￿￿),
caulersin (￿￿) and arcyriacyanin A (￿￿); Schemes ￿-￿￿, ￿-￿￿, ￿-￿￿, ￿-￿￿, ￿-￿￿, and ￿-￿￿—date back
to the ￿￿￿￿s. The total syntheses of actinophyllic acid (￿￿, Schemes ￿-￿￿, ￿-￿￿, and ￿-￿￿) have
been accomplished very recently. Analysis, especially of the most recent syntheses, reveals that
the methodology development for the construction of cyclohepta[b]indoles of the last decade has
so far not found its way into application in complex molecule synthesis. This is a very promising
perspective, since further advancement can therefore be expected with regard to an e￿cient
access to these compounds. Evermore, this shows the urgent demand for the development
of synthetic methodologies involving the construction of cyclohepta[b]indoles, explicitly when
￿￿
￿ The Cyclohepta[b]indole Motif
it comes to the development of methods for enantioselective construction of this privileged
structural motif.
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￿.￿ Structure and Reactivity of Cyclopropanes
Cyclopropane, the smallest possible cycloalkane, was discovered in ￿￿￿￿ by A. Freund when
trying to expand the Wurtz reaction to a,w-dihaloalkanes.[￿￿￿] He named the new compound
trimethylene and—surprisingly—proposed the correct structure. Five years later G. Gustavson
formed cyclopropane by using more manageable zinc instead of sodium.[￿￿￿] While the cyclo-
propane ring is a highly strained entity, it is nonetheless found in a wide variety of naturally
occurring compounds including terpenes, pheromones, fatty acid metabolites and unusual
amino acids. Furthermore, its rigidity renders this group an attractive structural motif for the
preparation of molecules with defined orientation of functional groups.[￿￿￿]
Cyclopropane derivatives undergo a manifold of ring-opening reactions under the influence
of a variety of chemical reagents (e.g., electrophiles, nucleophiles, radicals) or external physical
forces (e.g., heat, light).[￿￿￿] The C–C–C bond angles are ￿￿°[￿￿￿] and therefore considerably less
than the ideal ￿￿￿.￿° for sp³-hybridized orbitals which results in significant angular (Bayer)
strain. Furthermore, cyclopropanes have additional torsional (Pitzer) strain as all hydrogens are
eclipsed due to the coplanar arrangement of the carbon atoms (Fig. ￿-￿a).
The high reactivity is often rationalized by the relief of strain associated with ring opening.
Though, the strain energies of cyclopropane and cyclobutane are similar: ￿￿.￿ and ￿￿.￿ kcalmol ￿,
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Figure ￿-￿. a) Cyclopropane. b) The Coulson-Mo￿tt model. Arrows denote directions of hybrid orbitals at the carbon atoms of
cyclopropane.
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respectively. Also, the required energy for the homolytic C–C cleavage is quite similar: ￿￿.￿ and
￿￿.￿ kcalmol ￿, respectively. Whereas the chemistry of cyclopropanes resembles that of a carbon-
carbon double bonds, the chemistry of cyclobutanes does not. Therefore, the thermodynamical
considerations alone are insu￿cient to explain the unusual reactivity of cyclopropanes.[￿￿￿]
Several models try to describe the bonding situation in cyclopropanes. A popular description
has been proposed by Coulson and Mo￿tt and describes the construction of the cyclopropane
ring from three sp³-hybdridized CH￿-groups which make an angel of ￿￿￿° with one another
(Fig. ￿-￿b).[￿￿￿,￿￿￿] This results in about ￿￿% less e￿ective overlap than the C–C bond of ethane
and for this reason, the bonds are often referred to as “banana bonded”. The less e￿ective overlap
is also the source of the angular strain.
E
Ψ1
Ψ2 Ψ3
Figure ￿-￿. The Walsh model (basis set).
The Walsh model[￿￿￿–￿￿￿] proposes that cyclopropanes
can be considered as an insertion of methylene into
ethylene, therefore as being constructed from three sp²-
hybdridized CH￿-groups, giving rise to the D￿h symmetric
product. Thus, cyclopropanes have a significant sp² char-
acter and should react in analogy to olefins. The sp² hybrid
orbitals are oriented towards the center of the cyclopropane
ring (Fig. ￿-￿). As in the model of Coulson and Mo￿tt the
angular strain is attributed to poor orbital overlap, too.
Y￿ can be regarded as distorted p-bond which o￿ers an
explanation of the reactivity of cyclopropanes toward electrophilic reagents.[￿￿￿,￿￿￿]
A property of cyclopropanes is that they are magnetically anisotropic but with the protons
coming into resonance in their NMR spectra at unusually high field, typically ￿ ppm upfield of
the protons of an open-chain methylene group.
￿.￿.￿ Thermal Ring Fission
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Scheme ￿-￿. a) Cyclopropyl carbene rearrangement. b) Cy-
clopropylmethyl carbene rearrangement. c) Vinylcyclopropane
rearrangement.
There are four types of thermal cyclopropyl
rearrangements which induce a ring fis-
sion: the cyclopropyl carbene rearrange-
ment, the cyclopropylmethyl carbene re-
arrangement, the vinylcyclopropane rear-
rangement, and the divinylcyclopropane-
cycloheptadiene rearrangement.
Treatment of gem-dihalocyclopropanes
with magnesium results in the formation
of a cyclopropyl carbenoid (via a-elimina-
tion) which undergoes a rearrangement
(Scheme ￿-￿a). The product of this reac-
tion is an allene and nowadays this reac-
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Scheme ￿-￿. Synthesis of octalene ￿￿￿ via cyclopropylmethyl carbene rearrangement.[￿￿￿]
tion is known as Doering–LaFlamme allene synthesis.[￿￿￿,￿￿￿] Alkyllithiums can also be used to
generate allenes via cyclopropyl carbenoids (nowadays known as the Skattebøl-Moore rearrange-
ment).[￿￿￿,￿￿￿b]
The generation of a carbene at a cyclopropylmethyl carbon results in a ring expansion through
a ￿,￿-migration of the cyclopropyl C-C bond. This results in the formation of a cyclobutene
(Scheme ￿-￿b).[￿￿￿] Although this rearrangement has been used in the synthesis of octalene
￿￿￿[￿￿￿] it is not as remarkble as the other types of rearrangements and has therefore not been
widely used in syntheses of natural products.
Cyclopropanes with adjactent p-systems have di￿erent chemical properties. Vinylcyclopro-
pane ￿￿￿ undergoes a rearrangement to yield cyclopentene ￿￿￿ upon heating (Scheme ￿-￿c).[￿￿￿]
The activation energy for this process has been determined to be ￿￿.￿ kcalmol ￿.[￿￿￿,￿￿￿] The
mechanism of this vinylcyclopropane rearrangement has been discussed extensively and involves
biradical intermediates.[￿￿￿–￿￿￿] The rearrangement allows the preparation of functionalized
cyclopentenes and has a great synthetical benefit since vinylcyclopropanes are readily accessible
and cyclopentenes are important structural motifs in natural products. In the case of trans-
alkylvinylcyclopropanes a ￿,￿-hydrogen shift (retro-ene reaction) can be a competing process but
is controllable by temperature adjustment and sometimes can be reversible (Scheme ￿-￿b).[￿￿￿]
The vinylcyclopropane rearrangement strategy has been applied widely in the syntheses of com-
plex natural products. In the synthesis of (±)-antheridium-inducing factor (AAn, ￿) a vinylcyclo-
propane-cyclopentene rearrangement was a crucial step in the formation of the perhydrofluorene
skeleton (Scheme ￿-￿a).[￿￿￿]
A number of di￿erent functional groups can be introduced via this rearrangement at various
positions, too. Under appropriate conditions, cyclopropanes in conjugation with an unsaturated
functional group can also undergo this type of rearrangement. In this case it represents a
heterocyclic variant of the vinylcyclopropane rearrangement. The acid-catalyzed thermal rear-
O
TBSO
Me
O
H Et2AlCl
O
TBSO
Me
O
H H
a) b) H
[1,5]-H shift H
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Scheme ￿-￿. a) A vinylcyclopropane rearrangement was a crucial step in the synthesis of (±)-antheridium-inducing factor (AAn,￿).
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b) The a ￿,￿-hydrogen shift (retro-ene reaction) can be a competing process.
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Scheme ￿-￿. The synthesis of mesembrine (￿￿￿) by Stevens took advantage of the thermal rearrangement of cyclopropyl imines.[￿￿￿]
rangement of cyclopropyl imines is a general method for the synthesis of D￿-pyrrolines ￿￿￿,
which are useful compounds in the synthesis of alkaloids.[￿￿￿,￿￿￿]
￿.￿.￿.￿ Divinylcyclopropane-Cycloheptadiene Rearrangement
The most relevant rearrangement in the context of this work is the divinylcyclopropane-cyclohep-
tadiene rearrangement (Scheme ￿-￿). It is a [￿,￿] sigmatropic rearrangement and is conceptually
related to the Cope rearrangement but has the benefit of a thermodynamic driving force due
to the release of ring strain. It involves the isomerization of a ￿,￿-divinylcyclopropane ￿￿￿ into
a cycloheptadiene ￿￿￿ and was first discovered by E. Vogel in ￿￿￿￿.[￿￿￿c] Vogel did not isolate
divinylcyclopropane ￿￿￿, since, under the conditions he used for the formation, it rearranges
rapidly to ￿￿￿. A decade later, divinylcyclopropane could be isolated for the first time and it was
shown to rearrange to cycloheptadiene ￿￿￿ with half-lives of approximately ￿￿ s and ￿￿min at
￿￿ °C and ￿￿ °C, respectively.[￿￿￿–￿￿￿]
Its first synthetic applicationwas in ￿￿￿￿ in the syntheses of (±)-dictyopterene C byG.Ohlo￿[￿￿￿]
and to this day it continues to be a useful approach since it provides a versatile, e￿ective method
for the construction of functionalized mono-, bi- and tricyclic substances (cf. Section ￿.￿).
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Scheme ￿-￿. The divinylcyclopropane–cycloheptadiene rearrangement.
Only a (Z)-double bond geometry is observed in cycloheptadienes (Fig. ￿-￿) and (E)–cyclooctene
is the smallest reported cyclic structure with a trans double bond that is stable at room tempera-
ture[￿￿￿] The rearrangement proceeds in a concerted fashion via endo-boatlike transition state
￿￿￿ where both vinyl groups are located above the cyclopropane. Only this transition state yields
cycloheptadiene with the correct double bond geometry, whereas the chairlike transition state
￿￿￿ and the exo-boatlike transition state ￿￿￿ would yield (Z,E)- or even (E,E)-cycloheptadiens
(￿￿￿ and ￿￿￿, respectively). The activation energy Ea for the rearrangement of ￿￿￿ to ￿￿￿ was
established to be ￿￿.￿ kcalmol ￿.[￿￿￿–￿￿￿]
M. Zora has made an ab initio study about the transition structures and energetics for the
rearrangement of cis-￿,￿-divinylcyclopropane, using the restricted Hartree-Fock and second-
￿￿
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Table 1 summarizes the energies, zero-point
vibrational energies (ZPVE) and imaginary
vibrational frequencies (IMF) of the reactants,
transition structures and products for the rearrange-
ment of divinylcyclobutane 1. The activation enthalpy
DH–0 and reaction enthalpy DH0 are the energies at
0 K including unscaled ZPVE’s. The relative energies
correspond to enthalpies DH–0 and DH0 and are
provided in Scheme 2. Unless indicated, MP2
energies are discussed throughout the text. It should
be noted that for the reactants and transition
structures, c denotes a vinyl group in endo orientation
while t shows that in exo orientation. For the products,
c denotes a cis double bond while t shows a trans one.
Fig. 1. RHF/6-31G* optimized structures and point groups of reactants, transition states and products shown in Scheme 2.
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Figure ￿-￿. Transition states of the divinylcyclopropane-cycloheptadiene rearrangement: only endo-boat transition state ￿￿￿ yields
in (Z,Z)-cycloheptadiene ￿￿￿, highly unfavoured transition states ￿￿￿ and ￿￿￿ would yield virtually impossible (Z,E)-
and (E,E)-cycloheptadiens ￿￿￿ and ￿￿￿, respectively. The graphical structures are RHF/￿–￿￿G* optimized structures
and show the particular transition state and the resulting cycloheptadiene.[￿￿￿]
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Figure ￿-￿. Energy diagram of cycloheptadiene formation via divinylcyclopropane-cycloheptadiene rearrangement. Energies are in
kcalmol–￿ and relative to that of ￿￿￿. All energy calculations used the second-order Møller-Plesset perturbation theory
which is based on the Hartree-Fock method (MP￿(full)￿–￿￿G*//RHF/￿–￿￿G*).[￿￿￿–￿￿￿] All values include zero-point
vibrational energies.
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order Møller-Plesset perturbation theory (MP￿(full)￿–￿￿G*//RHF/￿–￿￿G*) and was the first
to examine the formation of severely strained (Z,E)- and (E,E)-cycloheptadiens from these
rearrangements (cf. Fig. ￿-￿).[￿￿￿,￿￿￿] The conversion of ￿￿￿ into ￿￿￿ and ￿￿￿ is facile since the
conformational energy barrier is ￿.￿ kcalmol ￿ and ￿.￿ kcalmol ￿ from ￿￿￿ to ￿￿￿ and from ￿￿￿
to ￿￿￿, respectively. There is no direct conversion of ￿￿￿ into ￿￿￿. The endo-boatlike transition
state ￿￿￿ has a calculated energy of activation of ￿￿.￿ kcalmol ￿ which is in good agreement
with the experimentally measured energy and is less strained than the chairlike and exo-boatlike
transition states ￿￿￿ and ￿￿￿, respectively. The formation of cycloheptadiene ￿￿￿ is exothermic,
whereas ￿￿￿ and ￿￿￿ are not energetically favorable due to increasing ring strain. It has to be
noted, that the calculated relative energy of ￿￿￿ is less than that of the resulting cycloheptadiene
￿￿￿. According to that, this conversion is e￿ectively barrierless. This feature has also been
observed in related systems.[￿￿￿]
It is plausible that only cis-configured divinylcyclopropanes (￿￿￿) are eligible for a [￿,￿] sig-
matropic rearrangement (Scheme ￿-￿). For example, cis isomer ￿￿￿ cyclizes already at ambient
temperature or below. However, the trans configured counterparts (￿￿￿) are usually thermo-
dynamically more stable[￿￿￿c] but rearrangement products are not directly formed since the
required cyclic transition state cannot be adopted due to the absence of orbital overlap of the
two p-bonds. Nevertheless, high temperature leads to the same rearrangement product ￿￿￿ as
it is obtained from the cis configured counterpart. The reason is a homolytic dissociation of the
central linkage, to give trans-allyl biradical ￿￿￿.[￿￿￿] Isomerization of the allyl groups enables
the correct orbital geometry to perform a [￿,￿] sigmatropic rearrangement. To this day, it is not
known whether only the isomerization occurs via a biradical mechanism or also the cyclization
itself.
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Scheme ￿-￿. Radical isomerisation of trans-divinylcyclopropane.
A very special case of the divinylcyclopropane-cycloheptadiene rearrangement can be found in
tricyclo[￿.￿.￿.￿￿,￿] deca-￿,￿,￿-triene, also named bullvalene (￿￿￿, Scheme ￿-￿).[￿￿￿] The bullvalene
molecule is a cyclopropane with three vinyl arms conjoined at a methine group. Its molecular
structure has the astonishing feature of having no permanent carbon–carbon bonds. All carbon
atoms are bonded, or not bonded, to the same extent with every other carbon atom in themolecule,
i.e., degenerated. Such molecules are named fluxional and this situation is the consequence of
rapid Cope rearrangements. Its high-temperature proton NMR spectrum consists of exactly one
sharp singlet at d = ￿.￿ ppm and the ￿￿C spectrum shows only one sharp singlet at d = ￿￿.￿ ppm.
In total, there are ￿￿!￿ = ￿ ￿￿￿ ￿￿￿ bonding possibilities. This explains why this structure is
named fluxional.[￿￿￿]
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￿￿￿a ￿￿￿b ￿￿￿c ￿￿￿d ￿￿￿e ￿￿￿f
Scheme ￿-￿. a) Bullvalene (￿￿￿) with highlighted Cope systems. b)One possible rearrangement: bullvalene rearranges to bullvalene.
In total, there are ￿￿!￿ = ￿ ￿￿￿ ￿￿￿ possibilities.
[￿￿￿]
￿.￿ Synthesis of Cyclopropanes
There are several methodologies for the generation of cyclopropanes. They can be classified into
￿,￿-cyclization reaction and [￿+￿] cycloaddition reactions. In the former case the cyclopropane
ring is formed through the formation of a carbon–carbon bond in the immediate precursor, in
the latter case two carbon–carbon bonds of the cyclopropane ring are formed in one preparative
step. Several reviews for the construction of cyclopropanes have been published.[￿￿￿–￿￿￿]
￿.￿.￿ Cyclopropanes via ￿,￿-Cyclization Reactions
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Scheme ￿-￿. Cyclopropanes from ￿,￿-
cyclization reactions, a retrosynthetic view.
￿,￿-Cyclizations are widely used for the construction of sub-
stituted cyclopropanes. In general, the three-membered
ring can be formed as a result of a heterolytic or homolytic
cleavage of two single bonds (￿￿￿  ￿￿￿, Scheme ￿-￿), one
single and one double bond (￿￿￿/￿￿￿  ￿￿￿), or two double
bonds (￿￿￿/￿￿￿  ￿￿￿).
￿.￿.￿.￿ Via Cleavage of Two Single Bonds
The first synthesis of cyclopropane was discovered in ￿￿￿￿
by A. Freund when trying to expand the Wurtz reaction to
a,w-dihaloalkanes (cf. Section ￿.￿, see Scheme ￿-￿a).[￿￿￿]
Other quite similar examples for the generation of cyclopropanes via ￿,￿-cyclization reactions
are presented in Schemes ￿-￿b and ￿-￿c, and show the synthesis of methylenecyclopropane
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Scheme ￿-￿. a) Synthesis of cyclopropane by A. Freund (￿￿￿￿).[￿￿￿] b) Synthesis of methylenecyclopropane from ￿-methylallyl
chloride (Boord, ￿￿￿￿).[￿￿￿] c) Large scale synthesis of methylenecyclopropane (Salaün, ￿￿￿￿).[￿￿￿]
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Scheme ￿-￿￿. a) a-Cyclopropyl ketones from g-haloketones.[￿￿￿] b) Diastereoselective iodocarbocyclization reaction (R* = (–)-￿-
phenylmenthyl).[￿￿￿]
(￿￿￿) starting from ￿-methylallyl chloride (￿￿￿). Small amounts of ￿￿￿ were prepared by ￿,￿-
dechlorination of dichloride ￿￿￿ upon treatment with magnesium, large amounts were prepared
by ￿,￿-dehydrochlorination of chloride ￿￿￿.
g-Haloketones (￿￿￿) are synthetically important building blocks for the synthesis of a-cyclo-
propyl ketones (￿￿￿, Scheme ￿-￿￿a).[￿￿￿] Treatment of this readily available compounds with
aqueous sodium hydroxide leads smoothly to a-cyclopropyl ketones like ￿￿￿. This structure
motif is often used in the synthesis of isoprenoids and other natural products. Taguchi et al.
described the iodocarbocyclization of allylmalonate ￿￿￿ using (–)-￿-phenylmenthol as a chiral
auxiliary which proceeded with high diastereoselectivity to give the iodomethylcyclopropane
dicarboxylic ester ￿￿￿ in ￿￿% yield and ￿￿% ee (Scheme ￿-￿￿b).
￿.￿.￿.￿ Via Cleavage of One Double Bond and One Single Bond
The rearrangement of homoallylic compounds into cyclopropylcarbinyl derivatives is a well
known reaction and has received much attention from the synthetic community. Mangoni et
al. described the synthesis of cyclopropylcarbinyl acetates (￿￿￿) based on the reaction of ho-
moallylic iodides (￿￿￿) with silver(I) acetate in anhydrous media (Scheme ￿-￿￿a).[￿￿￿] Taylor and
co-workers described a similar intramolecular cyclization of homoallyl alcohol ￿￿￿ bearing a silyl
substituent (Scheme ￿-￿￿b).[￿￿￿] Treatment with thionyl chloride under basic conditions leads
to a homoallylic rearrangement. Similar to the Sakurai reaction,[￿￿￿] the silyl group stabilizes
the cyclopropylcarbinyl cation (beta-silicon e￿ect); elimination of the silyl group leads to the
formation of the vinyl cyclopropane ￿￿￿. En route to (±)-trans-chrysanthemic acid, Ficini et
al. described a cyclopropane formation starting from sulfonylestser ￿￿￿ (Scheme ￿-￿￿c).[￿￿￿]
Treatment with sodium hydride leads to a homoallylic carbanion, SN￿’ substitution of the acetate
group furnishes pentasubstituted cyclopropane ￿￿￿ in a diastereomeric ration of ￿:￿. Guibé
and co-workers described the formation of cyclopropylmethyl esters (￿￿￿) from d-iodo-a,b-
unsaturated esters (￿￿￿), with various substituents at the b- and g-positions, in the presence of
samarium diiodide and a proton source (Scheme ￿-￿￿d).[￿￿￿] Another very common strategy is
the use of the so-called MIRC￿ reaction (also known as Hassner–Ghera–Little MIRC reaction,
cf. Scheme ￿-￿￿e).[￿￿￿,￿￿￿,￿￿￿] This Michael initiated ring closure synthetic methodology is espe-
cially useful with sulfones and leads to the formation of b-substituted acceptor cyclopropanes.
Formally, this reaction is a stereoselective [￿+￿] cycloaddition and is also applicable for the
￿ MIRC = Michael initiated ring closure
￿￿
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Scheme ￿-￿￿. a) Cyclopropylcarbinyl compounds from homoallylic iodides.[￿￿￿] b) Vinylcyclopropanes from homoallylic alcohols.[￿￿￿]
c) En route to (±)-trans-chrysanthemic acid (Ficini, ￿￿￿￿).[￿￿￿] d) Cyclopropane ring formation by an SmI￿ mediated
cyclization of d-halo-a, b-unsaturated esters.[￿￿￿] e)MIRC reaction.[￿￿￿]
formation of five-, six- and seven-membered rings. Enantioselective syntheses of MIRC reaction
products starting from chiral sulfone imines have been described.[￿￿￿]
￿.￿.￿.￿ Via Cleavage of Two Double Bonds
The photochemical rearrangement of ￿,￿-dienes to cyclopropane derivatives is known as di-
pi-methane rearrangement, or oxa-di-pi-methane rearrangement if one of both p-systems
is a carbonyl.[￿￿￿] The main requirement then is that a carbon bears two p-moieties. The
rearrangement product therefore, more generally, is a p-substituted cyclopropane. The very
broad spectrum of types of organic molecules obtainable by the di-pi-methane rearrangement is
remarkable and particularly useful in synthesis. More often than not, the photoproducts are not
available by alternative routes.[￿￿￿a] The biradical mechanisms is shown in Scheme ￿-￿￿a. The
skeletal rearrangement where one of the two p-substituents is an aryl group is also possible
and would yield aryl cyclopropanes. The (oxa-)di-pi-methane rearrangement has received much
attention from the synthetic community and many syntheses with this skeletal rearrangement
are described. Singh et al. irradiated tricyclic compound ￿￿￿, which is easy accessible from
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Scheme ￿-￿￿. a)Mechanism of the di-pi-methane rearrangement (X––CH￿) and oxa-di-pi-methane rearrangement (X––O).
[￿￿￿] b) En
route to (±)-hirsutene via oxa-di-p-methane rearrangement (Singh, ￿￿￿￿).[￿￿￿] c) Di-pi-methane rearrangement occurs
naturally in some unique marine diterpenoids.[￿￿￿]
salicyl alcohol in a few steps (Scheme ￿-￿￿b). The result is tetracyclic cyclopropane containing
product ￿￿￿ which would be di￿cult to synthesize by alternative routes.[￿￿￿] Interestingly, this
skeletal rearrangement occurs naturally in the that are unique marine diterpenoids interrelated
by a naturally occuring di-pi-methane-rearrangement.[￿￿￿] Look and co-workers showed, that
irradiation of erythrolide B (￿￿￿) under a variety of conditions yielded erythrolide A (￿￿￿) as the
sole product (Scheme ￿-￿￿c): irradiation of ￿￿￿ in benzene in a quartz tube using a medium-
pressure Hg lamp yielded ￿￿￿ in ￿￿% yield, irradiation of ￿￿￿ in ￿%methanolic seawater in a
glass tube with sunlight yielded also ￿￿￿ (￿￿% conversion in ￿ days).
￿.￿.￿ Cyclopropanes via [￿+￿] Cyclization Reactions
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Scheme ￿-￿￿. Cyclopropanes from [￿+￿]
cyclization reactions, a retrosynthetic view.
In general, the formation of cyclopropanes via [￿+￿] cycliza-
tion reactions leads to reactions of methylene and ethylene
fragments (Scheme ￿-￿￿). Homolytic or heterolytic cleavage
of two carbon-carbon bonds of the three-membered ring
gives two disconnection products: methylene and ethylene
species (￿￿￿ + ￿￿￿  ￿￿￿). The unidirectional heterolytic
fragmentation gives methylene ￿,￿-carbodianion and ethy-
lene ￿,￿-carbodication (￿￿￿ + ￿￿￿   ￿￿￿), or methylene
￿,￿-carbodication and ethylene ￿,￿-carbodianion pairs (￿￿￿ +
￿￿￿  ￿￿￿). Although all methodologies in this section can be described with the coupling of
the particular pairs from Scheme ￿-￿￿, it cannot be excluded that some reactions for the forma-
￿￿
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tion of cyclopropanes may be described more precisely by the recombination of the respective
ion-radical species.
￿.￿.￿.￿ Simmons-Smith Cyclopropanation
In ￿￿￿￿, H. E. Simmons and R.D. Smith utilized diiodomethane in the presence of zinc-copper
couple to convert unfunctionalized alkenes to cyclopropanes.[￿￿￿,￿￿￿] This transformation proved
to be general and has become one of the most powerful methods of cyclopropane formation,
since a wide range of alkenes is suitable for this reaction. Due to the electrophilic nature of the
formed carbenoid ￿￿￿ the rate of cyclopropanation is faster with more electron rich alkenes since
these double bonds have a higher coe￿cient of the HOMO. The carbenoid Simmons-Smith
reaction with isoprene confirms this theory: the reaction takes place on the double bond with
the largest coe￿cient of the HOMO (Scheme ￿-￿￿).[￿￿￿] However, in some cases steric hindrance
of highly substituted alkenes can reduce the reaction rate.
Since the cyclopropane formation is a concerted process (cf. Scheme ￿-￿￿), it is a stereospecific
reaction. In case of chiral substrates, the cyclopropanation is highly diastereoselective and occurs
from the less hindered face of the double bond. If the alkene has functional groups containing
heteroatoms (e.g., OH, OAc, OMe, OBn, NHR), the new methylene group adds stereoselectively
to the same face of the double bond as the functional group.
Nowadays, several modifications are known for the formation of the active reagent. The most
popular modification uses diethylzinc with methylene iodide which gives highly reproducible
results (Furukawa modificaion, Scheme ￿-￿￿).[￿￿￿] Furthermore, there are two modifications
for chemoselective cyclopropanation of allylic alcohols in the presence of other olefins and vice
versa. The Molander modification uses iodomethylsamarium iodide (Sm/Hg/CH￿I￿)
[￿￿￿,￿￿￿]
for the chemoselective cyclopropanation of allylic alcohols in the presence of other olefins.
Dialkyl(iodomethyl)aluminium (iBu￿Al/CH￿I￿) exclusively cyclopropanates unfunctionalized
olefins (Yamamoto modification).[￿￿￿]
There are two di￿erent approaches for asymmetric Simmons-Smith cyclopropanations: either
the use of cleavable chiral auxiliaries[￿￿￿–￿￿￿] or the addition of stoichiometric amounts of chiral
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Scheme ￿-￿￿. The carbenoid Simmons-Smith reaction with isoprene. The values represent the Y￿-coe￿cients of isoprene.
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additives, such as dioxaborolanes (Charette asymmetric modification).[￿￿￿] However, the latter
approach is usually only suitable for allylic alcohols. It has often been used in syntheses of
natural products, e.g. in the total synthesis of (+)-ambruticin by E.N. Jacobsen.[￿￿￿]
￿.￿.￿.￿ Cyclopropanation via Diazo Compounds and viaMetal Carbenoids
Certain diazo compounds can react with olefins to furnish cyclopropanes in a two-step manner
(Scheme ￿-￿￿a). The first step involves a ￿,￿-dipolar cycloaddition to form pyrazoline ￿￿￿ which
then undergoes radical denitrogenation to yield cyclopropane ￿￿￿. The latter step occurs either
photochemically or by thermal decomposition. The thermal route is also known as the Kishner
cyclopropane synthesis.[￿￿￿] The mechanism of decomposition has been studied but remains
controversial, although it is assumed to proceed via a diradical species.[￿￿￿]
More common is the cyclopropanation of olefins with a diazo compound under metal catal-
ysis, which usually proceeds e￿ectively in the presence of copper, palladium, and rhodium
catalysts, but cyclopropanations with iron, nickel, and cobalt catalysts are also described. The
general mechanism of this transformation is shown in Scheme ￿-￿￿b.[￿￿￿] After formation of
the a-diazomethyl organometallic intermediate ￿￿￿, elimination of nitrogen takes place to give
metal-carbene complex ￿￿￿. The cyclopropanation of the olefin proceeds either by direct re-
placement of the metal or by formation of a metallacyclobutane intermediate which undergoes
reductive elimination to a￿ord cyclopropane ￿￿￿. The most likely active species in these trans-
formation are copper(I),[￿￿￿] palladium(￿)[￿￿￿c] and rhodium(II).[￿￿￿a] However, copper(II) and
palladium(II) salts can be used since they are reduced to the active copper(I) and palladium(￿)
species, respectively, with the diazo compound.
Literature contains a number of examples for the catalytic enantioselective cyclopropanation
utilizing transition metal carbenoids generated from diazo compounds (Scheme ￿-￿￿). On the
one hand, the use of chiral metal catalysts (e.g. ￿￿￿) is possible and usually leads to high ee’s.
Doyle et al. used a new azetidine-ligated dirhodium(II) catalyst that possesses a ￿-menthyl ester
attachment. This chiral Rh-catalyst provides a significant diastereocontrol and high enantio-
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Scheme ￿-￿￿. a) Mechanism for the cyclopropanation using diazo compounds. b) Mechanism of the metal-catalyzed carbenoid
cyclopropanation reaction.[￿￿￿]
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a) En route to a cyclopropane-configured urea-PETT analogue (Doyle, ￿￿￿￿).[￿￿￿] b) cyclopropanation of alkenes
with aryldiazoacetates catalyzed by trisoxazoline/Cu(I).[￿￿￿] c) Catalytic asymmetric intramolecular cyclopropanation
reaction.[￿￿￿]
control for the formation of cis-cyclopropane products from reactions of substituted styrenes
with diazo esters (Scheme ￿-￿￿a).[￿￿￿] On the other hand, the use of common metal salts in
combination with chiral ligands (e.g. ￿￿￿ or ￿￿￿) is possible. Tang and co-workers published
a highly enantioselective cyclopropanation of alkenes with phenyldiazoacetates catalyzed by
CuPF￿(CH￿CN)￿/trisoxazoline (Scheme ￿-￿￿b).
[￿￿￿] Nakada and co-workers studied the catalytic
asymmetric intramolecular cyclopropanation reactions of ￿-aryl-￿-diazo-￿-mesitylsulfonyl-￿-
hexen-￿-ones using BOX ligands (Scheme ￿-￿￿c).[￿￿￿]
￿.￿.￿.￿ Sulfur Ylides: Corey-Chaykovsky reaction
Sulfonium and sulfoxonium ylides were first described by R. Kuhn in ￿￿￿￿,[￿￿￿] but it were A.W.
Johnson and E. J. Corey who saw its synthetic value and described syntheses of epoxides from
the reaction of carbonyls and sulfur ylides.[￿￿￿,￿￿￿] The general reaction involves the addition of a
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[￿￿￿]
sulfur ylide to a ketone, aldehyde, imine, or enone to produce the corresponding ￿-membered
ring. Therefore, it can be used for the synthesis of epoxides, aziridines and cyclopropanes,
respectively. For addition of sulfur ylides to enones, higher ￿,￿-selectivity is typically obtained
with sulfoxonium reagents than with sulfonium reagents. This type of [￿+￿] cycloaddition
has found widespread application in organic chemistry. The reaction proceeds via Michael
addition of ylide ￿￿￿ to an a,b-unsaturated compound followed by ￿,￿-cyclization of the betaine
indermediate ￿￿￿ to a￿ord cyclopropane ￿￿￿ (Scheme ￿-￿￿).[￿￿￿]
The Corey-Chaykovsky reaction has received much attention from the synthetic community
and numerous examples of application can be found in literature. C.H. Heathcock used this
reaction in his synthesis of (±)-isovelleral (Scheme ￿-￿￿a).[￿￿￿] A catalytic asymmetric cyclopropa-
nation of enones with dimethyloxosulfoniummethylide promoted by a La–Li￿–(Biphenyldiolate)￿
+ NaI complex was described by M. Shibasaki (Scheme ￿-￿￿b).[￿￿￿]
￿.￿.￿.￿ Halocarbene Equivalents
A highly e￿ective method for cyclopropanation is to employ free carbenes, but the scope is
limited because only few carbenes can be prepared conveniently and nearly all are unstable.
Dihalocarbenes (￿￿￿) are an exception and the preparation of heterosubstituted cyclopropanes
with these carbenes was first documented by W. v. E. Doering in ￿￿￿￿ (Scheme ￿-￿￿).[￿￿￿] A very
e￿ective way for the preparation of dihalocarbenes is the generation in a two-phase system upon
treatment of the particular haloform species with concentrated aqueous lye in the presence of
triethylbenzylammonium chloride. Only a small part of the generated carbene reacts with the
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Scheme ￿-￿￿. Cyclopropanation via in situ formed dihalocarbene from methane trihalide. a-Elimination leads to an electrophilic
carbene which reacts with the double bond with the largest coe￿cient in the HOMO (cf. Scheme ￿-￿￿).
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water and the major part can be e￿ectively trapped with an olefine.[￿￿￿] Another e￿ective way
for the preparation of dichlorocarbene is the use of dichlorodiazirine, which is a nitrogenous
precursor for dichlorocarbene. It is stable in the dark but decomposes into dichlorocarbene and
nitrogen via photolysis.[￿￿￿]
￿.￿.￿.￿ Cyclopropanes from ￿,￿-Carbodianions and ￿,￿-Carbodications
The unidirectional heterolytic fragmentation of cyclopropane can also give methylene ￿,￿-carbo-
dianion and ethylene ￿,￿-carbodication (￿￿￿ + ￿￿￿  ￿￿￿, Scheme ￿-￿￿). An early example for
this reaction dates back to ￿￿￿￿: W. Perkin described the preparation of diethyl cyclopropane-￿,￿-
dicarboxylate from diethyl malonate (￿￿￿) and ￿,￿-dibromoethane (￿￿￿).[￿￿￿] S.M. Danishefsky
and co-workers described a similar reaction (Scheme ￿-￿￿a), but used aqueous caustic soda
as a base and therefore yielded cyclopropane ￿,￿-dicarboxylic acid (￿￿￿).[￿￿￿] A more recent
example has been published by Shioiri et al. and shows an asymmetric cyclopropanation reaction
using chiral quaternary ammonium salts as the phase-transfer catalyst (Scheme ￿-￿￿b).[￿￿￿]
En route to (±)-bicifadine (￿￿￿)—a potent inhibitor of both the serotonin and norepinephrine
reuptake transporters—Xu and co-workers used an epoxy nitrile coupling (Scheme ￿-￿￿c).[￿￿￿]
Deprotonated nitrile ￿￿￿ reacts with epichlorohydrin (￿￿￿) to form intermediate ￿￿￿. The
chlorine undergoes SN￿ displacement and the newly generated epoxide is attacked in situ by a
second nitrile anion to give cyclopropane ￿￿￿ which is transformed into (±)-￿￿￿ in two additional
steps.
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￿.￿.￿.￿ Cyclopropanes from ￿,￿-Carbodications and ￿,￿-Carbodianions: the Kulinkovich Reaction
An example for the synthesis of cyclopropanes from ￿,￿-carbodications and ￿,￿-carbodianions is
the recently developed Kulinkovich reaction.[￿￿￿] The reaction of carboxylic esters with alkylmag-
nesium bromide in the presence of titanium(IV) isopropoxide smoothly leads to the correspond-
ing cyclopropanols (Scheme ￿-￿￿c). A synthesis of cyclopropyl derivatives is also possible via the
pyrolysis of ￿-acetoxy-￿-pyrazolines (￿￿￿) which are obtained by the action of lead tetraacetate on
￿-pyrazolines (￿￿￿, Scheme ￿-￿￿a),[￿￿￿] or via Simmons-Smith cyclopropanation reaction of silyl
enol ethers (Scheme ￿-￿￿b),[￿￿￿] but these are not examples for the synthesis of cyclopropanes
from ￿,￿-carbodications and ￿,￿-carbodianions.
Themechanism of the Kulinkovich reaction is not trivial and is shown in Scheme ￿-￿￿.[￿￿￿] Tita-
nium(IV) isopropoxide is converted into the thermally unstable diethyltitanium intermediate ￿￿￿
with two equivalents of ethylmagnesium bromide. This intermediate undergoes a b-hydride
elimination followed by reductive elimination of ethane and forms titanacyclopropane ￿￿￿. This
titanacyclopropane acts as a ￿,￿-dicarbanion equivalent when it reacts with the carboxylic ester
and with an additional equivalent of ethylmagnesium bromide the titanacyclopropane-ester
complex ￿￿￿ is transformed into the oxatitanacyclopentane ate-complex ￿￿￿. The alkoxy group
is eliminated as its magnesium salt, forming intermediate ￿￿￿. This undergoes cyclopropane
formation and gives titanium cyclopropoxide ￿￿￿ which undergoes alkylation at the titanium by
ethylmagnesium bromide. Thus, the diethyltitanium intermediate is regenerated. The formed
magnesium cyclopropoxide ￿￿￿ is converted into the corresponding cyclopropyl alcohol upon
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Scheme ￿-￿￿. Catalytic diastereoselective synthesis of cis-￿,￿-disubstituted cyclopropanols from esters.[￿￿￿]
aqueous acidic work-up. In reactions with higher homologues than ethylmagnesium bromide,
the formation of cis-￿,￿-disubstituted cyclopropyl alcohols occurs with high diastereoselectivity
(usually ￿￿:￿ or higher, cf. Scheme ￿-￿￿c). The driving force for this high diastereoselectivity
is explained by the relief of the steric strain at the titanium atom during the formation of the
corresponding cyclopropanolates.[￿￿￿]
A catalytic diastereoselective synthesis of cis-￿,￿-disubstituted cyclopropyl alchols from esters is
also knownwith a TADDOL-based catalyst, developed byCorey and co-workers (Scheme ￿-￿￿).[￿￿￿]
The Kulinkovich reaction is also known with carboxylic amides instead of esters, the reaction
product is a cyclopropyl amine (de Meijere variation).[￿￿￿] The substrate can also be a nitrile,
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the reaction product in this case is again a cyclopropyl amine (Szymoniak variation).[￿￿￿] Many
intramolecular Kulinkovich reactions are known, making this reaction a very versatile tool in
synthetic organic chemistry.[￿￿￿–￿￿￿]
￿.￿ Cycloheptanes from Cyclopropane Precursors
Cycloheptanes can be synthesized by means of transformation of cyclopropane precursors and
this strategy is widely used in the synthesis of natural products (Tab. ￿-￿).￿ The first person
who demonstrably used a cyclopropane containing structure for the synthesis of a cycloheptane
in a total synthesis was W. v. E. Doering in ￿￿￿￿.[￿￿￿] A benzene solution of diazomethane was
irradiated to furnish the cyclopropane product bicyclo[￿.￿.￿]hepta-￿,￿-diene. The oxidation with
￿% potassium permanganate produced a small amount of material which was identified as
a-tropolone (Tab. ￿-￿, Entry ￿). The divinylcyclopropane-cycloheptadiene rearrangement was not
yet fully described at this time, but this synthesis used a special variant of the divinylcyclopropane-
cycloheptadiene rearrangement: the Buchner ring expansion reaction which was already known
since ￿￿￿￿.[￿￿￿,￿￿￿] The first application of the divinylcyclopropane-cycloheptadiene rearrange-
ment in total synthesis was almost ￿￿ years later; G. Ohlo￿ used the rearrangement for the
synthesis of (±)-dictyopterene C in ￿￿￿￿.[￿￿￿]
The table lists syntheses of carbocyclic natural compounds with seven-membered rings derived
from cyclopropane precursors. The reactions can be divided in groups shown in Scheme ￿-￿￿. By
far the largest part are cyclization reactions of divinylcyclopropane compounds (Scheme ￿-￿￿a,
Entries ￿, ￿, ￿, ￿, ￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿,
￿￿, and ￿￿). ￿￿ times the seven-membered ring construction occured by this intramolecular
cyclization reaction. In addition, five syntheses of carbocyclic natural compounds with the
application of the Buchner ring expansion reaction (Scheme ￿-￿￿b) are described (Entries ￿, ￿,
￿￿, ￿￿, and ￿￿).
Due to the large amount of syntheses which used the divinylcyclopropane-cycloheptadiene
rearrangement, a more detailed di￿erentiation is taken into account (Scheme ￿-￿￿). The most
simple outcome is a seven-membered ring with an attached alkyl chain (Scheme ￿-￿￿a). This was
used in the synthesis of (±)-dictyopterene C (Entry ￿, Ohlo￿, ￿￿￿￿),[￿￿￿] (±)-ectocarpene (Entry ￿,
Schneider, ￿￿￿￿),[￿￿￿] (+)-dictyopterene A and (+)-dictyopterene C’ (Entry ￿￿, Genet, ￿￿￿￿),[￿￿￿]
and (–)-dictyopterene C (Entry ￿￿, Jaenicke, ￿￿￿￿).[￿￿￿] All these natural products belong to a large
number of constituents of marine brown algae, some of which exhibit remarkable physiological
activities. Overman used the divinylcyclopropane-cycloheptadiene rearrangement for the gener-
ation of a monosubstituted cycloheptane in an early stage of the synthesis of (–)-scopadulcic
acid A (Entry ￿￿, ￿￿￿￿).[￿￿￿] The same is true for the synthesis of ￿-epi-vibsanin E (Entry ￿￿,
Williams, ￿￿￿￿).[￿￿￿] Most often, the divinylcyclopropane-cycloheptadiene rearrangement is used
for the synthesis of monoannulated cycloheptanes (Scheme ￿-￿￿b and Scheme ￿-￿￿c): synthesis
￿ Although the list in Tab. ￿-￿ is quite comprehensive, the author makes no claim to completeness.
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of (±)-damsinic acid (Entry ￿, Wender, ￿￿￿￿),[￿￿￿] (±)-b-himachalene (Entry ￿, Piers, ￿￿￿￿),[￿￿￿]
phorbol related compounds (Entry ￿￿, Wender, ￿￿￿￿),[￿￿￿] (±)-tremulenolide A (Entry ￿￿, Davies,
￿￿￿￿),[￿￿￿] cyathin releated compound (Entry ￿￿, Takeda, ￿￿￿￿),[￿￿￿] (+)-frondosin B (Entry ￿￿,
Davies, ￿￿￿￿),[￿￿￿] cyathane related compound (Entry ￿￿, Sarpong, ￿￿￿￿),[￿￿￿] guianolide related
compound (Entry ￿￿, Donaldson, ￿￿￿￿),[￿￿￿] (±)-actinophyllic acid related compound (Entry ￿￿,
Wood, ￿￿￿￿),[￿￿￿] (–)-bakerol (Entry ￿￿, Sarpong, ￿￿￿￿),[￿￿￿] and (+)-schisanwilsonene A (En-
try ￿￿, Echavarren, ￿￿￿￿).[￿￿￿] There is only one example of the generation of a bisannulated
cycloheptane (Scheme ￿-￿￿d) which was accomplished by Wender in the synthesis of a tigliane
related compound (Entry ￿, ￿￿￿￿).[￿￿￿] The most advanced application of the divinylcyclopropane-
cycloheptadiene rearrangement is for the generation of bridged cycloheptanes (Scheme ￿-￿￿e).
The rearrangement provides a simple entry to more or less complex bridged structures and was
applied in the synthesis of (±)-quadrone (Entry ￿￿, Piers, ￿￿￿￿),[￿￿￿] (±)-prezizaene (Entry ￿￿, Piers,
￿￿￿￿),[￿￿￿] sinularene (Entry ￿￿, Piers, ￿￿￿￿),[￿￿￿] tropane related compound (Entry ￿￿, Davies,
￿￿￿￿),[￿￿￿] (±)-isostemofoline (Entry ￿￿, Kende, ￿￿￿￿),[￿￿￿] (+)-gelsemine (Entry ￿￿, Fukuyama,
￿￿￿￿, and Entry ￿￿, Danishefsky, ￿￿￿￿),[￿￿￿–￿￿￿] (±)-clavubicyclone (Entry ￿￿, Iguchi, ￿￿￿￿),[￿￿￿,￿￿￿]
gelsemoxonine (Entry ￿￿, Fukuyama, ￿￿￿￿),[￿￿￿] and gelsenicine (Entry ￿￿, Ferreira, ￿￿￿￿).[￿￿￿]
The [￿+￿] cycloaddition reaction of vinylcyclopropanes and alkynes, as well as the divinylcyclo-
propane-cycloheptadiene rearrangement, a￿ords ￿,￿-cycloheptadiene derivatives (Scheme ￿-￿￿c).
This strategy for the construction of seven-membered rings has also been applied e￿ciently in
the total synthesis of natural products. Pioneered by Wender, this reaction was also used and
extended by other groups (Entries ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, and ￿￿).
Other methodologies are the use of cyclopropyl activated precursors (Scheme ￿-￿￿d: Entries ￿,
￿￿, ￿￿, ￿￿, and ￿￿; Scheme ￿-￿￿f: Entries ￿￿ and ￿￿) and cyclopropylcarbinyl activated precursors
(Scheme ￿-￿￿e: Entries ￿, ￿￿, ￿￿, ￿￿, ￿￿, ￿￿, and ￿￿; Scheme ￿-￿￿g: Entries ￿￿, ￿￿, ￿￿, ￿￿, and
￿￿). In all four cases the formation of the seven-membered ring occurs via cyclohexane ring
expansion reactions and not via de novo ring formation reactions like in the divinylcyclopropane-
cycloheptadiene rearrangement or the [￿+￿] cycloaddition reaction.
Theses data indicates that cyclopropanes are widely used for the construction of seven-
membered rings. Among all presented methodologies, the construction is mostly e￿ected
by intramolecular cyclization reactions and [￿+￿] cycloaddition reactions. Disconnections of
carbon–carbon and carbon–heteroatom double bonds should be considered as strategic for
retrosynthetic analysis.
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￿￿
￿Ervatamia Alkaloids
￿.￿ General
A large group of alkaloids with a cyclohepta[b]indole skeleton are the ervitsine–ervatamine
alkaloids (Fig. ￿-￿). The following text about this alkaloids in this Section ￿.￿ is merely a recap,
for additional general information see Section ￿.￿.￿, for total syntheses of Ervatamia alkaloids
the author refers to Section ￿.￿.￿.
Ervatamine (￿￿) is the main alkaloid of the Ervatamia alkaloids which are corynanthean-
type ￿-acylindole alkaloids, but the side chain from the indole C-￿ positions contains three
linearly disposed carbon atoms and therefore lacks the characteristic tryptamine moiety.[￿￿]
Compound ￿￿ was isolated from Ervatamia orientalis and Ervatamia lifuana (Apocynaceae),[￿￿,￿￿]
and is a sodium channel blocker in nerve fibers and a local anesthetic blocker.[￿￿] From the same
sources ￿￿-epiervatamine (￿￿) and ￿￿,￿￿-didehydroervatamine (￿￿) have been isolated.[￿￿,￿￿]
￿￿,￿￿-didehydro-N￿-methoxyervatamine (￿￿) is an alkaloid from Ervatamia malaccensis (Apoc-
ynaceae),[￿￿] ￿￿,￿￿-didehydro-￿-oxoervatamine (￿￿) has been isolated from leaves of Tabernae-
montana corymbosa (Apocynaceae),[￿￿] ￿￿,￿￿ didehydro-￿a-hydroxyervatamine (￿￿) and dehydrox-
yervataminol (￿￿) are alkaloids from Ervatamia divaricate.[￿￿]
Decarboxylation of the ester at C-￿￿ leads to the series of the methuenine–silicine alkaloids.
Methuenine (￿￿) is an alkaloid from Ervatamia o￿cinalis,Hazunta spp., Pterotaberna inconspicua,
and can also be isolated from the leaves and stem bark of Ervatamia malaccensis. It is an
anticholinergic agent.[￿￿,￿￿–￿￿] Also known is its ￿￿-epimer (￿￿),[￿￿,￿￿,￿￿,￿￿] its N-oxide (￿￿),[￿￿] its
￿￿-epimer-N-oxide (￿￿),[￿￿] the ￿-oxo derivative (￿￿),[￿￿,￿￿,￿￿] and theN￿-methoxy derivative (￿￿).[￿￿]
Silicine (￿￿) possesses an ethyl group at C-￿￿ instead of an ethylidene function.[￿￿,￿￿–￿￿]
Furthermore, seven derivatives of silicine (￿￿) have been isolated: ￿￿-episilicine (￿￿),[￿￿] ￿￿-
episilicine (￿￿),[￿￿,￿￿] ￿￿,￿￿-episilicine (￿￿),[￿￿] ￿-oxosilicine (￿￿),[￿￿,￿￿,￿￿] ￿-oxo-￿￿-episilicine (￿￿),[￿￿]
￿-oxo-￿￿,￿￿-episilicine (￿￿),[￿￿] and ￿,￿￿-didehydro-￿￿-episilicine (￿￿).[￿￿]
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Figure ￿-￿. Ervitsine–ervatamine alkaloids.
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￿.￿ Monoterpene Indole Alkaloid Biosynthesis
Ervitsine (￿￿) is a minor alkaloid from the root bark of Pandaca boiteaui (Apocynaceae).[￿￿,￿￿]
It is the only member of this alkaloid family which has an additional link between C-￿ and
the C-￿ and is therefore the only bridged alkaloid. Total syntheses of several members of the
ervitsine–ervatamine alkaloids have been published (cf. Section ￿.￿.￿).[￿￿–￿￿]
￿.￿ Monoterpene Indole Alkaloid Biosynthesis
The indole alkaloids comprise a diverse class of naturally occurring organic compounds, pos-
sessing the indole or indoline nucleus. Currently, the large and complex group of indole terpene
alkaloids comprises over ￿￿￿￿members andmany of them possess biological activities.[￿￿￿] Some
of these alkaloids gained famousness even for average persons, e.g. strychnine, a convulsant
poison, or lysergic acid, the diethylamide derivative of which is the powerful psychedelic drug
LSD, known for its psychological e￿ects similar to schizophrenia.
The majority of all these alkaloids is formally derived from a Pictet–Spengler reaction with
an aliphatic aldehyde having nine or ten carbons (Scheme ￿-￿). In ￿￿￿￿, Perkin and Robinson
were the first who suggested that the aromatic moiety is derived from tryptophan which un-
derwent decarboxylation to tryptamine (￿￿￿).[￿￿￿] This was proven experimentally by Battersby
et al.[￿￿￿] The origin of the C￿￿-unit has been the subject of much speculation for many years.
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Scheme ￿-￿. The majority of the indole alkaloids is formally derived from a Pictet–Spengler reaction with an aliphatic aldehyde
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￿￿
￿ Ervatamia Alkaloids
N
H
N
MeO2C
O
H
H
H
H
H
OH
O
MeO O
O
Glc
CH2OH
N
CO2Me
N
H
N
Me
N
MeO OAc
CO2MeHO
H
N
H
HN
O
H
H
CO2Me
geraniol (￿￿￿) loganin (￿￿￿)
ajmalicine (￿￿￿)
vindoline (￿￿￿)
catharanthine (￿￿￿)
perivine (￿￿￿)
Labelling experiment by
Arigoni et al.
Labelling experiment by
Battersby et al.
Scheme ￿-￿. Labelling experiments by Arigoni et al. and Battersby et al.[￿￿￿–￿￿￿]
Based on similarities between several non-alkaloidal and non-nitrogenous glucosides such as
verbenalin (￿￿￿), genipin (￿￿￿), and asperuloside (￿￿￿) and the non-tryptophan moiety of some
alkaloids such as corynantheine (￿￿￿) and ajmalicine (￿￿￿), R. Thomas and E.Wenkert suggested
independently that they may have a common precursor (Fig. ￿-￿) and proposed that this precur-
sor was formed from two mevalonate units.[￿￿￿,￿￿￿] In the following years, numerous feeding
experiments followed to prove these statements including the incorporation of a mevalonate
unit, the incorporation of geraniol derivatives, and the incorporation of iridoids.[￿￿,￿￿￿] Finally,
after the elucidation of the structure of several iridoid terpenes, Arigori et al. and Battersby
etal. independently fed Vinca rosea plants with ￿￿C-labeled loganin (￿￿￿) and could observe the
incorporation of ring-labelled loganin into a variety of indole alkaloids (Scheme ￿-￿).[￿￿￿–￿￿￿]
Loganin (￿￿￿) was thus proved to be a precursor of representative examples from the three major
classes of indole alkaloids (Yohimbe, Aspidosperma, and Iboga).[￿￿￿]
Nowadays it is known, that all terpene indole alkaloids are derived from tryptamine (￿￿￿) and
the iridoid terpene secologanin (￿￿￿), forming the alkaloid strictosidine (￿￿￿) by the enzyme
Strictosidine synthase (STR, Scheme ￿-￿). Tryptamine itself arises from the decarboxylation of
the amino acid tryptophan, promoted by the Aromatic ￿-amino acid decarboxylase, a pyridoxal
phosphate dependent enzyme.[￿￿￿,￿￿￿] Thus, the suggestion of Perkin and Robinson from almost
a century ago has been proven true.
Secologanin is a secoiridoid monoterpene synthesized from geranyl pyrophosphate (￿￿￿)
which in turn is synthesized from isopentenyl pyrophosphate (￿￿￿) and dimethylallyl pyrophos-
phate (￿￿￿, Scheme ￿-￿). Isopentenyl pyrophosphate is produced by either themevalonate biosyn-
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Scheme ￿-￿. Biosynthesis of secologanin. IPP and DMAPP are synthesized by the non-mevalonate pathway from DXP.
thetic pathway or the triose phosphate/pyruvate pathway (“non-mevalonate pathway”).[￿￿￿,￿￿￿] In
the biosynthesis of secologanin, mevalonate was considered for a long time to be the exclusive
precursor of isopentenyl diphosphate, but feeding studies of Contin et al. showed, that the non-
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mevalonate pathway and not the mevalonate pathway was the major route for the biosynthesis
of secologanin.[￿￿￿] Therefore, isopentenyl pyrophosphate (￿￿￿) derives from ￿-deoxy-￿-xylulose
￿-phosphate (DXP, ￿￿￿). The enzyme Geraniol synthase (GES) transforms geranyl pyrophos-
phate (￿￿￿) into geraniol (￿￿￿)[￿￿￿] which in turn is transformed into ￿-hydroxygeraniol (￿￿￿)
by the enzyme Geraniol ￿-hydroxylase (G￿￿).[￿￿￿] ￿-Hydroxygeraniol (￿￿￿) is a substrate for
￿-Hydroxygeraniol dehydrogenase (￿-HGO) which synthesizes ￿-oxogeranial (￿￿￿). ￿￿￿ itself is
a substrate for the Iridoid synthase (IS) which synthesizes cis–trans-iridodial (￿￿￿) and cis–trans-
nepetalactol (￿￿￿). Iridodial (￿￿￿) is then transformed into ￿-deoxyloganetic acid (￿￿￿) by the
enzyme Iridoid oxidase (IO). ￿￿￿ is a substrate for ￿-deoxyloganetic acid glucosyltransferase
(￿-DLGT) which synthesizes ￿-deoxyloganic acid (￿￿￿). ￿￿￿ is then transformed into loganic acid
(￿￿￿) by the enzyme ￿-deoxyloganic acid hydroxylase (￿-DLH). Loganic acid (￿￿￿) is a substrate
for the enzyme loganic acid O-methyltransferase (LAMT) for the production of loganin (￿￿￿).
Finally, ￿￿￿ then becomes a substrate for the enzyme secologanin synthase (SLS) to form secolo-
ganin (￿￿￿) which is incorporated in the synthesis of strictosidine (￿￿￿), the key intermediate in
the biosynthesis of numerous terpene indole alkaloids.[￿￿￿]
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Figure ￿-￿. Peduncularine.
Plants of the genus Aristotelia produce about ￿￿ indole alkaloids,
the most important of which is peduncularine. It should be noted,
that this indole alkaloids are a rare example for indole alkaloids which
contain a monoterpenoid C￿￿ part originating not from secologanin.
The terpene moiety is divided by the N-atom into three (N-iPr) plus
seven carbon atoms.[￿￿￿,￿￿￿]
￿.￿.￿ Biogenetic Classification of Indole Alkaloids
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Scheme ￿-￿. Class I, II, and III alkaloid skeletons.
The terpene indole alkaloids class of natural prod-
ucts comprises over ￿￿￿￿members and includes a
large number of di￿erent highly complex structures.
The alkaloids can be divided in two units: the tryp-
tophan unit and the non-tryptophan unit. Focussing
on the non-tryptophan unit, the alkaloids can be read-
ily assigned to five broad classes.[￿￿,￿￿￿] Usually, the
terpenoid moiety contains ten carbons, but in some
alkaloids of these classes only a nine carbon unit is
found.
The first class includes alkaloids which contain
the skeletal system of secologanin (￿￿￿) in an unre-
arranged form (￿￿￿, Scheme ￿-￿). These a- or b-con-
densation products can be found in several common
types of indole alkaloids (Fig. ￿-￿), e.g. corynantheine
(￿￿￿, Corynanthe group), ajmalicine (￿￿￿, Ajmalicine
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Figure ￿-￿. Examples for indole class I, II, and III alkaloids.
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group), polyneuridine (￿￿￿, Sarpagine group), akuammiline (￿￿￿, Picraline group), ajmaline
(￿￿￿, Ajmaline group), and strychnine (￿￿, Strychnos group).￿
The second class of indole alkaloids does not contain the secologanin skeletal system in its
original form. The carbon–carbond bond between C-￿ and C-￿ has been cleaved; instead a
new bond between carbon C-{￿,￿} and carbon C-￿ has been formed (Scheme ￿-￿, ￿￿￿  ￿￿￿).
The rearrangement of the terpenoid moiety occurs after the condensation of tryptamine with
secologanin (￿￿￿). Examples for the second class of indole alkaloids (Fig. ￿-￿) are quebrachamine
(￿￿￿, Quebrachamine group), vincadi￿ormine (￿￿￿, Aspidospermine group), fendleridine (￿￿￿,
Aspidoalbidine group), kopsine (￿￿￿, Kopsine group), schizozygine (￿￿￿, Schizozygine group), and
vincamine (￿￿￿, Vincamine group).
The third class of indole alkaloids does not contain the secologanin skeletal system in its
original form as well and is divided into two sub-groups. Again, the carbon–carbond bond
between C-￿ and C-￿ has been cleaved, but in this case a new bond between carbon C-{￿,￿} and
carbon C-￿ has been formed (Scheme ￿-￿, ￿￿￿  ￿￿￿). The second sub-group contains terpene
indole alkaloids which possess a novel C￿￿ skeleton due to expansive rearrangement. Examples
for the third class of indole alkaloids (Fig. ￿-￿) are catharanthine (￿￿￿, Iboga group), pandoline
(￿￿￿, Pandoline group), iboxyphylline (￿￿￿, Ibophyllidine group), nitrarine (￿￿￿, Nitramidine
group), ervatamine (￿￿, Ervatamia group), and ervitsine (￿￿, Ervatamia group).
Due to their broad variety, the fourth and fifth classes are not going to be discussed in detail.
The fourth class contains non-tryptophan indole alkaloids (carbazoles, etc.), non-isoprenoid
tryptophan alkaloids, and indole alkaloids from fungi. The fifth class contains the bis-indole
alkaloids.[￿￿￿]
￿.￿.￿ Biosyntheis of Ervatamia Alkaloids
Ervatamia alkaloids contains an indole nucleus, but the “backbone” from the indole ￿-position
to the basic nitrogen Nb contains three carbon atoms and is thus the product of a fairly extensive
rearrangements. There are several hypothetical proposals from G.A. Cordell[￿￿] and A.-U. Rah-
man,[￿￿￿] but till this day no further studies for the elucidation of the biosynthesis have been
made. Therefore, there is no “right” and “wrong” proposal, but from the author’s point of view
some proposals make more sense than others.
There are some general remarks which are to be considered: (i) an examination of the carbon
skeleton of the non-tryptophan moiety of ervatamine (￿￿) shows that the C￿￿ skeleton is identical
with that in secologanin (￿￿￿), (ii) the indole ￿-position is connected to C-￿ of loganin (￿￿￿) and a
condensation reaction between an amine and the hemiacetal moiety of ￿￿￿may have taken place,
(iii) it should be taken note of the point that the ￿￿,￿￿-dehydro species of Ervatamia alkaloids
exists whereas the ￿￿,￿￿-dehydro species were not isolated. This may led to the assumption that
the Ervatamia alkaloids may derived by reaction of tryptamine (￿￿￿) and loganin ￿￿￿.
￿ The broad range of terpene indole alkaloids cannot be discussed within the scope of this section, only some impor-
tant examples for each class are shown. For detailed information the author refers to specialized literature.[￿￿,￿￿￿,￿￿￿]
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Scheme ￿-￿. Biosynthesis of ervatamine (￿￿) from tryptamine (￿￿￿) and loganin (￿￿￿).[￿￿]
￿.￿.￿.￿ Ervatamia Alkaloids from Tryptamine
A potential biosynthesis starts from tryptamine (￿￿￿) which undergoes a condensation reaction
with the hemiacetal moiety of loganin (￿￿￿) yielding indole terpenoide ￿￿￿. Attachment of
C-￿ of ￿￿￿ to the indole ￿-position is followed by a C-￿ hydroxylation furnishing alkaloid ￿￿￿,
which undergoes ring cleavage to a￿ord the ethylidene group directly and install the indole
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Scheme ￿-￿. Biosynthesis of ervatamine (￿￿) from ￿-carboxygeissoschizine (￿￿￿).[￿￿]
￿-acyl moiety simultaneously. Compound ￿￿￿ is possibly a key intermediate in this biogenetic
proposal. It can turn into ervatamine (￿￿) by fragmentation of the tryptamine bridge either via
intermediate ￿￿￿ or via intermediate ￿￿￿ followed by cyclization to a￿ord ￿￿ as indicated in
Scheme ￿-￿.
An alternative biogenetic proposal describes the biosynthesis of ervatamine (￿￿) from ￿-car-
boxygeissoschizine (￿￿￿, Scheme ￿-￿).[￿￿] Oxidative decarboxylation and loss of carbon C-￿￿
followed by attachment of C-￿￿ to C-￿ leads to Sarpagine group like intermediate ￿￿￿. Oxidation
at carbon C-￿ followed by cyclopropane formation and cleavage as indicated a￿ords ￿￿￿ which
is subsequently methylated. The primary product is ￿￿,￿￿-didehydroervatamine (￿￿) which is
converted into ervatamine (￿￿).
Feeding ￿￿C-tryptophan and observing the remaining ￿￿C could lead to an evidence for the
correctness of one of these proposals.
￿.￿.￿.￿ Ervatamia Alkaloids from Gramine Derivatives
As mentioned before the C￿￿ skeleton of ervatamine (￿￿) is identical with that in secologanin
(￿￿￿) and contains an extra carbon atom which is attached to the indole ￿-position. It could
therefore arise from the reaction of gramine derivatives (￿￿￿) with ￿￿￿ (Scheme ￿-￿).[￿￿￿] This
would lead to intermediate ￿￿￿. Formal condensation with methylamine and oxidation leads to
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Scheme ￿-￿. Ervatamia alkaloids from gramine derivatives and secologanin.[￿￿￿]
intermediate ￿￿￿. The ester moiety is attacked by the indole to form the indole ￿-acyl moiety.
This sequence would lead to ￿￿-epiervatamine (￿￿). Nevertheless, a drawback of this proposal is
that the ￿￿,￿￿-dehydro species of Ervatamia alkaloids exists whereas the ￿￿,￿￿-dehydro species
were never isolated.
￿.￿.￿.￿ Ervatamia Alkaloids from Vobasine Derivatives
Another plausible proposal is that Ervatamia alkaloids can derive from vobasine derivatives as
shown in Scheme ￿-￿. A fragmentation and reprotonation sequence leads to intermediate ￿￿￿.
The iminium ion is then attacked intramolecularly by the enamine to a￿ord ￿￿,￿￿-dehydro
derivative ￿￿￿ which is then transformed into ervatamine (￿￿).
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Scheme ￿-￿￿. Conversion of diverse vobasine derivatives into Ervatamia alkaloids using a Polonovski-type sequence.[￿￿￿]
The author himself proposes a di￿erent biogenetic proposal for the synthesis of Ervatamia al-
kaloids from vobasine derivatives (Scheme ￿-￿￿). An oxidative process transforms vobasine (￿￿￿)
into vobasine derivative ￿￿￿ which undergoes indicated fragmentation to a￿ord compound ￿￿￿.
The iminium ion is then attacked intramolecularly by the enamine to a￿ord the ￿￿,￿￿-dehydro
derivative which is then transformed into ervatamine (￿￿).
Potier et al. have demonstrated the conversion of diverse vobasine derivatives into Ervatamia
alkaloids using a Polonovski-type sequence (Scheme ￿-￿￿).[￿￿￿] Vobasine (￿￿￿) and the vobasine
derivatives dregamine (￿￿￿) and tabernaemontanine (￿￿￿) were transformed into the correspond-
ing N-oxide using hydrogen peroxide. These compounds were described as unstable and there-
fore directly treated with trifluoroacetic anhydride to induce the Polonvski-type rearrangement.
This a￿ords an analogous intermediate (￿￿￿) to that whichwas proposed in some aforementioned
biosynthetic proposals (Schemes ￿-￿ and ￿-￿￿). The iminium ion is then attacked intramolecu-
larly by the enamine to a￿ord Ervatamia alkaloids: (i) tabernaemontanine (￿￿￿) was converted
into ervatamine (￿￿) in ￿￿% yield, (ii) dregamine (￿￿￿) was converted into ￿￿-epiervatamine
(￿￿) in ￿￿% yield, (iii) vobasine (￿￿￿) was converted into ￿￿,￿￿-didehydroervatamine (￿￿) in
￿% yield. Some years later Potier et al. could demonstrate the successful rearrangement of
￿￿
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dregamine (￿￿￿) into ￿￿-epiervatamine (￿￿) catalyzed by liver microsomes. This result may
provide strong support for such a pathway and biogenetic filiation between alkaloids of the
vobasine and ervatamine types. This may also led to the hypothesis of the modified Polonovski
reaction being “biomimetic”.[￿￿￿]
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Scheme ￿-￿. General idea: indoline ￿￿￿ un-
dergoes a divinylcyclopropane-cycloheptadiene
rearrangement to form cyclohepta[b]indole ￿￿￿.
This chapter describes the development of a method-
ology for the synthesis of cyclohepta[b]indoles via sig-
matropic rearrangement, that is a divinylcyclopropane-
cycloheptadiene rearrangement. The central idea of
this methodology is shown in Scheme ￿-￿: Fischer’s
base derivative ￿￿￿ undergoes a divinylcyclopropane-
cycloheptadiene rearrangement to a￿ord cyclohepta[b]-
indole ￿￿￿. Having the methodology in hands it should
be applied to the total synthesis of diverse indole alkaloids from the ervatamine–ervitsine group.
A small part of the development overlaps with the work which has been done in the course of the
Master’s thesis, therefore a small introduction at the beginning covers the work hitherto done
and shows the most important transformations and intermediates to get a full understanding
for the choice of the final strategy and the results.
￿.￿ Failed Strategies
At the outset the feasibility of the proposed key step could be demonstrated. Model compound
￿￿￿ was synthesized via rhodium catalyzed cyclopropanation reaction of isoprene and benzyl
protected diazo isatine. The oxindole ￿￿￿ could then be transformed into Fischer’s base derivative
￿￿￿ by addition of methyl lithium followed by dehydration. This a￿ords the divinylcyclopropane
system ￿￿￿ (Scheme ￿-￿). Although the yields were exceedingly low for this transformation,
upon heating ￿￿￿ underwent smoothly a divinylcyclopropane rearrangement to yield cyclo-
hepta[b]indole ￿￿￿. By reason of very low yields the work towards the cyclohepta[b]indoles via
Fischer’s base derivatives from oxindoles was discontinued. Additional work towards the opti-
mization of this conversion were also not successful. However, when oxindole ￿￿￿ was refluxed
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Scheme ￿-￿. Obtaining two di￿erent products from racemic cyclopropane ￿￿￿.
in high-boiling-point solvents, stereochemical scrambling at the cyclopropane moiety occurred
(equilibrium between ￿￿￿ and ￿￿￿). As a result the vinyl moiety has the correct geometry for a
potential Cope rearrangement with the aromatic indole core. Indeed, the divinylcyclopropane
rearrangement took place yielding cyclohepta[cd]indolone ￿￿￿. This transformation provided
both the first experimental evidence for a possible enzyme-catalyzed sigmatropic process in
the C-￿ prenylation of indole alkaloids and the first direct C-C-bond forming cyclization which
functionalizes the very unreactive C-￿ indole position.[￿￿￿] However, the formation of cyclo-
hepta[b]indoles via divinylcyclopropane-cycloheptadiene rearrangement from Fischer’s base
derivatives required optimization work and a new strategy which does not rely on the trans-
formation of oxindoles because various attempts for the transformation of ￿,￿-disubstituted
oxindoles failed or proceeded with exceedingly low yield (Scheme ￿-￿).
Another strategy should a￿ord cyclohepta[b]indole precursor ￿￿￿ viametal-catalyzed ￿-exo-dig
ring closure reaction (Scheme ￿-￿). In a first step, trisubstituted cyclopropane ￿￿￿ was simplified
to disubstituted cyclopropane ￿￿￿ which was synthesized from ￿-nitrophenylacetic acid. It
N
R
O
N
R
CH2
￿￿￿ ￿￿￿
Scheme ￿-￿. Various attempts for the transformation of ￿,￿-disubstituted oxindoles failed or proceeded with exceedingly low yield.
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Scheme ￿-￿. Strategy: Fischer’s base derivatives viametal-catalyzed ring closure.
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Scheme ￿-￿. Synthesis of Fischer’s base derivatives.
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Scheme ￿-￿. a) Transformation of lactone ￿￿￿ into Fischer’s base derivative ￿￿￿ was not successful. b) o-Iodonitrobenzene was
converted into trisubstituted vinylcyclopropane ￿￿￿.
was elaborated that the desired ￿-exo-dig cyclization could be accomplished either by metal
catalysis using Pd￿(dba)￿ or by base-induced ring closure (Scheme ￿-￿). This methodology was
applicable to both terminal alkynes and internal alkynes and produced the particular Fischer’s
base derivative in very good yield.
Although the synthesis of the discussed test system was just to demonstrate the ring closure
and the formation of Fischer’s base derivatives it was conceivable to use this compounds for the
synthesis of cyclohepta[b]indoles anyway using the [￿+￿] cycloaddition of vinylcyclopropanes
with alkynes. However, any attempt for a [￿+￿] cycloaddition reaction was not successful.
Albeit the synthesis of disubstituted cyclopropanes ￿￿￿was quite straightforward, the synthesis
of trisubstituted vinylcyclopropane ￿￿￿ was somewhat troublesome. On the one hand the
conversion of bicyclo g-lactone ￿￿￿ into Fischer’s base derivative ￿￿￿ could not be managed
(Scheme ￿-￿a). On the other hand o-iodonitrobenzene (￿￿￿) was indeed successfully converted
into trisubstituted vinylcyclopropane ￿￿￿, but this route turned out to be somewhat cumbersome
(Scheme ￿-￿b). On account of this result, this route was not acceptable; although this route was
potentially able to a￿ord Fischer’s base derivatives, it had no benefit over the finally established
route for the synthesis of cyclohepta[b]indoles which is going to be discussed in the following
sections.
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￿.￿ Methodology: Cyclohepta[b]indoles from Indolylvinylcyclopropanes￿
Many methodologies for the construction of cyclohepta[b]indoles have been described in Sec-
tion ￿.￿ (p. ￿￿). By far the biggest progress in methodology development has been made within
the last decade. This coincides with the enhanced attention of pharmaceutical industry towards
compounds exhibiting the cyclohepta[b]indole motif. Analysis especially of the most recent total
syntheses of natural products which contains this structure motif reveals that the methodology
development of the last decade has so far not found its way into application in complex molecule
synthesis. This shows the urgent demand for the development of synthetic methodologies
involving the construction of cyclohepta[b]indoles, explicitly when it comes to the development
of methods for enantioselective construction of this privileged structure motif.
As already described at the beginning of this chapter (cf. p. ￿￿￿) the central idea is the creation
of cyclohepta[b]indoles via a sigmatropic rearrangement, that is a divinylcyclopropane-cyclo-
heptadiene rearrangement (Scheme ￿-￿, p. ￿￿￿). The first approach and its results were briefly
discussed in Section ￿.￿, the focus now rests on the second approach (Scheme ￿-￿a). Since the
synthesis of Fischer’s base derivative ￿￿￿ turned out to be somewhat troublesome, the idea was
now to “move” the p-system: the indole C-￿ position is not anymore part of the vinylcyclopropane
moiety, but instead the whole vinylcyclopropane moiety is attached to the indole C-￿ carbon
(￿￿￿, Scheme ￿-￿a, ￿nd approach). This movement can lead to a contingent drawback: whereas
the divinylcyclopropane-cycloheptadiene rearrangement of Fischer’s base derivative ￿￿￿ a￿ords
an aromatic system, the rearrangement of ￿￿￿ requires the loss of the aromaticity. At this point
it was only possible to speculate about the successful outcome of this rearrangement since one
p-system of the divinylcyclopropane belongs to an aromatic system. Literature examples for
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Scheme ￿-￿. a) Comparison: ￿st approach vs. ￿nd approach. b) Retrosynthetic analysis of indolylvinylcyclopropane ￿￿￿, the precursor
of cyclohepta[b]indole ￿￿￿.
￿ Parts of this section have already been published in a peer-reviewed journal: Enantioselective Synthesis of Cyclo-
hepta[b]indoles: Gram-Scale Synthesis of (S)-SIRT￿-Inhibitor IV. Org. Lett. ￿￿￿￿, ￿￿, ￿￿￿￿–￿￿￿￿.[￿￿,￿￿￿] The content
of the published article is not as thoroughly as this section and some passages have been shortened.
￿￿￿
￿.￿ Cyclohepta[b]indoles from Indolylvinylcyclopropanes
similar transformations are scarce; examples for the use of the C￿–C￿ indole bond as ￿p unit in
a sigmatropic rearrangement remains a terra incognita.
The retrosynthetic analysis for indolylvinylcyclopropane ￿￿￿ is outlined in Scheme ￿-￿b. ￿￿￿
derives from (Z)-allylic alcohol ￿￿￿, the disubstituted cyclopropane is planned to be installed
via Simmons–Smith cyclopropanation reaction. (Z)-Allylic alcohol ￿￿￿ in turn is accessible
from indole-￿-carbaldehyde (￿￿￿), a compound which is inexpensive enough (￿￿￿ ￿/￿￿￿ g =ˆ
￿￿￿ ￿/mol)￿ to serve as starting compound for a synthetic route.
The choice of the indole protecting group is not trivial and the correct choice can be a key
to a successful synthetic route. The protecting group should reduce the electron density in the
heterocycle but also make it more stable towards oxidation. The decision was in favor of the
toluenesulfonyl group. Arylsulfonyl groups are known to be highly e￿ective protecting groups
for a wide range of amine derivatives, indoles in particular, and are stable to most reaction
conditions. Due to the robustness the removal can sometimes be troublesome, but a large
amount of procedures—especially for the reductive removal—are described in literature.[￿￿￿]
Starting from indole-￿-carbaldehyde (￿￿￿), the free nitrogen was tosyl protected (Scheme ￿-￿).
Usual conditions (TsCl, Et￿N, CH￿Cl￿) provided aldehyde ￿￿￿ already in good yield (￿￿%). How-
ever, the yield could be optimized by using an aqueous biphasic system (￿￿% aq. NaOH–Et￿O,
￿:￿) to a￿ord aldehyde ￿￿￿ in almost quantitative yield, even at ￿.￿ mol scale. Whereas the
starting material ￿￿￿ is air sensitive, aldehyde ￿￿￿ is indefinitely bench-stable.
Modified Horner–Wadsworth–Emmons olefination reaction with phosphonate ￿￿￿ (Ando
phosphonate) a￿orded ester ￿￿￿ with a Z:E-ratio >￿￿:￿ in almost quantitative yield, but the
material was usually used crude for the next reactions. Crucial points were strongly dissociating
conditions, that are the use of a potassium base (KHMDS) and the addition of ￿￿-crown-￿.
Although usual literature procedures use ￿.￿ equivalents of the crown ether, it was worked
out that ￿.￿ equivalents were su￿cient and the addition of more equivalents of ￿￿-crown-￿
did not a￿ect the very good (Z)-selectivity. The absence of a crown ether however drastically
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Scheme ￿-￿. Synthesis of Simmons-Smith precursor ￿￿￿.
￿ http://www.abcr.de/shop/de/Indole-3-carboxaldehyde-98-26658.html (￿￿/￿￿￿￿)
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reduced the good (Z)-selectivity (only ￿:￿). There is no satisfying explanation for the (Z)-
selectivity. Ando himself proposed that the use of electron-deficient phosphonates accelerates
the elimination of the oxaphosphetane intermediates.[￿￿￿] In addition, themethyl ester equivalent
of a,b-unsaturated ester ￿￿￿ was a￿orded via Still-Gennari olefination reaction using methyl ￿-
(bis(￿,￿,￿-trifluoroethoxy)phosphoryl)acetate.[￿￿￿] The olefination product was obtained in similar
Z:E-selectivity (approx. ￿￿:￿), but the yield was only ￿￿%; still a good yield for this transformation
but not competitive to the quantitative yield of the Ando olefination.
DiBAL reduction of a,b-unsaturated ester ￿￿￿ a￿orded Simmons-Smith precursor ￿￿￿ in
quantitative yield. Allylic alcohol ￿￿￿ was usually directly transformed into the corresponding
TBS silyl ether ￿￿￿ using usual protection conditions (TBSCl, imid., DMF). The ￿-step sequence
starting from aldehyde ￿￿￿ usually a￿orded pure silyl ether ￿￿￿ in ￿￿% yield (￿ to ￿￿mmol scale).
Allylic alcohol ￿￿￿, required for the Simmons-Smith cyclopropanation, was usually obtained in
￿￿% yield in a ￿-step sequence.
Since the first approach (Scheme ￿-￿a) towards the synthesis of cyclohepta[b]indoles already
included numerous cyclopropanations via Simmons–Smith reaction, the conditions for the
transformation of allylic alcohol ￿￿￿ into its cyclopropane derivative ￿￿￿ (Scheme ￿-￿￿) were es-
tablished quickly (￿.￿ eq. Et￿Zn, ￿.￿ eq. CH￿I￿, CH￿Cl￿, –￿￿ °C, ￿.￿ h). Oxidation of the primary
alcohol ￿￿￿ with IBX a￿orded the corresponding aldehyde ￿￿￿. The key step in the synthesis of
cyclohepta[b]indoles is a Wittig reaction/divinylcyclopropane-cycloheptadiene rearrangement
cascade. Aldehyde ￿￿￿ underwent olefination reaction to a￿ord divinylcyclopropane ￿￿￿‡. Partial
rearrangement already begun during the work-up and full rearrangement occurred after addi-
tional ￿ h at ambient temperature yielding cyclohepta[b]indoline ￿￿￿. As it turned out, involving
the indole moiety as a ￿p-unit did not a￿ect the successful outcome of this rearrangement.
A marginal drawback was that tautomerization to the indole did not occur spontaneously, even
not during chromatography; the rearrangement product happened to be an indoline. Nonethe-
less, it could be shown that this product could be easily converted into the corresponding
indole (Scheme ￿-￿￿). According to Spicer et al.,[￿￿￿] treatment of indoline ￿￿￿ with a catalytic
N
Ts
OH
Et2Zn, CH2I2,
CH2Cl2, –10 °C, 90 min
N
Ts
OH
89%
IBX, DMSO,
rt., 180 min
N
Ts
O
91%
MePPh3Br, NaHMDS, THF,
 –78 ° C → 0 °C, 60 min,
then ald, THF, –78 °C, 30 min
N
Ts
rt.
54%N
Ts
￿￿￿ ￿￿￿
￿￿￿￿￿￿‡￿￿￿
￿￿￿, , –￿￿ °C, ￿￿min
Scheme ￿-￿￿. Conversion of allylic alcohol ￿￿￿ into cyclohepta[b]indoline ￿￿￿.
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Scheme ￿-￿￿. Transformation of cyclohepta[b]indoline ￿￿￿ into cyclohepta[b]indoles ￿￿￿ and ￿￿￿.
amount of para-toluenesulfonic acid in CH￿Cl￿ at ambient temperature smoothly furnished cy-
clohepta[b]indole ￿￿￿. However, this conditions were optimized by increasing the equivalents of
para-toluenesulfonic acid (￿.￿ eq.), changing the solvent system (CH￿Cl￿ –acetone, ￿:￿) and tem-
perature (T = ￿￿ °C). These optimized conditions smoothly furnished cyclohepta[b]indole ￿￿￿
in ten minutes in very good yield (￿￿%). In addition, it could be shown, that treatment of
indoline ￿￿￿ with an equimolar amount of Wilkinson’s catalyst {RhCl(PPh￿)￿} in benzene at
￿￿ °C a￿orded a rearomatized product, too, but both double bonds were shifted in conjugation
(￿￿￿). Therefore, the marginal drawback was turned into an advantage, since indoline ￿￿￿ can
be transformed into two di￿erent cyclohepta[b]indoles.
￿.￿.￿ Cyclohepta[b]indoles from ￿-vinylcyclopropylindoles
After the methodology has been established, the idea was to repeat the route, but start with
indole-￿-carbaldehyde instead of indole-￿-carbaldehyde. This work was then accomplished by my
colleague Philipp J. Gritsch, but is mentioned here for the sake of completeness. The chemistry is
pretty much the same as already shown for the synthesis of cyclohepta[b]indole ￿￿￿ (Schemes ￿-￿
and ￿-￿￿) and requires no detailed explanation. Indole-￿-carbaldehyde (￿￿￿) is a commercially
available compound. In contrast, indole-￿-carbaldehyde (￿￿￿) is not commercially available
and had to be synthesized in a short sequence starting from ethyl indole-￿-carboxylate.[￿￿￿]
Tosyl protected indole-￿-carbaldehyde (￿￿￿) was then transformed into (Z)-a,b-unsaturated
ester ￿￿￿ which in turn was reduced to the corresponding alcohol ￿￿￿. Simmons–Smith cy-
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Scheme ￿-￿￿. Comparison of the di￿erent cyclohepta[b]indoles.
clopropanation followed by Parikh–Doering oxidation[￿￿￿] furnished aldehyde ￿￿￿. The Wittig
reaction/divinylcyclopropane-cycloheptadiene rearrangement cascade proceeded smoothly to
yield directly cyclohepta[b]indole ￿￿￿, the tautomer ￿￿￿b‡has never been observed.
Comparing both synthetic routes leads to an interesting conclusion (Scheme ￿-￿￿): depending
on either starting from indole-￿-carbaldehyde (￿￿￿) or indole-￿-carbaldehyde (￿￿￿) three di￿erent
cyclohepta[b]indoles can be generated: ￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indole (￿￿￿), ￿,￿,￿,￿￿-tetra-
hydrocyclohepta[b]indole (￿￿￿), and ￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indole (￿￿￿). The position
of the olefinic moiety can be controlled specifically and therefore can be of use for successful
synthetic planning.
￿.￿.￿ Asymmetric Synthesis of Cyclohepta[b]indoles
The described synthetic route for the synthesis of cyclohepta[b]indoles is ideally suited to be
carried out in an asymmetric fashion. The Simmons–Smith cyclopropanation reaction can
be rendered asymmetric by using a chiral boronic acid ester as a reagent, for this an allylic
hydroxyl group is needed as a directing group.[￿￿￿–￿￿￿] (Z)-Indolyl allylic alcohol ￿￿￿ fulfills this
requirement.
The asymmetric Charette–Juteau cyclopropanation reaction is shown in detail in Scheme ￿-￿￿.
The chirality derives from dioxaborolane ￿￿￿, a simple amphoteric bifunctional ligand de-
rived from (R,R)-(+)-N,N,N’,N’-tetramethyltartaric acid diamide. This ligand usually allows
e￿cient chirality control for the Simmons–Smith cyclopropanation, furnishing cyclopropanes
with an enantiomeric excess over ￿￿% both for trans-substituted, cis-substituted, and trisubsti-
tuted olefins. It allows both the simultaneous chelation of the acidic Simmons–Smith reagent
{Zn(CH￿I)￿} and the basic allylic alcohol or its corresponding metal alkoxide (￿￿￿
‡). In addition,
the chiral ligand can be easily removed and recovered from the organic reaction mixture.[￿￿￿]
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The developed methodology for the asymmetric cyclopropanation was first applied to allylic
alcohol ￿￿￿ (Scheme ￿-￿￿a). Reaction of ￿￿￿ with Et￿Zn, CH￿I￿, and (R,R)-dioxaborolane ￿￿￿
furnished cyclopropyl alcohol (R,S)-￿￿￿ in ￿￿% yield. The enantiomeric excess was determined
to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿, ￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm).
IBX oxidation a￿orded aldehyde (R,S)-￿￿￿ which then can be transformed into di￿erent enan-
tioenriched cyclohepta[b]indole precursors via olefination reactions. Same is true for the indole-
￿-carbaldehyde series. Asymmetric Charette–Juteau cyclopropanation reaction furnished cyclo-
propyl alcohol (R,R)-￿￿￿ (￿￿% ee, determined via chiral HPLC analysis: AD-H, ￿.￿ mlmin–￿,
￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm). Oxidation to the corresponding aldehyde (R,S)-￿￿￿ leads to
the the starting compound for further di￿erent enantioenriched cyclohepta[b]indole precursors
(￿￿￿, Scheme ￿-￿￿b).
This divinylcyclopropane-cycloheptadiene rearrangement not only assembles the seven-mem-
bered ring, but due to orbital symmetry considerations,[￿￿￿] chirality is transferred stereospecifi-
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cally from the cyclopropane ring to the benzylic positions, which are very labile and therefore
di￿cult to access in a stereoselective way by other methods. The transfer of chirality for both
￿- and ￿-indole vinylcyclopropanes ￿￿￿ and ￿￿￿ is depicted in Scheme ￿-￿￿. In the case of
￿-indole vinylcyclopropanes ￿￿￿, it can be clearly seen that R￿ and the indole C￿-proton will
adopt the cis-stereorelationship on the seven-membered ring. The relative configuration is
therefore governed by the geometry of the double bond; hence, a (Z)-double bond will give the
cis-compound, whereas the (E)-double bond will give the trans-compound. The same holds true
for ￿-indole vinylcyclopropanes ￿￿￿, but due to spontaneous aromatization in the course of the
reaction, only one stereocenter is retained in the final product ￿￿￿ (indicated with dashed line).
The absolute stereochemistry in products ￿￿￿ and ￿￿￿ is governed by the stereocenters of the
cyclopropane ring.
￿.￿.￿ Extension of the Scope
To validate the concept and to explore the scope of the described domino sequence, a variety of
olefins of type ￿￿￿ (indole-￿-cabraldehyde series) and ￿￿￿ (indole-￿-carbaldehyde series) were
tested (Tables ￿-￿ and ￿-￿). These olefins derived from enantioenriched aldehydes ￿￿￿ or ￿￿￿,
respectively (Scheme ￿-￿￿), and aldehyde ￿￿￿ (Scheme ￿-￿￿). The reaction turned out to be very
robust, and tolerated a broad range of substituents (electron-rich and -deficient), which could
be introduced at any position on the seven-membered ring. Even the formation of quaternary
stereocenters was possible (Table ￿-￿, Entry ￿, and Table ￿-￿, Entries ￿ and ￿). All Wittig adducts
cyclized in situ to deliver cyclohepta[b]indoles in good to excellent yields. In all cases, the indoline
product of the indole-￿-carbaldehyde series was never observed, only the rearomatized product.
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￿.￿ Synthesis of (S)-SIRT￿-inhibitor IV (￿￿)
It could be observed, that more substituted alkenes required a higher temperature and/or a
prolonged reaction time. This becomes particularly apparent when comparing Tab. ￿-￿, Entries ￿,
￿, and ￿. Whereas the rearrangement for the unsubstituted cyclohepta[b]indole ￿￿￿ (derived
from terminal alkene, ￿￿￿: R￿ = R￿ = H) took place at ambient temperature in ￿.￿ h, the
rearrangement for monosubstituted cyclohepta[b]indole ￿￿￿ (derived from disubstituted alkene,
￿￿￿: R￿ = H, R￿ = Me) required ￿.￿ h at ￿￿ °C, and the rearrangement for gem-disubstituted
cyclohepta[b]indole ￿￿￿ (derived from trisubstituted alkene, ￿￿￿: R￿ = R￿ = Me) required an
even higher temperature and prolonged reaction time (￿.￿ h, ￿￿￿ °C). Notwithstanding this, all
cyclohepta[b]indoles could be obtained in good to excellent yields.
￿.￿ Synthesis of (S)-SIRT￿-inhibitor IV (￿￿)
N
H NH2
O
Cl
￿￿
Figure ￿-￿. SIRT￿-inhibitor IV.
The cyclohepta[b]indole core, which occurs in a variety of indole
alkaloids, is associated with a broad spectrum of biological profiles
ranging from anti-inflammation and anti-aging to anti-tuberculosis
activities (cf. Section ￿.￿.￿ and Fig. ￿-￿, p. ￿￿). Among the pharma-
ceutically active compounds based on this structure motif, around
two dozen patents have been issued within the past decade.[￿￿￿] The
SIRT￿-inhibitor IV (￿￿) shows outstanding biological activity and
is therefore being heavily investigated. It belongs to a new class of
histone deacetylase (HDAC) inhibitors and is involved in gene silencing via a new mode of
action. Data shows that inhibition of SIRT￿ enhances acetylation of p￿￿.[￿￿,￿￿￿] Compound ￿￿ is
one of the most potent compounds described, with IC￿￿ values of ￿￿–￿￿￿ n￿ representing a
￿￿￿-fold improvement over previously reported inhibitors.[￿￿]
This compound contains a single stereocenter and so far has only been synthesized as a
racemate, which is separated by chiral HPLC. The two enantiomers di￿er drastically in their
biological potency, with (S)-￿￿ (IC￿￿ = ￿￿ n￿) being ￿￿￿-fold more potent than (R)-￿￿ (IC￿￿ =
￿￿ ￿￿), rendering an enantioselective access especially to the more potent (S)-￿￿ enantiomer
utmost important.[￿￿]
The synthesis of SIRT￿-inhibitor IV (￿￿) has been carried out in the style of the developed
methodology and required only slightly modifications (Scheme ￿-￿￿). Starting from ￿-chloro-
indole-￿-carbaldehyde (￿￿￿, commercially available, ￿ g/￿￿￿ ￿￿) the free nitrogen was tosyl
protected under usual conditions (Et￿N, TsCl) to furnish aldehyde ￿￿￿. Ando olefination with
phosphonate ￿￿￿ and subsequent DiBAL reduction of the formed ester a￿orded (Z)-allylic
alcohol ￿￿￿ in ￿￿% combined yield. Asymmetric Simmons–Smith cyclopropanation with dioxa-
borolane (S,S)-￿￿￿ gave cyclopropane ￿￿￿ in good yield (￿￿%). The enantiomeric excess was
determined to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿ mlmin–￿, ￿￿:￿￿ iPrOH/hexanes,
l = ￿￿￿ nm). IBX oxidation furnished aldehyde ￿￿￿ and the enantiomeric excess was rechecked
￿ http://www.sigmaaldrich.com/catalog/product/aldrich/533076, (￿￿/￿￿￿￿)
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Scheme ￿-￿￿. Synthesis of (S)-SIRT￿-inhibitor IV (￿￿).
via chiral HPLC. In addition, NMR analysis showed only one single product which exluded
potential racemization of the a-stereogenic center, which might occur during the oxidation
process.
Next in line was the olefination/rearrangement tandem reaction sequence to a￿ord cyclo-
hepta[b]indoline ￿￿￿, which required some tuning. For this purpose, olefination of the ￿-dechloro
analogon ￿￿￿ with phosphonate ￿￿￿ were investigated. Finally, deprotonation of ￿￿￿ with potas-
sium tert-butoxide at ￿ °C in THF for ￿￿ min followed by the addition of aldehyde ￿￿￿ and
subsequent stirring in absolute refluxing benzene for ￿￿ min a￿orded ￿-dechloro analogon
of cyclohepta[b]indoline ￿￿￿. Fortunately, these conditions could also be applied to ￿-chloro
aldehyde ￿￿￿ and cyclohepta[b]indoline ￿￿￿ was formed in ￿￿% combined yield (from ￿￿￿).
The removal of the superfluous double bond was achieved with usual hydrogenation condi-
tions (palladium on charcoal, ethanol, ￿ bar H￿, ￿￿min) which were in turn first investigated
on the ￿-dechloro analogon ￿￿￿. Fortunately, it turned out that these conditions not only accom-
plished the reduction of the superfluous double bond but also caused the rearomatization of the
second double bond. This was found out when the reaction mixture was stopped after ￿￿% of
the mentioned reaction time and both the indoline product ￿￿￿ and the rearomatized indole
product ￿￿￿ could be observed on TLC and identified after separation and ￿H NMR analysis.
Once again these conditions could be applied unmodified to the ￿-chloro compound ￿￿￿ to
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Figure ￿-￿. Chiral HPLC analysis of ￿￿ (AD-H, ￿.￿mlmin–￿, ￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm), ee = ￿￿￿￿￿￿ ￿￿￿￿￿￿￿￿￿￿￿+￿￿￿￿￿ = ￿￿.￿%.
furnish cyclohepta[b]indole ￿￿￿ in ￿￿% yield which usually was not purified but used crude for
the final detosylation step. A potential dechlorination was not observed under these conditions.
The final step requires the removal of the protecting group. Several procedures for the detosy-
lation of arenesulfonamides are described in literature.[￿￿￿–￿￿￿] Best results were obtained using
a procedure of Hilmersson et al. who described an instantaneous deprotection of tosylamides
with samarium diiodide.[￿￿￿] This reaction requires a minimum amount of time and is usually
directly quenched with an amine (pyrrolidine) and water. These conditions furnished (S)-SIRT￿-
inhibitor IV (￿￿) with ￿￿% ee and an overall yield of ￿￿% (starting from commercially available
aldehyde ￿￿￿) with complete retention of the labile stereocenter. It is important to note that even
the exposure of ￿￿￿ to magnesium and methanol did not result in racemization, as opposed to
the treatment of the corresponding ester. For practical purposes it is important to note that the
synthetic sequence requires only three purification steps and can be performed on a gram scale.
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￿.￿ General Strategy
Nature’s way of synthesizing natural products is via privileged intermediates which in turn are
generated from simple and basic building blocks (Fig. ￿-￿). The privileged intermediates are
converted into di￿erent natural products with di￿erent bioindications. These conversions can
include complex transformations, sometimes it is even not obvious that two di￿erent natural
products have the same precursor. In some cases, a natural product itself can be a privileged
intermediate. An example for a privileged intermediate is strictosidine (￿￿￿, Section ￿.￿, p. ￿￿)
which derives from basic building block ￿-deoxy-￿-xylulose ￿-phosphate (DXP, ￿￿￿).
Basic
Building Blocks A   B   C   D
Biosynthetic Sequence
Privileged
Intermediate
Natural
Product I
Natural
Product II
Natural
Product III
bioindi-
cation I
bioindi-
cation II
bioindi-
cation III
Figure ￿-￿. Biosynthetic sequence to a privileged intermediate.
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Commercial
Starting Material A   B   C   D
Synthetic Sequence
Natural
Product
Figure ￿-￿. Usual synthetic strategy for the total synthesis of a natural product.
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Starting Material A   B   C   D
Synthetic Sequence
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Intermediate
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Product I
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Product II
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Product III
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cation I
bioindi-
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bioindi-
cation III
Figure ￿-￿. “Verbund”-synthesis.
On the contrary, classic total synthesis aims for one single target and the synthetic strategy is in
most cases designed to exclusively furnish the desired target (Fig. ￿-￿). The so-called “Verbund”-
synthesis tries to join both strategies (Fig. ￿-￿). The synthetic route is designed for the conversion
of commercial available materials into a privileged intermediate which can be transformed into
further di￿erent natural products. In the best case case scenario, this transformation requires
only one single step. Admittedly, a biomimetic synthesis of indole monoterpene alkaloids allows
a large amount of privileged intermediates since the biosynthetic pathways have been studied
very well and various intermediates are known to be convertible into di￿erent natural products
(cf. Section ￿.￿).
The first general retrosynthetic idea for the synthesis of Ervatamia alkaloids is shown in
Scheme ￿-￿. Both (±)-ervitsine (￿￿) and (±)-methuenine (￿￿) derivatives can derive from target
compound ￿￿￿. Transformation of ￿￿￿ into (±)-ervitsine (￿￿) occurs via ￿,￿-addition of a building
block similar to ￿￿￿ followed by a DDQ mediated ring closure. Similar late-stage ring-closing
reactions are known from the literature, e.g. synthesis of (–)-tubifolidine (M. Shibasaki, ￿￿￿￿)[￿￿￿]
or synthesis of (±)-uleine (E. Ertürk, ￿￿￿￿).[￿￿￿] On the contrary, methuenine (￿￿) can be formed
by displacement of the alcohol moiety of ￿￿￿ followed by an intramolecular radical ring closure.
Once more a building block similar to vinyl iodide ￿￿￿ is required for the transformation making
￿￿￿ a general building block for both synthetic approaches. Cyclohepta[b]indole ￿￿￿ itself derives
from cyclohepta[b]indoline ￿￿￿ via rearomatization and allylic oxidation. The precursor of
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Scheme ￿-￿. Retrosynthetic analysis for Ervatamia alkaloids..
cyclohepta[b]indoline ￿￿￿ is indolylvinylcyclopropane ￿￿￿ which transformation into ￿￿￿ via
divinylcyclopropane-cycloheptadiene rearrangement has been discussed in Section ￿.￿. This
transformation marks one key-step in this synthetic proposal and the elaborated methodology
for this transformation has been successfully applied to several substrates. Straightforward
transformations lead to trisubstituted cyclopropane precursor ￿￿￿ which in turn derives from
(Z)-allylic alcohol ￿￿￿ via cyclopropanation using diazo compounds withmetal catalysis. Starting
material for the synthesis is aforementioned and commercially available indole-￿-carbaldehyde
(￿￿￿).
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￿.￿ First Approach
An important building block towards the synthesis of Ervatamia alkaloids is trisubstituted cyclo-
propane ￿￿￿ (Scheme ￿-￿). Simmons–Smith cyclopropanation conditions were not applicable to
this system but instead metal-catalyzed cyclopropanations with ethyl diazoacetate (￿￿￿). Many
trials were carried out to find optimal conditions for this transformation and the most important
results are listed in Tab. ￿-￿.
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Scheme ￿-￿. Cyclopropanation of allylic silyl alcohol ￿￿￿ using ethyl diazoacetate with metal catalysis.
The most crucial point was the correct concentration of the starting material. First attempts
used a concentration of ￿.￿ ￿ for the starting material and additional ￿.￿ ￿ for ethyl diazoacetate
(￿￿￿, equals to ￿.￿￿ ￿ in total after complete addition). This resulted only in little formation of
desired cyclopropane ￿￿￿ and mostly furnished diethyl fumarate (viametal-catalyzed formation
of to the dimer of ￿￿￿, exclusive formation of the trans-dimer; Tab. ￿-￿, Entries ￿ and ￿). By
gradually decreasing the concentration of the starting material ￿￿￿ and reducing the catalyst load
from ￿mol % to ￿mol % it was found out that the cyclopropanation works best when dissolving
the starting material only in a minimal amount of degassed CH￿Cl￿ (usually '￿.￿ ￿) followed
by the addition of a diluted solution of ethyl diazoacetate in CH￿Cl￿ over ￿￿ h (Entries ￿ and ￿).
Unfortunately, it was not possible to separate the cyclopropane product from diethyl fumarate
and small amounts of this dimer were apparent in the NMR. The diastereomers were also
not separable, the diastereomeric ratio was therefore determined via NMR analysis or after
reduction of the ester to the corresponding alcohol which yielded two separable diastereomers.
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J = 4.7 Hz
￿￿￿
Figure ￿-￿. Assignment
of the relative stereochem-
istry of the major diastere-
omer via examination of
the cyclopropane proton
coupling constants.
The correct assignment of both diastereomers is only possible via NMR
analysis and is somehow not trivial. The best indicators are the coupling
constants between the three cyclopropane protons. Since the starting ma-
terial contains a (Z)-double bond, these two protons must consequently
be cis configured in the cyclopropane product. Due to overlapping cyclo-
propane proton signals of the minor diastereomer, the analysis was only
successful for the major formed diastereomer. According to the careful
analysis, the major formed product was also the desired product where
the ester moiety and the indole moiety have a trans relation (Fig. ￿-￿).
As to the metal, it turned out that copper catalyzed cyclopropanation
furnished better results than rhodium catalyzed cyclopropanation in
￿￿￿
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Table ￿-￿. Cyclopropanation conditions for the generation of ￿￿￿ (cf. Scheme ￿-￿).
# Conditions￿) Yield [%] a : b ee [%] Notes
￿ CH￿Cl￿ (￿.￿ ￿), Rh￿(OAc)￿ (￿mol %), ￿￿￿ (￿.￿ eq.) in
CH￿Cl￿ (￿.￿ ￿), addition over ￿ h, rt.
traces — — ￿) ￿)
￿ CH￿Cl￿ (￿.￿ ￿), [Cu(OTf)]  PhH (￿mol %), ￿￿￿ (￿.￿ eq.)
in CH￿Cl￿ (￿.￿ ￿), addition over ￿ h, rt.
traces — — ￿) ￿) ￿)
￿ CH￿Cl￿ (￿.￿ ￿), [Cu(OTf)]  PhH (￿mol %), ￿￿￿ (￿.￿ eq.)
in CH￿Cl￿ (￿.￿ ￿), addition over ￿￿ h, rt.
￿￿ ￿:￿ — ￿) ￿)
￿ CH￿Cl￿ (' ￿ ￿, degas.), [Cu(OTf)]  PhH (￿mol %), ￿￿￿
(￿.￿ eq.) in CH￿Cl￿ (￿.￿ ￿, degas.), addition over ￿￿ h, rt.
￿￿ ￿.￿:￿ — ￿)
￿ CH￿Cl￿ (' ￿ ￿, degas.), [Cu(OTf)]  PhMe (￿mol %), ￿￿￿
(￿.￿ eq.) in CH￿Cl￿ (￿.￿ ￿, degas.), addition over ￿￿ h, rt.
￿￿ ￿.￿:￿ — ￿)
￿ CH￿Cl￿ (' ￿ ￿, degas.), [Cu(OTf)]  PhH (￿mol %), ￿￿￿
(￿.￿ eq.) in PhH (￿.￿ ￿, degas.), addition over ￿￿ h, rt.
￿￿ —￿) — ￿) ￿) ￿)
￿ CH￿Cl￿ (' ￿ ￿, degas.), Rh￿(OAc)￿ (￿mol %), ￿￿￿
(￿.￿ eq.) in CH￿Cl￿ (￿.￿ ￿, degas.), addition over ￿￿ h, rt.
￿￿ ￿.￿:￿ — ￿) ￿)
￿ hexanes (￿.￿ ￿), CuSO￿ (￿￿mol %), ￿￿￿ (￿.￿ eq.) in
hexanes (￿.￿ ￿), addition over ￿.￿ h, ￿￿￿ °C
￿￿ ￿:￿ — ￿)
￿ CH￿Cl￿ (￿.￿ ￿, degas.), [Cu(OTf)]  PhH (￿.￿mol %), BOX
ligand ￿￿￿ (￿.￿mol %), ￿￿￿ (￿.￿ eq.) in CH￿Cl￿ (￿.￿ ￿,
degas.), addition over ￿￿ h, rt. (￿.￿ g scale)
￿￿ >￿￿:￿ ￿￿ ￿)
￿￿ CH￿Cl￿ (￿.￿ ￿, degas.), [Cu(OTf)]  PhH (￿.￿mol %), BOX
ligand ￿￿￿ (￿.￿mol %), ￿￿￿ (￿.￿ eq.) in CH￿Cl￿ (￿.￿￿ ￿,
degas.), addition over ￿￿ h, rt. (￿.￿ g scale)
￿￿ >￿￿:￿ ￿￿ ￿)
￿￿ CH￿Cl￿ (￿.￿ ￿, degas.), [Cu(OTf)]  PhH (￿.￿mol %), BOX
ligand ￿￿￿ (￿.￿mol %), ￿￿￿ (￿.￿ eq.) in CH￿Cl￿ (￿.￿￿ ￿,
degas.), addition over ￿￿ h, rt. (￿.￿ g scale)
￿￿ >￿￿:￿ ￿￿ ￿)
￿) highly contaminated with ethyl diazoacetate dimer ￿) slightly contaminated with the dimer of ethyl diazoacetate ￿) many
by-products ￿) no full conversion ￿) not determined ￿) contaminated with Buchner ring expansion product of benzene
￿) concentrations based on allylic silyl alcohol ￿￿￿
terms of yield and diastereomeric ratio ([Cu(OTf)]  PhH: ￿￿% yield, a:b = ￿.￿:￿; Rh￿(OAc)￿:
￿￿% yield, a:b = ￿:￿; Entries ￿ and ￿). Copper(I) trifluoromethanesulfonate is commercially
available as its benzene or toluene complex. In terms of reactivity no noteworthy di￿erences have
been observed. The benzene complex furnished cyclopropane ￿￿￿ in slightly higher yield and
diastereomeric ratio (Entries ￿ and ￿). The addition of of a diluted solution of ethyl diazoacetate
in PhH instead of CH￿Cl￿ reduced the yield drastically. Apparently, the cyclopropanation of
benzene is faster than the cyclopropanation of allylic silyl alcohol ￿￿￿ since the Buchner ring
expansion product of benzene has been obtained predominantly.
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The yield of product ￿￿￿ has been increased by the use of copper(I) sulfate (￿￿mol %) and
the addition of a diluted solution of ethyl diazoacetate in hexanes to allylic silyl alcohol ￿￿￿ in
refluxing hexanes over ￿.￿ h (Entry ￿). Albeit the diastereomeric ratio was slightly diminished in
this case, this procedure allowed rapid access to multigram amounts of cyclopropane ￿￿￿.
O
N (S)(S) N
O
￿￿￿
Figure ￿-￿. ￿,￿’-Isopropylidene-
bis[(￿S)-￿-tert-butyl-￿-oxazoline].
The diastereomeric ratio could be improved drastically by using
bisoxazoline ligands, ￿￿￿ in particularly (Fig. ￿-￿).[￿￿￿,￿￿￿] Not
only the desired product was furnished in a great diastereomeric
ratio (a:b > ￿￿:￿) but also the yield was almost quantitative (at
least ￿￿%, usualy ￿￿–￿￿%, Entries ￿–￿￿). In addition, the use
of bisoxazoline ligands for the metal-catalyzed cyclopropanation
of olefins furnishes enantioenriched products. In accordance to
literature di￿erent ligand ratios have been investigated and the best obtained enantiomeric ratio
was ￿￿:￿￿ (Entry ￿￿). At this point, no further investigations concerning the improvement of the
enantiomeric excess have been carried out and this procedure was used to produce multigram
amounts of almost diasteriomerically pure cyclopropane ￿￿￿.
￿.￿.￿ Towards Divinylcyclopropane Precursor ￿￿￿
With trisubstituted cyclopropane product ￿￿￿ in hand, attention next turned to the synthesis
of divinylcyclopropane precursor ￿￿￿ (Scheme ￿-￿)—an important building block towards the
syntheses of Ervatamia alkaloids, the methuenine series in particular. Formally, this requires
the transformation of the ester moiety into the corresponding Boc-protected methylamine which
includes a lowering of the oxidation state. Many approaches towards this building block have
been carried out to find the optimal conditions for this transformations (Scheme ￿-￿).
The most obvious conversion is the transformation of ester ￿￿￿ into amide ￿￿￿ followed by
Boc protection and reduction. Treatment of ester ￿￿￿ with ￿￿% aqueous methylamine solution
in methanol for ￿ hours at ￿￿ °C smoothly furnished secondary amide ￿￿￿ in ￿￿% yield. Boc
protection with Boc￿O and a catalytic amount of DMAP a￿orded imide ￿￿￿ in almost quanti-
tative yield. However, this approach found an abrupt end when several reduction conditions
(NaBH￿, LiAlH￿, LiTEBH) failed to transform imide ￿￿￿ into the corresponding Boc-protected
methylamine ￿￿￿. Therefore, ester ￿￿￿ was first reduced to alcohol ￿￿￿. This reaction was not
consistently reproducible with similar yields probably due to fumarate residues from the previ-
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Scheme ￿-￿. Towards divinylcyclopropane precursor ￿￿￿.
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Scheme ￿-￿. Reagents and conditions: a)MeNH￿ (￿￿% aq.)–MeOH (￿:￿), ￿￿ °C, ￿.￿ h, ￿￿%. b) Boc￿O, DMAP, THF, rt., ￿￿min,
￿￿%. c) DiBAL, CH￿Cl￿, –￿￿ °C, ￿ h, ￿￿–￿￿%; or LiBH￿, PhMe, ￿ °C, ￿￿min, then ￿￿￿ °C, ￿.￿ h, ￿￿%. d) see text and
Tab. ￿-￿. e) NaN￿, DMF, ￿￿ °C, ￿￿ min, ￿￿% from ￿￿￿ and ￿￿% from ￿￿￿. f ) PBu￿, THF–H￿O (￿￿:￿), rt., ￿.￿ h. g)
Boc￿O, Et￿N, CH￿Cl￿, rt., ￿￿min h)H￿ (￿ atm), Pd/C, Boc￿O, MeOH–THF (￿:￿), quant. i)MeI, NaH, DMF, ￿ °C to rt.,
￿.￿ h, ￿￿% (￿ steps). j)MeNH￿ (￿￿% in MeOH), rt., ￿.￿ h. k) Boc￿O, Et￿N, rt., ￿￿min, ￿￿% (from ￿￿￿). l) NHMeBoc,
NaH, DMAc, ￿ °C  rt., ￿.￿ h, ￿￿% from ￿￿￿ and ￿￿% from ￿￿￿.
ous step. Several reduction conditions were investigated, best results were achieved both with
DiBAL at –￿￿ °C and LiBH￿ at ￿￿￿ °C. With alcohol ￿￿￿ in hand, transformations into several
di￿erent derivatives were carried out (Tab. ￿-￿). Those derivatives which contains a potential
leaving group were sometimes unstable and tended to elimination forming methylenecyclo-
propanes (X = I, ONs, and OTs). In most cases, these intermediates were used crude for the
next step to circumvent stability issues. Compounds ￿￿￿ (X = OMs), ￿￿￿ (X = Br), and ￿￿￿
(X = I) were then transformed into azide ￿￿￿ using straightforward SN￿ conditions (NaN￿, DMF,
￿￿￿
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Table ￿-￿. Transformations of alcohol ￿￿￿.
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# Conditions X Product Yield [%]
￿ MsCl, Et￿N, CH￿Cl￿, ￿ °C, ￿￿min OMs ￿￿￿ —
￿)
￿ CBr￿, PPh￿, CH￿Cl￿, ￿ °C, ￿min Br ￿￿￿ —
￿) ￿) ￿)
￿ I￿, PPh￿, imid., PhH, rt., ￿min I ￿￿￿ —
￿) ￿) ￿)
￿ NsCl, Et￿N, CH￿Cl￿, ￿ °C  rt., ￿￿￿min ONs ￿￿￿ ￿￿
￿)
￿ TsCl, Et￿N, CH￿Cl￿, ￿ °C  rt., ￿￿￿min OTs ￿￿￿ ￿￿
￿)
￿ NaH, BnBr, DMF, ￿°C  rt. OBn ￿￿￿ decomp.
￿ NaH, PMBCl, THF, ￿ °C  rt., ￿￿￿min OPMB ￿￿￿ ￿￿
￿ NaH, MeI, THF, ￿ °C  rt., ￿￿￿min OMe ￿￿￿ ￿￿
￿) used crude for the next step ￿) short reaction time is crucial ￿) unstable (tends to elimination)
￿￿ °C). It turned out that mesylate ￿￿￿ and bromide ￿￿￿ were the most suitable compounds for
this transformation furnishing azide ￿￿￿ in more than ￿￿% yield. Iodide ￿￿￿ underwent the
competing elimination reaction at elevated temperatures, no SN￿ reaction occurred at ambient
temperature.
Azide ￿￿￿ was then transformed into amine ￿￿￿ via Staudinger reaction (PBu￿, THF–H￿O
￿￿:￿) and the labile amine was immediately converted into its corresponding Boc derivative ￿￿￿.
Although this sequence proceeded with decent yield, this two-step sequence has been shortened
and optimized. Hydrogenation of azide ￿￿￿ over palladium on charcoal in MeOH–THF (￿:￿)
in the presence of Boc￿O furnished directly amide ￿￿￿ in almost quantitative yield which was
methylated to a￿ord the target compound ￿￿￿.
Since this synthetic route for Boc protected amine ￿￿￿ contains quite a few transformations,
a simpler access to ￿￿￿ was investigated. Bromide ￿￿￿, and iodide ￿￿￿ were treated with
a methanolic solution of methylamine (￿￿%) for ￿ hours at ambient temperature to a￿ord
amine ￿￿￿ which then was directly treated with Boc￿O in the presence of Et￿N to yield Boc
protected amine ￿￿￿. Best yields were obtained with bromide ￿￿￿ (￿￿% over two steps). This
procedure could even be reduced to a single-step reaction by treatment of bromide ￿￿￿ with the
sodium amide of NHMeBoc in dimethylacetamide. This a￿orded target compound ￿￿￿ in ￿￿%
yield. Once again, best results were obtained with bromide ￿￿￿. Iodide ￿￿￿ furnished target
compound ￿￿￿ in reduced yield, once again the competitive elimination reaction predominated.
A lot of synthetic routes for one and the same compound have been discussed. The final
optimized sequence for amide ￿￿￿ is shown in Scheme ￿-￿.
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Scheme ￿-￿. Optimized synthetic sequence for amide ￿￿￿ and conversion into the divinylcyclopropane precursor ￿￿￿.
With amide ￿￿￿ in hand, attention next turned to the synthesis of divinylcyclopropane precur-
sor ￿￿￿ (Scheme ￿-￿). The silyl protecting group was removed with HF   pyr. in THF followed
by subsequent oxidation of the primary alcohol to aldehyde ￿￿￿ using Dess–Martin periodinane
(￿￿￿). This sequence a￿orded aldehyde ￿￿￿ in ￿￿% combined yield. Alcohol ￿￿￿ could also
be oxidized with IBX (￿￿￿) in similar yields but prolonged reaction times. Parikh–Doering
oxidation could also be used for alcohol ￿￿￿, but it was observed that under these conditions the
stereochemistry at the a-carbon atom was scrambled and a diastereomeric mixture of ￿￿￿ was
obtained.
￿.￿.￿ Cyclohepta[b]indoles from Divinylcyclopropane Precursor ￿￿￿
According to the developedmethodology (Section ￿.￿), aldehyde ￿￿￿was converted into divinylcy-
clopropane compound ￿￿￿‡ via usual Wittig conditions. Quick work-up and subsequent stirring
in refluxing benzene for additional ￿ hours smoothly furnished cyclohepta[b]indoline ￿￿￿ in
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Scheme ￿-￿. Synthesis of cyclohepta[b]indole ￿￿￿.
￿￿￿
￿ Towards the Total Synthesis of Ervatamia Alkaloids
￿￿% yield. As expected, the additional rest at the cyclopropane had an e￿ect on the rearrange-
ment. Whereas the rearrangement for the unsubstituted cyclohepta[b]indole ￿￿￿ (derived from
terminal alkene, ￿￿￿: R￿ = R￿ = H; Scheme ￿-￿￿, p. ￿￿￿) took place at ambient temperature in
￿.￿ h, the rearrangement of ￿￿￿‡ required increased temperatures and prolonged reaction times.
However, in consideration of the fact that the steric hindrance has increased drastically due to
the bulkiness of the attached substituent, the rearrangement proceeded in an adequate amount
of time under moderate heating.
With cyclohepta[b]indoline ￿￿￿ in hand, a significant building block towards the synthesis of
Ervatamia alkaloids has been synthesized. More importantly, the generality of the methodology
has been proven one more time. But unfortunately, the joy was short-lived. At this time it
was observed, that several synthesized cyclohepta[b]indolines were not permanently stable and
began to decompose after a short period of time, even below ￿ °C. A simple workaround was
to convert the cyclohepta[b]indolines into their corresponding cyclohepta[b]indoles, which has
been already described in Section ￿.￿. The obtained cyclohepta[b]indoles seemed to be bench-
stable for an indefinite period of time. At this point, it turned out that compound ￿￿￿ was very
acid-sensitive. Every attempt to rearomatize cyclohepta[b]indoline ￿￿￿ under acidic conditions
yielded in decomposition of the material (Scheme ￿-￿). It could be observed via TLC, that the
Boc group was cleaved under the acidic conditions, but apparently the liberated secondary amine
was not stable under these required conditions. Several attempts remained unsuccessful and
led to the end of this synthetic route towards Ervatamia alkaloids.
N
Ts
H
NMeBoc
N
Ts
NMeBoc
N
H
N
H
H
O
Me
￿￿￿ ￿￿￿
(±)-methuenine (￿￿)
Scheme ￿-￿. Unsuccessful conversion of cyclohepta[b]indoline ￿￿￿ into cyclohepta[b]indole ￿￿￿.
￿.￿ Variations
Since the first approach led to a dead end, several di￿erent synthetic proposals were taken into
account. This section deals with the introduction of several intermediates via various synthetic
routes which then will be referenced in subsequent sections. In addition, some variations for
the synthesis of already presented or upcoming intermediates are discussed briefly.
￿.￿.￿ Cyclopropanation Precursors via Hydrogenation of Alkynes
The divinylcyclopropane-cycloheptadiene rearrangement of indolylvinylcyclopropanes requires
the indole moiety and the vinyl rest to be syn. As a consequence of this, the double bond geometry
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Scheme ￿-￿. Alternative route to (Z)-allylic silyl alcohol ￿￿￿ and synthesis of acetal ￿￿￿.
of the cyclopropanation precursor has to be (Z). As shown before, this double bond geometry can
be installed via Ando or Still–Gennari olefination (Section ￿.￿). An alternative approach is the
(Z)-selective hydrogenation of alkynes such as propargylic alcohols ￿￿￿ or ￿￿￿. Alcohol ￿￿￿ is ac-
cessible via Sonogoshira coupling of propargyl alcohol (￿￿￿) and N-tosyl-￿-iodoindole (￿￿￿),[￿￿￿]
the latter can be synthesized in one step from indole (￿￿￿).[￿￿￿] The hydrogenation of alkyne ￿￿￿
was investigated, but all attempts failed and overreduction was observed. However, silyl protec-
tion of the free alcohol furnished propargylic silyl alcohol ￿￿￿ which was successfully reduced
to the corresponding cis-alkene ￿￿￿ (￿￿￿ psi H￿, Lindlar catalyst, MeOH–EtOAc ￿:￿￿, ￿￿min).
Additionally, propargylic alcohol ￿￿￿ was oxidized to the corresponding propynal derivative ￿￿￿
via dimethyl sulfoxide pivaloyl chloride,[￿￿￿] an alternative to the classical Swern oxidation.[￿￿￿b]
The aldehyde was then transformed to acetal ￿￿￿ and hydrogenation over Pd/CaCO￿ (￿%) with
addition of quinoline furnished acrolein ethylene acetal derivative ￿￿￿ in ￿￿% overall yield (from
propargylic alcohol ￿￿￿).
￿.￿.￿ Cyclopropanation Variations
En route to the optimal conditions for the cyclopropanation of olefin ￿￿￿ (Tab. ￿-￿, p. ￿￿￿), several
investigations concerning di￿erent cyclopropanation products were carried out (Scheme ￿-￿).
Since ethyl diazoacetate (￿￿￿) is commercially available and comparatively a￿ordable it is quite
common to use ￿￿￿ as source for a diazo compound. The generation and handling of other diazo
sources with a small molecular weight can sometimes be utterly cumbersome. Notwithstanding
this, following diazo compounds were synthesized: diazoacetonitrile (￿￿￿), ￿,￿-di-tert-butyl-￿-
methylphenyl ￿-diazoacetate (BHT diazoacetate, ￿￿￿), and diazoacetone (￿￿￿). Furthermore,
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Scheme ￿-￿. Cyclopropanation variations.
tert-Butyl diazoacetate (￿￿￿) was used as an additional commercially available diazo compound.
Cyclopropanations with this diazo compounds were investigated.
tert-Butyl diazoacetate (￿￿￿) and BHT diazoacetate (￿￿￿) were chosen to investigate the in-
fluence of a bulky substituent to the endo/exo ratio of the cyclopropanation product. tert-Butyl
diazoacetate (￿￿￿) is known to undergo metal-catalyzed cyclopropanation reactions.[￿￿￿–￿￿￿] How-
ever, trisubstituted cyclopropane ￿￿￿ was only formed in trace amounts. On the other hand,
metal-catalyzed cyclopropanation of ￿￿￿ with BHT diazoacetate (￿￿￿) was fortunate, but (i) the
yield was very low (< ￿￿%), (ii) interestingly, the endo/exo ratio was about ￿:￿, and (iii) reduction
of the bulky ester moiety to the corresponding alcohol ￿￿￿ was unfruitful.
The cyclopropanation of olefin ￿￿￿ with diazoacetonitrile (￿￿￿) would lead to useful intermedi-
ate ￿￿￿ due to the introduction of a masked amine. Unfortunately, there is only little knowledge
about this diazo compound. Harada et al. have reported ￿￿￿ to be highly explosive at high
concentrations and disadvised to concentrate or isolate this diazo compound.[￿￿￿] However, the
￿￿ wt% solution of ￿￿￿ in CH￿Cl￿ is not so dangerous. Although ￿￿￿ has been synthesized
successfully, several attempts to synthesize cyclopropane product ￿￿￿ remained unfruitful.
Acrolein ethylene acetal derivative ￿￿￿ was also an appropriate precursor for a metal-catalyzed
cyclopropanation reaction with ethyl diazoacetate (￿￿￿). In combination with BOX ligand ￿￿￿,
enantioenriched trisubstituted cyclopropane ￿￿￿ has been formed in decent yield. Once again
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the diastereomeric ratio was excellent and formation of the all-cis-product was not observed.
The acetal then was cleaved under aqueous acidic conditions to obtain aldehyde ￿￿￿. This
intermediate becomes important at a later stage of the synthesis. The alternative synthesis and
the use in a di￿erent approach is discussed later (Section ￿.￿, p. ￿￿￿).
￿.￿.￿ Cyclohepta[b]indoles from (E)-Olefins
Since the first approach found an abrupt end due to rearomatization problems (p. ￿￿￿), attention
next turned to methanolyl-cyclohepta[b]indole ￿￿￿ (Scheme ￿-￿￿) which is a precursor for both
(±)-ervitsine (￿￿) and (±)-methuenine (￿￿, cf. Scheme ￿-￿, p. ￿￿￿). The already established route
via the cyclopropanation of (Z)-olefin ￿￿￿ required only slight modifications. The ester moiety
of cyclopropanation product ￿￿￿ needs to be reduced to the corresponding alcohol ￿￿￿ which
requires protection. This is a real drawback since it necessitates another orthogonal protecting
group. For this reason, only two intermediates of type ￿￿￿ have been synthesized (cf. Tab. ￿-￿,
p. ￿￿￿): ￿￿￿ (PG￿ = PMB) and ￿￿￿ (PG￿ = Me).
Since the racemic cyclopropanation of (Z)-olefin ￿￿￿ furnished the endo- and exo-product in
a moderate ratio, it was worth to investigate the cyclopropanation of (E)-olefin ￿￿￿. In addition,
according to Scheme ￿-￿￿ this approach would make the need for a second orthogonal protecting
group for an alcohol functionality superfluous.
For thisN-tosyl protected aldehyde ￿￿￿was reacted with triethyl phosphonoacetate (￿￿￿) in the
presence of LiHMDS followed by DiBAL reduction to obtain allylic alcohol ￿￿￿ (Scheme ￿-￿￿).
The ratio of E:Z here is over ￿￿:￿. Alternatively, ￿￿￿ can be synthesized from the reduction of
alkyne ￿￿￿ with lithium aluminium hydride.[￿￿￿,￿￿￿] This reaction is completely (E)-selective.
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Scheme ￿-￿￿. Synthesis of four di￿erent cyclohepta[b]indole precursors ￿￿￿, ￿￿￿, ￿￿￿, and ￿￿￿ from the cyclopropanation of (E)-allylic
silyl alcohols ￿￿￿, ￿￿￿, and ￿￿￿.
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Interestingly, the reduction of alkyne ￿￿￿ furnished allylic alchol ￿￿￿, too, and not allylic silyl
alcohol ￿￿￿. Although the TBS group is usually stable to reductive conditions, it is yet cleaved
in this case. With allylic alcohol ￿￿￿ in hands, protection with di￿erent silyl protecting groups
(SEM, TBS, TBDPS) was carried out and all three silyl alcohols ￿￿￿, ￿￿￿, and ￿￿￿ were obtained
in excellent yield (￿￿–￿￿% over three steps). The primary reason for di￿erent protecting groups
was the investigation of their influence during the cyclopropanation in terms of bulkiness and
endo/exo ratio. In the case of TBS and TBDPS, usual conditions using ￿mol % [CuOTf]  PhH
and an excess of ethyl diazoacetate (￿￿￿) a￿orded trisubstituted cyclopropanes ￿￿￿ and ￿￿￿ in
good to moderate yield. Surprisingly, the SEM group was cleaved under these conditions and no
cyclopropanation took place. However, CuSO￿-mediated cyclopropanation with ￿￿￿ in refluxing
benzene a￿orded trisubstituted cyclopropane ￿￿￿ in moderate yield. The endo- and exo-products
were not separable at this stage, but DiBAL reduction of the ester moiety yielded two separable
diastereomers in each case (￿￿￿, ￿￿￿, ￿￿￿, and ￿￿￿). In all three cases the main diastereomer
was also the desired one (that means, the methanolyl rest is syn to the indolyl rest). Surprisingly,
best results were achieved with the smallest protecting group (SEM: a:b = ￿:￿.￿, TBS: a:b =
￿:￿.￿, TBDPS: a:b = ￿:￿.￿￿). This concludes that olefins which contain a bulky group tend to
produce the exo-product in higher yield. Finally, the primary alcohols were oxidized to obtain
the corresponding aldehydes ￿￿￿, ￿￿￿, ￿￿￿, and ￿￿￿ in moderate to good yields (￿￿–￿￿%).
With aldehydes ￿￿￿, ￿￿￿, ￿￿￿, and ￿￿￿ in hand, attention next turned to the transformation
of these aldehydes into the corresponding cyclohepta[b]indoles. This is shown exemplary for
the transformation of aldehyde ￿￿￿ (Scheme ￿-￿￿). Both diastereomers of this aldehyde were
prepared (￿￿￿ and ￿￿￿). At first glance, only aldehyde ￿￿￿ is an appropriate substrate for the
upcoming divinylcyclopropane-cycloheptadiene rearrangement since it is plausible that only
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cis-configured divinylcyclopropanes are eligible for a [￿,￿] sigmatropic rearrangement. The
trans-configured counterparts usually cannot undergo a [￿,￿] sigmatropic rearrangement since
the required cyclic transition state cannot be adopted due to the absence of orbital overlap of the
two p-bonds. Nevertheless, high temperature can lead to the same product as it is obtained from
the cis configured counterpart. The reason is a homolytic dissociation of the central linkage, to
give a trans-allyl biradical. Isomerization of the allyl groups enables the correct orbital geometry
to perform a [￿,￿] sigmatropic rearrangement. To this day it is not known whether only the
isomerization occurs via a biradical mechanism or also the cyclization itself (cf. Scheme ￿-￿ on
p. ￿￿).[￿￿￿c,￿￿￿]
Aldehyde ￿￿￿ was transformed into indolylvinylcyclopropane ￿￿￿ which is stable at ambient
temperature (Scheme ￿-￿￿). However, stirring in benzene at ￿￿ °C for ￿.￿ h smoothly furnished
cyclohepta[b]indoline ￿￿￿ in very good overall yield (￿￿%). The same sequence was repeated with
the trans-configured counterpart ￿￿￿, but several attempts for the rearrangement of ￿￿￿—even
heating up to ￿￿￿ °C—remained unfruitful.
￿.￿.￿ Generation of ￿-Acylindoles — Oxidation (I)
With silyl protected methanolyl-cyclohepta[b]indoline ￿￿￿ in hands, attention next turned to
the synthesis of the ￿-acylindole counterpart, that is the oxidation of the C-￿ position (natural
product counting, Scheme ￿-￿￿). The silyl protecting group was cleaved with hydrogen fluoride
to obtain alcohol ￿￿￿ which was subsequently treated with p-toluenesulfonic acid to a￿ord
methanolyl-cyclohepta[b]indole ￿￿￿ in ￿￿% combined yield. Alternatively, silyl compound ￿￿￿
is treated with a catalytic amount of p-toluenesulfonic acid and an equimolar amount of pyri-
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dinium p-toluenesulfonate to obtain methanolyl-cyclohepta[b]indole ￿￿￿ via desilylation and
rearomatization in one single step in ￿￿% yield.
There is only little knowledge about the direct oxidation of cycloalkan[b]indoles to their
￿-acylindole counterparts. Basically the only e￿ective methodology was published in ￿￿￿￿
by Yoshida et al. who described the oxidation of cycloalkan[b]indoles with iodine pentoxide
(I￿O￿).
[￿￿￿] This methodology found some minor application in synthesis, e.g. in the synthesis
of new NPY-￿ antagonists.[￿￿￿] The mechanism of this transformation is shown in Scheme ￿-￿￿.
Quite recently, Banwell et al. published an oxidation using harsh conditions with PCC.[￿￿￿]
An unprotected indole is used in all cases. However, several attempts with N-tosyl protected
compound ￿￿￿ were carried out. But both iodine pentoxide and selenium dioxide turned out
to be ine￿ective as starting material was recovered in all cases. Therefore, the tosyl group was
cleaved using an excess of magnesium in methanol[￿￿￿] and unprotected cyclohepta[b]indole ￿￿￿
was obtained in almost quantitative yield. But again, several attempts for the oxidation remained
unfruitful and ￿-acylindole ￿￿￿ was not obtained.
It might be a legitimate point that the unprotected alcohol may cause trouble during this
oxidation process. Therefore, several protected derivatives were synthesized (Scheme ￿-￿￿).
With derivatives ￿￿￿, ￿￿￿, and ￿￿￿ in hands, several oxidative conditions were investigated
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Scheme ￿-￿￿. Attempts for the synthesis of ￿-acylindoles.
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(see Scheme ￿-￿￿). To put it in a nutshell, not a single oxidation reaction was successful and
￿-acylindoles ￿￿￿, ￿￿￿, or ￿￿￿ were never obtained either due to inertness of the substrate to the
applied conditions or due to rapid decomposition.
At this point, the generality of this oxidative sequence was questioned. For this reason, a simple
test system was synthesized (Scheme ￿-￿￿). According to Bulman et al.,[￿￿￿] cycloheptanone
(￿￿￿) was reacted with phenylhydrazine in the presence of trichloroacetic acid to obtain “naked”
cyclohepta[b]indole ￿￿￿ in quantitative yield. This compound was subjected to iodine pentoxide
mediated oxidative conditions as before and ￿-acylindole ￿￿￿ was obtained in almost quantitative
yield. To investigate if a late-stage oxidation would be possible, cyclohepta[b]indole ￿￿￿ was
transferred into ￿-acylindole ￿￿￿ with DDQ in aqueous THF.[￿￿￿] Subsequent Mannich reaction
with formaldehyde and dimethylamine[￿￿￿] generates a compound similar to the Ervatamia
alkaloids bearing an alkyl chain with a tertiary amine at C-￿￿. This compound was oxidized with
iodine pentoxide to the corresponding ￿-acylindole ￿￿￿ without di￿culty.
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Scheme ￿-￿￿. Test system for the synthesis of ￿-acylindole derivatives.
No confirmed statements concerning the failed iodine pentoxide mediated oxidations in
previous systems can be made. It is assumed, that the p-bond between C-￿￿ and C-￿￿ somehow
prevents the successful oxidation of the C-￿ position. This assumption is supported by the result
of the unfruitful oxidation of simple cyclohepta[b]indole ￿￿￿ (Scheme ￿-￿￿).
This results led to a general question: how to introduce an oxygen or an oxygen equivalent, re-
spectively, before the divinylcyclopropane-cycloheptadiene rearrangement takes place? Attempts
to this problem are described in the following two sections.
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Scheme ￿-￿￿. Oxidation of simple cyclohepta[b]indole ￿￿￿.
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Since the first approaches led to an end due to massive oxidation problems, the introduction of
an oxygen or an oxygen equivalent, respectively, before the divinylcyclopropane-cycloheptadiene
rearrangement takes place was taken into account. Since this section is for the most part about
methodology development, the third rest at the cyclopropane was omitted consciously to simplify
and accelerate the development.
Several possibilities are shown in Scheme ￿-￿￿. The keto functionality can derive from nitro
compound ￿￿￿ via Nef reaction.[￿￿￿] Nitro compound ￿￿￿ itself is the product of the divinylcyclo-
propane-cycloheptadiene rearrangement of olefin ￿￿￿ which can be synthesized via Henry
reaction[￿￿￿] (and potential dehydration) from known aldehyde ￿￿￿.
Another possibility can be the Kornblum oxidation[￿￿￿] (or more updated procedures with
pyridine N-oxide[￿￿￿]) of benzylic iodide ￿￿￿. The precursor ￿￿￿ can again be synthesized from
already known aldehyde ￿￿￿ via Stork–Zhao olefination.[￿￿￿]
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Scheme ￿-￿￿. New retrosynthetic analysis of ￿-acylindoles.
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A more direct way is the introduction of the keto functionality via ketene acetal ￿￿￿ (X = S
or O) or ketene ￿￿￿. Ketene acetal ￿￿￿ derives from aldehyde ￿￿￿ via olefination reaction as well
as ketene ￿￿￿, which is accessible from aldehyde ￿￿￿ via transformation into the corresponding
a-diazo ketone followed by Wol￿ rearrangement.[￿￿￿]
￿.￿.￿ Approach via Henry Reaction and Stork–Zhao Olefination
Both the proposal from Scheme ￿-￿￿ for the Henry reaction and the proposal for the Stork–Zhao
approach can be sum up in a very short way (Scheme ￿-￿￿). The transformation of aldehyde ￿￿￿
into nitro olefin ￿￿￿ was not successful. Instead the reaction of aldehyde ￿￿￿ with the ylide
of Stork–Zhao reagent ￿￿￿ smoothly furnished (Z)-vinyl iodide ￿￿￿ in ￿￿% yield. But several
attempts for the rearrangement of compound ￿￿￿ to synthesize cyclohepta[b]indoline ￿￿￿ re-
mained unfruitful and led to decomposition of the material. Hence, attention turned to the
generation of ketene acetals.
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Scheme ￿-￿￿. Transformations of aldehyde ￿￿￿.
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￿.￿.￿.￿ Ketene O,O-Acetals
The generation of ketene O,O-acetals is widely known and especially silyl ketene acetals have
found widespread use in organic synthesis. However, literature for the synthesis of ketene
O,O-acetals from aldehydes via homologation is scarce. Basically, there are only two methodolo-
gies reported: (i) a copper-catalyzed cross-coupling between ￿,￿-dibromoalkenes and phenols
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Scheme ￿-￿￿. Transformation of carbonyls into their homologous ketene O,O-acetals.[￿￿￿–￿￿￿]
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Scheme ￿-￿￿. Attempts for the generation of the homologous ketene O,O-acetal of aldehydes ￿￿￿ and ￿￿￿.
(Scheme ￿-￿￿a),[￿￿￿] and (ii) the conversion of aldehydes as well as ketones into their homolo-
gous ketene O,O-acetals by a Horner–Wittig reaction with dialkoxymethyl diphenylphosphine
oxides (Scheme ￿-￿￿b).[￿￿￿,￿￿￿] Since the first methodology requires the previous transformation
of the aldehyde into its ￿,￿-dibromoalkene derivative, only the Horner–Wittig reaction with
dialkoxymethyl diphenylphosphine oxides was taken into account.
The Horner–Wittig protocol was then applied to aldehyde ￿￿￿. Deprotonation of dime-
thoxymethyl diphenylphosphine oxide (￿￿￿) with LDA at –￿￿￿ °C in THF–ether (￿:￿) smoothly
furnished the ylide which was visible due to a bright yellow color of the anion. Nevertheless,
several attempts for the reaction of this ylide with aldehyde ￿￿￿ remained unfruitful and the
formation of cyclohepta[b]indoline ￿￿￿ could not be investigated (Scheme ￿-￿￿a). Due to the
careful handling of phosphine oxide ￿￿￿ and its ylide, similar reaction conditions were applied
to the reaction with benzaldehyde (￿￿￿) to check the generality of this Horner–Wittig reaction.
The formation of intermediate ￿￿￿ was observed and subsequent treatment with potassium
tert-butoxide furnished ketene O,O-acetal ￿￿￿ (Scheme ￿-￿￿b). Therefore, the formation of
ketene O,O-acetal of aldehyde ￿￿￿ was given up and attention next turned to the formation of
ketene S,S-acetals of ￿￿￿.
￿.￿.￿.￿ Ketene S,S-Acetals
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Figure ￿-￿. Reagents ￿￿￿, ￿￿￿, and ￿￿￿.
As for the synthesis for ketene O,O-acetals, the
literature for the synthesis of ketene S,S-acetals
from aldehydes via homologation is also very
scarce. Juaristi et al. described the synthe-
sis of (￿,￿-dithian-￿-yl)diphenylphosphine ox-
ide (￿￿￿) and its application as Wittig–Horner/
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Scheme ￿-￿￿. Synthesis of ketene S,S-acetal ￿￿￿ and its divinylcyclopropane-cycloheptadiene rearrangement product ￿￿￿.
Corey–Seebach reagent (Fig. ￿-￿).[￿￿￿] Also known is its Horner–Wadsworth–Emmons/Corey–
Seebach counterpart diethyl (￿,￿-dithian-￿-yl)phosphonate (￿￿￿, Fig. ￿-￿).[￿￿￿] The latter reagent
has an additional advantage since it is also known as its chiral sulfoxide counterpart ￿￿￿.[￿￿￿]
Based on the protocol of Juaristi et al., aldehyde ￿￿￿was reacted with the ylide of Horner–Wads-
worth–Emmons/Corey–Seebach reagent ￿￿￿ at –￿￿ °C for ￿￿min and ketene S,S-acetal ￿￿￿ was
a￿orded in impressive yield (￿￿%, Scheme ￿-￿￿). With ￿￿￿ in hands, attention next turned to
its divinylcyclopropane-cycloheptadiene rearrangement product. Usual conditions (refluxing
benzene) a￿orded desired rearrangement product ￿￿￿ very slowly. However, several attempts
revealed, that the rearrangement product was a￿orded smoothly in benzene–dimethyl sulfox-
ide (￿:￿) at ￿￿￿ °C in ￿ h (￿￿% yield).
With this good results in hands, attention next turned to the synthesis of trisubstituted
cyclopropane ketene S,S-acetals. For this reason, aldehyde ￿￿￿ was transformed into ketene
S,S-acetal ￿￿￿ in ￿￿% yield using the same conditions as before (Scheme ￿-￿￿). However,
ketene S,S-acetal ￿￿￿ turned out to be very stable. Several attempts (listed in Tab. ￿-￿) for the
divinylcyclopropane-cycloheptadiene rearrangement of ￿￿￿ failed and cyclohepta[b]indoline ￿￿￿
could not be obtained.
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Scheme ￿-￿￿. Synthesis of ketene S,S-acetal ￿￿￿ and attempts for its rearrangement.
Table ￿-￿. Conditions (Scheme ￿-￿￿).
# Conditions
￿ PhH, ￿￿￿ °C, ￿￿ h ￿)
￿ PhH, ￿￿￿ °C, ￿￿ h ￿)
￿ PhH, ￿￿ °C, ￿w ￿)
￿ (CH￿OH)￿, ￿￿￿ °C, ￿ h
￿)
￿ PhH–DMSO (￿:￿),
￿￿￿ °C, ￿ h ￿)
￿ PhMe–MeCN (￿:￿),
￿￿￿ °C, ￿ h ￿)
￿ dichlorobenzene,
￿￿￿ °C, ￿￿min ￿)
￿ PhCN, ￿￿￿ °C, ￿￿min ￿)
￿) no reaction ￿) decomposition
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Scheme ￿-￿￿. Syntheses of ketene S,S-acetals ￿￿￿, ￿￿￿, and ￿￿￿ and failed attempts for the divinylcyclopropane-cycloheptadiene
rearrangement of these compounds. Reagents and conditions: ￿￿￿, nBuLi, –￿￿ °C   ￿ °C, ￿￿ min, then aldehyde
￿￿￿/￿￿￿, THF, –￿￿ °C, ￿￿min .
Having in mind, that the third additional substituent at the cyclopropane moiety is quite bulky
due to the Boc group, several other derivatives were transformed into their ketene S,S-acetals
followed by the divinylcyclopropane-cycloheptadiene rearrangement into the corresponding
cyclohepta[b]indolines. The e￿ect of a third substituent was investigated with these experiments.
For this reason, ketene S,S-acetals ￿￿￿ and ￿￿￿ were synthesized from the corresponding
aldehydes ￿￿￿ and ￿￿￿ (Scheme ￿-￿￿). In addition, the ester moiety of ketene S,S-acetal ￿￿￿
was reduced to the corresponding primary alcohol ￿￿￿ yielding three additional ketene S,S-
acetals with various steric demand concerning the additional rest at the cyclopropane moiety.
Compounds ￿￿￿, ￿￿￿, and ￿￿￿ were subjected to most of the conditions listed in Tab. ￿-￿, but
the rearranged products ￿￿￿, ￿￿￿, and ￿￿￿ could not be obtained. The prior removal of the tosyl
group did not a￿ect this result.
In summary, the generation of ketene acetals and the divinylcyclopropane-cycloheptadiene
rearrangement of these compounds is possible and extends the developed methodology nicely.
However, a main drawback is, that this extension only works with disubstituted cyclopropanes.
Any attempt for the rearrangement of the trisubstituted counterparts fails.
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￿.￿.￿.￿ Disubstituted Cyclopropanes
Since the rearrangement of disubstituted cyclopropane ketene S,S-acetals proceeded smoothly
but failed with the trisubstituted counterparts, attention next turned to the synthesis of a-
diazo ketone ￿￿￿ (Scheme ￿-￿￿). This compound can be transformed into the corresponding
ketene ￿￿￿ via Wol￿ rearrangement (cf. Scheme ￿-￿￿ on p. ￿￿￿). The ketene derivatives are
assumed to be highly reactive intermediates, giving a much higher overall reaction rate of the
rearrangement in comparison to the ketene acetal counterparts.
The attempts to the synthesis are outlined in Scheme ￿-￿￿. Although the modified Sim-
mons–Smith reaction of acrylic acid derivatives is known,[￿￿￿] all attempts to convert carboxylic
acid ￿￿￿—which is easy accessible from already known ester ￿￿￿—into the corresponding cyclo-
propane derivative ￿￿￿ failed.￿ Therefore, well-known aldehyde ￿￿￿ was oxidized to carboxylic
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Scheme ￿-￿￿. Attempts to the synthesis of a-diazo compound ￿￿￿.
￿ Several attempts to the Corey-Chaykovsky reaction of a,b-unsaturated ester ￿￿￿ and derivatives were not successful.
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acid ￿￿￿ via Pinnick–Lindgren oxidation in ￿￿% yield.[￿￿￿] ￿￿￿ turned out to be very labile;
temperatures above ￿￿ °C (e.g. rotary evaporator) led to full decomposition of this compound.
Therefore, careful handling during the reaction (reaction was carried out at ￿￿ °C instead of
ambient temperature) and the work-up (solvent evaporation at ￿￿ °C) was necessary. Carboxylic
acid ￿￿￿ was then transformed into acid chloride ￿￿￿ under mild and acid-free chlorination con-
ditions with PPh￿ and CCl￿CN.
[￿￿￿,￿￿￿] ￿￿￿ turned out to be even more labile than its carboxylic
acid precursor. Every attempt to purify this compound failed. Therefore, acid chloride ￿￿￿ was
prepared freshly and used crude in upcoming reactions. Reaction of ￿￿￿ with freshly prepared
diazomethane finally a￿orded a-diazo ketone ￿￿￿ (reverse addition was crucial). However, the
yield was very poor (￿￿% over two steps) and no consistent reproduction was possible. Therefore,
a new synthetic route was sought. For this reason, aldehyde ￿￿￿ was transformed into the
corresponding methyl ketone derivative ￿￿￿ in a two-step Grignard addition/oxidation sequence.
This compound could also be prepared in a nice single-step sequence via the addition of trimethy-
laluminium followed by the addition of ￿-nitrobenzaldehyde (in situ oxidation via Oppenauer
chemistry),[￿￿￿,￿￿￿] but unfortunately the stereochemistry at the a-carbon atom was scrambled
under these conditions and a diastereomeric mixture of methyl ketone ￿￿￿ was obtained. With
￿￿￿ in hands, attention next turned to the formation of a-diazo ketone ￿￿￿. Direct diazo transfer
to ketone enolates is usually not a feasible process, although highly stabilized b-dicarbonyl
enolates do react with sulfonyl azide reagents to a￿ord a-diazo ketones in good yield. Diazo
transfer to simple ketones can be achieved, however, by employing an indirect deformylative
diazo transfer strategy in which the ketone is first formylated under Claisen condensation
conditions and then treated with a sulfonyl azide reagent.[￿￿￿] This strategy was only successful
with the Danheiser protocol for the generation of a-diazo ketones:[￿￿￿] the lithium enolate of ￿￿￿
was acylated by exposure to trifluoroethyl trifluoroacetate, the resulting a-trifluoroacetyl ketone
was then treated with methanesulfonyl azide in acetonitrile containing one equivalent of water.
This sequence a￿orded a-diazo ketone ￿￿￿ in ￿￿% combined yield. Next in line was the Wol￿
rearrangement/divinylcyclopropane-cycloheptadiene rearrangement tandem reaction of a-diazo
compound ￿￿￿ (Scheme ￿-￿￿). Wol￿ rearrangements can be induced under thermolytic, pho-
tolytic, and transition-metal-catalyzed conditions. Thermal conditions to induce rearrangement
require heating to relatively high temperatures and therefore have limited use. The method
of choice is often a transition-metal-catalyzed rearrangement since transition metals intensely
lower the temperature for this reaction via stabilization of a metal-carbene intermediate. Some
metals are known to build stable carbenes to such an extent as no rearrangement occurs; instead,
non-Wol￿ products are obtained (primarily carbene insertion products). These metals include
rhodium, copper, and palladium.[￿￿￿] The most commonly used metal is silver and the most
commonly used catalysts are silver benzoate, silver trifluoroacetate, and silver(I) oxide. Usually,
these reactions are run in the presence of a weak base.
A similar tandem Wol￿/Cope rearrangement sequence for the synthesis of fused carbocyclic
skeletons have been published by B. Stoltz and R. Sarpong.[￿￿￿] Therefore, their used conditions
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Scheme ￿-￿￿. Wol￿ rearrangement/divinylcyclopropane-cycloheptadiene rearrangement tandem reaction for the synthesis of ￿-
acylindole ￿￿￿ (conditions see Tab. ￿-￿).
Table ￿-￿. Conditions for Scheme ￿-￿￿.
# Conditions Yield
￿ AgOBz (￿.￿ eq.), Et￿N, ￿￿ °C, ultrasonic —
￿ hn (￿￿￿ nm), THF —
￿ hn (￿￿￿ nm), CH￿Cl￿ —
￿ AgTFA (￿.￿ eq.), Et￿N, THF, –￿￿ °C  rt. —
￿ Ag￿O (￿mol %), THF, ￿￿ °C, ￿ h ￿￿%
were the first choice (￿￿mol % of AgOBz,
Et￿N, THF, ￿￿ °C, ultasonic, ￿￿min). Many
products were generated with this proto-
col, but none of them could be identified
as ￿-acylindole ￿￿￿ or ￿￿￿. Furthermore,
several photochemical attempts were car-
ried out (Tab. ￿-￿). Triplet sensitizers were
not added since they are known to result in
non-Wol￿ carbene by-products.[￿￿￿] How-
ever, the formation of ￿￿￿ or ￿￿￿ could not
be observed in both THF and CH￿Cl￿ as solvent. Finally, the rearrangement turned out to work
best with a catalytic amount of silver(I) oxide (￿mol %) in THF at ￿￿ °C in the absence of a weak
base. These conditions directly furnished cyclohepta[b]indole ￿￿￿ via ketene intermediate ￿￿￿;
cyclohepta[b]indoline ￿￿￿ was never observed.
￿.￿.￿.￿ Trisubstituted Cyclopropanes
With ￿-acylindole ￿￿￿ in hands, attention next turned to the syntheses of the more challenging
trisubstituted counterparts. Based on the (E)-olefin series (cf. Section ￿.￿.￿), syntheses started
either from already available aldehydes ￿￿￿ (R = TBS), ￿￿￿ (R = TBDPS), and ￿￿￿ (R = SEM)
or directly from cyclopropanation product ￿￿￿ (R = TBS), see Scheme ￿-￿￿. Aldehydes ￿￿￿ and
￿￿￿ were transformed into their corresponding carboxylic acid derivatives ￿￿￿ and ￿￿￿ via Pin-
nick–Lindgren oxidation. Alternatively, this compound could also be obtained via saponification
of ester ￿￿￿ with potassium trimethylsilanolate.[￿￿￿] Once again, this products turned out to
be very labile and decomposition occurred above ￿￿ °C (cf. Section ￿.￿.￿.￿). Notwithstanding
this, ￿￿￿ and ￿￿￿ were subjected to mild and acid-free chlorination conditions with PPh￿ and
CCl￿CN to obtain the corresponding acid chlorides ￿￿￿ and ￿￿￿. With ￿￿￿ and ￿￿￿ in hands,
several attempts for the formation of the a-diazo counterparts were carried out, but once again
this reactions gave a-diazo compounds only in very low yield. Similar results were also obtained
for the disubstituted cyclopropane counterparts (cf. Section ￿.￿.￿.￿).
Therefore, aldehydes ￿￿￿ (R = TBS), ￿￿￿ (R = TBDPS), and ￿￿￿ (R = SEM) underwent Grignard
addition reaction with MeMgBr to give alcohols ￿￿￿, ￿￿￿, and ￿￿￿ followed by PDC oxidation
￿￿￿
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Scheme ￿-￿￿. Synthesis of a-diazo ketones ￿￿￿ and ￿￿￿. Reagents and conditions: a) NaClO￿, NaH￿PO￿,
tBuOH–H￿O (￿:￿),
￿-methylbut-￿-ene, ￿￿ °C, ￿￿ min (￿￿% crude from ￿￿￿, ￿￿% crude from ￿￿￿). b) TMSOK, THF, rt., ￿.￿ h (￿￿%
crude). c) PPh￿, Cl￿CCN, CH￿Cl￿, rt., ￿￿ min. d) MeMgBr, THF, ￿ °C, ￿￿ min (￿￿% from ￿￿￿, ￿￿% from ￿￿￿, ￿￿%
from ￿￿￿). e) PDC, MS ￿ Å, CH￿Cl￿, rt., ￿￿ h (￿￿% from ￿￿￿, — from ￿￿￿, ￿￿% from ￿￿￿). f ) (i) LiHMDS, THF, –￿￿ °C,
F￿CCO￿CH￿CF￿, ￿￿min, (ii) MsN￿, Et￿N, H￿O, MeCN, ￿￿min (￿￿% brsm. from ￿￿￿, ￿￿% from ￿￿￿) .
to the corresponding methyl ketones ￿￿￿, ￿￿￿, ￿￿￿ (Scheme ￿-￿￿). With the aforementioned
protocol for the synthesis of a-diazo ketones frommethyl ketones from R. L. Danheiser, TBS and
SEM derivatives ￿￿￿ and ￿￿￿ were transformed into a-diazo ketones ￿￿￿ and ￿￿￿ in moderate
yields (￿￿% and ￿￿%, respectively). For a start, a single run of this synthetic sequence a￿orded
enough material, to investigate the Wol￿ rearrangement/divinylcyclopropane-cycloheptadiene
rearrangement tandem reaction (Scheme ￿-￿￿a and Tab. ￿-￿).
Table ￿-￿. Conditions for the attempts to the synthesis of ￿-acylindoles ￿￿￿ and ￿￿￿.
# R = Conditions Product
￿ TBS Ag￿O, THF, ￿￿ °C —
￿)
￿ TBS Ag￿O, PhH, ￿￿ °C —
￿)
￿ TBS AgOBz (￿.￿ eq.), THF, ￿￿ °C — ￿) + ￿)
￿ TBS AgOBz (￿.￿ eq.), Et￿N, THF, ￿￿ °C —
￿) + ￿)
￿ TBS AgOBz (￿.￿ eq.), Et￿N, ￿￿ °C, ultrasonic —
￿)
￿ TBS hn (￿￿￿ nm), THF — ￿)
(continued on next page…)
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Table ￿-￿. (continued)
# R = Conditions Product
￿ TBS hn (￿￿￿ nm), CH￿Cl￿ —
￿)
￿ SEM THF, ￿￿ °C, Ag￿O —
￿)
￿ SEM Rh￿(OAc)￿, CH￿Cl￿, ￿￿ °C, ￿min —
￿)
￿￿ SEM AgOBz (￿.￿ eq.), Et￿N, ￿￿ °C, ultrasonic —
￿)
￿￿ SEM AgOAc (￿￿mol %), ￿,￿-dichloroethane, ￿￿ °C — ￿)
￿￿ SEM AgTFA (￿￿mol %), ￿,￿-dichloroethane, ￿￿ °C — ￿)
￿￿ SEM PhMe, ￿￿￿ °C, ￿￿￿min — ￿) + ￿)
￿￿ TBS dichlorobenzene, ￿￿￿ °C, ￿￿min ￿￿￿
￿) unidentified products (no plausible NMR spectrum, no correct mass)
￿) decomposition ￿) recovered starting material
When the investigations concerning theWol￿ rearrangement/divinylcyclopropane-cyclohepta-
diene rearrangement tandem reaction began it became apparent very quickly, that this transfor-
mation would be very cumbersome. Reaction conditions which a￿orded the ￿-acylindole from
disubstituted cyclopropanes (cat. Ag￿O, THF, ￿￿ °C) yielded in decomposition of the material
and the formation of many by-products which could not be identified both for the TBS and the
￿￿￿
￿.￿ Third Approach: One Carbon Elongation
SEM series. Unfortunately, several other metal based or photochemical conditions also did not
a￿ord the desired products (cf. Tab. ￿-￿). Only in one case the formation of a defined product
could be observed (Entry ￿￿) and the outcome was very piquant. Heating in dichlorobenzene at
￿￿￿ °C for ￿￿min did not a￿ord ￿-acylindole ￿￿￿ but apparently regioisomeric compound ￿￿￿
(Scheme ￿-￿￿a). This became clear after intense NMR analyses. Based on a similar observa-
tion (Padwa, ￿￿￿￿[￿￿￿]), a proposed mechanism for this obscure transformation is shown in
(Scheme ￿-￿￿b). After formation of carbene ￿￿￿, it is assumed that a carbene C–H insertion takes
place and annelated cyclobutane ￿￿￿ is formed. Under these reaction conditions, the cyclobutane
ring is cleaved homolytically to give biradical ￿￿￿. Abstraction of a hydrogen yields ketene ￿￿￿.
It should be pointed out, that this ketene is di￿erent to the ketene which arises from the Wol￿
rearrangement (cf. Scheme ￿-￿￿ on p. ￿￿￿); the ketene is now attached to a di￿erent carbon
atom, forming a geminal disubstituted cyclpropane which divinylcyclopropane-cycloheptadiene
rearrangement yields observed product ￿￿￿.
Based on this results it is absolutely possible that the same sequence also occurs with the
disubstituted cyclopropane series. But since no carbon atoms are labeled, the outcome appears
to be identical either way.
￿.￿ Third Approach: One Carbon Elongation￿
After several a-diazo compounds were synthesized successfully, it turned out that the carbene
intermediate underwent an unexpected rearrangement. Therefore, one last trial was to elon-
gate the cyclopropane rest to yield cyclohepta[b]indole precursors like ￿￿￿ (Scheme ￿-￿￿). This
compound can be useful in two di￿erent points of view. On the one hand (R￿ = Cl) it can be
transformed with an amine base into the corresponding ketene ￿￿￿ (Wedekind’s method).[￿￿￿–￿￿￿]
This approach towards the ketene intermediate would furnish the ketene without a carbene
intermediate, thus avoiding an undesirable rearrangement. On the other hand (R￿ = alkoxy), the
enolate of this compound (￿￿￿) can undergo a divinylcyclopropane-cycloheptadiene rearrange-
ment. This rearrangement should even proceed at low temperatures as it has the driving force
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Scheme ￿-￿￿. Retrosynthetic analysis: third approach.
￿ Work on the third approach was undertaken contemporaneously with the work which finally led to the final
approach and the syntheses of Ervatamia alkaloids. Therefore, the investigation of several reactions of some advanced
intermediates found a more or less abrupt end in favor to the final approach.
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Scheme ￿-￿￿. Synthesis of (Z)-olefin ￿￿￿.
from the enolate. Several enolate driven divinylcyclopropane-cycloheptadiene rearrangement
are known from literature (cf. Section ￿.￿).
En route to the synthesis of compounds like ￿￿￿ the synthesis of (Z)-olefin ￿￿￿ was carried
out (Scheme ￿-￿￿). On the one hand, this olefin can be generated by a Wittig olefination from
N-tosyl protected indole-￿-carbaldehyde (￿￿￿). The corresponding Wittig salt ￿￿￿ was prepared,
but it turned out that this reaction a￿orded olefin ￿￿￿ only in low yield (￿￿%). Since the coupling
of alkynes to N-tosyl protected ￿-iodoindole (￿￿￿) has already been carried out successfully in
a previous approach (Scheme ￿.￿.￿ on p. ￿￿￿), once again a coupling strategy was taken into
account. Sonogashira coupling of ￿￿￿ with ￿-butyn-￿-ol (￿￿￿) a￿orded alkyne ￿￿￿ in very good
yield even at large scale. Modified hydrogenation conditions for the reduction of the alkyne to the
corresponding (Z)-olefin ￿￿￿ and subsequent silyl protection of the primary alcohol furnished
compound ￿￿￿ in ￿￿% overall yield (from ￿￿￿). Alternatively, the Sonogashira coupling can also
be carried out with silyl protected ￿-butyn-￿-ol ￿￿￿. This reaction a￿orded alkyne ￿￿￿ in ￿￿%
yield. Subsequent hydrogenation furnished (Z)-olefin ￿￿￿ in ￿￿% overall yield.
Both the sequence via the coupling with ￿-butyn-￿-ol (￿￿￿) and the sequence with the coupling
of its silyl derivative ￿￿￿ furnished more than enough material to investigate the upcoming
cyclopropanation reaction. Pleasingly, the developed conditions for the cyclopropanation of
olefin ￿￿￿ (Tab. ￿-￿ on p. ￿￿￿) could be applied to the cyclopropanation of olefin ￿￿￿ yielding
trisubstituted cyclopropane ￿￿￿ in ￿￿% yield (a:b = ￿:￿, work was continued only with the
a-isomer), see Scheme ￿-￿￿. Removal of the silyl protecting group with hydrogen fluoride
and subsequent oxidation of the primary alcohol with Dess–Martin periodinane (￿￿￿) a￿orded
aldehyde ￿￿￿ in ￿￿% yield. Alternatively, this aldehyde can be synthesized from aldehyde ￿￿￿
via homologization with methoxymethylenetriphenylphosphine and subsequent hydrolysis
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Scheme ￿-￿￿. Third approach: presentation of the most important reactions.
of the generated enol ether ￿￿￿. One the one hand, aldehyde ￿￿￿ was transformed into the
corresponding carboxylic acid ￿￿￿ which served as precursor for enol ether ￿￿￿. On the other
hand, the steric demand was decreased by the reduction of the ester moiety to the corresponding
alcohol. Therefore, aldehyde ￿￿￿ was converted into its acetal ￿￿￿ followed by the reduction with
DiBAL and subsequent treatment with acidic THF to obtain aldehyde ￿￿￿ in ￿￿% combined
yield. Finally, Pinnick–Lindgren oxidation furnished carboxylic acid ￿￿￿ which itself served as
precursor for enol ether ￿￿￿.
As the fourth and final approach began to provide promising results, the work of this approach
came to an end at this point and was no longer pursued.
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￿.￿ Excursus: Syntheses of Vinyl Iodide Building Blocks
Starting with the upcoming sections an olefinic fragment plays an important role. All Ervatamia
alkaloids (and also many other indole monoterpenoid alkaloids, cf. Section ￿.￿.￿ on p. ￿￿) have
in common an characteristic terminal propene moiety; based on the whole alkaloid skeleton
the olefin mostly is (E)-configured. In retrosynthetic view (Scheme ￿-￿￿) this leads to two
di￿erent synthon pairs: cyclohepta[b]indole ￿￿￿ and (Z)-iodo allylamine ￿￿￿ (Disconnection ￿),
or cyclohepta[b]indole ￿￿￿ and (Z)-iodo allyl halide ￿￿￿ (Disconnection ￿). The closure of the
piperidine ring is planned to be done by a Heck coupling reaction as Heck couplings of vinyl
halides and alkenes have proved to be useful for this fragment in the syntheses of Strychnos
alkaloids,[￿￿￿,￿￿￿] including strychnine (￿￿)[￿￿￿–￿￿￿] and minfiensine,[￿￿￿] as well as in syntheses
of sarpagine alkaloids,[￿￿￿–￿￿￿] strictamine[￿￿￿–￿￿￿] and approaches to the geissoschizine[￿￿￿] and
apogeissoschizine[￿￿￿] skeletons. All these syntheses have in common the (Z)-iodo allyl halide
building block ￿￿￿. By reason of its broad use one can think that smart and convenient pro-
cedures exist for the synthesis of this building block. Indeed, that is true nowadays due to a
straightforward protocol for the a-iodination of croton aldehyde from ￿￿￿￿.[￿￿￿] Before, it had
to be synthesized in a cumbersome multistep procedure via stannane chemistry based on a
protocol from ￿￿￿￿.[￿￿￿] Whereas (Z)-iodo allyl halide ￿￿￿ is a well-known building block, its
amine counterpart ￿￿￿ has not been investigated so far and no syntheses have been described
in literature.
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The synthesis of (Z)-￿-bromo-￿-iodobut-￿-ene (￿￿￿) is shown in Scheme ￿-￿￿ and relies on
the protocol of Kra￿t.[￿￿￿] An isomeric mixture of crotonaldehyde (￿￿￿) reacts with iodine and a
catalytic amount of DMAP in basic aqueous THF. This reaction yielded vinyl iodide ￿￿￿ and is
proposed to follow a Baylis–Hillman type pathway. Straightforward reduction of the aldehyde
followed by SN￿ displacement a￿orded pure (Z)-iodo allyl bromide ￿￿￿ in ￿￿% overall yield.
Furthermore, several additional building blocks containing the vinyl iodide motif were syn-
thesized. Aldehyde ￿￿￿ is oxidized to the corresponding carboxylic acid in ￿￿% yield with the
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Scheme ￿-￿￿. Syntheses of various intermediates which contains the vinyl iodide fragment.
Pinnick–Lindgren protocol. This building block served for upcoming amidation reactions, as
well as acid chloride ￿￿￿ which usually was used crude.
Apart from the transformation of alcohol ￿￿￿ into its corresponding bromide ￿￿￿ it was also
converted into its tosylate ￿￿￿ and its mesylate ￿￿￿ under usual conditions. The latter was then
directly transformed into azide ￿￿￿ in ￿￿% combined yield.
The most straightforward way to synthesize the amine counterpart ￿￿￿ is via reductive am-
ination of (Z)-iodo crotonaldehyde ￿￿￿ (Scheme ￿-￿￿). Numerous di￿erent protocols were
carried out,[￿￿￿–￿￿￿] but unfortunately the formation of amine ￿￿￿ was never observed and
decomposition/polymerization took place thus taking other synthetic routes into account.
The synthesis of methylamine ￿￿￿ required a lot of trials compared to its complexity and size,
and numerous attempts remained fruitless. Dominant problems were often polyalkylation or
even the formation of quaternary amine salts. In addition, all vinyl iodide building blocks turned
out to be very base-labile thus forming the corresponding alkynes quite easily via elimination
reaction.
In a first fruitful synthetic sequence (Scheme ￿-￿￿), allyl bromide ￿￿￿ was reacted with hexam-
ethylenetetramine and transformed into quaternary ammonium salt ￿￿￿ which was hydrolyzed
with ethanolic ￿￿￿ hydrochloric acid furnishing allyl amine ￿￿￿ in ￿￿% combined yield. This
reaction is known for over a century and is the so-called Delépine reaction which has general
applications in the conversion of alkyl halides into primary amines.[￿￿￿] ￿￿￿ could also be syn-
thesized from azide ￿￿￿ via Staudinger reaction.[￿￿￿] Alternatively, bromide ￿￿￿ was transferred
into carbamate ￿￿￿. For this, ￿￿￿ was reacted with potassium cyanate in methanolic dimethyl
formamide at ￿￿￿ °C for ￿￿min—a very elegant way for the introduction of a nitrogen.[￿￿￿] The
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Scheme ￿-￿￿. Syntheses of methyl amine derivative ￿￿￿.
reaction of carbamate ￿￿￿ with trimethylsilyl iodide in refluxing chloroform furnished primary
amine ￿￿￿ in ￿￿% combined yield.
Finally, the only methylation protocol which furnished methylamine ￿￿￿ was the Eschweil-
er–Clarke methylation—a special case of the Leuckart–Wallach reaction.[￿￿￿] For this, primary
amine ￿￿￿ was reacted with an aqueous solution of formaldehyde and formic acid in refluxing
ethanol. At least, this sequence a￿orded methyl amine ￿￿￿ in moderate yield.
The most straightforward approach is the SN￿ displacement of bromine by methylamine.
However, this transformation was accompanied by many problems (polyalkylation, alkyne
formation via elimination, see above). Appropriate conditions for this transformation were
obtained after extensive investigations: bromide ￿￿￿ was reacted with an aqueous solution of
methylamine (￿￿%) in EtOH–THF (￿:￿) to a￿ord methylamine ￿￿￿ in ￿￿% yield. Therefore,
the solvent was a mixture of three components and every single component was required. The
absence of one component led to the failure of this transformation. Slightly better yields were
obtained with tosylate ￿￿￿ (￿￿%). Allyl methylamine ￿￿￿ will play a major role in the synthesis
of Ervatamia alkaloids.
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￿.￿ Preliminary Considerations
So far, many experiments and approaches have been carried out and in some points the systems
became predictable concerning certain transformations. The forth and final approach towards
the syntheses of Ervatamia alkaloids took the results of all approaches so far into account and
following assumptions were made: (i) the crucial oxidation for the formation of the ￿-acylindole
moiety is one of the last steps after the piperidine ring has already been formed; (ii) the second
￿p-unit of the divinylcyclopropane-cycloheptadiene rearrangement is a terminal alkene; (iii)
installation of the vinyl iodide moiety is carried out very early in the synthesis (cf. retrosynthetic
analysis in Scheme ￿-￿).
It was shown before, that the iodine pentoxide based oxidation was successfully carried
out with di￿erent cyclohepta[b]indoles. It was indicated, that this oxidation did not a￿ord the
oxidation product when the cyclohepta[b]indole bore an additional double bond (Section ￿.￿.￿
on p. ￿￿￿), thus assuming that this oxidation is successful as soon as the piperidine ring has
been formed.
In several preliminary studies it was shown, that substituted alkenes required harsher and
prolonged reaction times for the divinylcyclopropane-cycloheptadiene rearrangement (Fig. ￿-￿).
Whereas the simplest precursor ￿￿￿‡ rearranged at ambient temperature in one hour, the disub-
stituted counterpart ￿￿￿‡ required two hours at ￿￿ °C and the trisubstituted counterpart ￿￿￿‡
even three hours at ￿￿￿ °C. Trisubstituted cyclopropane ￿￿￿‡ which also bears a terminal olefin
rearranged in two hours at ￿￿ °C. On the contrary, disubstituted cyclopropane ￿￿￿ which bears
a dithiane at the olefinic moiety required four hours at ￿￿￿ °C. This comparison shows very
well, that additional substitutions at the cyclopropane are much more tolerated than additional
substitutions at the olefinic moiety. This comparison also indicates, why the cyclohepta[b]indole
product of precursor ￿￿￿ was never obtained.
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Based on this facts, the installation of the vinyl iodide moiety is carried out very early in
the new synthetic approach to avoid additional protections. Since divinylcyclopropane ￿￿￿‡
rearranged under appropriate conditions despite the bulky rest, it is assumed that derivatives
bearing the vinyl iodide moiety and a terminal alkene (like ￿￿￿ or ￿￿￿, see Fig. ￿-￿) will also
rearrange smoothly to the corresponding cyclohepta[b]indole. Furthermore, it is assumed that
the use of an amide (￿￿￿, X = O) will yield in more robust compounds than the use of the
corresponding amine (￿￿￿, X = H,H). By reason of robustness and the knowledge, that the
planned Heck coupling reaction for the formation of the piperidine ring can be troublesome
with tertiary amines,[￿￿￿] a late-stage reduction to the required amine is proposed.
￿.￿ Towards the Final Synthesis of Ervatamia Alkaloids
This section is a short description about important results which paved the way for the final
synthetic route of Ervatamia alkaloids.
I
R
H
base
base
R
Scheme ￿-￿. Alkyne formation via
elimination.
As already foreshadowed in Section ￿.￿, many vinyl iodide
building blocks turned out to be very base-labile thus forming the
corresponding alkynes quite easily via elimination reaction. This
is shown in detail in Scheme ￿-￿. Indeed, the base-mediated cou-
pling per se of carbamate ￿￿￿ and cyclopropyl acid chloride ￿￿￿
was successful, but the product turned out to be alkyne ￿￿￿ and
not vinyl iodide ￿￿￿. Several constellations were permuted. In
almost all cases a similar result was obtained and alkyne formation was observed. Only the
coupling of cyclopropyl carbamate ￿￿￿ and acid chloride ￿￿￿ was di￿erent; not only the coupling
did not proceed but also the silyl protecting group was cleaved under this conditions thus yielding
alcohol ￿￿￿. Therefore, the coupling was postponed at this stage and attention next turned to
the rearrangement of divinylcyclopropane ￿￿￿ (cf. Scheme ￿-￿ on p. ￿￿￿).
Enantioenriched cyclopropanation product ￿￿￿ (cf. Section ￿.￿) was reacted with hydrogen flu-
oride in THF at ￿ °C to remove the silyl protecting group and forming alcohol ￿￿￿ (Scheme ￿-￿).
Alternatively, the TBS ether was cleaved with acetic acid in aqueous THF at ambient tem-
perature.[￿￿￿,￿￿￿] Both procedures furnished alcohol ￿￿￿ in excellent yield. Next in line was
the oxidation of the primary alcohol to the corresponding aldehyde. This transformation was
best achieved using the Ley–Gri￿th oxidation;[￿￿￿,￿￿￿] the reaction with a catalytic amount of
tetrapropylammonium perruthenate and N-methylmorpholine N-oxide a￿orded aldehyde ￿￿￿
in ￿￿% yield. Nowadays, this oxidation is carried out in CH￿Cl￿ in most cases. However, the
original protocol was described in acetonitrile. And indeed, the yields for aldehyde ￿￿￿ were ￿￿%
higher on average when using acetonitrile instead of CH￿Cl￿. With ￿￿￿ in hands, Wittig reaction
a￿orded the corresponding alkene. A partial rearrangement was already observed above ￿￿ °C,
full rearrangement occurred after one hour in refluxing benzene and the rearrangement product
was obtained in ￿￿% yield. However, NMR analysis revealed that the obtained product was
not cyclohepta[b]indoline ￿￿￿ but cyclohepta[b]indole ￿￿￿. Apparently, for once this compound
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rearomatized spontaneously followed by double bond migration. This unusual transformation
made the divinylcyclopropane-cycloheptadiene rearrangement of ￿￿￿ useless. On the one hand,
the position of the migrated double bond cannot be used in a practical way for the synthesis of
Ervatamia alkaloids. On the other hand and far more important is the fact, that all stereochemical
information has been lost since obtained product ￿￿￿ lacks stereogenic centers.
The crucial ideawas then to trap divinylcyclopropane ￿￿￿ and transform it into other derivatives
before the rearrangement takes place. This required some investigations and learning concerning
the handling of compound ￿￿￿ and its intermediates. As already mentioned, ￿￿￿ starts to
rearrange at about ￿￿￿ K. To avoid any rearranged product, work-ups were carried out with
ice-cold ether and the solvent was removed in vacuo at ￿–￿ °C. All operations had to be carried out
quite quickly and upcoming transformations of divinylcyclopropane ￿￿￿ required procedures
which a￿ord the appropriate derivative in a short amount of time at ￿ °C or below.
In a first sequence divinylcyclopropane ￿￿￿ was immediately cooled down to –￿￿ °C after work-
up and treated with diisobutylaluminium hydride at this temperature for ￿￿min (Scheme ￿-￿).
To the formed aluminium species ￿￿￿‡ was added Rochelle salt and the reaction mixture was
stirred for ￿￿ h while warming up to ambient temperature. This furnished already completely
rearranged product ￿￿￿ in ￿￿% overall yield (from aldehyde ￿￿￿). During some investigations
on other cyclohepta[b]indolines it was observed, that the rearomatization step could be carried
out with two equivalents of trimethylsilyl trifluoromethanesulfonate. And indeed, reaction
of cyclohepta[b]indoline ￿￿￿ with this reagent furnished cyclohepta[b]indole ￿￿￿ after ￿￿min
at ￿ °C in ￿￿% yield. In an additional step, removal of the tosyl group was carried out with
￿￿￿
￿ Total Syntheses of Ervatamia Alkaloids
N
Ts
O
O
OEt
NaHMDS, MePPh3Br,
THF, –78 °C → 0 °C, 1 h,
then ald, THF,
–78 °C, 60 min
N
Ts
O
OEt
N
Ts
OH
work-up
at 0 °
DiBAL, CH2Cl2,
–78 °C, 60 min
N
Ts
OAliBu2
add
Rochelle salt,
–78 °C → rt.,
12 h
86%
TMSOTf, CH2Cl2,
0 °C, 15 min
85%N
Ts
OH
H
Mg (20 eq.),
NH4Cl (4 eq.),
MeOH, rt., 15 min
ultrasonic
89%N
H
OH
￿￿￿
￿￿￿, ,
￿￿￿ ￿￿￿‡
￿￿￿￿￿￿￿￿￿
Scheme ￿-￿. Trapping the divinylcyclopropane intermediate.
magnesium in methanol using ultrasonic.[￿￿￿a] Indole ￿￿￿ was obtained in ￿￿% yield. N-Tosyl
indole ￿￿￿ and indole ￿￿￿ served as backup compounds as they could be transformed very easily
into the corresponding mesylate or bromide and subsequent SN￿ displacement to build the
corresponding tertiary amine/vinyl iodide moiety (read more about the amine/amide problem
above, Section ￿.￿).
With the knowledge of generating divinylcyclopropane-cycloheptadiene rearrangement prod-
ucts from trapped divinylcyclopropane ￿￿￿, attention next turned to a bold synthetic sequence
which led to the total syntheses of Ervatamia alkaloids after all.
￿.￿ Total Synthesis of (+)-￿-Oxoisomethuenine
￿.￿.￿ Trapping of Divinylcyclopropane Intermediates
The total synthesis of (+)-￿-oxoisomethuenine began with known enantioenriched aldehyde ￿￿￿
(Scheme ￿-￿). Investigations led to a synthetic route, which transformed ￿￿￿ into ￿￿￿. As de-
scribed hitherto, ￿￿￿was transformed into divinylcyclopropane ￿￿￿. With appropriate knowledge
about the handling of this compound and its upcoming derivatives, saponification of the ethyl
ester a￿orded carboxylic acid ￿￿￿. As already observed with other intermediates (Section ￿.￿.￿.￿,
p. ￿￿￿), a-cyclopropyl carboxylic acid turned out to be be very labile; temperatures above ￿￿ °C
(e.g. rotary evaporator) led to full decomposition of this compound, decomposition even occurred
partially at ￿￿ °C. Once again, work-ups were carried out with ice-cold ether and the solvent was
removed in vacuo at ￿–￿ °C. Several trials of the coupling of allyl amine ￿￿￿ with an acid chloride
resulted in alkyne formation or decomposition (Section ￿.￿). Therefore, an amide synthesis
via coupling reagents was taken into account. To avoid decomposition of carboxylic acid ￿￿￿,
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Scheme ￿-￿. Synthesis of crucial cyclohepta[b]indole derivative ￿￿￿.
the coupling should proceed at low temperatures. Best results for the coupling of amine ￿￿￿
and ￿￿￿ were achieved with HBTU and DIPEA in DMF. Pleasingly, this reaction was finished
after two hours at ￿ °C. The obtained divinylcyclopropane ￿￿￿ was then subjected to benzene (or
chloroform) and stirred four hours at ￿￿ °C to a￿ord cyclohepta[b]indoline ￿￿￿. Alternatively,
￿￿￿ was stirred in toluene at ￿￿￿ °C for just about ￿￿ min to obtain the rearranged product.
However, higher temperatures yielded in a diminished overall yield for this sequence. Cyclo-
hepta[b]indoline ￿￿￿ turned out to be somewhat unstable and decomposed slowly. Therefore,
the crude mixture was usually subjected to rearomatization conditions (TMSOTf, CH￿Cl￿, ￿ °C,
￿￿ h) and cyclohepta[b]indole was furnished in ￿￿% overall yield from aldehyde ￿￿￿.
It should be noted, that this sequence can be carried out in gram-scale and only one purification
is necessary. However, it demands knowledge about the handling of occurring intermediates,
especially ester ￿￿￿, carboxylic acid ￿￿￿, and amide ￿￿￿. In addition, simple building block ￿￿￿
can be transformed into advanced intermediate ￿￿￿ in just a day.
￿.￿.￿.￿ Variations
The synthetic route towards cyclohepta[b]indole ￿￿￿ requires certain knowledge and experience
about the handling of the intermediates. Therefore, it was tried to attach the vinyl iodide
moiety before installing the second vinyl moiety viaWittig reaction by using identical chemical
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Scheme ￿-￿. Alternative approach to aldehyde ￿￿￿.
operations. Enantioenriched cyclopropanation product ￿￿￿was therefore reacted with potassium
hydroxide in aqueous ethanol at ￿ °C for one hour to obtain the corresponding carboxylic acid
(Scheme ￿-￿) which was immediately coupled with allyl amine ￿￿￿ using the coupling reagent
HBTU and DIPEA as base. This two-step sequence a￿orded a-cyclopropyl amide ￿￿￿ in ￿￿%
overall yield. Removal of the silyl protecting group under acidic conditions and subsequent
oxidation of the primary alcohol to the corresponding aldehyde with DMP furnished ￿￿￿ in
almost quantitative yield. Although this variation looked promising so far, the transformation
into the methylene group viaWittig reaction followed by divinylcyclopropane-cycloheptadiene
rearrangement gave cyclohepta[b]indoline ￿￿￿ (cf. Scheme ￿-￿) only in moderate ￿￿% yield.
In another trial, aldehyde ￿￿￿ was converted into vinylmethoxyvinylcyclopropane ￿￿￿ with
methoxymethylenetriphenylphosphine ylide (Scheme ￿-￿). Similar to the first sequence, this
intermediate was kept at low temperatures and transformed immediately to the carboxylic acid
followed by amide formation using once again HBTU and DIPEA. The divinylcyclopropane-
cycloheptadiene rearrangement proceeded in ￿ h at ￿￿￿ °C in toluene and a￿orded cyclohep-
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Scheme ￿-￿. Rearrangement of vinylmethoxyvinylcyclopropane ￿￿￿.
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ta[b]indoline ￿￿￿ in moderate ￿￿% overall yield (unoptimized). However, this variation found
and abrupt end when rearomatization conditions were applied to ￿￿￿. Treatment of ￿￿￿ with
TMSOTf in CH￿Cl￿ at ￿ °C resulted not only in rearomatization but also in elimination of the
methoxy group. This yielded cyclohepta[b]indole ￿￿￿ and resulted in loss of not only the ketone
surrogate but also the chirality.
￿.￿.￿ Piperidine Ring Formation
Next in linewas theHeck coupling reaction for the formation of the piperidine ring (Scheme ￿-￿￿).
Extensive literature search was done in order to find Heck ring closing reactions on similar
systems. Finally, best reactions conditions were found to be: Pd(PPh￿)￿ (￿￿ mol %), K￿PO￿
(￿.￿ eq.), PhOH (￿￿mol %), Et￿N (￿.￿ eq.), PhMe (￿.￿￿ ￿), ￿￿￿ °C, ￿ h (Tab. ￿-￿, Entry ￿). This
conditions furnished the desired Heck product ￿￿￿ in excellent yield (scale: ￿￿mg up to ￿.￿ g).
However, formation of a by-product under these conditions was observed. Unfortunately, the
separation of this by-product from the desired product was quite time-consuming. By exchanging
Pd(PPh￿)￿ to Pd￿(dba)￿ and addition of DavePhos
® the formation of the undesired by-product
could be suppressed. However, the yield was about ￿￿% lower than with Pd(PPh￿)￿. In addition,
phenol was added as additive (￿￿mol %). Its positive role in some palladium-catalyzed arylations
of ketone enolates has been observed by Buchwald.[￿￿￿a] It is assumed, that the intermediacy of
a palladium phenoxide (￿￿￿, Scheme ￿-￿￿b) stabilizes an otherwise unstable intermediate and
accounts for the beneficial e￿ect of the added phenol.[￿￿￿,￿￿￿]
N
Ts
Me
NO
I
Heck reaction
N
Ts
Me
N
H
H
O
(+)-￿￿￿ (–)-￿￿￿
cf. Tab. ￿-￿
Scheme ￿-￿￿. Heck coupling reaction for the formation of the piperidine ring.
Table ￿-￿. Heck coupling conditions for the formation of the piperidine ring (cf. Scheme ￿-￿￿).
# Conditions Scale Yield [%] Notes
￿ Pd(PPh￿)￿ (￿￿mol %), K￿PO￿ (￿.￿ eq.), PhOH (￿￿mol %),
Et￿N (￿.￿ eq.), PhMe (￿.￿￿ ￿), ￿￿￿ °C, ￿ h
￿￿mg
￿￿mg
￿￿￿mg
￿￿￿mg
￿￿￿mg
￿￿￿￿mg
￿￿
￿￿
￿￿
￿￿
￿￿
￿￿
￿)
￿ Pd￿(dba)￿ (￿￿mol %), DavePhos
® (￿￿mol %), K￿PO￿ (￿.￿ eq.),
PhOH (￿￿mol %), Et￿N (￿.￿ eq.), PhMe (￿.￿￿ ￿), ￿￿￿ °C, ￿ h
￿￿￿mg
￿￿￿mg
￿￿
￿￿
—
￿) formation of a by-product which was di￿cult to separate from the product
￿￿￿
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Scheme ￿-￿￿. a) Plausible explanation for the generation of a trans-fused piperidine ring. b) Role of the phenol additive.
The determination of the configuration of the annulated ring turned out to be quite cumber-
some. ￿HNMR analysis could not reveal the relative configuration between protons H￿￿ (double
allylic proton) and H￿￿ (a-amide proton, cf. Fig. ￿-￿￿ for numeration), due to the appearance of
H￿￿ as a very broad singlet. Measurements in di￿erent solvents could not circumvent this result.
The relative configuration was finally revealed via NMR decoupling experiments. Decoupling is
the process of removing specific kinds of J-coupling interactions in order to simplify a spectrum
or identify which pairs of nuclei are involved in the J-coupling. Selected and characteristic
spectra are shown in Figures ￿-￿ to ￿-￿ and the multiplicities and coupling constants for selected
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Table ￿-￿. Multiplicities and coupling constants for selected protons (cf. Fig. ￿-￿￿ for numeration),
= decoupling of this proton took place.
# H￿￿ H￿￿ H￿￿
mult. J [Hz] mult. J [Hz] mult. J [Hz]
￿ dd ￿￿.￿, ￿.￿ br s — ddd ￿￿.￿, ￿.￿, ￿.￿
￿ d ￿.￿ ddd ￿￿.￿, ￿.￿, ￿.￿
￿ d ￿￿.￿ dd ￿￿.￿, ￿.￿
￿ dd ￿￿.￿, ￿.￿ br s —
￿￿￿
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H￿b
H￿￿
H￿￿
H￿￿
H￿a
H￿￿
Figure ￿-￿￿. Calculated conformation of Heck
product ￿￿￿, selected NOEs are highlighted.
Figure ￿-￿￿. Calculated conformation of Heck
product ￿￿￿, di￿erent viewing direction.
protons are listed in Tab. ￿-￿. This experiments revealed that ￿JH￿￿,H￿￿ = ￿.￿Hz. This evidence
supports the relative trans-configuration. The modeled trans conformer is shown in Figures ￿-￿￿
and ￿-￿￿ (the indole aromatic ring has been omitted for visibility reasons).
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_ ______ _ _0
2
4
6
8
10
12
14
20 40 60 80 100 120 140 160 1800
0
2
4
6
8
10
12
14
³J
H
H
ɸ
ɸtrans ɸcis
Figure ￿-￿￿. Graph of the Karplus relation.
In addition, the conformation of the cis- and
trans-configured products was modeled using
a professional computational chemistry soft-
ware (Spartan ’￿￿). Measurements of the dihe-
dral angle f of both conformers and compar-
ison with the Karplus equation[￿￿￿] supported
the trans relationship (ftrans = –￿￿￿°, fcis = ￿￿°).
Furthermore, extended ￿D-NOE studies were
carried out. The results of this studies could
not absolutely determine the relative configu-
ration but were consistent with the decoupling
experiments. In addition, the ￿D-NOE exper-
iments confirmed the (E)-configuration of the double bond, thus proving the double bond
did not isomerize during the Heck coupling reaction. The absolute stereochemistry was then
determined at the very end of the synthesis by comparing optical rotation signs of the synthe-
sized natural products with the original natural products. The final results confirmed the NMR
experiments and computational calculations.
Based on precedent literature,[￿￿￿,￿￿￿,￿￿￿] it was assumed that the ring closure will proceed in a
cis fashion. Based on the obtained results concerning the trans relationship and the absolute
stereochemistry, a plausible explanation for this outcome is shown in Scheme ￿-￿￿a (p. ￿￿￿).
This transformation required relatively high temperatures, no reaction occurred below ￿￿￿ °C.
Due to the excess of base, it is proposed that an epimerization at the a-amide carbon took place.
The complete tetracyclic skeleton as it occurs in the natural products have been generated.
En route to isomethuenine (￿￿, is equal to ￿￿-epimethuenine) some minor transformations
remained: (i) the reduction of the tertiary amide, (ii) reduction of the superfluous double bond,
(iii) oxidation to the corresponding ￿-acylindole, and (iv) removal of the protecting group.
￿￿￿
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￿.￿.￿ Endgame
￿.￿.￿.￿ Total Synthesis of ￿-Oxo-￿￿,￿￿-diepisilicine
With tetracycle ￿￿￿ in hands, attention next turned to the regioselective reduction or conversion
of the superfluous double bond. Several transformations were studied. The most important
investigations are shown in Scheme ￿-￿￿. Neither the selective reduction of the double bond with
diimide[￿￿￿] nor its transformation into alcohol ￿￿￿ via hydroboration was successful. In terms of
an amide reduction, the amide moiety was transferred into thioamide ￿￿￿. However, thionation
reactions with Lawesson’s[￿￿￿] reagent or Belleau’s reagent[￿￿￿] furnished thioamide ￿￿￿ only in
traces and the formation of many by-products was observed.
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Scheme ￿-￿￿. Selected failed transformations of tetracycle ￿￿￿.
Since no regioselective reduction seemed possible, tetracycle ￿￿￿ was hydrogenated at atmo-
spheric pressure in the presence of Adams’s catalyst.[￿￿,￿￿￿,￿￿￿] Although ￿￿￿ is almost insoluble
in all common alcoholic solvents, hydrogenation was completed after ￿ h in ethanol. As expected,
both olefins have been reduced and compound ￿￿￿ was obtained in ￿￿% yield (Scheme ￿-￿￿). As
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Scheme ￿-￿￿. Synthesis of ￿-oxo-￿￿,￿￿-diepisilicine.
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the oxidation to the ￿-acylindole derivative with iodine pentoxide requires an unprotected indole,
attention next turned to the removal of the tosyl group. Once again this was achieved with
magnesium in methanol using ultrasonication. Due to solubility issues of the starting material,
indole ￿￿￿was obtained in only moderate yield. Next in line was the crucial oxidation to the corre-
sponding ￿-acylindole derivative. Many approaches failed because of this crucial transformation.
Although the oxidation with iodine pentoxide was successful on test systems (Scheme ￿-￿￿ on
p. ￿￿￿), oxidation products of real substrates could never be observed (cf. Section ￿.￿.￿, p. ￿￿￿).
It was assumed, that the p-bond between C-￿￿ and C-￿￿ somehow prevented the successful
oxidation of the C-￿ position. This assumption was supported by the result of the unfruitful
oxidation of simple cyclohepta[b]indole ￿￿￿ (Scheme ￿-￿￿ on p. ￿￿￿). Cyclohepta[b]indole ￿￿￿
lacks this olefinic moiety and, pleasingly, reaction with iodine pentoxide smoothly furnished
￿-oxo-￿￿,￿￿-diepisilicine (￿￿￿) in ￿￿% yield. Once again, this result supports the assumption that
an additional olefinic moiety in the annulated cycloheptane prevents the successful oxidation.
The only remained transformation was the chemoselective reduction of the amide in the
presence of the ketone at C-￿ (basically, this moiety is more like a vinylogous amide than a
ketone). A few attempts were carried out to achieve this transformation, but attention turned
to the synthesis of (+)-￿-oxoisomethuenine (￿￿￿) as a regioselective reduction of the olefinic
moieties was achieved. ￿￿￿ is a more valuable derivative, since it can be reduced to ￿-oxo-￿￿,￿￿-
diepisilicine (￿￿￿) anyway and additionally gives access to the methuenine-type alkaloids.
￿.￿.￿.￿ Total Synthesis of (+)-￿-Oxoisomethuenine
All attempts to di￿erentiate both double bonds came to nothing so far. Another idea was a
di￿erentiation based on the fact that one of both olefins is a benzylic double bond. Acid-mediated
activation of this double bond should generate an iminium ion which could be trapped by a mild
reducing agent. Literature examples for such an ionic reduction including an indole nucleus are
scarce, only one example has been published (Sarpong, ￿￿￿￿).[￿￿￿]
However, this transformation required the removal of the tosyl group at this stage as the strong
electron-withdrawing group would probably prevent the planned activation and ionic reduction.
Usual conditions with magnesium in methanol were not applicable since tetracycle ￿￿￿ is
almost insoluble in all common alcoholic solvents. Whereas the reduction with Adam’s catalyst
proceeded despite the poor solubility in methanol (Section ￿.￿.￿.￿), only traces of detosylated
compound ￿￿￿ could be observed with magnesium in methanol. Several procedures for the deto-
sylation of arenesulfonamides are described in literature.[￿￿￿–￿￿￿] Best results were obtained using
a procedure of Hilmersson et al. who described an instantaneous deprotection of tosylamides
with samarium diiodide.[￿￿￿] This reaction requires a minimum amount of time (literally not
more than five seconds) and is usually directly quenched with an amine (pyrrolidine) and water.
This protocol furnished indole ￿￿￿ in probably quantitative yield (Scheme ￿-￿￿). The exact
yield could not be determined, since indole ￿￿￿ turned out to be very sensitive to oxidation and
therefore was usually directly used in the next step.
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Scheme ￿-￿￿. Total synthesis of (+)-￿-oxoisomethuenine (￿￿￿).
With indole ￿￿￿ in hands, the protocol of Sarpong was applied (methanesulfonic acid, triethyl-
silane, DCE, ￿￿ °C). Unfortunately, this protocol led to decomposition both at ￿￿ °C and ambient
temperature. Extended literature research was carried out[￿￿￿] and conditions were chosen which
are usually applied for the reduction of alcohols. Indole ￿￿￿ was reacted with triethylsilane
(￿￿ eq.) in CH￿Cl￿ –TFA (￿:￿) at ambient temperature for ￿ h. This protocol smoothly furnished
tetracycle ￿￿￿ via proposed iminium ion ￿￿￿ in ￿￿% combined yield (￿ steps).
As already described in Section ￿.￿.￿.￿ towards the synthesis of ￿-oxo-￿￿,￿￿-diepisilicine, the
oxidation of indole ￿￿￿ to the corresponding ￿-acylindole was carried out with iodine pentoxide in
aqueous THF at ambient temperature. This protocol smoothly furnished (+)-￿-oxoisomethuenine
(￿￿￿) in up to ￿￿% yield.￿
The only remained transformation was the chemoselective reduction of the amide in the
presence of the ketone at C-￿ (basically, this moiety is more like a vinylogous amide than a
ketone), which is described in the next section.
￿.￿ Total Synthesis of Ervatamia Alkaloids
The chemoselective reduction of amides in the presence of other more reactive reducible func-
tional groups is a highly challenging transformation, and successful examples thereof are most
valuable in synthetic organic chemistry. Only a limited amount of protocols have been described
for such transformations (Fig. ￿-￿￿). Very common are protocols for the hydrosilylation of
amides catalyzed by various platinum-group metals,[￿￿￿] as well as iron,[￿￿￿] zinc,[￿￿￿] gold,[￿￿￿]
cobalt,[￿￿￿] indium,[￿￿￿] magnesium,[￿￿￿] boron,[￿￿￿] rhodium,[￿￿￿a,￿￿￿] ruthenium,[￿￿￿] and quite
￿ It was observed, that this high yields were only observed with fresh iodine pentoxide. The yields dropped slightly
from time to time with the ongoing use of this reagent.
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Figure ￿-￿￿. General concepts for the chemoselective reduction of amides.
recently molybdenum.[￿￿￿] Another option is the transformation of the amide into the corre-
sponding thioamide via thionation reagents (e.g. Lawesson’s reagent[￿￿￿] or Belleau’s reagent[￿￿￿]).
Thioamides can then be selectively reduced via desulfurization with Raney nickel.[￿￿￿] A third
option is the activation of the amide carbonyl with strong activating agents, this yields an
imidate cation which can be selectively reduced with mild hydrides (e.g. sodium cyanoborohy-
dride). Protocols for the activation with Meerwein salts,[￿￿￿] triflic anhydride,[￿￿￿] and phosphorus
oxychloride[￿￿￿] are described.
Many protocols suggest chemoselectivity, but it is very often obvious that this is not the case.
In addition, many protocols are described with very simple molecules thus keeping the reader
in the dark about the tolerance and compatibility of many functional groups. Furthermore, in
the case of ￿-oxoisomethuenine (￿￿￿), the protocol needs to distinguish between an amide and
a vinylogous amide, thus demanding a very good chemoselectivity.
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Scheme ￿-￿￿. Conversion of amide ￿￿￿, cf. Tab. ￿-￿ for conditions.
Table ￿-￿. Attempts for the reduction of amide ￿￿￿.
# Conditions Result Ref.
￿ Tf￿O, ￿,￿-di-tert-butylpyridine, CH￿Cl￿, –￿￿ °C to ￿ °C, then NaBH￿CN,
￿ °C  rt.
—￿) [￿￿￿a]
￿ Tf￿O, ￿,￿-di-tert-butylpyridine, CH￿Cl￿, –￿￿ °C to ￿ °C, then TESH, ￿ °C  rt. —
￿) [￿￿￿a]
￿ BH￿   THF, THF, ￿ °C —
[￿￿￿,￿￿￿]
(continued on next page…)
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Table ￿-￿. (continued)
# Conditions Result Reference
￿ ￿–BBN (￿.￿ eq.), rt., ￿ h ￿￿￿ —
￿ RhH(CO)(PPh￿)￿ (￿mol %), Ph￿SiH￿, rt., ￿￿ h —
[￿￿￿a]
￿ Mo(CO)￿ (￿mol %), TMDS (￿.￿ eq.), THF, ￿￿ °C, ￿￿ h —
[￿￿￿]
￿ Ru￿(CO)￿￿ (￿mol %), TMDS (￿.￿ eq.), PhMe, ￿￿ °C, ￿ h —
￿) [￿￿￿]
￿ Zn(OAc)￿, (EtO)￿SiH, THF, ￿￿ °C —
[￿￿￿a]
￿ Me￿OBF￿, ￿,￿-di-tert-butylpyridine, CH￿Cl￿, MS ￿ Å, rt., ￿ h, then
NaBH￿CN, ￿ °C
— [￿￿￿a,￿￿￿d]
￿￿ Et￿OBF￿, CH￿Cl￿, rt., ￿￿ h, then NaBH￿, MeOH, ￿ °C ￿￿￿
[￿￿￿a,￿￿￿b]
￿￿ H￿PtCl￿   ￿H￿O (￿mol %), TMDS (￿.￿ eq.), PhMe, ￿￿ °C —
￿) [￿￿￿c]
￿￿ Tf￿O (￿.￿ eq.), CH￿Cl￿, ￿ °C, ￿￿min, then HEH (￿.￿ eq.), rt. —
￿) [￿￿￿b]
￿￿ Karstedt’s catalyst (￿mol %), Ph￿SiH￿ (￿.￿ eq.), THF, ￿￿ °C, ￿ h —
[￿￿￿e]
￿￿ RhCl(PPh￿)￿ (￿mol %), Ph￿SiH￿ (￿.￿ eq.), THF, rt., ￿￿ h —
[￿￿￿a]
￿￿ Et￿Zn (￿mol %), LiCl (￿￿mol %), TMDS, THF, rt., ￿ h —
[￿￿￿c]
￿￿ TiCl￿, NaBH￿, DME, rt., ￿￿ h ￿￿￿
[￿￿￿]
￿￿ NaBH￿, DMSO, MsOH, rt., ￿ h ￿￿￿
[￿￿￿]
￿￿ POCl￿, NaBH￿, EtOH, ￿ °C, ￿￿min ￿￿￿
[￿￿￿]
￿￿ Belleau’s reagent, THF, ￿ °C, ￿ h — —
￿￿ Lawesson’s reagent, PhH, ￿￿￿ °C, ￿ h ￿￿￿ —
￿) decomposition
As listed in Tab. ￿-￿, a chemoselective reduction of amide ￿￿￿ under a variety of conditions was
not possible. An important drawback were the demanded concentrations for the metal-catalyzed
hydrosilylation reactions. Very often a very high concentration for the successful reaction was
required, typically the protocols are run with ￿.￿ ￿ of solvent (based on the amide). Although
the developed synthetic route can produce a considerable amount of amide ￿￿￿, the reduction
attempts were usually run on scales between ￿ mg and ￿￿ mg; to make it clear, this means
less than ￿￿ ￿l of solvent even for the largest scale of ￿￿ mg. Obviously, the reactions were
carried out slightly more diluted which might have an e￿ect to the reactivity. Other special
reducing conditions furnished in some cases either alcohol ￿￿￿ or indole ￿￿￿ (Entries ￿, ￿￿,
￿￿–￿￿), thionation attempts a￿orded dithionated compound ￿￿￿ (Entry ￿￿).
At this point, plans for a chemoselective reduction were given up and attention next turned
to three further synthetic attempts. In a first attempt, the order of synthetic transformations
was changed. Amide ￿￿￿, which was obtained from the ionic reduction sequence, was first
reduced to the corresponding tertiary amine ￿￿￿ using lithium aluminium hydride in refluxing
THF (Scheme ￿-￿￿). However, attempts for the oxidation to the corresponding ￿-acylindole
￿￿￿
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Scheme ￿-￿￿. Amide reduction followed by oxidation failed to furnish ￿￿-epimethuenine (￿￿).
failed once again. It was assumed, that the tertiary amine prevented the successful oxidation.
Therefore, the reaction was repeated with the addition of one equivalent of TFA to block the
tertiary amine but without any e￿ect.
Next in line was the idea to mask the keto functionality via its transformation into a ketal
(Scheme ￿-￿￿a). Surprisingly, literature examples for similar transformation are scarce and
dated decades ago.[￿￿￿] Several attempts to synthesize dioxolane derivative ￿￿￿ a￿orded this
compound only in traces.
A third option is to reduce (+)-￿-oxoisomethuenine (￿￿￿) under harsh conditions (Scheme ￿-￿￿).
Needless to say, that the ￿-acylindole moiety will be reduced under these conditions, too. As
already mentioned, this moiety is more like a vinylogous amide than a ketone. Therefore, a
hydride reduction under harsh conditions have not necessarily a￿ord the desired product ￿￿￿;
both completely reduced compound ￿￿￿ and indole ￿￿￿ with a rearranged skeleton are conceiv-
able. Similar results were obtained by Bosch and co-workers en route to (–)-quebrachamine.[￿￿￿]
The final reduction and re-oxidation sequence is described in the next section.
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Scheme ￿-￿￿. Two additional possible attempts en route to Ervatamia alkaloids from amide ￿￿￿.
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￿.￿.￿ Total Synthesis of ￿￿-Epimethuenine
(+)-￿-oxoisomethuenine (￿￿￿) was reduced with LiAlH￿ at ￿￿ °C in THF in ￿ h. However,
LC–MS analysis revealed, that the resulted compound lacked both carbonyl functions ([M +
H]+ = ￿￿￿). Same was true for the reduction with Red-Al®. Best results to obtain isomethueni-
nol ￿￿￿ were achieved with LiAlH￿ at ￿ °C for ￿ h followed by the addition of sodium fluoride
(Scheme ￿-￿￿).[￿￿￿] Several protocols for the benzylic oxidation to the corresponding ￿-acylindole
are known. Usually, this transformation is achieved by activated manganese dioxide,[￿￿,￿￿￿–￿￿￿]
pyridinium chlorochromate,[￿￿￿] chromium trioxide,[￿￿￿] tert-butyl hypochlorite,[￿￿￿] or under
Swern type conditions.[￿￿￿] Best results for the conversion of alcohol ￿￿￿ into ￿￿-epimethuenine
(￿￿) were obtained with activated manganese dioxide (￿￿.￿ eq.) in chloroform at ambient tem-
perature (Tab. ￿-￿, Entries ￿ and ￿). This reaction was accompanied by the formation of an
unknown by-product and prolonged reaction times led to its predominated generation (Entry ￿).
The use of activated manganese dioxide in CH￿Cl￿ –THF (￿:￿) instead of chloroform led only to
the formation of minimal amounts of the natural product (Entry ￿).
With synthetic ￿￿-epimethuenine (￿￿) in hands, attention next turned to the comparison of
synthetic analytical data with the analytical data from the isolation. ￿￿ has been isolated five
times: fromHazunta modesta (Potier, ￿￿￿￿, named “Alkaloid M”),[￿￿] Pterotabema inconspicua (Le
Men-Olivier, ￿￿￿￿),[￿￿] Tabernaemontana dichotoma (Verpoorte, ￿￿￿￿),[￿￿] Pterotaberna inconspicua
(Bakana, ￿￿￿￿),[￿￿] and Ervatamia malaccensis (Clivio, ￿￿￿￿).[￿￿]
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Table ￿-￿. Conditions for the oxidation of alcohol ￿￿￿ to ￿￿-epimethuenine (￿￿).
# Conditions Scale Yield [%]￿) Notes
￿ MnO￿ (￿￿ eq.), CH￿Cl￿ –THF (￿:￿), rt., ￿ h ￿mg traces
￿)
￿ PCC, CH￿Cl￿, rt. ￿mg —
￿)
￿ oxalyl chloride, DMSO, CH￿Cl￿, –￿￿ °C, ￿ h, then Et￿N, –￿￿ °C ￿mg ￿￿
￿)
￿ CrO￿, pyridine, rt., ￿min ￿mg ￿￿
￿)
￿ MnO￿ (￿￿ eq.), CHCl￿, rt., ￿ h ￿mg ￿￿
￿)
￿ MnO￿ (￿￿ eq.), CHCl￿, rt., ￿ h ￿￿mg ￿￿ —
￿ MnO￿ (￿￿ eq.), CHCl￿, rt., ￿ h ￿￿mg ￿￿ —
￿) combined yield with previous reduction ￿) formation of by-product predominated
￿) decomposition ￿) with impurities
￿￿￿
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Figure ￿-￿￿. ￿￿-Epimet-
huenine counting.
Comparison of all reported data revealed, that it is not consistent at all.
The most detailed analysis was reported by Clivio et al. and contains full
￿H and ￿￿C NMR data. The rest published only ￿H NMR data for the
most characteristic signals: H￿, H￿￿, H￿￿, NMe and NH (cf. Fig. ￿-￿￿).
These four reports were very consistent among themselves and almost
identical data for this protons were reported, whereas the reported data
from Clivio et al. di￿ered immensely from the rest. Interestingly, the
synthetic data of ￿￿-epimethuenine was not identical to Clivio et al. but
in full accordance to the other four reports. Tab. ￿-￿ lists and compares the whole ￿H NMR data
(reported and synthetic).
In addition, comparison of ￿￿C NMR data led to the same result. The synthetic data was in
full accordance with reported data from Bakana et al. but di￿ered from Clivio et al. (Tab. ￿-￿).
Especially the olefinic signals of C￿￿ (Clivio et al.: ￿￿￿.￿ ppm, synthetic: ￿￿￿.￿ ppm, D =
 ￿.￿ ppm) and C￿￿ (Clivio et al.: ￿￿￿.￿ ppm, synthetic: ￿￿￿.￿ ppm, D = ￿.￿ ppm) di￿ered
immense.
Finally, comparison of IR data was also in full accordance with reported data (Tab. ￿-￿).
The comparison of the [a]￿￿D value is not significant, since the synthesis was started with ￿￿%
enantiomeric excess. Furthermore, the reported data is once again inconsistent (Tab. ￿-￿).
Table ￿-￿. ￿￿-Epimethuenine: comparison of synthetic ￿￿C NMR data with isolation data (all values in ppm).
C Ref. ￿￿ Ref. ￿￿ Synthetic (￿￿) D ppm (Ref. ￿￿) D ppm (Ref. ￿￿)
￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ –￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ –￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ –￿.￿ –￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿
NMe ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ –￿.￿
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Table ￿-￿. ￿￿-Epimethuenine: comparison of synthetic IR data with isolation data (all values in cm–￿).
Ref. ￿￿ Ref. ￿￿ Ref. ￿￿ Ref. ￿￿ Synthetic (￿￿) Note
￿￿￿￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿
￿￿￿￿
￿￿￿￿ ￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿ ketone
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿
￿￿￿ ￿￿￿ indole
Table ￿-￿. ￿￿-Epimethuenine: comparison of [a]￿￿D values.
Ref. ￿￿ Ref. ￿￿ Ref. ￿￿ Synthetic (￿￿)
–￿￿￿° (c = ￿.￿, CHCl￿) –￿￿￿° (c = ￿, CHCl￿) +￿￿￿° (c = ￿.￿, EtOH) –￿￿° (c = ￿.￿, CHCl￿)
Due to several inconsistencies—especially the NMR data which on the one hand di￿ered
immense from Clivio et al. but on the other hand was in full accordance to Potier et al., Le
Men-Olivier et al., Verpoorte et al., and Bakana et al. for individual protons—additional ￿￿mg of
pure ￿￿-epimethuenine (￿￿) were synthesized. This amount was su￿cient for extended NMR
studies. ￿H NMR, ￿￿C NMR, ￿H,￿H-COSY NMR, ￿H,￿￿C-HSQC NMR, ￿H,￿￿C-HMBC NMR,
and ￿H,￿H-NOESY NMR in chloroform and dimethyl sulfoxide, respectively, have confirmed
absolutely the correct structure of ￿￿-epimethuenine (￿￿). The (E)-geometry of the double
bond have been confirmed definitively via ￿H,￿H-NOESY NMR (NOE correlations between H￿￿
and H￿￿). No crystal of high quality for an X-ray analysis could be obtained of synthetic ￿￿-
epimethuenine ￿￿. Therefore, ￿￿was transformed into its ￿,￿-dinitrophenylhydrazone derivative
with Brady’s reagent.[￿￿￿] After all, the crystal quality of the ￿,￿-dinitrophenylhydrazone derivative
was not su￿cient for an X-ray analysis but its extended NMR analysis in pyridine once again
confirmed the correct structure of ￿￿-epimethuenine (￿￿).
￿.￿.￿ Total Syntheses of ￿￿,￿￿-diepisilicine and ￿￿-episilicine
A final ultimate proof for the correctness would be the transformation of synthetic ￿￿-epimethue-
nine (￿￿) into its silicine derivative via hydrogenation of the double bond. If the obtained com-
pound can be clearly identified as a silicine derivative, the precursor had to be ￿￿-epimethuenine
(￿￿) unerringly. The conversion of ￿￿-epimethuenine (￿￿) into its silicine derivatives has
not been described so far. However, similar transformation of other alkaloids have been re-
ported, e.g. the conversion of vobasine (￿￿￿) into dregamine (￿￿￿, Scheme ￿-￿￿a),[￿￿￿] or ￿￿,￿￿-
didehydroervatamine (￿￿) into ervatamine (￿￿, Scheme ￿-￿￿b).[￿￿￿] Both reports describe both
the reduction of the olefinic moiety and the reduction of the ￿-acylindole moiety. In both cases,
￿￿￿
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Scheme ￿-￿￿. Conversion of ￿￿-epimethuenine in ￿￿,￿￿-diepisilicine and ￿￿-episilicine.
the alcohol is re-oxidized to the corresponding ￿-acylindole with chromium trioxide in pyridine.
￿￿-epimethuenine ￿￿ was hydrogenated under atmospheric pressure over a catalytic amount
of Adams’s catalyst in ethanol. Full consumption of the starting material was observed already
after ￿.￿ h and NMR analysis revealed, that the ￿-acylindole moiety remained untouched and
that ￿￿,￿￿-diepisilicine (￿￿) and ￿￿-episilicine (￿￿) have been formed in a ratio of ￿￿:￿. Extended
NMR analysis of ￿￿,￿￿-diepisilicine (￿￿) confirmed its correct structure.
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Figure ￿-￿￿. ￿￿,￿￿-Diepi-
silicine counting.
￿￿,￿￿-diepisilicine (￿￿) has been isolated once so far from Ervatamia
o￿cinalis (Yue, ￿￿￿￿).[￿￿] The synthetic data of ￿￿ was in full accordance
with the reported isolation data. The obtained ￿HNMR data was almost
identical to the reported one in all properties (Tab. ￿-￿). The synthetic
compound could be definitely assigned to ￿￿,￿￿-diepisilicine. Due to the
high favorable formation of the b-epimer, the a-epimer ￿￿-episilicine
(￿￿) was produced only in traces. However, its NMR data was in ac-
cordance with the isolation data (Debray, ￿￿￿￿)[￿￿] and with the data
from the synthesis of (–)-￿￿-episilicine from Bosch and co-workers.[￿￿￿]
Furthermore, the ￿￿C NMR data and IR data were in full accordance to the reported data, too
(Tables ￿-￿￿ and ￿-￿￿). No discrepancies were observed.
￿￿￿
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Table ￿-￿. ￿￿,￿￿-Diepisilicine: comparison of synthetic ￿H NMR data with isolation data.
H ￿￿,￿￿-Diepisilicine[￿￿] Synthetic (￿￿)
ppm mult. J [Hz] ppm mult. J [Hz]
￿a ￿.￿￿ ddd ￿￿.￿, ￿.￿, ￿.￿ ￿.￿￿ ddd ￿￿.￿, ￿.￿, ￿.￿
￿b ￿.￿￿ dd ￿￿.￿, ￿￿.￿ ￿.￿￿ dd ￿￿.￿, ￿￿.￿
￿a ￿.￿￿ dd ￿￿.￿, ￿.￿ ￿.￿￿ dd ￿￿.￿, ￿.￿
￿b ￿.￿￿ dd ￿￿.￿, ￿.￿ ￿.￿￿ dd ￿￿.￿, ￿.￿
￿ ￿.￿￿ dd ￿.￿, ￿.￿ ￿.￿￿ dd ￿.￿, ￿.￿
￿￿ ￿.￿￿ ddd ￿.￿, ￿.￿, ￿.￿ ￿.￿￿ ddd ￿.￿, ￿.￿, ￿.￿
￿￿ ￿.￿￿–￿.￿￿ m ￿.￿￿–￿.￿￿ m
￿￿ ￿.￿￿–￿.￿￿ m ￿.￿￿–￿.￿￿ m
￿￿a ￿.￿￿ dd ￿￿.￿, ￿.￿ ￿.￿￿ dd ￿￿.￿, ￿.￿
￿￿b ￿.￿￿ dd ￿￿.￿, ￿.￿ ￿.￿￿ dd ￿￿.￿, ￿.￿
￿￿ ￿.￿￿–￿.￿￿ m ￿.￿￿–￿.￿￿ m
￿￿ ￿.￿￿–￿.￿￿ m ￿.￿￿ dtd ￿￿.￿, ￿.￿, ￿.￿
￿￿ ￿.￿￿ t ￿.￿ ￿.￿￿ t ￿.￿
￿￿a ￿.￿￿ dqd ￿￿.￿, ￿.￿, ￿.￿ ￿.￿￿ dqd ￿￿.￿, ￿.￿, ￿.￿
￿￿b ￿.￿￿–￿.￿￿ m ￿.￿￿–￿.￿￿ m
￿￿ ￿.￿￿–￿.￿￿ m ￿.￿￿–￿.￿￿ m
￿￿a ￿.￿￿ ddd ￿￿.￿, ￿.￿, ￿.￿ ￿.￿￿ ddd ￿￿.￿, ￿.￿, ￿.￿
￿￿b ￿.￿￿ dd ￿￿.￿, ￿￿.￿ ￿.￿ dd ￿￿.￿, ￿￿.￿
NMe ￿.￿￿ s ￿.￿￿ s
NH ￿.￿￿ br s ￿.￿￿ br s
[￿￿] H. Zhang, J. M. Yue, Helv. Chim. Acta ￿￿￿￿, ￿￿, ￿￿￿￿–￿￿￿￿
Table ￿-￿￿. ￿￿,￿￿-Diepisilicine: comparison of synthetic IR data with isolation data (all values in cm–￿).
Ref. ￿￿ Synthetic (￿￿) Note
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿ ketone
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿ ￿￿￿ indole
These results clearly proved the correct structure of ￿￿-epimethuenine (￿￿). One the one hand,
extensive ￿D and ￿D NMR analyses showed, that this data clearly belongs to the assigned struc-
ture. The (E)-geometry of the olefinic moiety have been demonstrated by the NOE correlations
between H￿￿ and H￿￿. One the other hand, the conversion of ￿￿ into ￿￿,￿￿-diepisilicine (￿￿)
￿￿￿
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Table ￿-￿￿. ￿￿,￿￿-Diepisilicine: comparison of synthetic ￿￿C NMR data with isolation data (all values in ppm).
C Ref. ￿￿ Synthetic (￿￿) D ppm (Ref. ￿￿)
￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿￿ ￿￿￿.￿ ￿￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
￿￿ ￿￿.￿ ￿￿.￿ ￿.￿
NMe ￿￿.￿ ￿￿.￿ ￿.￿
and ￿￿-episilicine (￿￿) showed, that the precursor definitely had to be ￿￿-epimethuenine (￿￿).
This leads to the result, that the reported data for ￿￿ from Clivio et al. can not be correct. It is
impossible to say, whether the group just made an unseen typo and printed the wrong values
or actually did not isolate ￿￿-epimethuenine (￿￿) from the leaves and stem bark of Ervatamia
malaccensis but a di￿erent alkaloid and misinterpreted the analytical data. In addition, this
reported data was already not in accordance with previously reported data for ￿￿ at the time of
publication (￿￿￿￿).
￿.￿.￿ Total Syntheses of Additional Ervatamia Derivatives
It was already shown, that ￿￿-epimethuenine (￿￿) was successfully transformed into two further
natural products: ￿￿,￿￿-diepisilicine (￿￿) and ￿￿-episilicine (￿￿). Furthermore, ￿￿ was converted
into another natural product: its N-oxide derivative ￿￿-epimethuenine-N-oxide (￿￿). For this
purpose, ￿￿-epimethuenine was reacted with meta-chloroperoxybenzoic acid for ￿￿min. TLC in-
dicated the presence of two compounds, the least polar one being identical to ￿￿-epimethuenine-
N-oxide (￿￿) after TLC separation (Scheme ￿-￿￿).[￿￿]
In another run, ￿￿,￿￿-diepisilicine (￿￿) was reacted with Jones reagent in acetone at ambient
temperature for ￿min. This a￿orded ￿-oxo-￿￿,￿￿-diepisilicine (￿￿) in ￿￿% yield (unoptimized)
and spectral data was in accordance to literature (Scheme ￿-￿￿).[￿￿] An alternative procedure
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using IBX in EtOAc–DMSO (￿:￿) at ￿￿ °C (according to Cook and co-workers)[￿￿￿] could not
a￿ord ￿￿.
No further transformations and syntheses of additional Ervatamia natural products have been
carried out. Some additional ideas are described in Section ￿.￿.
￿￿￿
￿Outlook and Summary
￿.￿ Outlook
Total syntheses of five Ervatamia alkaloids have been discussed. Two additional synthetic
intermediates—(+)-￿-oxoisomethuenine (￿￿￿) and ￿￿-epimethueninol (￿￿￿), Section ￿.￿.￿ on
p. ￿￿￿—have not been isolated so far from natural sources and therefore are not classified as
natural products. However, there is a high probability that this might happen in the future since
analogous derivatives from other Ervatamia alkaloids are known (Fig. ￿-￿ on p. ￿￿).
Although the final approach described a fast and reliable synthesis of Ervatamia alkaloids,
there is always room for improvement. Some proposals are discussed briefly in the upcoming
sections.
￿.￿.￿ Enantioselective Cyclopropanation
The cyclopropanation was carried out in an enantioselective fashion during the last approaches.
The use of bisoxazoline ligand ￿￿￿ improved the diastereomeric ratio drastically and led to the
formation of almost one single diastereomer. In addition, the yield was almost quantitative.
Usually, the use of bisoxazoline ligands for the metal-catalyzed cyclopropanation of olefins
furnishes enantioenriched products. In accordance to literature di￿erent ligand ratios have been
investigated. Unfortunately, the best obtained enantiomeric ratio was only ￿￿:￿￿ (Section ￿.￿,
p. ￿￿￿). Fortunately, a lot of protocols for asymmetric cyclopropanation reactions have been
described in literature. An asymmetric transition-metal-catalyzed decomposition of diazoalkanes
is known not only with copper, but also with cobalt, rhodium, ruthenium, iridium, palladium,
and mercury.[￿￿￿] Therefore, there are still lots of possibilities to raise the enantiomeric excess.
Alternatively, the investigated cyclopropanation reaction could be continued to be carried out
with copper but using other bisoxazoline ligands since many di￿erent bisoxazoline ligands are
known (Fig. ￿-￿).
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Figure ￿-￿. Structure of bisoxazoline ligands for asymmetric cyclopropanation reactions.
￿.￿.￿ Approach to Ervatamine-type Alkaloids
Heck reaction furnished tetracycle ￿￿￿ en route to ￿￿-epimethuenine. This intermediate is
ideally suited for the transformation to a-acyl amide ￿￿￿ (Scheme ￿-￿). This compound is the
precursor for all ervatamine-type alkaloids. For this purpose, several attempts for the conversion
of ￿￿￿ into ￿￿￿ were carried out (Tab. ￿-￿). The potassium or lithium enolate, respectively, was
reacted with methyl chloroformate or Mander’s reagent (methyl cyanoformate/Zyklon A).[￿￿￿] So
far, no acylation could be achieved. Alternative attempts could use the LICKOR superbase[￿￿￿]
or phosphazene bases (Schwesinger bases)[￿￿￿] for the enolate formation. Precedent literature
examples for the a-acylation of a-disubstituted amides is scarce.[￿￿￿–￿￿￿] In addition, one protocol
for the selective a-acylation of amides via dual reactivity of O-acylhydroxylamines toward zinc
enolates has been described.[￿￿￿]
With a-acyl amide ￿￿￿ in hands, almost all Ervatamia alkaloids are accessible via the described
synthetic approach towards the synthesis of ￿￿-epimethuenine (￿￿). Although ￿￿ is accessible
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Table ￿-￿. Attempts for the synthesis of compound ￿￿￿ (cf. Scheme ￿-￿).
# Conditions Yield [%]
￿ KHMDS, THF, –￿￿ °C  ￿ °C, then methyl chloroformate, THF, –￿￿ °C —￿)
￿ LDA, THF, HMPA, –￿￿ °C  ￿ °C, then Mander’s reagent, THF, –￿￿ °C —￿)
￿ tBuLi, THF, HMPA, –￿￿ °C, then Mander’s reagent, THF, –￿￿ °C —￿)
￿) no reaction
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through the described route, this natural product and its epimer methuenine (￿￿) could be
synthesized from ￿￿,￿￿-didehydroervatamine (￿￿), the direct precursor of ervatamine (￿￿), thus
making compound ￿￿￿ an ideal privileged intermediate in terms of the “Verbund”-synthesis
(Section ￿.￿).
￿.￿.￿ Piperidine Ring Formation
Section ￿.￿.￿ described the piperidine ring formation via Heck reaction. The reaction proceeded
with excellent yield and furnished Heck product ￿￿￿. A plausible explanation for the formation
of the trans-product has been described. However, this assumption has so far no evidence. This
is also important for the knowledge of the absolute stereochemistry of the cyclopropanation
product. The absolute stereochemistry was determined at the very end of the synthesis by
comparing optical rotation signs of the synthesized natural products with the original natural
products (assuming, the Heck reaction furnished the cis-product which epimerized under these
conditions, cf. Section ￿.￿.￿ on p. ￿￿￿). Based on literature protocols, the absolute stereochemistry
of the cyclopropanation product can be predicted in some cases. However, cyclopropanation
reactions with determination of the absolute stereochemistry of compounds like vinylindole ￿￿￿
are so far unprecedented, thus leading to a dubiety concerning the correct assignment of
the stereochemistry. As shown in Scheme ￿-￿, the knowledge about the correct formation
of tetracycle ￿￿￿ is important to deduce the absolute stereochemistry of the cyclopropanation
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product. Depending on the style of the ring closure, two enantiomeric cyclopropanation products
(R,S,S)-￿￿￿ and (S,R,R)-￿￿￿ can be the precursor. To investigate the piperidine ring formation,
this reaction can be carried out under radical conditions (e.g. TBTH, AIBN, PhMe, D) instead
of using a Heck coupling reaction.[￿￿￿] The a-stereogenic center cannot epimerize under these
conditions and the result should lead to a conclusion—assuming, that the same tetracyclic
skeleton with identical ring sizes is formed under radical conditions. Future work on this project
will hopefully clear all questions.
￿.￿ Résumé
This part of the thesis dealt with the cyclohepta[b]indole motif. This structural motif is found
both in natural products and in pharmaceutical compounds. Nowadays, ￿￿ natural products
containing this particular motif are known, by far the biggest part of them are Ervatamia alkaloids
(￿￿member) followed by Ambigua alkaloids (￿￿member). Several pharmaceuticals compounds
are known and six of them have been presented. Cyclohepta[b]indoles are often prepared by
means of the Fischer indoles synthesis. Although this reaction can be quite useful and satisfies
the requirements of a modern indole synthesis, it possesses certain limitations. The e￿cient
preparation of highly functionalized and unsymmetrically substituted cyclohepta[b]indoles has
therefore become of central interest for synthetic organic chemists. For the construction of
cyclohepta[b]indoles, eleven methodologies have been presented, additional ￿￿methodologies
have been described shortly and additional four methodologies for the construction of benzo-
cyclohepta[b]indoles have been shown. This makes ￿￿methodologies in total of which only two
are capable of the asymmetric construction of this structure motif.
By far the biggest progress in methodology development has been made within the last decade.
This coincides with the enhanced attention of pharmaceutical industry towards compounds
exhibiting the cyclohepta[b]indole motif. Total syntheses of natural products with this motif have
been presented and analysis especially of the most recent syntheses reveals that the methodology
development of the last decade has so far not found its way into application in complex molecule
synthesis (Fig. ￿-￿). Evermore, this showed the urgent demand for the development of synthetic
methodologies involving the construction of cyclohepta[b]indoles, explicitly when it comes to the
development of methods for enantioselective construction of this privileged structure motif.
The development of a methodology for the asymmetric construction of cyclohepta[b]indole via a
divinylcyclopropane-cycloheptadiene rearrangement has been presented. For this purpose, Chap-
ter ￿ gave an overview about the cyclopropanemotif, its syntheses and its role as a precursor in the
synthesis of cycloheptanes. Starting from indole-￿-carbaldehyde, several divinylcyclopropanes
like ￿￿￿were synthesized and it was shown, that these compounds rearrange smoothly to the cor-
responding cyclohepta[b]indolines ￿￿￿ (Scheme ￿-￿). Rearomatization could be carried out under
acidic conditions or under metal-catalyzed conditions; whereas skipped dienes like ￿￿￿ were
formed under acidic conditions, metal-catalyzed conditions furnished conjugated dienes ￿￿￿.
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Figure ￿-￿. Reported methodologies for the construction of cyclohepta[b]indoles: status quo.
Divinylcyclopropanes ￿￿￿ which were synthesized from indole-￿-carbaldehyde yielded directly
cyclohepta[b]indoles ￿￿￿. Comparing both synthetic routes leads to an interesting conclusion: de-
pending on either starting from indole-￿-carbaldehyde or indole-￿-carbaldehyde, three di￿erent
cyclohepta[b]indoles can be generated: ￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indoles (￿￿￿), ￿,￿,￿,￿￿-
tetra-hydrocyclohepta[b]indoles (￿￿￿), and ￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indoles (￿￿￿). The
position of the olefinic moiety can be controlled specifically and therefore can be of use for
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successful synthetic planning. The robustness of this methodology has been demonstrated by a
broad scope, both for the indole-￿-carbaldehyde and the indol-￿-carbaldehyde series.
Finally, the methodology has been applied for the first enantioselective total synthesis of
(S)-SIRT￿-inhibitor IV (￿￿, Scheme ￿-￿). (S)-￿￿ was furnished in ￿￿% ee and and an overall
yield of ￿￿% (starting from commercially available ￿-chloroindole-￿-carbaldehyde). For practical
purposes it is important to note that the synthetic sequence towards the synthesis of (S)-￿￿
requires only three purification steps and can be performed on a gram scale.
With the methodology in hands, attention next turned to the synthesis of Ervatamia alkaloids.
For this purpose, a brief delineation about Ervatamia alkaloids and the biosynthesis of them
has been given in Chapter ￿. The synthesis planning was based on the concept of a “Verbund”-
synthesis. Many approaches and variations have been described en route to Ervatamia alkaloids.
Although all approaches worked fine with simplified test systems, their application to the
“real” system which could lead to Ervatamia alkaloids was somehow cumbersome. Especially
the divinylcyclopropane-cycloheptadiene rearrangements of ketenes and ketene acetals are
noteworthy. Notwithstanding this, this approaches may not led to final synthesis of Ervatamia
alkaloids but extend the developed methodology nicely. Having all this results in hand, the
behavior of di￿erent systems under di￿erent conditions can be predicted very well now.
For the final approach, a synthetic route was designed to transform enantioenriched alde-
hyde ￿￿￿ into cyclohepta[b]indole ￿￿￿ (Scheme ￿-￿). This transformation was achieved via
a smart sequence by trapping the divinylcyclopropane intermediate. The whole sequence is
divided into five sub-steps; since many intermediates are instable and require direct conversion
this transformation is more or less a “one-pot”￿ conversion. This sequence contains only one
purification step and can be carried out in multigram scale. With cyclohepta[b]indole ￿￿￿ in
hands, piperidine ring formation was achieved via Heck coupling reaction which furnished the
trans-fused annulated ring. This tetracycle was then transformed in four additional steps into
the natural product ￿￿-epimethuenine (￿￿).
The total synthesis of ￿￿-epimethuenine (￿￿) contains ￿￿ steps from literature known cyclo-
propane product ￿￿￿ (and additional ￿ steps from commercially available purchased chemicals),
￿ The author distances oneself from the term “one-pot”. Although this term is very often used in publications,
supplemental data reveals, that many intermediate steps require a quick work-up thus making the synthetic sequence
not “one-pot”. Many authors just take advantage of this term to reduce the overall step count.
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only six intermediates require a purification. All steps have been optimized, thus yielding an
overall yield of ￿￿% (from literature known cyclopropanation product ￿￿￿). This overall yield
is drastically reduced in the last step: the transformation of ￿-oxoisomethuenine (￿￿￿) into
￿￿-epimethuenine (￿￿) was carried out in moderate ￿￿% yield. Notwithstanding this, this synthe-
sis is an optimized and scalable asymmetric total synthesis and allows a rapid access to Ervatamia
alkaloids. Many steps have also been carried out in multigram scale. For practical purposes it is
important to note that the synthetic sequence towards the synthesis of ￿￿-epimethuenine (￿￿)
can a￿ord approximately ￿￿￿mg of pure natural product by starting with ￿.￿ g of olefin ￿￿￿ in
less than two weeks.
With synthetic ￿￿-epimethuenine in hands, it turned out that the reported analytical data
from several isolations was inconsistent. Four reports were very consistent among them-
selves and almost identical data for characteristic protons were reported, whereas the reported
data from Clivio et al. di￿ered immensely from the rest. Interestingly, the synthetic data of
￿￿-epimethuenine (￿￿) was not identical to Clivio et al. but in full accordance to the other four
reports. Extensive ￿D–NMR and ￿D–NMR analysis and conversion of ￿￿-epimethuenine (￿￿)
into ￿￿,￿￿-diepisilicine (￿￿) and ￿￿-episilicine (￿￿) led to the result, that the reported data for
￿￿ from Clivio et al. can not be correct. It is impossible to say, whether the group just made an
unseen typo and printed the wrong values or actually did not isolate ￿￿-epimethuenine (￿￿) from
the leaves and stem bark of Ervatamia malaccensis but a di￿erent alkaloid and misinterpreted
the analytical data. In addition, this reported data was already not in accordance with previously
reported data for ￿￿ at the time of publication (￿￿￿￿).
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￿￿-Epimethuenine (￿￿) was converted into four additional Ervatamia alkaloids. As already
mentioned, ￿￿ was converted into ￿￿,￿￿-diepisilicine (￿￿) and ￿￿-episilicine (￿￿) via hydro-
genation of the olefinic moiety. In addition, ￿￿,￿￿-diepisilicine (￿￿) has been transformed into
￿-oxo-￿￿,￿￿-diepisilicine (￿￿) via Jones oxidation. Furthermore, ￿￿-epimethuenine (￿￿) was
transformed into ￿￿-epimethuenine-N-oxide (￿￿) with mCPBA.
In summary, a smart, short, optimized, high-yielding and scalable synthesis of ￿￿-epimethuenine
(￿￿) was described. Several transformations to further natural products have been demonstrated.
Nevertheless, such a big project never comes to an end. Although this work has already accom-
plished a large part, some points still need more detailed investigations as discussed above: (i)
the enantiomeric excess is only moderate and requires an optimization, (ii) this synthetic route
is ideally suited for the synthesis of a privileged intermediate which can be transformed into all
Ervatamia alkaloids, (iii) the mechanism of the Heck reaction was not fully clarified but this
knowledge is crucial for the determination of the absolute configuration of the cyclopropanation
product.
￿￿￿
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￿.￿ Biological Assays
A selection of three compounds ((+)-￿-deoxo-￿-oxoisomethuenine (￿￿￿), (+)-￿-oxoisomethueni-
ne (￿￿￿), and (–)-￿￿-epimethuenine (￿￿), Fig. ￿-￿) was tested in growth inhibitory assays with
the so-called ESKAPE panel that comprises the clinically relevant Gram-negative and Gram-
positive bacterial pathogens Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii,
and Klebsiella pneumoniae. The activity of all compounds against Methicillin-resistant S. aureus
(MRSA) and E. faecium was tested. In order to probe whether the compounds also a￿ected
eukaryotic cells, they were tested in a growth assay with the fungus C. albicans and in viability
assays with four mammalian cell lines.
The cytotoxicity was determined using WST-￿ cell proliferation assays. Targeting cell lines
were L￿￿￿mouse fibroblast, KB-￿-￿ epidermoid cervix carcinoma, and MCF-￿ breast cancer cell
lines which were incubated for ￿ days with the test substances. The acute toxicity was determined
using the FS￿-LTM conditionally immortalized human fibroblast cell line which was incubated
for ￿￿ hours with the test compounds.
These tests were carried out at Helmholtz Zentrum für Infektionsforschung in Braunschweig
by Bianka Karge under the supervision of Prof. Mark Brönstrup.
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￿.￿.￿ Investigation of the Antimicrobial Activities
Table ￿-￿. Results antimicrobial activity in % growth, E. coli.
E. coli growth in %
Ciprofloxacin –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ ￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿
￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Ciprofloxacin –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ ￿￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
Table ￿-￿. Results antimicrobial activity in % growth, P. aeruginosa.
P. aeruginosa growth in %
Amikacin –￿￿ –￿￿ –￿￿ ￿ ￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿￿.￿￿ ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Amikacin –￿￿ –￿￿ –￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿
AB ￿g/ml ￿￿.￿￿ ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
Table ￿-￿. Results antimicrobial activity in % growth. A. baumannii.
A. baumannii growth in %
Ciprofloxacin –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿ –￿ –￿ ￿￿ ￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Ciprofloxacin –￿￿ –￿￿ –￿￿ –￿￿ ￿ –￿ ￿￿ ￿￿ ￿￿ ￿￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿
￿.￿ Biological Assays
Table ￿-￿. Results antimicrobial activity in % growth. K. pneumoniae.
K. pneumoniae growth in %
Ciprofloxacin –￿ –￿ –￿ –￿ –￿ –￿ –￿ –￿ –￿ ￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Ciprofloxacin –￿ –￿ –￿ –￿ –￿ –￿ –￿ –￿ ￿￿ ￿￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
Table ￿-￿. Results antimicrobial activity in % growth. MRSA DSM.
MRSA DSM growth in %
Linezolid –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ ￿ ￿￿ ￿￿￿ ￿￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿
￿￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Linezolid ￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿ ￿￿ ￿￿ ￿￿￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
Table ￿-￿. Results antimicrobial activity in % growth. MRSA RKI.
MRSA RKI growth in %
Linezolid –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Linezolid –￿￿ –￿￿ –￿￿ –￿￿ –￿￿ ￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿
￿ Addendum
Table ￿-￿. Results antimicrobial activity in % growth. E. faecium.
E. faecium growth in %
Ciprofloxacin –￿￿ –￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Ciprofloxacin –￿ –￿ –￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿
AB ￿g/ml ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
Table ￿-￿. Results antimicrobial activity in % growth. C. albicans.
C. albicans growth in %
Amphotericin B –￿ ￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿
Compound ￿￿ ￿￿￿.￿ ￿￿.￿ ￿￿.￿ ￿￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
AB ￿g/ml ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿ ￿￿
￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿
￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿ ￿￿
Frichert F￿ ￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿ ￿￿ ￿￿
DMSO ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿ ￿￿￿
Amphotericin B –￿ –￿ –￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿ ￿￿
AB ￿g/ml ￿￿.￿￿ ￿￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿ ￿.￿￿
￿.￿.￿ Cell Viability Tests
Table ￿-￿. Results of the cell viability tests.
EC￿￿ (￿￿)
compound solvent test concentration (￿￿) L￿￿￿ KB-￿-￿ MCF-￿ FS￿-LTM
auranofin DMSO ￿￿￿ – ￿.￿ ￿.￿ ￿.￿ ￿.￿ ￿.￿
staurosporine DMSO ￿￿ – ￿.￿ — < ￿.￿ < ￿.￿ < ￿.￿
staurosporine DMSO ￿￿￿ – ￿.￿ < ￿.￿ — — —
￿￿￿ DMSO ￿￿￿ – ￿.￿ > ￿￿￿ ￿ ￿￿ ￿
￿￿￿ DMSO ￿￿￿ – ￿.￿ > ￿￿￿ > ￿￿￿ ￿￿ ￿￿
￿￿ DMSO ￿￿￿ – ￿.￿ > ￿￿￿ > ￿￿￿ ￿￿￿ ￿￿
￿￿￿
￿.￿ Biological Assays
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Chart ￿-￿. Cell viability test (FS￿-LTM).
￿￿￿
￿.￿ Biological Assays
￿.￿.￿ Short Discussion
Most alkaloids from the ervitsine–ervatamine group have never been evaluated in a bioassay.
Ervatamine (￿￿) is known to be a sodium channel blocker in nerve fibers and a local anesthetic
blocker; methuenine (￿￿) is known to be an anticholinergic agent (cf. Section ￿.￿.￿).
In these tests, (+)-￿-deoxo-￿-oxoisomethuenine (￿￿￿), (+)-￿-oxoisomethuenine (￿￿￿), and
(–)-￿￿-epimethuenine (￿￿, Fig. ￿-￿) were tested in growth inhibitory assays. In addition, the
cytotoxicity was determined using WST-￿ cell proliferation assays. No antimicrobial activity
could be observed. Concerning the cytotoxic activities, ￿￿￿ was found to be the most potent
candidate and shows a fairly antiproliferative activity against human fibroblast cells and decent
cytotoxic activities against epidermoid cervix carcinoma and breast cancer cell lines. ￿￿￿ was
also found to have moderate cytotoxic activities against breast cancer and human fibroblast cells.
Interestingly, the natural product itself (￿￿) was shown to be almost ine￿ective against the tested
cell lines; only a weak cytotoxic activity against human fibroblast cells was determined. Further
investigations are currently in progress.
￿￿￿
￿ Addendum
￿￿￿
￿￿Experimental
The experimental part follows the order of the particular sections and compounds are ordered
by appearance. The general methods are described in Section A.￿ on p. ￿￿￿ and are valid for all
other experimental parts in this thesis.
￿￿.￿ Experimental Part for Section ￿.￿
￿-Tosyl-￿H-indole-￿-carbaldehyde (￿￿￿).[￿￿￿]
N
Ts
O
￿￿￿
Indole-￿-carbaldehyde (￿￿￿, ￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) was dissolved in Et￿O
(￿￿￿￿ml). Tosyl chloride (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was added in one portion
and the mixture was cooled to ￿ °C. Sodium hydroxide (￿￿% aq. solution, ￿￿￿ml)
was added slowly. The ice-bath was removed and the reactionmixture was stirred
for ￿￿ h at ambient temperature (monitored by TLC). The mixture was filtered
through a medium porosity sintered-glass funnel. The solid was repeatedly rinsed with ether
and collected. The layers of the filtrate were separated and the aqueous layers were washed
once with ether. The combined organic layers were dried over MgSO￿ and the solvent was
removed in vacuo. The obtained solid was combined with the filtride. The combined solids
were recrystallized from ethyl acetate to obtain title compound ￿￿￿ as pale yellow solid￿ (￿￿.￿ g,
￿￿￿ mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). M.p. ￿￿￿ °C (EtOH).
￿H NMR (￿￿￿ MHz,
CDCl￿) d = ￿￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NO￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿ Some batches were also colorless or pale rose, nevertheless the compound was always ' ￿￿% pure according to
NMR analysis.
￿￿￿
￿￿ Experimental
Ethyl (Z)-￿-(￿-tosyl-￿H-indol-￿-yl)acrylate (￿￿￿).[￿￿￿]
N
Ts
CO2Et
￿￿￿
Ando phosphonate (￿￿￿, ￿￿.￿ g, ￿￿.￿ mmol, ￿.￿￿ eq.) was dissolved in
anhydrous THF (￿￿￿ ml). ￿￿-crown-￿ (￿￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was
added under argon and the resulting mixture was cooled down to –￿￿ °C.
KHMDS (￿.￿ ￿ in THF, ￿￿.￿ml, ￿￿.￿mmol ￿.￿￿ eq.) was added dropwise
over ￿￿ min. After complete addition, the reaction mixture was stirred
￿￿min at –￿￿ °C, then ￿￿min at ￿ °C, then again cooled down to –￿￿ °C. Aldehyde ￿￿￿ (￿￿.￿ g,
￿￿.￿mmol, ￿.￿ eq.) was dissolved in THF (￿￿ml, added small amount of CH￿Cl￿ for complete
dissolution) and was then added dropwise to the reaction mixture over ￿￿min. After complete
addition, the reaction mixture was warmed to –￿￿ °C and stirred ￿.￿ h at this temperature
(monitored by TLC). The reaction mixture was then quenched by the addition of sat. aq. NH￿Cl
and extracted thrice with ether. Drying over MgSO￿ followed by the removal of the solvent
in vacuo a￿orded title compound ￿￿￿ as pale yellow oil which solidified below ￿￿ °C (￿￿.￿ g,
￿￿.￿mmol, >￿￿%), which was analytically pure according to ￿HNMR. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (d,
J = ￿￿.￿ Hz, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H) ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-(￿-Tosyl-￿H-indol-￿-yl)prop-￿-en-￿-ol (￿￿￿).
N
Ts
OH
￿￿￿
Ester ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in absolute THF
(￿￿ml) and cooled to –￿￿ °C. To this solutionDiBAL (￿.￿￿ in hexanes, ￿￿.￿
ml, ￿￿.￿mmol, ￿.￿ eq.) in toluene was added dropwise. The reaction was
stirred for an additional hour at that temperature before it was cautiously
quenched with sat. aq. Rochelle’s salt and stirred at ambient temperature
over night. The layers were separated and the aqueous phase was extracted two times with ethyl
acetate. The combined organic layers were dried over magnesium sulfate, and the solvents were
removed under reduced pressure to yield crude (Z)-alcohol ￿￿￿, which was purified by flash
column chromatography (ethyl acetate–hexanes, ￿:￿) to give title compound ￿￿￿ as colorless oil
(￿.￿￿ g, ￿.￿￿mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
(Z)-￿-(￿-((tert-Butyldimethylsilyl)oxy)prop-￿-en-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
DMF (￿￿ml) at room temperature and imidazole (￿.￿￿ g, ￿￿.￿mmol,
￿.￿ eq.) and TBSCl (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) were added sequentially.
The reaction mixture was stirred for one hour at that temperature before
it was diluted with water and extracted three times with Et￿O–pentane
(￿:￿). The combined organic layers were dried over magnesium sulfate and the solvents were
removed under reduced pressure to give crude ￿￿￿ as a colorless oil, which was subjected to flash
column chromatography (pentane–ether, ￿:￿) to yield (￿.￿￿ g, ￿.￿￿mmol, ￿￿%) of desired ￿￿￿.
Rf = ￿.￿￿ (pentane–ether, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. IR (neat):
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
((￿S,￿R)-￿-(￿-Tosyl-￿H-indol-￿-yl)cyclopropyl)methanol (￿￿￿).
N
Ts
OH
￿￿￿
A solution of diethylzinc (￿.￿ ￿ in hexanes, ￿￿￿ ￿L, ￿￿￿ ￿mol, ￿.￿ eq.) in
￿.￿ mL of anhydrous CH￿Cl￿ was cooled to –￿￿ °C. Freshly distilled di-
iodomethane (￿￿￿ ￿L, ￿.￿￿mmol, ￿.￿ eq.) in ￿.￿mL of anhydrous CH￿Cl￿
was added dropwise to this solution and stirred at –￿￿ °C for ￿￿minutes.
A white precipitate was formed to which (￿)-dioxaborolane ￿￿￿ (￿￿.￿mg,
￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise. Upon addition the white precipitate disappeared and a
clear solution was obtained. The reaction mixture was stirred for another ￿￿ minutes at that
temperature before alcohol ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise. The reaction
mixture was warmed to ￿ °C over one hour and then to ambient temperature over another
two hours. Saturated aqueous NH￿Cl solution was added and the phases were separated. The
aqueous phase was washed twice with ethyl acetate, the combined organic layers were dried over
magnesium sulfate and the solvents were removed in vacuo to give crude cyclopropyl alcohol ￿￿￿,
which was purified by flash column chromatography (ethyl acetate-hexanes, ￿:￿) to give ￿￿mg
(￿￿￿ ￿mol), ￿￿% of desired ￿￿￿.
The enantiomeric excess was determined to be ￿￿%by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿,
￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm): tR(minor) = ￿￿.￿min, tR(major) = ￿￿.￿min.
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd,
J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (qt,
J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (bs, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H) ppm.
￿￿￿
￿￿ Experimental
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿S,￿R)-￿-(￿-Tosyl-￿H-indol-￿-yl)cyclopropane-￿-carbaldehyde (￿￿￿).
N
Ts
O
￿￿￿
Alcohol ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in of anhydrous
DMSO (￿.￿ ml) at ambient temperature. To this solution IBX (￿￿￿ mg,
￿.￿￿mmol, ￿.￿ eq.) was added in one portion. The reaction mixture was
stirred at that temperature for three hours before it was diluted with ethyl
acetate and extracted with water. The aqueous phase was washed with
ethyl acetate twice, the combined organic layers were dried over magnesium sulfate and the
solvents were removed under reduced pressure. Crude aldehyde ￿￿￿ was purified by flash
column chromatography (ethyl acetate–hexanes, ￿:￿) to give ￿￿￿mg, ￿￿% of aldehyde ￿￿￿ as a
pale yellow oil. The enantiomeric excess was determined to be ￿￿% by chiral HPLC analysis
(AD-H, ￿.￿mlmin–￿, ￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm): tR(minor) = ￿￿.￿ min, tR(major) =
￿￿.￿min. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (tdd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat):
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NO￿S
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
General procedure for the Wittig reaction–divinylcyclopropane-cycloheptadiene rearrangement cascade
of aldehyde ￿￿￿ with non-stabilized Wittig ylides to give ￿￿￿, ￿￿￿, and ￿￿￿:
￿.￿ eq. of the respective Wittig salt was dissolved in THF at a concentration of ￿.￿￿. The solution
was cooled to –￿￿ °C and NaHMDS (￿.￿ ￿ in THF, ￿.￿ eq.) was added dropwise. The reaction
mixture was stirred at that temperature for one hour before it was stirred at ￿ °C for another ￿￿
minutes. Then it was recooled to –￿￿ °C and the aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in
THF (￿.￿ ￿) was added dropwise to the mixture. The reaction was stirred another ￿￿minutes at
that temperature before it was warmed to room temperature. After complete consumption of
starting material the reaction mixture was quenched with sat. aq. NH￿Cl solution. The phases
were separated and the aqueous phase was extracted two times with ethyl acetate. The combined
organic layers were dried over magnesium sulfate and the solvents were removed under reduced
pressure. Crude NMR indicated partial cyclization, therefore the crude product was heated
to specified temperature in benzene until the TLC analysis showed complete consumption of
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
starting material. The solvent was removed under reduced pressure and the crude mixture
was submitted to flash column chromatography to obtain pure cyclohepta[b]indolines ￿￿￿, ￿￿￿,
and ￿￿￿.
(R)-￿-Tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole (￿￿￿).
N
Ts
H
￿￿￿
According to the general procedure (￿￿min at ambient temperature), cyclo-
hepta[b]indoline ￿￿￿ was obtained as pale yellow oil (￿￿mg, ￿￿￿ ￿mol, ￿￿%).
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J =
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dddd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿
(ddq, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (dp, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat):
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿aR,￿S)-￿-Methyl-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole (￿￿￿).
N
Ts
H Me
￿￿￿
According to the general procedure (￿ h at ￿￿ °C), cyclohepta[b]indoline ￿￿￿
was obtained as pale yellow oil (￿￿mg, ￿￿￿ ￿mol, ￿￿%). The enantiomeric ex-
cess was determined to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿,
￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm): tR(major) = ￿￿.￿ min, tR(minor) =
￿￿.￿ min. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿ MHz, CDCl￿)
d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(ddt, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddq, J =
￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NO￿S [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(R)-￿,￿-Dimethyl-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole (￿￿￿).
N
Ts
H Me
Me
￿￿￿
According to the general procedure (￿ h at ￿￿￿ °C, sealed tube), cyclo-
hepta[b]indoline ￿￿￿ was obtained as pale yellow oil (￿￿ mg, ￿￿￿ ￿mol,
￿￿￿%). The enantiomeric excess was determined to be ￿￿% by chiral
HPLC analysis (AD-H, ￿.￿mlmin–￿, ￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm):
tR(minor) = ￿.￿min, tR(major) = ￿￿.￿min. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd,
J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddq, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿,
￿￿￿
￿￿ Experimental
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d =
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿NO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿￿° (c =
￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
￿-Tosyl-￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indole (￿￿￿).
N
Ts
￿￿￿
Cyclohepta[b]indoline ￿￿￿ (￿￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was dissolved in
CH￿Cl￿–acetone (￿:￿, v/v, ￿.￿ ml) and TsOH  H￿O (￿￿.￿ mg, ￿￿.￿ ￿mol,
￿.￿ eq.) was added in one portion. The reaction mixture was stirred ￿￿min at
￿￿ °C (monitored by TLC) and was then diluted with ether (￿ml) and quenched
by the addition of sat. aqueous NaHCO￿ (￿ml). The layers were separated and
the aqueous layer was extracted once with ether. The combined organic layers were dried over
MgSO￿ and the solvent was removed in vacuo. Purification by flash column chromatography
(ethyl acetate–hexanes, ￿:￿) a￿orded pure aromatized cyclohepta[b]indole ￿￿￿ as a colorless oil
(￿￿.￿ mg, ￿￿.￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿ MHz, CDCl￿) d =
￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dtt, J = ￿￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dtt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (ddt, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for
C￿￿H￿￿NO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-Tosyl-￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indole (￿￿￿).
N
Ts
￿￿￿
Cyclohepta[b]indoline ￿￿￿ (￿￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was dissolved in
anhydrous benzene (￿.￿ml) and chloridotris(triphenylphosphane)rhodium(I)
(￿￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was added. The mixture was stirred for ￿ h
at ￿￿ °C. NMR analysis of the crude mixture indicated the formation of title
compound ￿￿￿. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H [overlapped by Wilkinson’s catalyst]), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS (ESI): calcd. for
C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
General procedure for the Wittig reaction-divinylcyclopropane-cycloheptadiene rearrangement cascade
of aldehyde ￿￿￿ with stabilized Wittig ylides to give ￿￿￿ and ￿￿￿:
Aldehyde ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in benzene to give a ￿.￿ ￿ solution.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
To this solution ￿.￿ eq. of the respective stabilized ylides were added and heated to reflux until
the TLC analysis showed complete consumption of starting material. The reaction time varied
between one hour for compound ￿￿￿ and six hours for compound ￿￿￿. The reaction mixture
was cooled to room temperature, the solvents were removed in vacuo, and the crude product
was submitted to flash column chromatography.
Methyl (￿aR,￿R)-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole-￿-carboxylate (￿￿￿).
N
Ts
H CO2Me
￿￿￿
According to the general procedure, cyclohepta[b]indoline ￿￿￿ was ob-
tained as pale yellow oil (￿￿mg, ￿￿￿ ￿mol, ￿￿%). The enantiomeric excess
was determined to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿,
￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm): tR(minor) = ￿￿.￿min, tR(major) =
￿￿.￿min. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿)
d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dtd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(dq, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿NO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿￿° (c =
￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
Methyl (￿aS,￿R)-￿-methyl-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole-￿-carboxylate (￿￿￿).
N
Ts
H CO2Et
Me
￿￿￿
According to the general procedure, cyclohepta[b]indoline ￿￿￿was obtained
as pale yellow oil (￿￿mg, ￿￿￿ ￿mol, ￿￿%). The enantiomeric excess was
determined to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿, ￿￿:￿￿
iPrOH/hexanes, l = ￿￿￿ nm): tR(minor) = ￿￿.￿min, tR(major) = ￿￿.￿min.
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿,
￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J =
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dp, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
[a]￿￿D = +￿￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
￿￿.￿ Experimental Part for Section ￿.￿:
Total Synthesis of (S)-SIRT￿-inhibitor IV (￿￿)
￿-Chloro-￿-tosyl-￿H-indole-￿-carbaldehyde (￿￿￿).
N
Ts
O
Cl
￿￿￿
Commercial available ￿-chloro-￿H-indole-￿-carbaldehyde (￿.￿￿ g, ￿￿.￿mmol,
￿.￿ eq.) was suspended in CH￿Cl￿ (￿￿ml). To this mixture was sequentially
added triethylamine (￿.￿mL, ￿￿.￿mmol, ￿.￿ eq.) and tosyl chloride (￿.￿￿ g,
￿￿.￿mmol, ￿.￿ eq.) at room temperature. The reaction mixture was stirred
for ￿￿ hours, then concentrated to yield a brown powder, which was washed
with CH￿Cl￿ then water and acetone yielding aldehyde ￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿￿%) as a white
amorphous powder. ￿H NMR (￿￿￿ MHz, DMSO) d = ￿￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
DMSO) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿ClNO￿S
[M + H]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-(￿-Chloro-￿-tosyl-￿H-indol-￿-yl)prop-￿-en-￿-ol (￿￿￿).
N
Ts
Cl
OH
￿￿￿
Sodium hydride (￿￿% suspension in mineral oil, ￿￿￿mg, ￿.￿￿mmol,
￿.￿￿ eq.) was suspended in THF (￿￿ml) and cooled to ￿ °C. To this
mixture ethyl ￿-(diphenoxyphosphoryl)acetate (￿.￿￿ g, ￿.￿￿ mmol,
￿.￿￿ eq.) dissolved in THF (￿￿ml) was added dropwise and stirred
at ￿ °C until gas evolution had ceased. The yellow solution was cooled
to –￿￿ °C and aldehyde ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) in THF–DMF (￿:￿, ￿￿ml) was added
dropwise. The reaction was stirred at that temperature for five hours before it was slowly warmed
to room temperature over night. The mixture was quenched with saturated NH￿Cl solution and
extracted three times with ethyl acetate. The combined organic layers were dried overmagnesium
sulfate and the solvents were removed under reduced pressure to yield crude product, which was
submitted to the next reaction without any further purification. The crude ester was dissolved in
THF (￿￿ml) and cooled to –￿￿ °C. To this solution DiBAL (￿ ￿ in PhMe, ￿￿.￿mL, ￿.￿ eq.) was
added dropwise. The reaction was stirred for one hour at –￿￿ °C before it was quenched with
sat. aq. Rochelle’s salt. The mixture was extracted three times with ethyl acetate, the combined
organic layers were dried over magnesium sulfate, and the solvents were removed under reduced
pressure. The crude product was recrystallized from ethyl acetate–hexanes (￿:￿) to furnish allylic
alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿￿%). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H),
￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿,
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿ClNO￿S
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
((￿R,￿S)-￿-(￿-Chloro-￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methanol (￿￿￿).
N
Ts
Cl
OH
￿￿￿
A solution of diethylzinc (￿.￿￿ in hexanes, ￿￿.￿ml, ￿￿.￿mmol, ￿.￿ eq.)
in anhydrous CH￿Cl￿ (￿￿ml) was cooled to –￿￿ °C. Freshly distilled
diiodomethane (￿.￿￿ml, ￿￿.￿mmol, ￿.￿ eq.) in anhydrous CH￿Cl￿ (￿￿
ml) was added dropwise to this solution and stirred for ￿￿minutes at
–￿￿ °C. A white precipitate was formed to which (￿)-dioxaborolane ￿￿￿
(￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) was added dropwise. Upon addition the white precipitate disappeared
and a clear solution was obtained. The reaction mixture was stirred for another ￿￿minutes at
that temperature before alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was added in portions. The
reaction mixture was warmed to ￿ °C over one hour and then to ambient temperature over
another two hours. Saturated aqueous NH￿Cl solution was added and the layers were separated.
The aqueous phase was washed twice with ethyl acetate, the combined organic layers were
dried over magnesium sulfate and the solvents were removed in vacuo to give crude cyclopropyl
alcohol ￿￿￿, which was purified by flash column chromatography (ethyl acetate-hexanes, ￿:￿) to
give ￿.￿￿ g (￿.￿￿mmol, ￿￿%) of desired ￿￿￿. The enantiomeric excess was determined to be ￿￿%
by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿, ￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm): tR(minor) =
￿￿.￿min, tR(major) = ￿￿.￿min.
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (qt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (q, J =
￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿ClNNaO￿S [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿R,￿S)-￿-(￿-Chloro-￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carbaldehyde (￿￿￿).
N
Ts
Cl
O
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
DMSO (￿￿ml) at ambient temperature. To this solution IBX (￿.￿￿ g,
￿.￿￿mmol, ￿.￿ eq.) was added in one portion. The reactionmixture was
stirred at that temperature for three hours before it was diluted with
ethyl acetate and extracted with water. The aqueous phase was washed
with ethyl acetate twice, the combined organic layers were dried over magnesium sulfate and
the solvents were removed under reduced pressure. An analytical sample of crude aldehyde ￿￿￿
was purified by flash column chromatography (ethyl acetate–hexanes, ￿:￿) to give aldehyde ￿￿￿
as a pale yellow oil. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿,
￿￿￿
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￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (tt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿
(dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d =
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿ClNNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿°
(c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿aS,￿S)-￿-Chloro-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole-￿-carboxamide (￿￿￿).
N
Ts
Cl
NH2
O
H
￿￿￿
Phosphonoamide ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in
THF (￿￿ml) at ￿ °C. To this mixture potassium tert-butoxide (￿￿￿mg,
￿.￿￿mmol, ￿.￿ eq.) was added in one portion. The reaction mixture
was stirred for ￿￿minutes at that temperature before aldehyde ￿￿￿
(￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was added dropwise at ￿ °C. The reaction
was stirred for ￿￿minutes at ￿ °C and further ￿￿minutes at room temperature before it was
quenched with saturated NH￿Cl solution. The phases were separated extracted two times with
ethyl acetate and the combined organic layers were dried over magnesium sulfate and the
solvents were removed under reduced pressure. The crude product was redissolved in benzene
and heated at reflux for one hour. The mixture was cooled to room temperature the solvent
was removed in vacuo and crude ￿￿￿ was subjected to flash column chromatography (ethyl
acetate–hexanes, ￿:￿) to give ￿￿￿ mg (￿￿% over two steps) of pure ￿￿￿. ￿H NMR (￿￿￿ MHz,
CDCl￿) d = ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (dddd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (bs, ￿H), ￿.￿￿ (p,
J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR
(￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿ClN￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿￿°
(c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(S)-￿-Chloro-￿-tosyl-￿,￿,￿,￿,￿,￿￿-hexahydrocyclohepta[b]indole-￿-carboxamide (￿￿￿).
N
Ts
Cl
NH2
O
￿￿￿
Tricycle ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq) was dissolved in ethanol
(￿￿ ml). Palladium on charcoal (￿￿%, ￿￿ mg) was added and the
mixture was hydrogenated at ￿ bar for ￿￿minutes. The palladium
was filtered o￿ and an analytical sample of ￿￿￿ was purified for
characterization. ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (bs, ￿H), ￿.￿￿ (bs, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J =
￿￿.￿, ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿,
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿ClN￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿￿°
(c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(S)-￿-Chloro-￿,￿,￿,￿,￿,￿￿-hexahydrocyclohepta[b]indole-￿-carboxamide [ (S)-SIRT￿-Inhibitor IV ]
(￿￿).
N
H
Cl
NH2
O
￿￿
Crude ￿￿￿ was added to samarium iodide (￿.￿ ￿ solution in THF,
￿￿ ml) at room temperature, then immediately water (￿￿ eq.) and
pyrrolidine (￿￿ eq.) were added, and the reaction was quenched with
saturated NH￿Cl solution. The phases were separated extracted two
times with ethyl acetate and the combined organic layers were dried
over magnesium sulfate and the solvents were removed under reduced pressure. Crude ￿￿
was subjected to flash column chromatography (ethyl acetate–hexanes, ￿:￿) to a￿ord (S)-SIRT￿-
inhibitor IV (￿￿, ￿￿￿ mg, ￿.￿￿ mmol, ￿￿% over two steps). The enantiomeric excess was
determined to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿ mlmin–￿, ￿￿:￿￿ iPrOH/hexanes,
l = ￿￿￿ nm): tR(minor) = ￿￿.￿min, tR(major) = ￿￿.￿min.
￿H NMR (￿￿￿MHz, MeOD) d = ￿.￿￿
(dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (qd, J = ￿￿.￿, ￿￿.￿, ￿.￿ Hz, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, MeOD) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿ClN￿O [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿° (c = ￿.￿￿,
CHCl￿). NMR spectra on page ￿￿￿.
￿￿.￿ Experimental Part for Section ￿.￿
Ethyl (￿S,￿S,￿R)-￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-
carboxylate (￿￿￿).
N
Ts
OTBS
EtO2C
￿￿￿
A flame-dried Schlenk tube was charged with [Cu(OTf)]  PhH (￿￿.￿mg,
￿￿ ￿mol, ￿.￿ mol %), (S)-tBu-BOX ligand ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol,
￿.￿ mol %), and olefine ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) in the glove-
box. The tube was flushed with argon and freeze-pump-thaw degassed
CH￿Cl￿ (￿.￿ml) was added. The reaction mixture was stirred ￿￿min at
ambient temperature to produce a deep-green clear solution. A solution
of ethyl diazoacetate (commercial, contains '￿￿ wt. % dichloromethane; ￿.￿ ml, ￿￿.￿ mmol,
￿.￿ eq.) in freeze-pump-thaw degassed CH￿Cl￿ (￿￿.￿ml) was added via syringe pump over ￿￿ h
at ambient temperature (N￿ evolution) at which the solution became orange. The solution was
￿￿￿
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filtered over a plug of celite to a￿ord a clear yellow solution. The solvent was removed under
reduced pressure to obtain crude ￿￿￿ as yellow oil. Purification by flash column chromatography
a￿orded pure cyclopropane ￿￿￿ as pale yellow oil (￿.￿￿ g, ￿.￿￿ mmol, ￿￿%) which solidified
below ￿ °C.
Note: Depending on the quality of the purification, the product always containsmarginal amounts
of fumaric acid diethyl ester. For this reason, cyclopropane ￿￿￿ usually was subjected to the next
step without purification. The enantiomeric excess was determined after cleavage of the silyl
protecting group (cf. compound ￿￿￿, p. ￿￿￿).
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark blue with vanillin).
￿H NMR (￿￿￿MHz, CDCl￿) d =
￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (t,
J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (tt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿Hz, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. IR (neat): ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D =  ￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
￿-(((tert-Butyldimethylsilyl)oxy)methyl)-N-methyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-car-
boxamide (￿￿￿).
N
Ts
OTBS
NHMeO
￿￿￿
In a sealed tube, ester ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
MeOH (￿.￿ml) and methylamine (￿￿% aq. solution, ￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿￿ eq.) was added. The sealed tube was heated for ￿ h to ￿￿ °C (moni-
tored by TLC). The reactionmixture was diluted with ether and quenched
by the addition of sat. aq. NH￿Cl. The layers were separated, the aque-
ous layer was extracted once with ether and the combined organic layers
were dried over sodium sulfate. The solvent was removed in vacuo
and the crude was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain
amide ￿￿￿ as white foam (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(s, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
tert-Butyl (￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carbo-
nyl)(methyl)carbamate (￿￿￿).
N
Ts
OTBS
NMeBocO
￿￿￿
Amide ￿￿￿ (￿￿.￿ mg, ￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿￿￿ ￿l). Boc￿O (￿￿.￿mg, ￿￿ ￿mol, ￿.￿￿ eq.) and DMAP (￿.￿mg,
￿￿ ￿mol, ￿.￿ eq.) were added and the reaction mixture was stirred
￿￿min at ambient temperature. The reaction mixture was diluted with
ether and quenched by the addition of sat. aq. NH￿Cl. The layers
were separated, the aqueous layer was extracted once with ether and the
combined organic layers were dried over sodium sulfate. The solvent
was removed in vacuo and the crude was subjected to flash column chromatography to obtain
title compound ￿￿￿ as colorless oil (￿￿.￿ mg, ￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿,
stains dark green with vanillin). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd,
J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿
(s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿Hz, ￿H) ppm. HRMS
(ESI): calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methanol (￿￿￿).
N
Ts
OTBS
OH
￿￿￿
Racemic ester ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in an-
hydrous toluene (￿￿.￿ ml) and cooled to ￿ °C. LiBH￿ (￿.￿ ￿ in THF,
￿.￿￿ml, ￿￿.￿mmol, ￿.￿ eq.) was added dropwise to the bright yellow
solution. The reaction mixture was stirred ￿￿min at this temperature,
then additional ￿ h at ￿￿￿ °C (the solution became colorless now). The
reaction mixture was cooled to ￿ °C, chloroform was added and subse-
quent ￿% HCl. The layers were separated and the aqueous layer was
washed once with chloroform. The combined organic layers were dried over sodium sulfate and
the solvent was removed under reduced pressure. Purification by flash column chromatography
(hexanes–EtOAc, ￿:￿  ￿:￿) a￿orded pure alcohol ￿￿￿ as colorless oil (￿.￿￿ g, ￿.￿￿mmol, ￿￿%).
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd,
J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s,
￿H), –￿.￿￿ (d, J = ￿￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
–￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl methanesul-
fonate (￿￿￿).
N
Ts
OTBS
OMs
￿￿￿
Alcohol ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ ml) and cooled to ￿ °C. Et￿N (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.)
was added dropwise followed by the addition of MsCl (￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.). The reaction mixture was stirred at this temperature for ￿￿min
(monitored by TLC), then diluted with ether and quenched by the ad-
dition of sat. aq. NH￿Cl–NaCl (￿:￿). The aqueous layer was extracted
twice with ether, the combined organic layers were dried over sodium
sulfate and the solvent was removed under reduced pressure to obtain mesylate ￿￿￿ which was
used crude for the next steps. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains with CAN and vanillin).
HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿-(￿-(Bromomethyl)-￿-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
Br
￿￿￿
Alcohol ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ ml) and cooled to ￿ °C. Triphenylphosphine (￿￿￿ mg,
￿￿￿ ￿mol, ￿.￿ eq.) was added followed by tetrabromomethane (￿￿￿mg,
￿￿￿ ￿mol, ￿.￿ eq.). The reaction mixture was stirred ￿min at ￿ °C (pro-
longed reaction times lead to complete decomposition of the material),
then diluted with ether and quenched by the addition of brine. The
aqueous layer was washed once with ether and the combined organic
layers were dried over sodium sulfate. The solvent was removed under reduced pressure and
the material was subjected to a short filtration over a plug of silica (￿ cm) to obtain bromide ￿￿￿
(￿￿￿ mg, ￿￿￿ ￿mol, ￿￿%) as colorless oil. This compound tended to rapid decomposition,
therefore it was used quickly for the next steps. Rf = ￿.￿￿ (pentane–ether, ￿￿:￿). HRMS (ESI):
calcd. for C￿￿H￿￿BrNNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿-(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(iodomethyl)cyclopropyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
I
￿￿￿
Alcohol ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous ben-
zene (￿￿￿ ￿l). To this solution was added imidazole (￿￿.￿mg, ￿￿￿ ￿mol,
￿.￿ eq.) and PPh￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.). The mixture was stirred
until full dissolution of all components (slightly heating or ultrasonic
may be necessary). Iodine (￿￿.￿ mg, ￿￿￿ ￿mol ￿.￿ eq.) was dissolved
in benzene (￿￿￿ ￿l) to obtain a dark purple solution which was added
dropwise to the reaction mixture. After complete addition, the reaction
mixture was diluted with EtOAc and sat. aq. sodium thiosulfate was added. The layers were
separated and the aqueous layer was extracted once with EtOAc. The combined organic layers
were dried over magnesium sulfate and the solvent was then removed under reduced pressure.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
This a￿orded iodide ￿￿￿ as orange oil which was directly used in the next steps due to its insta-
bility. Rf = ￿.￿￿ (hexanes–EtOAc, ￿￿:￿). HRMS (ESI): calcd. for C￿￿H￿￿INNaO￿SSi [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl ￿-nitroben-
zenesulfonate (￿￿￿).
N
Ts
OTBS
ONs
￿￿￿
Alcohol ￿￿￿ (￿￿.￿ mg, ￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿￿￿ ￿l) and cooled to ￿ °C. Et￿N (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was
added dropwise followed by the addition of nosyl chloride (￿￿.￿ mg,
￿￿ ￿mol, ￿.￿ eq.). The reaction was stirred ￿￿ min at ￿ °C and ￿ h at
ambient temperature before diluted with EtOAc and quenched by the
addition of ￿%HCl. The layers were separated and the aqueous layer
was extracted once with EtOAc. The combined organic layers were dried
over sodium sulfate and the solvent was then removed under reduced pressure. This a￿orded
nosylate ￿￿￿ (￿￿.￿mg, ￿￿ ￿mol, ￿￿%) as orange oil which was directly used in the next steps
due to its instability. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd. for C￿￿H￿￿N￿O￿S￿Si
[M + H]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl ￿-methyl-
benzenesulfonate (￿￿￿).
N
Ts
OTBS
OTs
￿￿￿
Alcohol ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ml) and cooled to ￿ °C. Et￿N (￿￿ ￿l, ￿￿￿, ￿.￿ eq.) was added
dropwise followed by the addition of tosyl chloride (￿￿.￿mg, ￿￿￿ ￿mol,
￿.￿ eq.). The reaction was stirred ￿￿ min at ￿ °C and ￿ h at ambient
temperature before diluted with EtOAc and quenched by the addition of
￿% HCl. The layers were separated and the aqueous layer was extracted
once with EtOAc. The combined organic layers were dried over sodium
sulfate and the solvent was then removed under reduced pressure. This a￿orded tosylate ￿￿￿
(￿￿.￿ mg, ￿￿￿ ￿mol, ￿￿%) as yellow oil which was directly used in the next steps due to its
instability. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿￿
￿￿ Experimental
￿-(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(((￿-methoxybenzyl)oxy)methyl)cyclopropyl)-￿-tosyl-
￿H-indole (￿￿￿).
N
Ts
OTBS
OPMB
￿￿￿
Alcohol ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhy-
drous CH￿Cl￿ (￿.￿ ml) and cooled to ￿ °C. ￿-Methoxybenzyl-￿,￿,￿-
trichloroacetimidate (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added followed
by the addition of triflic acid (￿ drop). Stirring was continued at this
temperature for ￿￿￿ min (monitored by TLC). The reaction mixture
was then diluted with EtOAc and quenched by the addition of pH ￿.￿
phosphate bu￿er. The aqueous layer was extracted twice with EtOAc and
the combined organic layers were dried over sodium sulfate. After evaporation of the solvent,
the crude residue was subjected to a quick flash column chromatography (hexanes–EtOAc, ￿:￿)
to obtain pure PMB protected alcohol ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol, ￿￿%) as pale yellow oil. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains excellent with CAN to give a blue-purple color). ￿HNMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(tt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for
C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(methoxymethyl)cyclopropyl)-￿-tosyl-
￿H-indole (￿￿￿).
N
Ts
OTBS
OMe
￿￿￿
Alcohol ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿.￿ml) and cooled to ￿ °C. Sodium hydride (￿￿% in mineral oil,
￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added and the reaction was stirred ￿min
at this temperature. Methyl iodide (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was then
added and the reaction was stirred ￿￿ min at ￿ °C and additional ￿ h
at ambient temperature (monitored by TLC). The reaction mixture was
diluted with chloroform and quenched by the addition of ￿%HCl. The
aqueous layer was washed once with chloroform and the combined organic layers were dried
over sodium sulfate. After evaporation of the solvent, the crude residue was subjected to a quick
flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure methyl ether ￿￿￿ (￿￿.￿mg,
￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd,
J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm.￿ HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿ signals in aromatic area are overlapped by C￿D￿ signal
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿-(￿-(Azidomethyl)-￿-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
N3
￿￿￿
Mesylate ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous DMF
(￿.￿ ml) and sodium azide (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was added
in one portion. The reaction mixture was stirred for ￿￿￿min at ￿￿ °C
(monitored by TLC) before it was diluted with ether and quenched by the
addition of water. The layers were separated and the aqueous layer was
extracted twice with ether. The combined organic layers were dried over
magnesium sulfate and the solvent was removed in vacuo to obtain crude
azide ￿￿￿ as a pale yellow oil which was quickly purified by a short flash column chromatography
(hexanes–EtOAc, ￿￿:￿￿) and directly used for the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿-(((tert-Butyldimethylsilyl)oxy)methyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methanamine (￿￿￿).
N
Ts
OTBS
NH2
￿￿￿
Azide ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in THF–H￿O (￿￿:￿,
￿.￿ml) and PBu￿ (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) was added at ambient tem-
perature and stirring was continued until TLC analysis showed complete
consumption of starting material (￿ h). The solvent was removed in
vacuo and the residue was dissolved in benzene (￿ml), which in turn
again was removed under reduced pressure. This sequence was repeated
three times to obtain crude amine ￿￿￿ as a pale yellow oil which was
directly used for the next step without further purification. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains
dark purple with ninhydrin). HRMS (ESI): calcd. for C￿￿H￿￿N￿O￿SSi [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿.
tert-Butyl ((￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl)-
carbamate (￿￿￿).
N
Ts
OTBS
NHBoc
￿￿￿
Variant ￿: Crude amine ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhy-
drous CH￿Cl￿ (￿.￿ ml) and Et￿N (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added
dropwise at ambient temperature followed by the addition of Boc￿O
(￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.). The reactionmixture was stirred for ￿￿min
at ambient temperature (monitored by TLC) before it was diluted with
ether and quenched by the addition of sat. aq. NaHCO￿. The layers
were separated and the aqueous layer was extracted twice with ether.
The combined organic layers were dried over magnesium sulfate and the solvent was removed
in vacuo to obtain crude carbamate ￿￿￿ as an orange oil which was directly used for the next
step without further purification.
Variant ￿: Crude azide ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in absolute MeOH–THF
(￿:￿, ￿.￿ ml). Boc￿O (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) followed by palladium on charcoal (￿￿%,
￿￿￿
￿￿ Experimental
￿￿.￿mg, ￿.￿￿￿mmol, ￿.￿￿ eq.) were added and the reaction mixture was hydrogenated (p(H￿) =
￿ atm) at ambient temperature for ￿￿min (monitored by TLC). The reaction mixture was filtered
over a plug of celite to yield carbamate ￿￿￿ in quantitative yield, which was directly used for
the next step without further purification. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
tert-Butyl ((￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl)-
(methyl)carbamate (￿￿￿).
N
Ts
OTBS
NMeBoc
￿￿￿
Variant ￿: Carbamate ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved
in anhydrous DMF (￿.￿ml) and the solution was cooled to ￿ °C. NaH
(￿￿% in mineral oil, ￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) was added in one
portion followed by the addition of methyl iodide (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿
eq.) and the solution was stirred ￿￿min at ￿ °C and ￿￿￿min at ambient
temperature. The reaction mixture was diluted with ether and quenched
by the addition of water. The layers were separated and the aqueous layer
was extracted thrice with ether. The combined organic layers were dried over magnesium sulfate
and the solvent was removed in vacuo to obtain crude N-methylcarbamate ￿￿￿. Purification by
flash column chromatography (hexanes–EtOAc, ￿:￿) a￿orded pure N-methylcarbamate ￿￿￿ as a
colorless oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿% over five steps).
Variant ￿: Crude amine ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous CH￿Cl￿
(￿.￿ml) and Et￿N (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise at ambient temperature followed
by the addition of Boc￿O (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.). The reactionmixture was stirred for ￿￿min
at ambient temperature (monitored by TLC) before it was diluted with ether and quenched
by the addition of sat. aq. NaHCO￿. The layers were separated and the aqueous layer was
extracted twice with ether. The combined organic layers were dried over magnesium sulfate
and the solvent was removed in vacuo to obtain crude carbamate ￿￿￿ which was subjected to
flash column chromatography (hexanes–EtOAc, ￿:￿) to a￿ord pure N-methylcarbamate ￿￿￿ as a
colorless oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿% over three steps).
Variant ￿: tert-Butyl methylcarbamate (￿￿￿, ￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
anhydrous DMAc (￿.￿ ml) and cooled to ￿ °C under an argon atmosphere. Sodium hydride
(￿￿% in mineral oil, ￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added and the reaction mixture was stirred
￿￿min at this temperature. A solution of bromide ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous
DMAc (￿.￿ml) was added to the reaction mixture and stirring was continued for additional ￿ h at
ambient temperature. The reaction mixture was diluted with ether and brine. The aqueous layer
was extracted once with EtOAc and the combined organic layers were dried over magnesium
sulfate. The solvent was evaporated in vacuo and the crude residue was subjected to flash column
chromatography to obtain pure N-methylcarbamate ￿￿￿ as a colorless oil (￿￿￿mg, ￿￿￿ ￿mol,
￿￿%). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
(dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿Hz, ￿H) ppm. ￿￿C NMR
(￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, -￿.￿, –￿.￿ ppm. IR (neat): ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for
C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)-N-methyl-
methanamine (￿￿￿).
N
Ts
OTBS
NHMe
￿￿￿
Bromide ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in EtOH–THF
(￿:￿, ￿.￿ml) and cooled to ￿ °C. Methylamine (￿￿% aq. solution, ￿￿￿ ￿l,
￿.￿￿ mmol, ￿￿.￿ eq.) was added and the reaction mixture was stirred
￿￿min at this temperature before it was diluted with ether and sat. aq.
K￿CO￿. The phases were separated and the aqueous layer was extracted
twice with ether. The combined organic layers were dried over sodium
sulfate and the solvent was removed under reduced pressure to yield
amine ￿￿￿ as pale yellow oil which was directly used in the next step. HRMS (ESI): calcd. for
C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
tert-Butyl ((￿-(hydroxymethyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl)(methyl)-
carbamate (￿￿￿).
N
Ts
OH
NMeBoc
￿￿￿
A solution of TBS protected alcohol ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous THF (￿.￿ ml) was added dropwise to HF   pyr. (￿￿% w/w,
￿.￿ml) at ￿ °C. The reaction mixture was stirred ￿￿min at ￿ °C and ￿￿min
at ambient temperature (monitored by TLC) before it was diluted with
ether and quenched by the addition of sat. aq. NaHCO￿. The layers
were separated and the aqueous layer was extracted twice with ether and
once with ethyl acetate. The combined organic layers were extracted
once with ￿ ￿ HCl and the organic layer was dried over magnesium sulfate. The solvents were
removed under reduced pressure and the crude oil was purified by flash column chromatography
(hexanes–EtOAc, ￿:￿) to obtain pure alcohol ￿￿￿ as a colorless foam (￿￿mg, ￿￿￿ ￿mol, ￿￿%). Rf =
￿.￿￿ (hexanes–EtOAc, ￿:￿). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS
(ESI): calcd. for C￿￿H￿￿N￿O￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
tert-Butyl ((￿-formyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl)(methyl)carbamate (￿￿￿).
N
Ts
O
NMeBoc
￿￿￿
Alcohol ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ml) and sodium bicarbonate (￿￿.￿mg, ￿.￿￿mmol, ￿￿.￿ eq.)
was added in one portion followed by the addition of Dess–Martin periodi-
nane (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.). The suspension was stirred for ￿￿min at
ambient temperature before the addition of sat. aq. NaHCO￿ quenched the
reaction. Sat. aq. Na￿S￿O￿ was added and the solution was stirred ￿￿min
at ambient temperature. The layers were separated and the aqueous phase
was extracted thrice with CH￿Cl￿. The combined organic layers were dried over magnesium
sulfate and the solvent was removed under reduced pressure to furnish crude title compound ￿￿￿.
Purification by flash column chromatography (hexanes–EtOAc, ￿:￿) gave aldehyde ￿￿￿ as white
foam (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark red with vanillin).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (br s,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d =
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI):
calcd. for C￿￿H￿￿N￿O￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
tert-Butyl methyl((￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indol-￿-yl)methyl)carbamate (￿￿￿).
N
Ts
H
NMeBoc
￿￿￿
Methyltriphenylphosphonium bromide (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿￿ eq.)
was dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under an
argon atmosphere. NaHMDS (￿.￿ ￿ in THF, ￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.)
was added dropwise and the reaction mixture was stirred ￿￿ min at
–￿￿ °C, then ￿￿min at ￿ °C and then again ￿min at –￿￿ °C to obtain a
bright yellow suspension. A solution of aldehyde ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol,
￿.￿ eq.) in anhydrous THF (￿.￿ml) was added dropwise at –￿￿ °C and the reaction mixture was
continued stirring at this temperature for ￿￿min, then additional ￿￿min at ambient temperature.
The reactionmixture was diluted with ether and quenched by the addition of sat. aq. NH￿Cl. The
aqueous layer was extracted twice with ether and the combined organic layers were dried over
sodium sulfate. The solvent was removed under reduced pressure, the crude was dissolved in
benzene and was stirred ￿￿￿min at ￿￿ °C (monitored by TLC). The solvent was removed in vacuo
and the residue was purified by flash column chromatography (hexanes–EtOAc, ￿.￿:￿) to a￿ord
cyclohepta[b]indoline ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%) as colorless oil. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, Wittig product, stains brown with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, [￿,￿] product,
stains brown with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J =
￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (dd, J =
￿￿￿
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￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿, ￿￿￿ K) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿, ￿￿￿ K) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, –￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd.
for C￿￿H￿￿N￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
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￿-Iodo-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
I
￿￿￿
Indole (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was dissolved in absolute DMF (￿￿￿ml). Potas-
sium hydroxide pellets (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) were added to this solution
and stirring was continued at ambient temperature until full dissolution of all
components. A solution of iodine (￿￿.￿ g, ￿￿￿mmol, ￿.￿￿ eq.) in absolute DMF
(￿￿￿ml) was added dropwise to the reaction mixture at ambient temperature over
￿￿ min. After complete addition, the reaction mixture was stirred for additional ￿￿ min at
this temperature. Once again, potassium hydroxide pellets (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) were
added to the reaction mixture followed by the subsequent addition of tosyl chloride (￿￿.￿ g,
￿￿￿ mmol, ￿.￿ eq.). The reaction mixture was stirred at ambient temperature for additional
￿￿ h (monitored by TLC) and then divided into two parts. To each part ￿￿￿￿ ml of H￿O and
￿￿￿ ml of ether were added. After separation of the layers, the aqueous layer was extracted
thrice ether and the combined organic layers were dried over sodium sulfate. The solvent was
removed under reduced pressure to obtain a crude red residue. Title compound ￿￿￿was obtained
after recrystallization from hexanes (￿￿.￿ g, ￿￿.￿mmol, ￿￿%) as a pale orange solid. Rf = ￿.￿￿
(hexanes–EtOAc, ￿￿:￿). M.p. ￿￿￿ °C. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿
(s, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿INNaO￿S [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-Tosyl-￿H-indol-￿-yl)prop-￿-yn-￿-ol (￿￿￿).[￿￿￿]
N
Ts
OH
￿￿￿
￿-Iodo-￿-tosyl-￿H-indole (￿￿￿, ￿￿￿mg, ￿.￿mmol, ￿.￿ eq.), bis(triphenylphos-
phine)palladium(II) dichloride (￿￿mg, ￿￿ ￿mol, ￿.￿mol %) and copper(I)
iodide (￿￿mg, ￿￿￿ ￿mol, ￿.￿mol %) were dissolved in anhydrous degassed
DMF (￿ml). Et￿N (￿.￿ml, ￿￿mmol, ￿.￿ eq.) and propargyl alcohol (￿￿￿ ￿l,
￿.￿ mmol, ￿.￿ eq.) were added at ambient temperature and the reaction
mixture was stirred ￿￿min at this temperature under an argon atmosphere
(monitored by TLC). The reaction mixture was diluted with ether and sat. aq. NH￿Cl. The
aqueous layer was separated and washed three additional times with ether. The combined organic
￿￿￿
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layers were dried over magnesium sulfate and the solvent was removed under reduced pressure.
The crude was subjected to flash column chromatography (hexanes–EtOAc, ￿.￿:￿  ￿:￿) to obtain
title compound ￿￿￿ as white powder (￿￿￿mg, ￿.￿￿mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd,
J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (br s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿-(￿-((tert-Butyldimethylsilyl)oxy)prop-￿-yn-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
DMF (￿￿ ml). Imidazole (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) and TBSCl (￿.￿￿ g,
￿￿.￿mmol, ￿.￿ eq.) were added at ambient temperature and the reaction
mixture was stirred ￿￿min at this temperature before it was diluted with
brine and pentane–ether (￿:￿). The layers were separated and the aqueous
layer was washed twice with pentane–ether (￿:￿). The combined organic
layers were dried over sodium sulfate and the solvent was removed in vacuo. The crude was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain title compound ￿￿￿
as pale yellow powder (￿￿.￿ g, ￿￿.￿ mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NO￿SSi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(Z)-￿-(￿-((tert-Butyldimethylsilyl)oxy)prop-￿-en-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
￿￿￿
Alkyne ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in MeOH–EtOAc
(￿:￿￿, ￿ ml) and Lindlar catalyst (￿￿ mol %) was added. The reaction
mixture was stirred vigorously and hydrogenated (p = ￿￿￿ psi) at ambient
temperature for ￿￿min. The reaction mixture was filtered over a plug of
silica to obtain title compound ￿￿￿ as pale yellow oil (￿￿￿mg, ￿￿￿ ￿mol,
￿￿%). Rf = ￿.￿￿ (pentane–ether, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿￿
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–￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for
C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-Tosyl-￿H-indol-￿-yl)propiolaldehyde (￿￿￿).
N
Ts
O
￿￿￿
To anhydrous CH￿Cl￿ (￿.￿ml) were added DMSO (￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.)
and pivaloyl chloride (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) and the solution was cooled
down to –￿￿ °C under an argon atmosphere. The solution was stirred ￿￿min
at this temperature, then a solution of alcohol ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous CH￿Cl￿ (￿.￿ ml) was added dropwise. After consumption of
the starting material (￿￿min), Et￿N (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) was added
and the reaction mixture was stirred additional ￿￿min at –￿￿ °C and then additional ￿￿min
at ambient temperature. The reaction mixture was diluted with CH￿Cl￿ and quenched by the
addition of sat. aq. NH￿Cl. The layers were separated and the aqueous layer was extracted twice
with CH￿Cl￿. The combined organic layers were dried over sodium sulfate and the solvent
was removed in vacuo to obtain crude ￿￿￿ which was directly used in the next step. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿).
￿-((￿,￿-Dioxolan-￿-yl)ethynyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
O
O
￿￿￿
Crude aldehyde ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous benzene
(￿.￿ml). Ethylene glycol (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) and TsOH  H￿O (￿.￿mg,
￿￿ ￿mol, ￿.￿ eq.) were added. To this solution, some magnesium sulfate
was added and the resulting suspension was refluxed for seven hours. The
reaction mixture was cooled to ambient temperature, diluted with EtOAc and
sat. aq. NH￿Cl was added. The layers were separated and the aqueous layer
was extracted twice with EtOAc. The combined organic layers were dried over
sodium sulfate and the solvent was removed in vacuo to obtain crude ￿￿￿ which was filtered
over a plug of silica to obtain purified dioxolane ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿% over two steps),
which was directly used in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd.
for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(Z)-￿-(￿-(￿,￿-Dioxolan-￿-yl)vinyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
O
O
￿￿￿
Pd/CaCO￿ (￿%, ￿￿.￿mg, ￿ ￿mol, ￿mol %) was added to ￿.￿ml of absolute
methanol. Quinoline (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) was added and themixture
was stirred vigorously at ambient temperature for ￿￿min (this step was
crucial for the poisoning of the palladium). A solution of alkyne ￿￿￿ (￿￿mg,
￿￿￿ ￿mol, ￿.￿ eq.) was added and the reaction mixture was hydrogenated
(p(H￿) = ￿￿￿ psi) at ambient temperature for ￿￿min (monitored by TLC). The reaction mixture
was filtered over a plug of celite and the solvent was removed in vacuo to obtain crude diox-
￿￿￿
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olane ￿￿￿ which was subjected to flash column chromatography (pentane–ether, ￿:￿) to a￿ord
pure dioxolane ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%) as a colorless oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl (￿S,￿S,￿R)-￿-(￿,￿-dioxolan-￿-yl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
Ts
O
O
EtO2C
￿￿￿
A flame-dried Schlenk tube was charged with [Cu(OTf)]  PhH (￿.￿ mg,
￿.￿ ￿mol, ￿.￿mol%), (S)-tBu-BOX ligand ￿￿￿ (￿.￿mg, ￿.￿ ￿mol, ￿.￿mol%),
and olefine ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in the glovebox. The tube was
flushed with argon and freeze-pump-thaw degassed CH￿Cl￿ (￿.￿ml) was
added. The reaction mixture was stirred ￿￿min at ambient temperature
to produce a deep-green clear solution. A solution of ethyl diazoacetate
(commercial, contains '￿￿ wt. % dichloromethane; ￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) in freeze-pump-
thaw degassed CH￿Cl￿ (￿.￿ml) was added via syringe pump over ￿￿ h at ambient temperature
(N￿ evolution) at which the solution became orange. The solution was filtered over a plug
of celite to a￿ord a clear yellow solution. The solvent was removed under reduced pressure
to obtain crude ￿￿￿ as yellow oil which was directly subjected to the next step due to large
amounts of fumaric acid diethyl ester. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd. for
C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
Ethyl (￿S,￿S,￿R)-￿-formyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
Ts
EtO2C
O
￿￿￿
Crude dioxolane ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in acetone–H￿O
(￿:￿, ￿ml) and pyridinium p-toluenesulfonate (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
was added. The reaction mixture was refluxed for ￿ h, then the solvent
was evaporated and the residue was partitioned between EtOAc and bicarb.
The layers were separated and the aqueous layer was washed once with
EtOAc. The combined organic layers were dried over sodium sulfate and the
solvent was removed in vacuo to yield crude aldehyde ￿￿￿ which was subjected to flash column
chromatography (hexanes–EtOAc, ￿:￿) to obtain pure aldehyde ￿￿￿ as white foam (￿￿.￿ mg,
￿￿￿ ￿mol, ￿￿%). ￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J =
￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR
(￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿
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￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
Methyl (E)-￿-(￿-tosyl-￿H-indol-￿-yl)acrylate (￿￿￿).
N
Ts
CO2Me
￿￿￿
General procedure: a solution of aldehyde ￿￿￿ (￿.￿ eq.) and methyl (triph-
enylphosphoranylidene)acetate (￿.￿ eq.) in benzene (￿.￿ ￿) was refluxed
for ￿ h. The solvent was removed in vacuo and the residue was subjected to
flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain ester ￿￿￿ in
￿￿% yield (E/Z =￿:￿, separable). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d =
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl (E)-￿-(￿-tosyl-￿H-indol-￿-yl)acrylate (￿￿￿).
N
Ts
CO2Et
￿￿￿
nBuLi (￿.￿ ￿ in hexanes, ￿.￿￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) was added to an-
hydrous THF (￿￿ml) at –￿￿ °C under an argon atmosphere. To this solu-
tion was added dropwise a solution of triethyl phosphonoacetate (￿.￿ ml,
￿￿.￿mmol, ￿.￿ eq.) in anhydrous THF (￿￿ml). The resulting solution was
stirred additional ￿￿min at –￿￿ °C, then a solution of aldehyde ￿￿￿ (￿.￿￿ g,
￿￿.￿mmol, ￿.￿ eq.) in anhydrous THF (￿￿ml, in some cases a little amount
of anhydrous CH￿Cl￿ was added to get a full dissolution of the aldehyde) was added dropwise.
The resulting solution was stirred additional ￿￿￿min at –￿￿ °C (monitored by TLC) before it was
diluted with ether and quenched by the addition of sat. aq. NH￿Cl. The layers were separated
and the aqueous layer was extracted twice with ether. The combined organic layers were dried
over sodium sulfate and the solvent was evaporated. The residue can be purified by flash column
chromatography (hexanes–EtOAc, ￿:￿) to obtain pure (E)-ester ￿￿￿ in quantitative yield as pale
yellow oil which solidified below ￿ °C. Usually, it was used crude in the upcoming steps. Rf =
￿.￿￿ (hexanes–EtOAc, ￿:￿). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t,
J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NO￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
(E)-￿-(￿-Tosyl-￿H-indol-￿-yl)prop-￿-en-￿-ol (￿￿￿).
N
Ts
OH
￿￿￿
Ester ￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous CH￿Cl￿
(￿￿￿ml) and cooled to –￿￿ °C. DiBAL (￿.￿￿ in hexanes, ￿￿.￿ml, ￿￿.￿mmol,
￿.￿ eq.) was added dropwise and after complete addition the reaction
mixture was stirred additional ￿ h at –￿￿ °C. Sat. aq. Rochelle’s salt was
added and the resulting suspension was diluted with CH￿Cl￿ and stirred
vigorously for ￿￿ h at ambient temperature. The layers were separated and
the organic layer was extracted once with water and once with brine. The combined aqueous
layers were then extracted thrice with EtOAc. The combined organic layers were dried over
sodium sulfate and the solvent was removed in vacuo to obtain title compound ￿￿￿ as yellow
solid (￿￿.￿ g, ￿￿.￿ mmol, ￿￿%) which was analytically pure according to NMR analysis. Rf =
￿.￿￿ (hexanes–EtOAc, ￿:￿). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd,
J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(E)-￿-Tosyl-￿-(￿-((￿-(trimethylsilyl)ethoxy)methoxy)prop-￿-en-￿-yl)-￿H-indole (￿￿￿).
N
Ts
OSEM
￿￿￿
Crude alcohol ￿￿￿ (￿￿.￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿￿ml) and cooled to ￿ °C. To this solution SEMCl (￿￿%, ￿.￿￿ml,
￿￿.￿ mmol, ￿.￿ eq.) was added at which the solution turned dark red.
Hünig’s base (￿.￿￿ml, ￿￿.￿mmol, ￿.￿￿ eq.) was added dropwise over
￿￿min at ￿ °C and the resulting solution was stirred for additional ￿￿min
at this temperature, then additional ￿.￿ h at ambient temperature before
it was diluted with ether and quenched by the addition of sat. aq. NH￿Cl. The layers were
separated and the aqueous layer was extracted once with ether. The combined organic layers were
dried over magnesium sulfate and the solvent was removed under reduced pressure to obtain
crude title compound ￿￿￿which was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿  ￿:￿) to obtain pure SEM protected alcohol ￿￿￿ as colorless oil (￿.￿￿ g, ￿￿.￿mmol, ￿￿%
yield over three steps).
Note: Caution! SEM protected alcohol ￿￿￿ turned out to be a strong lachrymator and should only be
handled in a well ventilated fume hood.
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿
(t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd,
J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿
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￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd.
for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(E)-￿-(￿-((tert-Butyldiphenylsilyl)oxy)prop-￿-en-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBDPS
￿￿￿
Crude alcohol ￿￿￿ (￿￿.￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
DMF (￿￿ ml). Imidazole (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) and TBDPSCl
(￿.￿ml, ￿￿.￿mmol, ￿.￿￿ eq.) were added at ambient temperature and
the reaction mixture was stirred ￿￿ min at this temperature before
it was diluted with brine and pentane–ether (￿:￿). The layers were
separated and the aqueous layer was washed twice with pentane–ether
(￿:￿). The combined organic layers were dried over sodium sulfate and the solvent was removed
in vacuo. The crude was subjected to flash column chromatography (pentane–ether, ￿￿:￿) to
obtain title compound ￿￿￿ as pale yellow foam (￿.￿￿ g, ￿￿.￿mmol, ￿￿% over three steps). Rf =
￿.￿￿ (hexanes–EtOAc, ￿:￿). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d,
J = ￿.￿ Hz, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd,
J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(E)-￿-(￿-((tert-Butyldimethylsilyl)oxy)prop-￿-en-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
￿￿￿
Crude alcohol ￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous
DMF (￿￿ml). Imidazole (￿.￿￿ g, ￿￿￿mmol, ￿.￿ eq.) and TBSCl (￿.￿￿ g,
￿￿.￿mmol, ￿.￿￿ eq.) were added at ambient temperature and the reaction
mixture was stirred ￿￿min at this temperature before it was diluted with
brine and pentane–ether (￿:￿). The layers were separated and the aqueous
layer was washed twice with pentane–ether (￿:￿). The combined organic
layers were dried over sodium sulfate and the solvent was removed in vacuo. The crude was
subjected to flash column chromatography (pentane–ether, ￿￿:￿) to obtain title compound ￿￿￿
as pale yellow foam (￿￿.￿ g, ￿￿.￿mmol, ￿￿% over three steps). Rf = ￿.￿￿ (pentane–ether, ￿￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J =
￿.￿ Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J =
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d =
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
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Ethyl-￿-(￿-tosyl-￿H-indol-￿-yl)-￿-(((￿-(trimethylsilyl)ethoxy)methoxy)methyl)cyclopropane-￿-car-
boxylate (￿￿￿).
N
Ts
OSEM
EtO2C
￿￿￿
Olefine ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
benzene (￿ ml) and anhydrous copper(I) sulfate (￿￿￿ mg, ￿￿￿ ￿mol,
￿￿ mol %) was added. The resulting suspension was stirred under
refluxing conditions and a solution of ethyl diazoacetate (commercial,
contains '￿￿ wt. % dichloromethane; ￿.￿￿ml, ￿￿.￿mmol, ￿.￿ eq.) in
benzene (￿￿ml) was added via syringe pump over a period of ￿ hours.
After complete addition, the reaction mixture was refluxed additional ￿￿min. The reaction was
cooled to ambient temperature and filtered over celite. A short flash column chromatography
(hexanes–EtOAc, ￿:￿) was done to separate the obtained product ￿￿￿ (inseparable cis/trans-
mixture) which then was used directly in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿-(￿-Tosyl-￿H-indol-￿-yl)-￿-(((￿-(trimethylsilyl)ethoxy)methoxy)methyl)cyclopropyl)-
methanol (￿￿￿).
N
Ts
OSEM
OH
￿￿￿
Crude ester ￿￿￿ (￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿￿ml) and cooled to –￿￿ °C. DiBAL (￿.￿ ￿ in hexanes, ￿.￿ml,
￿.￿ eq.) was added dropwise and the reaction mixture was stirred for
additional ￿ h at –￿￿ °C before quenched by the addition of sat. aq.
Rochelle’s salt. The resulting mixture was stirred vigorously over night.
The layers were separated and the aqueous layer was extracted twice
with CH￿Cl￿. The combined organic layers were dried over sodium
sulfate and the solvent was removed under reduced pressure. The remained crude was subjected
to flash column chromatography (hexanes–EtOAc, ￿:￿   ￿.￿:￿   ￿:￿   ￿:￿) to separate the
diastereomeric alcohols. Cis-product ￿￿￿ was obtained as colorless oil (￿￿￿ mg, ￿.￿￿ mmol),
the corresponding diastereomer was also obtained as colorless oil (￿￿￿ mg, ￿￿￿ mmol). The
endo/exo-ratio of the cyclopropanation was therefore determined to be ￿.￿:￿ and the combined
yield was ￿￿% over two steps. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, minor diastereomer, stains dark
blue with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, major diastereomer, stains dark blue with
vanillin). ￿H NMR (￿￿￿ MHz, CDCl￿, major diastereomer) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (tt,
J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿H NMR (￿￿￿MHz, CDCl￿, minor
diastereomer) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H),
￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI):
￿￿￿
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calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿ (major diastereomer). HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿ (minor diastereomer).
NMR spectra on page ￿￿￿.
￿-(￿-Tosyl-￿H-indol-￿-yl)-￿-(((￿-(trimethylsilyl)ethoxy)methoxy)methyl)cyclopropane-￿-carbalde-
hyde (￿￿￿).
N
Ts
OSEM
O
￿￿￿
Alcohol ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ ml). Cornforth reagent (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) and
molecular sieves (￿ Å, ￿￿￿mg) were added. The resulting mixture was
stirred ￿ h at ambient temperature (monitored by TLC) before it was
diluted with ether and filtered through a plug of silica (￿ cm). The
filtrate was reduced, diluted with ether and once again filtered through
a plug of silica (￿ cm). Evaporation of the solvent yielded aldehyde ￿￿￿
(￿￿￿ mg, ￿￿￿ ￿mol, ￿￿%) as yellow oil which was directly used in the next steps. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿.
Ethyl ￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate
(￿￿￿).
N
Ts
OTBS
EtO2C
￿￿￿
A flame-dried Schlenk tube was charged with [Cu(OTf)]  PhH (￿￿.￿mg,
￿￿.￿ ￿mol, ￿.￿ mol %) and olefine ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) in
the glovebox. The tube was flushed with argon and freeze-pump-thaw
degassed CH￿Cl￿ (￿.￿ml) was added. A solution of ethyl diazoacetate
(commercial, contains '￿￿ wt. % dichloromethane; ￿￿￿ ￿l, ￿.￿￿mmol,
￿.￿ eq.) in freeze-pump-thaw degassed CH￿Cl￿ (￿￿.￿ml) was added via
syringe pump over ￿￿ h at ambient temperature (N￿ evolution) at which the solution became
orange. The solution was filtered over a plug of celite to a￿ord a clear yellow solution. The
solvent was removed under reduced pressure to obtain crude ￿￿￿ as yellow oil which was
directly subjected to the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd. for
C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methanol (￿￿￿).
N
Ts
OTBS
OH
￿￿￿
Crude ester ￿￿￿ (￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿￿.￿ml) and cooled to –￿￿ °C. DiBAL (￿.￿ ￿ in hexanes, ￿.￿ml,
￿.￿mmol, ￿.￿ eq.) was added dropwise and stirring was continued for ad-
ditional ￿ h at –￿￿ °C after complete addition. The reaction was quenched
by the addition of sat. aq. Rochelle’s salt and diluted with CH￿Cl￿. The
suspension was stirred vigorously over night. The layers were separated
and the aqueous layer was extracted twice with CH￿Cl￿. The combined
￿￿￿
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organic layers were dried over sodium sulfate and the solvent was removed under reduced
pressure. The remained crude was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿  ￿:￿) to separate the diastereomeric alcohols. Cis-product ￿￿￿ was obtained as colorless oil
(￿￿￿ mg, ￿.￿￿ mmol), the corresponding diastereomer ￿￿￿ was also obtained as colorless oil
(￿￿￿mg, ￿￿￿ ￿mol). The endo/exo-ratio of the cyclopropanation was therefore determined to
be ￿.￿:￿ and the combined yield was ￿￿% over two steps. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, major
diastereomer, stains dark blue with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, minor diastereomer,
stains dark blue with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿, major diastereomer) d = ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (tt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (p, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J =
￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿, major diastereomer) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿, –￿.￿ ppm. ￿HNMR (￿￿￿MHz, CDCl￿, minor diastereomer) d =
￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd,
J = ￿￿.￿, ￿￿.￿, ￿￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿, minor diastereomer) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿, –￿.￿ ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿ (major diastereomer). HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿ (minor diastereomer).
NMR spectra on page ￿￿￿.
￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carbalde-
hyde (￿￿￿).
N
Ts
OTBS
O
￿￿￿
Alcohol ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in CH￿Cl￿
(￿.￿ml). Dess–Martin periodinane (￿￿￿, ￿￿￿mg, ￿.￿￿mmol, ￿.￿￿ eq.)
and NaHCO￿ (￿.￿￿ g, ￿￿.￿ mmol, ￿￿.￿ eq.) were added and the reac-
tion mixture was stirred ￿￿ min at ambient temperature (monitored
by TLC). The reaction mixture was diluted with ether and quenched by
the addition of sat. aq. NaHCO￿. The layers were separated and the
aqueous layer was extracted once with EtOAc. The combined organic
layers were dried over magnesium sulfate and the solvent was removed under reduced pressure.
The resulting crude was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿)
to obtain aldehyde ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿%) as white foam. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿￿￿
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￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Note: Title compound ￿￿￿ tended to decomposition, storage is recommended as solution in anhydrous
benzene below –￿￿ °C.
￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carbalde-
hyde (￿￿￿).
N
Ts
OTBS
O
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
DMSO (￿.￿ml). IBX (￿￿￿, ￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) was added and the
reactionmixture was stirred at ambient temperature for five hours before
it was diluted with ethyl acetate and extracted with water. The aqueous
phase was washed with ethyl acetate twice, the combined organic layers
were dried over magnesium sulfate and the solvents were removed
under reduced pressure to obtain title compound ￿￿￿ as white foam,
which was directly used in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd.
for C￿￿H￿￿NO￿SSi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indole (￿￿￿).
N
Ts
H
OTBS
￿￿￿
Methyltriphenylphosphonium bromide (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was
dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under an argon
atmosphere. NaHMDS (￿.￿ ￿ in THF, ￿.￿ ml, ￿.￿￿ mmol, ￿.￿ eq.) was
added dropwise and the reaction mixture was stirred ￿￿ min at –￿￿ °C,
then additional ￿￿min at ￿ °C and then again recooled to –￿￿ °C to yield a
bright yellow suspension. A solution of aldehyde ￿￿￿ (￿￿￿mg, ￿.￿￿mmol,
￿.￿ eq.) in anhydrous THF (￿.￿ ml) was added and the reaction mixture was stirred ￿￿ min
at –￿￿ °C (monitored by TLC) and then additional ￿￿ min at ￿ °C. The reaction mixture was
diluted with ether and quenched by the addition of sat. aq. NH￿Cl. The layers were separated
and the aqueous layer was extracted twice with ether. The organic layers were combined, dried
over magnesium sulfate and the solvent was removed in vacuo. TLC indicated, that partial
rearrangement already took place. The crude was therefore dissolved in benzene and stirred
￿ h at ￿￿ °C to complete the rearrangement and a￿ord cyclohepta[b]indoline ￿￿￿ as white foam
(￿￿￿mg, ￿￿￿ ￿mol, ￿￿%) after removal of the solvent. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(br s, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H),
￿￿￿
￿￿ Experimental
￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿-Tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indol-￿-yl)methanol (￿￿￿).
N
Ts
H
OH
￿￿￿
A solution of crude cyclohepta[b]indoline ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) in anhy-
drous THF (￿.￿ml) was added dropwise to HF   pyr. (￿￿% w/w, ￿.￿ml) at
￿ °C. The reaction mixture was stirred ￿￿min at ￿ °C and ￿￿min at ambi-
ent temperature (monitored by TLC) before it was diluted with ether and
quenched by the addition of sat. aq. NaHCO￿. The layers were separated
and the aqueous layer was extracted twice with ether and once with ethyl
acetate. The combined organic layers were extracted once with ￿ ￿HCl and the organic layer
was dried over magnesium sulfate. The solvents were removed under reduced pressure and the
crude oil was purified by flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to obtain
pure alcohol ￿￿￿ as a colorless oil (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (ddd,
J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿-Tosyl-￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indol-￿-yl)methanol (￿￿￿).
N
Ts
OH
￿￿￿
Variant ￿: Cyclohepta[b]indoline ￿￿￿ (￿￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was
dissolved in ￿￿￿ ￿l of anhydrous CH￿Cl￿ and p-toluenesulfonic acid mono-
hydrate (￿.￿mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was added. The reaction mixture was
stirred over night at ambient temperature and then subjected to flash col-
umn chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to obtain rearomatized
cyclohepta[b]indole ￿￿￿ as colorless oil (￿￿.￿mg, ￿￿.￿ ￿mol, ￿￿%).
Variant ￿: Cyclohepta[b]indoline ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ ml) and pyridinium p-toluenesulfonate (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added
to yield an orange solution. To this solution was added p-toluenesulfonic acid monohydrate
(￿￿.￿ mg, ￿￿.￿ ￿mol, ￿￿ mol %) at which point the solution turned dark green. The reaction
mixture was stirred over night at ￿￿ °C and then diluted with CH￿Cl￿ and quenched by the
addition of sat. aq. NaHCO￿. The aqueous layer was extracted thrice with CH￿Cl￿, the combined
organic layers were dried over sodium sulfate and the solvent was evaporated. The residue was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to obtain rearomatized
cyclohepta[b]indole ￿￿￿ as colorless oil (￿￿￿ mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc,
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿:￿). ￿HNMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt,
J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿,￿,￿,￿￿-Tetrahydrocyclohepta[b]indol-￿-yl)methanol (￿￿￿).
N
H
OH
￿￿￿
To cyclohepta[b]indole ￿￿￿ (￿￿.￿mg, ￿￿ ￿mol, ￿.￿ eq.) in absolute MeOH
(￿.￿ ml) was added NH￿Cl (￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) and magnesium
turnings (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿.￿ eq.). The reaction mixture was irradiated
with ultrasonic at ambient temperature for ￿￿￿ min before it was diluted
with EtOAc and quenched by the addition of sat. aq. NH￿Cl. The layers
were separated and the aqueous layer was extracted twice with EtOAc. The
combined organic layers were dried over sodium sulfate and reduced in vacuo. The crude was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain indole ￿￿￿ as pale
yellow foam (￿.￿ mg, ￿￿.￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains bordeaux with
vanillin and bright red with Ehrlich’s reagent). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NNaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿,￿,￿,￿,￿,￿￿-Hexahydrocyclohepta[b]indole (￿￿￿).[￿￿￿]
N
H
￿￿￿
To phenylhydrazine (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added cycloheptanone
(￿￿.￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) and trichloroacetic acid (￿￿.￿ g, ￿￿￿ mmol,
￿.￿ eq.) (caution, highly exothermic). The reaction mixture was carefully
heated to ￿￿￿ °C for ￿min. The mixture was cooled to ambient temperature
and water was added. The mixture was filtered through a medium porosity
sintered-glass funnel and the retentate was washed with an appropriate amount of water. Cyclo-
hepta[b]indole ￿￿￿ was obtained as pale rose solid in quantitative yield. M.p. ￿￿￿ °C. ￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ (ddt, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿N [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
￿,￿,￿,￿￿-Tetrahydrocyclohepta[b]indol-￿(￿H)-one (￿￿￿).[￿￿￿]
N
H
O
￿￿￿
Cyclohepta[b]indole ￿￿￿ (￿￿￿ mg, ￿.￿ mmol, ￿.￿ eq.) was dissolved in
THF–H￿O (￿:￿, ￿￿.￿ml) and I￿O￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was added.
The resulting mixture was stirred ￿￿min at ambient temperature at which
point the reaction mixture became dark orange. The solvent was evaporated
in vacuo and the residue was partitioned between EtOAc and water. The layers
were separated and the organic layer was additionally washed once with sat. aq. Na￿S￿O￿, sat.
aq. NaHCO￿, and brine, respectively. Drying over sodium sulfate followed by flash column
chromatography (hexanes–EtOAc, ￿:￿) a￿orded ￿-oxo-cyclohepta[b]indole ￿￿￿ as pale yellow
solid (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%). M.p. ￿￿￿ °C. ￿HNMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (br s, ￿H), ￿.￿￿
(dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (p, J = ￿.￿ Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H) ppm.
￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿,￿,￿,￿-Tetrahydrocyclohepta[b]indol-￿￿(￿H)-one (￿￿￿).[￿￿￿]
N
H
O
￿￿￿
Cyclohepta[b]indole ￿￿￿ (￿￿.￿mg, ￿￿ ￿mol, ￿.￿ eq.) was dissolved in THF–H￿O
(￿:￿, ￿.￿ml) and cooled to ￿ °C. DDQ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added
and the reaction mixture was stirred at this temperature for ￿ h before it
was diluted with CH￿Cl￿ and quenched by the addition of water. The phases
were separated and the aqueous layer was extracted twice with CH￿Cl￿. The
combined organic layers were dried over sodium sulfate and the solvent was removed in vacuo to
obtain title compound ￿￿￿ (￿￿.￿mg, ￿￿ ￿mol, ￿￿%) as yellow solid. M.p. ￿￿￿ °C.HRMS (ESI):
calcd. for C￿￿H￿￿NNaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿.￿ Experimental Part for Section ￿.￿
(Z)-￿-(￿-(￿-Iodovinyl)cyclopropyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
I
￿￿￿
(Iodomethyl)triphenylphosphonium iodide (￿￿￿, ￿￿￿ mg, ￿.￿￿ mmol,
￿.￿ eq.) was dissolved in anhydrous THF (￿.￿ ml). NaHMDS (￿.￿ ￿
in THF, ￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) was added dropwise at ambient tem-
perature and stirred was continued for ￿min. The reaction mixture was
then cooled to –￿￿ °C and a solution of aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol,
￿.￿ eq.) in anhydrous THF (￿.￿ml) was added dropwise. After complete addition, the reaction
mixture was stirred ￿￿min at –￿￿ °C (monitored by TLC) and then additional ￿￿min at ￿ °C
before it was diluted with ether and quenched with sat. aq. NH￿Cl. The layers were separated
and the aqueous layer was extracted twice with ether. The combined organic layers were dried
over magnesium sulfate and the solvent was removed under reduced pressure. The residue
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure (Z)-vinyl
iodide ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%) as colorless oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark
blue with vanillin). ￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J =
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (td,
J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿INNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿-(￿-((￿,￿-Dithian-￿-ylidene)methyl)cyclopropyl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
S
S
￿￿￿
Diethyl (￿,￿-dithian-￿-yl)phosphonate (￿￿￿, ￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
was dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under
an argon atmosphere. nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) was added dropwise to yield an bright yellow solution. The
temperature was raised to ￿ °C and the reaction mixture was stirred
￿￿min at this temperature. The reaction mixture was then cooled to –￿￿ °C and a solution of
aldehyde ￿￿￿ (￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ml) was added dropwise. The
resulting mixture was stirred ￿￿ min at –￿￿ °C (monitored by TLC), then additional ￿￿ min
at ambient temperature, and then diluted with ether and quenched by the addition of sat. aq.
NH￿Cl. The aqueous layer was extracted twice with ether and the combined organic layers were
dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain S,S-ketene acetal ￿￿￿
as colorless oil (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains extensively with
CAN). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿
(ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dtd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H) ppm.￿ ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NO￿S￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿ One aromatic signal is missing due to overlapping with the solvent signal.
￿￿￿
￿￿ Experimental
￿-Tosyl-￿a,￿-dihydro-￿H-spiro[cyclohepta[b]indole-￿,￿’-[￿,￿]dithiane] (￿￿￿).
N
Ts S
S
￿￿￿
S,S-Ketene acetal ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol) was dissolved in PhH–DMSO
(￿:￿, ￿.￿ ml) and was heated to ￿￿￿ °C for ￿ h (monitored by TLC). The
solvent was removed in vacuo and the residue was subjected to a quick
flash column chromatography (hexanes–EtOAc, ￿:￿) to a￿ord pure cyclo-
hepta[b]indole ￿￿￿ as colorless oil (￿￿.￿ mg, ￿￿.￿ ￿mol, ￿￿%) Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains extensively with CAN). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (d, J =
￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (t,
J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd,
J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NNaO￿S￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
tert-Butyl ((￿-((￿,￿-dithian-￿-ylidene)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl)(me-
thyl)carbamate (￿￿￿).
N
Ts
S
S
NMeBoc
￿￿￿
Diethyl (￿,￿-dithian-￿-yl)phosphonate (￿￿￿, ￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
was dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under
an argon atmosphere. nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) was added dropwise to yield an bright yellow solution. The
temperature was raised to ￿ °C and the reaction mixture was stirred
￿￿min at this temperature to obtain an orange solution. The reaction
mixture was then cooled to –￿￿ °C and a solution of aldehyde ￿￿￿
(￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ ml) was added dropwise. The resulting
mixture was stirred ￿￿min at –￿￿ °C (monitored by TLC), then additional ￿￿min at ambient
temperature, and then diluted with ether and quenched by the addition of sat. aq. NH￿Cl. The
aqueous layer was extracted twice with ether and the combined organic layers were dried over
sodium sulfate. The solvent was removed under reduced pressure and the residue was subjected
to flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to obtain S,S-ketene acetal ￿￿￿ as
colorless oil (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains extensively with
CAN). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dtd, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H + ￿H) ppm. ￿￿C NMR (￿￿￿ MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd.
for C￿￿H￿￿N￿NaO￿S￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿-(￿-((￿,￿-Dithian-￿-ylidene)methyl)-￿-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)-￿-tosyl-
￿H-indole (￿￿￿).
N
Ts
S
S
OTBS
￿￿￿
Diethyl (￿,￿-dithian-￿-yl)phosphonate (￿￿￿, ￿￿￿ mg, ￿.￿￿ mmol,
￿.￿ eq.) was dissolved in anhydrous THF (￿.￿ ml) and cooled to
–￿￿ °C under an argon atmosphere. nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l,
￿.￿￿ mmol, ￿.￿ eq.) was added dropwise to yield an bright yellow
solution. The temperature was raised to ￿ °C and the reaction mixture
was stirred ￿￿min at this temperature to obtain an orange solution.
The reaction mixture was then cooled to –￿￿ °C and a solution of
aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ml) was added dropwise. The
resulting mixture was stirred ￿￿ min at –￿￿ °C (monitored by TLC), then additional ￿￿ min
at ambient temperature, and then diluted with ether and quenched by the addition of sat. aq.
NH￿Cl. The aqueous layer was extracted twice with ether and the combined organic layers were
dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain S,S-ketene acetal ￿￿￿
as colorless oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains extensively with
CAN). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H),
￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S￿Si [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl ￿-((￿,￿-dithian-￿-ylidene)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
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EtO2C
￿￿￿
Diethyl (￿,￿-dithian-￿-yl)phosphonate (￿￿￿, ￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
was dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under
an argon atmosphere. nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) was added dropwise to yield an bright yellow solution. The
temperature was raised to ￿ °C and the reaction mixture was stirred
￿￿min at this temperature to obtain an orange solution. The reaction
mixture was then cooled to –￿￿ °C and a solution of racemic aldehyde ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol,
￿.￿ eq.) in anhydrous THF (￿.￿ ml) was added dropwise. The resulting mixture was stirred
￿￿￿ min at –￿￿ °C (monitored by TLC), then additional ￿￿ min at ambient temperature, and
then diluted with ether and quenched by the addition of sat. aq. NH￿Cl. The aqueous layer
was extracted twice with ether and the combined organic layers were dried over sodium sulfate.
The solvent was removed under reduced pressure to obtain crude S,S-ketene acetal ￿￿￿ as
pale yelow oil (￿￿.￿ mg, ￿￿￿ ￿mol, ￿￿%) which was directly used in the next steps. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stain extensively with CAN, stains purple with vanillin). HRMS (ESI):
calcd. for C￿￿H￿￿NO￿S￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿￿
￿￿ Experimental
(￿-((￿,￿-Dithian-￿-ylidene)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methanol (￿￿￿).
N
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￿￿￿
Ester ￿￿￿ (￿￿.￿ mg, ￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ml) and cooled to –￿￿ °C. DiBAL (￿.￿￿ in hexanes, ￿￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise and the reaction mixture was
stirred additional ￿.￿ h at –￿￿ °C after complete addition. The reaction
was diluted with CH￿Cl￿ and sat. aq. Rochelle’s salt was added. The
suspension was stirred vigorously for ￿￿ min. The layers were sep-
arated and the aqueous layers was extracted once with CH￿Cl￿. The
combined organic layers were dried over magnesium sulfate and the solvent was removed under
reduced pressure. The residue was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿) to obtain pure alcohol ￿￿￿ as white foam (￿￿.￿mg, ￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d,
J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (p,
J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm.￿ HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S￿
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-(￿-Tosyl-￿H-indol-￿-yl)cyclopropyl)ethan-￿-ol (￿￿￿).
N
Ts
OH
￿￿￿
Aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous THF
(￿.￿ml) and the solution was cooled to ￿ °C. Methylmagnesium bromide
solution (￿.￿ ￿ in ether, ￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿￿ eq.) was added dropwise
at ￿ °C and the reaction mixture was stirred for ￿ h at this temperature
(monitored by TLC). The reaction was diluted with ether and quenched
by the addition of ￿% HCl. The layers were separated and the aqueous layer was extracted twice
with ether. The combined organic layers were dried over sodium sulfate and the solvent was
removed in vacuo to obtain a diastereomeric mixture of alcohol ￿￿￿ as pale yellow oil which was
directly used in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, diastereomer I, stains blue with
vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, diastereomer II, stains blue with vanillin).
￿ Almost every signal appears twice.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿-(￿-(￿-Tosyl-￿H-indol-￿-yl)cyclopropyl)ethan-￿-one (￿￿￿).
N
Ts
O
￿￿￿
A crude diastereomeric mixture of alcohol ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was
dissolved in anhydrous DMSO (￿.￿ml) and IBX (￿￿￿, ￿￿￿mg, ￿.￿mmol,
￿.￿￿ eq.) was added. The reaction mixture was stirred ￿ h at ambient
temperature (monitored by TLC) and then diluted with EtOAc and water.
The layers were separated and the aqueous layer was extracted twice with
EtOAc. The combined organic layers were dried over sodium sulfate and the solvent was removed
in vacuo. The residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to
obtain pure methyl ketone ￿￿￿ as colorless oil (￿￿￿ mg, ￿￿￿ ￿mol, ￿￿% over two steps). Rf =
￿.￿￿ (hexanes–EtOAc, ￿:￿, stains umber with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt,
J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd.
for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-Diazo-￿-(￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)ethan-￿-one (￿￿￿).
N
Ts
O
N2
￿￿￿
Variant ￿ (from aldehyde ￿￿￿ via Pinnick–Lindgren oxidation and diazome-
thane): Aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in tBuOH
(￿.￿ml) at ￿￿ °C and ￿-methyl-￿-butene (￿￿￿ ￿l, ￿.￿￿mmol, ￿￿.￿ eq.) was
added. A solution of NaClO￿ (￿￿%, ￿￿￿ mg, ￿.￿ mmol, ￿￿.￿ eq.) and
NaH￿PO￿   ￿H￿O (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) in water (￿.￿ml, ultrasoni-
cation may be required for complete dissolution of both salts) was added dropwise to the reaction
mixture and stirring was continued for ￿￿ min at ambient temperature (monitored by TLC).
The reaction mixture was diluted with ether and brine was added. The layers were separated
and the aqueous layer was extracted twice with ether. The combined organic layers were dried
over sodium sulfate and the solvent was removed under reduced pressure at ￿￿ °C (important,
higher temperatures led to rapid decarboxylation and decomposition) to obtain crude carboxylic
acid ￿￿￿ as white foam which was directly used in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿,
carboxylic acid, stains dark red with vanillin).
The crude carboxylic acid was taken up in anhydrous CH￿Cl￿ (￿.￿ml) and triphenylphosphine
(￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added in one portion at ambient temperature. Trichloroace-
tonitrile (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise at which the color of the solution turned
from yellow to dark orange. After ￿￿min (monitored by TLC), the reaction mixture was filtered
over a plug of celite and the solvent was removed in vacuo to obtain acid chloride ￿￿￿ was yellow
oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, acid chloride, stains brownish blue with vanillin).
The crude acid chloride was dissolved in a small amount of ether and added dropwise to a solution
of diazomethane (￿￿￿, approx. ￿.￿ ￿, excess) at ￿ °C. The ice-bath was removed and the reaction
mixture was stirred for additional ￿￿ h at ambient temperature. The solvent was removed in
vacuo and the residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to
￿￿￿
￿￿ Experimental
obtain a-diazo compound ￿￿￿ as yellow oil (￿￿mg, ￿￿.￿ ￿mol, ￿￿% over three steps, contained
impurities). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains purple with vanillin). IR (neat): ￿￿￿￿, ￿￿￿￿
(C––N￿), ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿ cm
–￿. HRMS (ESI): calcd. for
C￿￿H￿￿N￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿-Diazo-￿-(￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)ethan-￿-one (￿￿￿).[￿￿￿]
N
Ts
O
N2
￿￿￿
Variant ￿: from methyl ketone ￿￿￿: Bis(trimethylsilyl)amine (￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) was dissolved in anhydrous THF (￿.￿ml) and cooled to ￿ °C. nBuLi
(￿.￿ ￿ in hexanes, ￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise and the
reaction mixture was stirred ￿￿min at ￿ °C before it was cooled down to
–￿￿ °C. A solution of methyl ketone ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in
anhydrous THF (￿.￿ ml) was added dropwise via syringe pump over a period of ￿￿ min and
the reaction mixture was stirred additional ￿￿min after complete addition at which point the
solution turned dark red. ￿,￿,￿-Trifluoroethyl ￿,￿,￿-trifluoroacetate (￿￿￿, ￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.)
was added quickly in one portion (important!) and the reaction mixture was stirred additional
￿￿min at –￿￿ °C at which point the solution turned bright yellow. The solution was diluted with
ether and quenched by the addition of ￿% HCl. The layers were separated and the aqueous
layer was extracted twice with ether. The combined organic layers were extracted once with
brine, dried over sodium sulfate and the solvent was removed under reduced pressure. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains bright red with vanillin).
The intermediate was immediately dissolved in anhydrous MeCN (￿.￿ml). H￿O (￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) and Et￿N (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) were added at ambient temperature. A solution
of MsN￿ (￿￿￿, ￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous MeCN (￿.￿ ml) was added via syringe
pump over a period of ￿￿ min and the reaction mixture was stirred additional ￿￿ min after
complete addition (monitored by TLC). The reaction mixture was then diluted with ether and
￿￿% NaOH was added. The layers were separated, the aqueous layer was extracted twice with
ether. The combined organic layers were extracted once with brine, dried over sodium sulfate
and the solvent was removed under reduced pressure. The residue was subjected to flash
column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure a-diazo ketone ￿￿￿ as yellow foam
(￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains purple with vanillin).
￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿ (C––N￿), ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿-Tosyl-￿,￿￿-dihydrocyclohepta[b]indol-￿(￿H)-one (￿￿￿).
N
Ts
O
￿￿￿
a-Diazo ketone ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿.￿ml) and silver(I) oxide (￿.￿mg, ￿.￿ ￿mol, ￿mol %) was added. The
resulting suspension was stirred at ￿￿ °C for ￿ h, then filtered over celite. The
solvent was removed in vacuo and the residue was subjected to flash column
chromatography to a￿ord cyclohepta[b]indolone ￿￿￿ as white solid (￿￿.￿mg,
￿￿ ￿mol ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dd, J = ￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dtd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ ppm.￿ HRMS (ESI): calcd. for C￿￿H￿￿NO￿S
[M + H]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)ethan-
￿-one (￿￿￿).
N
Ts
O
OTBS
￿￿￿
Aldehyde ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿.￿ml) and the solution was cooled down to ￿ °C. Methylmagnesium
bromide solution (￿.￿ ￿ in ether, ￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿￿ eq.) was added
dropwise at ￿ °C and the reaction mixture was stirred for ￿￿ min at this
temperature (monitored by TLC). The reaction was diluted with ether and
quenched by the addition of ￿%HCl. The layers were separated and the
aqueous layer was extracted twice with ether. The combined organic layers
were dried over sodium sulfate and the solvent was removed in vacuo to obtain a diastereomeric
mixture of alcohol ￿￿￿ as pale yellow oil which was directly used in the next step. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, diastereomer I, stains dark blue with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, diastereomer II stains dark blue with vanillin).
A crude diastereomeric mixture of alcohol ￿￿￿ (￿.￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous
DMSO (￿.￿ml) and IBX (￿￿￿, ￿￿￿mg, ￿.￿mmol, ￿.￿ eq.) was added. The reaction mixture was
stirred ￿ h at ambient temperature (monitored by TLC) and then diluted with EtOAc and water.
The layers were separated and the aqueous layer was extracted twice with EtOAc. The combined
organic layers were dried over sodium sulfate and the solvent was removed in vacuo. The residue
was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure methyl
ketone ￿￿￿ as colorless oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿% over two steps). Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿ stains brown vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J =
￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H),
￿ Some ￿￿C signals are overlapped by the solvent signal.
￿￿￿
￿￿ Experimental
￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-(￿-Tosyl-￿H-indol-￿-yl)-￿-(((￿-(trimethylsilyl)ethoxy)methoxy)methyl)cyclopropyl)ethan-
￿-one (￿￿￿).
N
Ts
O
OSEM
￿￿￿
Aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous THF
(￿.￿ml) and the solution was cooled to ￿ °C. Methylmagnesium bromide
solution (￿.￿ ￿ in ether, ￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) was added dropwise
at ￿ °C and the reaction mixture was stirred for ￿￿min at this temperature
(monitored by TLC). The reaction was diluted with ether and quenched by
the addition of ￿%HCl. The layers were separated and the aqueous layer
was extracted twice with ether. The combined organic layers were dried
over sodium sulfate and the solvent was removed in vacuo to obtain a diastereomeric mixture of
alcohol ￿￿￿ as pale yellow oil which was directly used in the next step. Rf = ￿.￿￿ (hexanes–E-
tOAc, ￿.￿:￿, diastereomer I, stains dark purple with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿,
diastereomer II stains dark purple with vanillin).
A crude diastereomeric mixture of alcohol ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
anhydrous CH￿Cl￿ (￿.￿ ml). Cornforth reagent (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) and molecular
sieves (￿ Å, ￿￿￿mg) were added. The resulting mixture was stirred ￿￿ h at ambient temperature
(monitored by TLC) before it was diluted with ether and filtered through a plug of silica (￿ cm).
The filtrate was reduced, diluted with ether and once again filtered through a plug of silica
(￿ cm). Evaporation of the solvent yielded crude ketone ￿￿￿ which was purified via flash column
chromatography (hexanes–EtOAc, ￿:￿) to a￿ord pure title compound ￿￿￿ as yellow oil (￿￿￿mg,
￿￿￿ ￿mol, ￿￿% over two steps). Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿ stains dark blue vanillin).
￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dq, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿-(￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)-￿-diazoethan-
￿-one (￿￿￿).
N
Ts
O
OTBS
N2
￿￿￿
Bis(trimethylsilyl)amine (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in an-
hydrous THF (￿.￿ml) and cooled to ￿ °C. nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise and the reaction mixture was stirred
￿￿min at ￿ °C before it was cooled down to –￿￿ °C. A solution of methyl
ketone ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ ml) was
added dropwise via syringe pump over a period of ￿￿min and the reaction
mixture was stirred additional ￿￿ min after complete addition at which
point the solution turned dark yellow. ￿,￿,￿-Trifluoroethyl ￿,￿,￿-trifluoroacetate (￿￿￿, ￿￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿ eq.) was added quickly in one portion (important!) and the reaction mixture was
stirred additional ￿￿min at –￿￿ °C at which point the solution turned bright yellow. The solution
was diluted with ether and quenched by the addition of ￿%HCl. The layers were separated and
the aqueous layer was extracted twice with ether. The combined organic layers were extracted
once with brine, dried over sodium sulfate and the solvent was removed under reduced pressure.
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
The intermediate was immediately dissolved in anhydrousMeCN (￿.￿ml). H￿O (￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) and Et￿N (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) were added at ambient temperature. A solution
of MsN￿ (￿￿￿, ￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous MeCN (￿.￿ml) was added via syringe
pump over a period of ￿￿ min and the reaction mixture was stirred additional ￿￿ min after
complete addition (monitored by TLC). The reaction mixture was then diluted with ether and
￿￿% NaOH was added. The layers were separated, the aqueous layer was extracted twice with
ether. The combined organic layers were extracted once with brine, dried over sodium sulfate
and the solvent was removed under reduced pressure. The residue was subjected to flash column
chromatography (hexanes–EtOAc, ￿:￿) to obtain pure a-diazo ketone ￿￿￿ as yellow oil (￿￿￿mg,
￿￿￿ ￿mol, ￿￿% brsm). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains purple with vanillin).
￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (br s,
￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
￿-Diazo-￿-(￿-(￿-tosyl-￿H-indol-￿-yl)-￿-(((￿-(trimethylsilyl)ethoxy)methoxy)methyl)cyclopropyl)-
ethan-￿-one (￿￿￿).
N
Ts
O
OSEM
N2
￿￿￿
Bis(trimethylsilyl)amine (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in an-
hydrous THF (￿.￿ml) and cooled to ￿ °C. nBuLi (￿.￿ ￿ in hexanes, ￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise and the reaction mixture was stirred
￿￿ min at ￿ °C before it was cooled to –￿￿ °C. A solution of methyl ke-
tone ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ml) was added
dropwise via syringe pump over a period of ￿￿min and the reactionmixture
was stirred additional ￿￿min after complete addition at which point the
solution turned brown. ￿,￿,￿-Trifluoroethyl ￿,￿,￿-trifluoroacetate (￿￿￿, ￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.)
was added quickly in one portion (important!) and the reaction mixture was stirred additional
￿￿min at –￿￿ °C at which point the solution turned bright yellow. The solution was diluted with
ether and quenched by the addition of ￿%HCl. The layers were separated and the aqueous layer
was extracted twice with ether. The combined organic layers were extracted once with brine,
dried over sodium sulfate and the solvent was removed under reduced pressure. Rf = ￿.￿￿ (hex-
anes–EtOAc, ￿:￿, stains light brown with vanillin). The intermediate was immediately dissolved
in anhydrous MeCN (￿.￿ml). H￿O (￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) and Et￿N (￿￿ ￿l, ￿￿￿mmol, ￿.￿ eq.)
were added at ambient temperature. A solution of MsN￿ (￿￿￿, ￿￿ ￿l, ￿￿￿ mmol, ￿.￿ eq.) in
anhydrous MeCN (￿.￿ml) was added via syringe pump over a period of ￿￿min and the reaction
mixture was stirred additional ￿￿min after complete addition (monitored by TLC). The reaction
mixture was then diluted with ether and ￿￿% NaOH was added. The layers were separated, the
aqueous layer was extracted twice with ether. The combined organic layers were extracted once
with brine, dried over sodium sulfate and the solvent was removed under reduced pressure. The
residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure
a-diazo ketone ￿￿￿ as yellow foam (￿￿.￿ mg, ￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿,
stains dark brown with vanillin). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J =
￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿
(s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (p, J = ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-tosyl-￿a,￿-dihydrocyclohepta[b]indol-￿(￿H)-one (￿￿￿).
N
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￿￿￿
a-Diazo ketone ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol) was dissolved in dichloroben-
zene (￿.￿ml) and heated to ￿￿￿ °C for ￿￿min. The reaction mixture
was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿)
to obtain undesired title compound ￿￿￿ as yellow oil which was addi-
tionally purified via HPLC. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H),
￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
(m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿.￿ Experimental Part for Section ￿.￿
￿-(￿-Tosyl-￿H-indol-￿-yl)but-￿-yn-￿-ol (￿￿￿).
N
Ts
OH
￿￿￿
￿-Iodo-￿-tosyl-￿H-indole (￿￿￿, ￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved
in diethylamine (￿￿.￿ml) and the resulting solution was degassed (ultra-
sonication plus argon). Pd(PPh￿)￿Cl￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿ mol %) and
copper(I) iodide (￿￿￿mg, ￿￿￿ ￿mol, ￿mol %) were added and the reaction
mixture was heated to ￿￿ °C. But-￿-yn-￿-ol (￿.￿ml, ￿￿.￿mmol, ￿.￿ eq.) was
added and stirring was continued for ￿￿￿min (monitored by TLC). The
solvent was removed in vacuo and the residue was dissolved in CH￿Cl￿. Silica was added and the
solvent was removed under reduced pressure. The residue was subjected to flash column chro-
matography (hexanes–EtOAc, ￿.￿:￿  ￿:￿) to obtain pure alcohol ￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿￿%)
as white powder. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains bright orange with vanillin).
￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H),
￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t,
J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-((tert-Butyldimethylsilyl)oxy)but-￿-yn-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
￿￿￿
￿-Iodo-￿-tosyl-￿H-indole (￿￿￿, ￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved
in diethylamine (￿￿.￿ ml) and the resulting solution was degassed (ul-
trasonication plus argon). Pd(PPh￿)￿Cl￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿ mol %)
and copper(I) iodide (￿￿￿ mg, ￿.￿￿ mmol, ￿ mol %) were added and
the reaction mixture was heated to ￿￿ °C. TBS-protected but-￿-yn-￿-ol
(￿.￿￿ g, ￿￿.￿mmol, ￿.￿￿ eq.) was added and stirring was continued for
￿￿min (monitored by TLC). The solvent was removed in vacuo and the residue was dissolved in
CH￿Cl￿. Silica was added and the solvent was removed under reduced pressure. The residue
was subjected to flash column chromatography (pentane–ether, ￿￿:￿  ￿￿:￿  ￿￿:￿) to obtain
pure alkyne ￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿￿%) as o￿-white powder. Rf = ￿.￿￿ (pentane–ether, ￿￿:￿,
stains orange with vanillin). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz,
￿￿￿
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￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J =
￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NO￿SSi [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-(￿-Tosyl-￿H-indol-￿-yl)but-￿-en-￿-ol (￿￿￿).
N
Ts
OH
￿￿￿
To anhydrous methanol (￿￿.￿ml) was added Pd/CaCO￿ (￿%, ￿￿￿.￿mg,
￿￿ ￿mol, ￿.￿mol %) and quinoline (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿￿ eq.). The
resulting suspension was stirred vigorously for ￿￿min at ambient tem-
perature. Alkyne ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was added in one
portion and the reaction mixture was hydrogenated (p(H￿) =￿￿￿ psi) at
ambient temperature for ￿ h. TLC analysis indicated, that only a small amount of material was
hydrogenated to the alkane. The reaction mixture was filtered over celite and the solvent was
removed in vacuo. The residue was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿) to obtain pure (Z)-alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿￿%) as colorless oil. Rf = ￿.￿￿ (hex-
anes–EtOAc, ￿:￿, stains purple with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (br s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-(￿-((tert-Butyldimethylsilyl)oxy)but-￿-en-￿-yl)-￿-tosyl-￿H-indole (￿￿￿).
N
Ts
OTBS
￿￿￿
Variant ￿ (via Wittig olefination): (￿-((tert-Butyldimethylsilyl)oxy)pro-
pyl)triphenylphosphonium bromide (￿￿￿, ￿.￿￿ g, ￿.￿￿mmol, ￿.￿￿ eq.)
was dissolved in anhydrous THF (￿￿.￿ ml) and cooled to –￿￿ °C.
KHMDS (￿.￿ ￿ in PhMe, ￿￿.￿ ml, ￿.￿￿ mmol, ￿.￿￿ eq.) was added
dropwise and the reaction mixture was then stirred additional ￿￿min
at –￿￿ °C, then ￿￿min at ￿ °C and then again ￿￿min at –￿￿ °C to yield a bright orange solution.
A solution of aldehyde ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous THF (￿￿.￿ml) was added
dropwise to the reaction mixture and stirring was continued for additional ￿￿ min at –￿￿ °C,
then ￿ h at –￿￿ °C and then ￿￿ h at ambient temperature. The reaction mixture was diluted with
ether and quenched by the addition of ￿%HCl. The layers were separated and the aqueous layer
was extracted twice with ether. The combined organic layers were dried over sodium sulfate and
the solvent was removed in vacuo. The residue was subjected to flash column chromatography
(hexanes–EtOAc, ￿￿:￿) to obtain pure (Z)-olefine ￿￿￿ as colorless oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%).
Variant ￿ (via TBS protection of alcohol ￿￿￿): To alcohol ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) in
￿￿￿
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anhydrous DMF (￿.￿ml) was added TBSCl (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) and imidazole (￿￿￿mg,
￿.￿￿mmol, ￿.￿ eq.) at ambient temperature. The reaction mixture was stirred ￿ h at this temper-
ature. Ether and brine were added and the mixture was stirred ￿￿min vigorously. The layers
were separated and the aqueous layer was extracted twice with ether. The combined organic
layers were extracted once with water and once with brine, then dried over sodium sulfate. The
solvent was removed in vacuo and the residue was subjected to flash column chromatography
(hexanes–EtOAc, ￿￿:￿)) to obtain pure ￿￿￿ as colorless oil (￿.￿￿ g, ￿.￿￿mmol, ￿￿%).
Variant ￿ (via) hydrogenation of alkyne ￿￿￿: To anhydrousmethanol (￿.￿ml) was added Pd/CaCO￿
(￿%, ￿￿.￿mg, ￿￿ ￿mol, ￿mol %) and quinoline (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.). The resulting suspen-
sion was stirred vigorously for ￿￿min at ambient temperature. Alkyne ￿￿￿ (￿￿￿mg, ￿.￿￿mmol,
￿.￿ eq.) was added in one portion and the reaction mixture was hydrogenated (p(H￿) =￿￿￿ psi) at
ambient temperature for ￿ h. TLC analysis indicated, that only a small amount of material was
hydrogenated to the alkane. The reaction mixture was filtered over celite and the solvent was
removed in vacuo. The residue was subjected to flash column chromatography (pentane–ether,
￿￿:￿) to obtain pure (Z)-olefine ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿%) as colorless oil. Rf = ￿.￿￿ (hex-
anes–EtOAc, ￿:￿, stains pink with vanillin). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J =
￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl ￿-(￿-((tert-butyldimethylsilyl)oxy)ethyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate
(￿￿￿).
N
Ts
OTBS
EtO2C
￿￿￿
A flame-dried Schlenk tube was charged with [Cu(OTf)]  PhH
(￿￿.￿mg, ￿￿ ￿mol, ￿mol%) and olefine ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.)
in the glovebox. The tube was flushed with argon and freeze-pump-
thaw degassed CH￿Cl￿ (￿.￿ ml) was added. A solution of ethyl dia-
zoacetate (commercial, contains '￿￿ wt. % dichloromethane; ￿.￿ml,
￿￿.￿mmol, ￿.￿ eq.) in freeze-pump-thaw degassed CH￿Cl￿ (￿￿.￿ml)
was added via syringe pump over ￿￿ h at ambient temperature (N￿ evolution) at which the
solution became orange. The solution was filtered over a plug of celite to a￿ord a clear yellow so-
lution. The solvent was removed under reduced pressure to obtain crude ￿￿￿ as yellow oil which
was subjected to flash column chromatography (pentane–ether, ￿￿:￿  ￿￿:￿￿) to obtain pure
cyclopropane ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿%) as pale yellow oil (the diastereomer was obtained
in ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, minor diastereomer). Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, major diastereomer). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ –
￿￿￿
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￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (qd,
J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (qt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿
(s, ￿H), ￿.￿￿ (dddd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl ￿-(￿-oxoethyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
Ts
O
EtO2C
￿￿￿
Variant ￿: A solution of silyl alcohol ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous THF (￿.￿ml) was added dropwise to HF   pyr. (￿￿% w/w,
￿.￿ ml) at ￿ °C. The reaction mixture was stirred ￿￿￿ min at ￿ °C and
￿￿min at ambient temperature (monitored by TLC) before it was diluted
with EtOAc and quenched by the addition of sat. aq. NaHCO￿. The layers
were separated and the aqueous layer was extracted twice with EtOAc.
The combined organic layers were extracted once with ￿ ￿ HCl and the organic layer was dried
over magnesium sulfate. The solvents were removed under reduced pressure and the crude
was dissolved in CH￿Cl￿ (￿.￿ml). Dess–Martin periodinane (￿￿￿, ￿￿￿mg, ￿￿￿ ￿mol, ￿.￿￿ eq.)
and NaHCO￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿.￿ eq.) were added and the reaction mixture was stirred
￿￿ min at ambient temperature (monitored by TLC). The reaction mixture was diluted with
CH￿Cl￿ and quenched by the addition of sat. aq. NaHCO￿. The layers were separated and the
aqueous layer was extracted once with CH￿Cl￿. The combined organic layers were dried over
magnesium sulfate and the solvent was removed under reduced pressure. The resulting crude
was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain aldehyde ￿￿￿
(￿￿￿mg, ￿￿￿ ￿mol, ￿￿% over two steps) as white foam.
Variant ￿: (Methoxymethyl)triphenylphosphonium chloride (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was
dissolved in anhydrous THF (￿.￿ ml) and cooled to –￿￿ °C. KHMDS (￿.￿ ￿ in PhMe, ￿.￿ ml,
￿￿￿ ￿mol, ￿.￿￿ eq.) was added dropwise and the resulting solution was stirred ￿￿min at –￿￿ °C
and additional ￿￿min at ￿ °C to obtain a dark red solution. A solution of aldehyde ￿￿￿ (￿￿.￿mg,
￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ ml) was added dropwise at ￿ °C and the reaction
mixture was stirred for ￿ h at this temperature (monitored by TLC). The reaction mixture was
diluted with ether and quenched by the addition of sat. aq. NH￿Cl/￿%HCl (￿:￿). The layers were
separated and the aqueous layer was extracted once with ether. The combined organic layers were
extracted once with brine and dried over sodium sulfate. The solvent was evaporated in vacuo
(below ￿￿ °C) and the residue was dissolved in THF (￿.￿ml) and cooled to ￿ °C. ￿￿ ￿ HCl/THF
(￿:￿, ￿.￿ml) were added dropwise at this temperature and stirring was continued for additional
￿￿￿min. The reaction mixture was diluted with ether and quenched by the addition of sat. aq.
NaHCO￿. The layers were separated and the aqueous layer was extracted twice with EtOAc. The
￿￿￿
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combined organic layers were extracted once with brine and dried over sodium sulfate. The
solvent was removed in vacuo and the residue was subjected to flash column chromatography
(hexanes–EtOAc, ￿:￿) to obtain aldehyde ￿￿￿ (￿￿.￿mg, ￿￿ ￿mol, ￿￿%) as white foam. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, CAN). ￿HNMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J =
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for
C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl ￿-((￿,￿-dioxolan-￿-yl)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
Ts
EtO2C
O
O
￿￿￿
Aldehyde ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ml) under an argon atmosphere. Ethylene glycol (￿.￿ml,
￿￿.￿ mmol, ￿￿ eq.) was added at ambient temperature followed by
the addition of TMSCl (￿￿￿ ￿l, ￿.￿￿ mmol, ￿.￿￿ eq.). The reaction
mixture was stirred ￿ h at this temperature, then diluted with CH￿Cl￿
and quenched by the addition of sat. aq. NaHCO￿. The layers were
separated and the aqueous layer was extracted once with CH￿Cl￿. The combined organic layers
were dried over magnesium sulfate and the solvent was removed under reduced pressure to
obtain acetal ￿￿￿ as colorless oil (￿￿￿ mg, ￿￿￿ ￿mol, quant.). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿,
CAN). ￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J =
￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-(Hydroxymethyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)acetaldehyde (￿￿￿).
N
Ts
OH
O
￿￿￿
Ester ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous CH￿Cl￿
(￿.￿ml) and cooled to –￿￿ °C. DiBAL (￿.￿ ￿ in hexanes, ￿.￿ml, ￿.￿mmol,
￿.￿ eq.) was added dropwise and stirring was continued for additional
￿ h at this temperature. The reaction mixture was diluted with CH￿Cl￿
and quenched by the addition of sat. aq. Rochelle’s salt. The mixture
was stirred vigorously for ￿ h. The layers were separated and the aqueous
layer was extracted twice with CH￿Cl￿. The combined organic layers were
washed once with brine and dried over sodium sulfate. The solvent was removed in vacuo and
the residue was subjected to a quick flash column chromatography to obtain alcohol ￿￿￿ (￿￿￿mg,
￿￿￿ ￿mol, ￿￿%) as colorless oil which was dissolved in THF–HCl (￿ ￿, ￿:￿, ￿.￿ml). This mixture
￿￿￿
￿￿ Experimental
was stirred ￿￿ h at ambient temperature (monitored by TLC) and was the diluted with ether
and carefully quenched by the addition of sat. aq. NaHCO￿. The layers were separated and the
aqueous layer was extracted twice with EtOAc. The combined organic layers were washed once
with brine and dried over sodium sulfate. The solvent was removed in vacuo and the residue was
subjected to a quick flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain aldehyde ￿￿￿
as colorless oil (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark blue with
vanillin). HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿.￿ Experimental Part for Section ￿.￿
(Z)-￿-Iodobut-￿-enal (￿￿￿).
O
I
￿￿￿
Crotonaldehyde (￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.) was dissolved in THF–H￿O (￿:￿,
￿￿￿ ml). Potassium carbonate (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.), DMAP (￿.￿￿ g,
￿￿.￿ mmol, ￿.￿ eq.), and iodine (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) were added suc-
cessively at ambient temperature. The reaction mixture was stirred at this temperature for ￿ h,
then diluted with EtOAc (￿￿￿￿ml) and sat. aq. Na￿S￿O￿ (￿￿￿￿ml). The mixture was divided in
two parts and the aqueous layer of each part was washed once with ￿.￿ ￿HCl. The combined
organic layers were concentrated to approximately ￿￿￿ml and were extracted once again with
sat. aq. Na￿S￿O￿ and once with brine. The organic layer was dried over sodium sulfate and
the solvent was removed in vacuo. The residue was usually directly used in the next step. A
purification can be carried out by flash column chromatography (hexanes–EtOAc, ￿:￿). Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains dark red with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for
C￿H￿INaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-Iodobut-￿-en-￿-ol (￿￿￿).
OH
I
￿￿￿
Crude aldehyde ￿￿￿ (￿￿￿mmol, ￿.￿ eq.) was dissolved in THF–H￿O (￿:￿, ￿￿￿ml)
and cooled to ￿ °C (inner temperature). Sodium borohydride (￿.￿￿ g, ￿￿￿mmol,
￿.￿ eq.) was added in portions, keeping the inner temperature below ￿ °C. After
complete addition, the reaction mixture was stirred additional ￿￿min (monitored by TLC) at
￿ °C. Water (￿￿￿ml) and EtOAc (￿￿￿ml) were added, the layers were separated and the aqueous
layer was extracted twice with EtOAc. The combined organic layers were extracted once with
brine, dried over sodium sulfate and concentrated in vacuo. The residue was subjected to flash
column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to obtain pure alcohol ￿￿￿ as colorless oil
(￿￿.￿ g, ￿￿.￿mmol, ￿￿% over two steps). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains teal blue with
vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (qt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿IO [M + H]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
(Z)-￿-Iodobut-￿-enoic acid (￿￿￿).
O
I
OH
￿￿￿
Aldehyde ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in tBuOH (￿￿.￿ ml)
at ￿￿ °C and ￿-methyl-￿-butene (￿.￿ ml, ￿￿.￿ mmol, ￿￿.￿ eq.) was added. A
solution of monosodium phosphate dihydrate (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) and
sodium chlorite (technical ￿￿%, ￿.￿￿ g, ￿￿.￿ mmol, ￿￿.￿ eq.) in H￿O (￿.￿ ml,
ultrasonication may be required for full dissolution, yields a yellow solution) was added and
the reaction mixture was stirred additional ￿￿min at ambient temperature (monitored by TLC).
The reaction mixture was diluted with ether and brine was added. The layers were separated
and the aqueous layer was extracted thrice with EtOAc. The combined organic layers were dried
over magnesium sulfate and concentrated in vacuo. The residue was subjected to flash column
chromatography (hexanes–EtOAc, ￿:￿) to obtain pure carboxylic acid ￿￿￿ as pale orange solid
(￿￿￿mg, ￿.￿￿mmol, ￿￿%) Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains red with vanillin). M.p. ￿￿￿ °C
(decomp.). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿￿.￿￿ (br s, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI):
calcd. for C￿H￿INaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-Iodobut-￿-enoyl chloride (￿￿￿).
O
I
Cl
￿￿￿
a-iodocarboxylic acid ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ml) and oxalyl chloride (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added. To this
orange solution was added one drop of DMF at ambient temperature. The solution
turned immediately bright yellow and became bubbly. TLC analysis indicated,
that the carboxylic acid has been complete transformed into the corresponding acid chloride
after ￿￿min. The solvent was removed in vacuo and the residue was directly used in the next
steps.
(Z)-￿-Bromo-￿-iodobut-￿-ene (￿￿￿).
Br
I
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in ether (￿￿.￿ ml) and
cooled to ￿ °C. Phosphorus tribromide (￿.￿￿ml, ￿￿.￿mmol, ￿.￿ eq.) was added
dropwise and stirring was continued for ￿￿ h. The reactionmixture was quenched
by the addition of sat. aq. K￿CO￿ and the layers were separated. The aqueous layer was extracted
twice with ether and the combined organic layers were dried over magnesium sulfate and
concentrated in vacuo. Purification by flash column chromatography (pentane–ether, ￿￿:￿)
a￿orded bromide ￿￿￿ as colorless oil (￿.￿￿ g, ￿￿.￿ mmol, ￿￿%) which was stored at –￿￿ °C
under an argon atmosphere. Rf = ￿.￿￿ (hexanes, pure, stains dark gray with vanillin).
￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dtd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (dt, J =
￿.￿, ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS
(ESI): calcd. for C￿H￿BrINa [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
(Z)-￿-Iodobut-￿-en-￿-yl methanesulfonate (￿￿￿).
OMs
I
￿￿￿
Alcohol ￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous CH￿Cl￿
(￿￿￿ ml), cooled to ￿ °C and triethylamine (￿￿.￿ ml, ￿￿.￿ mmol, ￿.￿ eq.)
was added. A solution of freshly distilled methanesulfonyl chloride (￿.￿ ml,
￿￿.￿mmol, ￿.￿ eq.) in CH￿Cl￿ (￿￿.￿ml) was added via syringe pump over a period of ￿￿min
and the reaction mixture was stirred additional ￿ h at this temperatures. Sat. aq. NH￿Cl was
added and the layers were separated. The aqueous layer was extracted twice with CH￿Cl￿ and
the combined organic layers were dried over MgSO￿. Evaporation of the solvent yielded crude
mesylate ￿￿￿ which was used in the next step without purification. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, stains with KMnO￿).
(Z)-￿-Azido-￿-iodobut-￿-ene (￿￿￿).
N3
I
￿￿￿
Crude mesylate ￿￿￿ (￿￿.￿ mmol, ￿.￿ eq.) was dissolved in anhydrous DMF
(￿￿￿ml) and sodium azide (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was added. The resulting
mixture was stirred at ￿￿ °C for ￿￿min (monitored by TLC). The reaction mixture
was diluted with chloroform and water (￿￿￿￿ml) was added. The layers were separated and the
aqueous layer was extracted twice with chloroform. The combined organic layers were extracted
once with brine, dried over sodium sulfate and concentrated in vacuo. The residue was subjected
to flash column chromatography (hexanes–EtOAc, ￿￿￿:￿￿) to obtain pure azide ￿￿￿ as colorless
oil (￿.￿￿ g, ￿￿.￿mmol, ￿￿%). Rf = ￿.￿￿ (hexanes, pure, stains with KMnO￿).
￿HNMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (qdd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H) ppm.
￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿H￿IN￿
[M + H]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Note: Concerning the waste disposal, the excess of sodium azide is destroyed by titration of an aqueous
solution of sodium azide containing a catalytic amount of Na￿S￿O￿ with an ethanolic solution of
iodine (evolution of N￿!).
(Z)-￿-Iodobut-￿-en-￿-yl ￿-methylbenzenesulfonate (￿￿￿).
OTs
I
￿￿￿
To a solution of alcohol ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous CH￿Cl￿
(￿￿.￿ml) was added tosyl chloride (￿.￿￿ g, ￿.￿￿mmol, ￿.￿￿ eq.) at ￿ °C followed
by the addition of DMAP (￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) and triethylamine (￿.￿￿ml,
￿.￿￿mmol, ￿.￿ eq.). The ice bath was removed and the reaction mixture was stirred at ambient
temperature for ￿￿min. Sat. aq. NH￿Cl/￿ ￿HCl (￿:￿) were added and the layers were separated.
The aqueous layer was extracted twice with ether and the combined organic layers were dried over
magnesium sulfate. Evaporation of the solvent yielded crude tosylate ￿￿￿ which was subjected
to flash column chromatography (pentane–ether, ￿:￿) to a￿ord pure tosylate ￿￿￿ as white solid
(￿￿￿ mg, ￿.￿￿ mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains with KMnO￿).
￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (qt, J = ￿.￿, ￿.￿Hz, ￿H),
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
￿.￿￿ (p, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for
C￿￿H￿￿INaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-((Z)-￿-Iodobut-￿-en-￿-yl)-￿,￿,￿,￿-tetraazaadamantan-￿-ium bromide (￿￿￿).
N
N
N+
N
I
Br–
￿￿￿
Bromide ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous chlo-
roform (￿.￿ml) and hexamethylenetetramine (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.)
was added in one portion. The resulting solution was stirred ￿￿ h at am-
bient temperature (or alternatively ￿ h at ￿￿ °C). The white precipitate was
filtered through a medium porosity sintered-glass funnel and the retentate
was washed with chloroform and dried under high vacuum for several hours to obtain title
compound ￿￿￿ as white solid (￿￿￿mg, ￿.￿￿mmol, ￿￿%) which was directly used in the next
step.
Methyl (Z)-(￿-iodobut-￿-en-￿-yl)carbamate (￿￿￿).
NHCO2Me
I
￿￿￿
Bromide ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
DMF–MeOH (￿￿:￿, ￿￿.￿ml) and potassium cyanate (￿.￿￿ g, ￿￿.￿mmol,
￿.￿ eq.) was added in one portion. The resulting suspension was stirred
at ￿￿￿ °C (sealed tube) for ￿￿min. The reaction mixture was diluted with ether and brine was
added. The layers were separated and the aqueous layer was extracted twice with ether. The
combined organic layers were dried over sodium sulfate and concentrated in vacuo to obtain crude
carbamate ￿￿￿ which was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to
a￿ord pure carbamate ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿￿%) as white powder. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿H￿￿INO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(Z)-￿-Iodobut-￿-en-￿-amine (￿￿￿).
NH2
I
￿￿￿
Variant ￿: A stirred solution of quaternary amine ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol) in
ethanol (￿.￿ml) was added dropwise slowly into ￿￿ ￿ hydrochloric acid (￿.￿ml)
in the ice/water bath. Upon completion of the addition, the mixture was stirred
at ￿￿ °C for ￿ h until a precipitate formed, then filtered through a medium porosity sintered-glass
funnel to give title compound ￿￿￿  HCl as a white solid in quantitative yield.
Variant ￿: Trimethylsilyl iodide (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿￿ eq.) was added at ambient temperature
to a solution of carbamate ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous chloroform (￿.￿ml).
The resulting solution was stirred at ￿￿ °C (sealed tube) over night, then cooled to ambient
temperature. Methanol (￿.￿ml) was added carefully (exothermic!) and stirred additional ￿.￿ h at
￿￿￿
￿￿ Experimental
ambient temperature. The solvent was removed in vacuo and the residue was subjected to flash
column chromatography (chloroform–methanol, ￿:￿  ￿:￿) to a￿ord pure amine ￿￿￿ as brown
solid (￿￿￿mg, ￿.￿￿mmol, ￿￿%).
Variant ￿: Azide ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in THF–H￿O (￿￿:￿, ￿.￿ ml).
PBu￿ (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) was added dropwise at ambient temperature and the reaction
was stirred ￿min at this temperature (monitored by TLC). Volatile components were evaporated
in vacuo and by azeotropic distillation with benzene (￿ times) to obtain title compound ￿￿￿ as
brown oil (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (chloroform–methanol, ￿:￿, stains intensively
with ninhydrin). ￿H NMR (￿￿￿ MHz, MeOD) d = ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(d, J = ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿IN [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(Z)-￿-Iodo-N-methylbut-￿-en-￿-amine (￿￿￿).
NHMe
I
￿￿￿
Methylamine (aq., ￿￿% wt., ￿.￿ ml, ￿￿.￿ mmol, ￿￿.￿ eq.) was added to a
solution of bromide ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous THF–EtOH
(￿:￿, ￿￿.￿ml) at –￿ °C. The resulting solution was stirred at this temperature
for ￿￿min (monitored by TLC) and then diluted with ether. Brine was added, the layers were
separated and the aqueous layer was extracted twice with ether. The combined organic layers
were dried over sodium sulfate and the solvent was removed in vacuo. The residue was subjected
to flash column chromatography (chloroform–methanol, ￿￿:￿) to a￿ord methylamine ￿￿￿ as
pale yellow oil (￿￿￿ mg, ￿.￿￿ mmol, ￿￿%). Rf = ￿.￿￿ (chloroform–methanol, ￿￿:￿).
￿H NMR
(￿￿￿ MHz, MeOD) d = ￿.￿￿ (qt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, MeOD) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿H￿￿INNa [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
Note: (i) The same sequence can be carried out with tosylate ￿￿￿, the yield is slightly higher (￿￿%). (ii)
Despite the purification, the compound decomposes rapidly (becomes dark brown after a short amount of
time, even at –￿￿ °C under an argon atmosphere, TLC analysis reveals several decomposition products).
Therefore, methylamine ￿￿￿ was usually freshly prepared and directly used as crude compound.
￿￿￿
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￿-(Hydroxymethyl)-N-methyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxamide (￿￿￿).
N
Ts
OH
NHMeO
￿￿￿
A solution of TBS protected alcohol ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous THF (￿.￿ ml) was added dropwise to HF   pyr. (￿￿% w/w,
￿.￿ml) at ￿ °C. The reactionmixture was stirred ￿￿￿min at ￿ °C (monitored
by TLC) before it was diluted with ether and quenched by the addition
of sat. aq. NaHCO￿. The layers were separated and the aqueous layer
was extracted twice with ether and once with ethyl acetate. The combined
organic layers were extracted once with ￿ ￿ HCl and the organic layer
was dried over sodium sulfate. The solvents were removed under reduced pressure to obtain
alcohol ￿￿￿ as a white foam (￿￿.￿ mg, ￿￿￿ ￿mol, quant.). Rf = ￿.￿￿ (EtOAc, pure).
￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
Methyl ((￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropyl)methyl)-
carbamate (￿￿￿).
N
Ts
OTBS
NHCO2Me
￿￿￿
Crude amine ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous THF
(￿.￿ml) and cooled to ￿ °C. Triethylamine (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿￿ eq.)
was added followed by the the dropwise addition of methyl chlorofor-
mate (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.). The reaction mixture was stirred for
￿￿ h (￿ °C   ambient temperature), TLC analysis revealed, that the
amine has been fully consumed. The reaction mixture was diluted with
EtOAc and quenched by the addition of sat. aq. NH￿Cl. The layers were
separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers
were extracted once with brine and dried over sodium sulfate. Evaporation of the solvent a￿orded
carbamate ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%) after purification by flash column chromatography (hex-
anes–EtOAc, ￿:￿). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains bright purple with vanillin).
￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd,
J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿O￿SSi
[M + H]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
Ethyl (￿S,￿S,￿R)-￿-(hydroxymethyl)-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
Ts
OH
EtO2C
￿￿￿
Crude enantioenriched silyl alcohol ￿￿￿ from cyclopropanation (￿.￿mmol,
￿.￿ eq.) was dissolved in AcOH–THF–H￿O (￿:￿:￿, v/v, ￿￿ml) at ambient
temperature. The resulting solution was stirred for ￿￿ h at ambient tem-
perature, then diluted with ether and carefully quenched by the addition
of sat. aq. K￿CO￿. The layers were separated and the aqueous layer was
extracted thrice with ether. The combined organic layers were extracted
once with brine and dried over magnesium sulfate. The solvent was removed under reduced
pressure and the residue was subjected to flash column chromatography (hexanes–EtOAc,
￿￿:￿) to a￿ord pure alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿￿% over two steps) as white foam. The
enantiomeric excess was determined to be ￿￿% by chiral HPLC analysis (AD-H, ￿.￿mlmin–￿,
￿￿:￿￿ iPrOH/hexanes, l = ￿￿￿ nm): tR(major) = ￿￿.￿ min, tR(minor) = ￿￿.￿ min. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains dark blue with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d,
J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿.￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
Note: Alternatively, the silyl protecting group can be cleaved with HF   pyr. (￿￿% w/w). The yield is
slightly higher (￿￿%), but the simple treatment with acetic acid was preferred on larger scales.
Ethyl (￿S,￿S,￿R)-￿-formyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxylate (￿￿￿).
N
Ts
EtO2C
O
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous MeCN
(￿￿.￿ml). N-MethylmorpholineN-oxide (￿.￿￿ g, ￿.￿￿mmol, ￿.￿￿ eq.), molec-
ular sieves (￿ Å, activated, ￿.￿￿ g), and tetrapropylammonium perruthenate
(￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿mol %) were added successively at ambient tem-
perature. The reaction mixture was stirred ￿￿ min at this temperature
(monitored by TLC). Silica was added and the solvent was removed in vacuo.
The residue was purified by flash column chromatography (hexanes–EtOAc, ￿:￿) to a￿ord pure
aldehyde ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿￿%) as white foam. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains
brownish purple with vanillin). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. ￿HNMR (￿￿￿MHz,
￿￿￿
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C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (q, J =
￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm.￿ ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿,
￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
[a]￿￿D = +￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
Ethyl ￿-tosyl-￿,￿,￿,￿-tetrahydrocyclohepta[b]indole-￿-carboxylate (￿￿￿).
N
Ts
CO2Et
￿￿￿
Methyltriphenylphosphonium bromide (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was
dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under an argon
atmosphere. NaHMDS (￿.￿ ￿ in THF, ￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was
added dropwise and the reaction mixture was stirred ￿￿min at –￿￿ °C, then
additional ￿￿min at ￿ °C and then again recooled to –￿￿ °C to yield a bright
yellow suspension. A solution of aldehyde ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous THF (￿.￿ml) was added and the reaction mixture was stirred ￿￿min at –￿￿ °C
(monitored by TLC) and then additional ￿￿min at ￿ °C. The reaction mixture was diluted with
ether and quenched by the addition of sat. aq. NH￿Cl. The layers were separated and the aqueous
layer was extracted twice with ether. The organic layers were combined, dried over magnesium
sulfate and the solvent was removed in vacuo. TLC indicated, that partial rearrangement already
took place. The crude was therefore dissolved in benzene and stirred ￿￿min at ￿￿ °C to complete
the rearrangement and a￿ord unexpected cyclohepta[b]indole ￿￿￿ as pale yellow oil (￿￿.￿mg,
￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, Wittig product, stains brown-gray with vanillin).
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, [￿,￿] product, stains brown with vanillin).
￿H NMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (dq, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿NO￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿ One aromatic signal is overlapped by the solvent signal.
￿￿￿
￿￿ Experimental
((￿aR,￿R)-￿-Tosyl-￿,￿a,￿,￿-tetrahydrocyclohepta[b]indol-￿-yl)methanol (￿￿￿).
N
Ts
H
OH
￿￿￿
Methyltriphenylphosphonium bromide (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was
dissolved in anhydrous THF (￿.￿ml) and cooled to –￿￿ °C under an argon
atmosphere. NaHMDS (￿.￿ ￿ in THF, ￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was
added dropwise and the reaction mixture was stirred ￿￿min at –￿￿ °C, then
additional ￿￿min at ￿ °C and then again recooled to –￿￿ °C to yield a bright
yellow suspension. A solution of aldehyde ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous THF (￿.￿ml) was added and the reaction mixture was stirred ￿￿min at –￿￿ °C
(monitored by TLC) and then additional ￿￿min at ￿ °C. The reaction mixture was diluted with
precooled ether and quenched by the addition of ice-cold ￿%HCl. The layers were separated and
the aqueous layer was quickly extracted twice with precooled ether. The combined organic layers
were dried over sodium sulfate and the solvent was removed under reduced pressure (at ￿￿ °C or
below, important) to yield crude Wittig intermediate as a yellow foam which was quickly taken up
in anhydrous CH￿Cl￿ (￿.￿ml) and cooled to –￿￿ °C. DiBAL (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added
dropwise and the resulting solution was stirred ￿￿ min at –￿￿ °C. The reaction was carefully
quenched by the addition of sat. aq. Rochelle’s salt at –￿￿ °C. The reaction was transferred into
a conical flask, diluted with CH￿Cl￿ and stirred vigorously at ambient temperature over night.
TLC analysis indicated, that complete rearrangement took place. The layers were separated and
the aqueous layer was extracted once with CH￿Cl￿. The combined organic layers were dried
over sodium sulfate. The solvent was removed in vacuo and the residue was subjected to flash
column chromatography (hexanes–EtOAc, ￿.￿:￿) to obtain cyclohepta[b]indoline ￿￿￿ as pale
yellow foam (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, Wittig product, stains
brown-gray with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿, DiBAL product, stains blue with
vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿, [￿,￿] product, stains brown with vanillin).
￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿-Tosyl-￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indol-￿-yl)methanol (￿￿￿).
N
Ts
OH
￿￿￿
To a solution of cyclohepta[b]indoline ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in
anhydrous CH￿Cl￿ (￿.￿ml) was added trimethylsilyl trifluoromethanesul-
fonate (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) dropwise at ￿ °C. The solution was stirred
￿￿min at this temperature (monitored by TLC) at which the solution turned
dark red. ￿ ￿ HCl was added, the layers were separated and the aqueous
layer was extracted twice with CH￿Cl￿. The combined organic layers were
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
dried over K￿CO￿ and the solvent was evaporated in vacuo. The residue was subjected to flash
column chromatography (hexanes–EtOAc, ￿:￿) to a￿ord pure cyclohepta[b]indole ￿￿￿ (￿￿.￿mg,
￿￿￿ ￿mol, ￿￿%) as pale yellow foam. Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿, stains red with vanillin).
￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt,
J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿S [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indol-￿-yl)methanol (￿￿￿).
N
H
OH
￿￿￿
To cyclohepta[b]indole ￿￿￿ (￿.￿mg, ￿￿.￿ ￿mol, ￿.￿ eq.) in absolute methanol
(￿.￿ ml) was added NH￿Cl (￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) and magnesium
turnings (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿.￿ eq.). The reaction mixture was irradiated
with ultrasonic at ambient temperature for ￿￿￿ min before it was diluted
with EtOAc and quenched by the addition of sat. aq. NH￿Cl. The layers
were separated and the aqueous layer was extracted twice with EtOAc. The
combined organic layers were dried over sodium sulfate and reduced in vacuo. The crude was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain indole ￿￿￿ as pale
yellow foam (￿.￿ mg, ￿￿.￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains bordeaux with
vanillin and bright red with Ehrlich’s reagent). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NNaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿.￿ Experimental Part for Section ￿.￿
(S,Z)-N-(￿-Iodobut-￿-en-￿-yl)-N-methyl-￿-tosyl-￿,￿,￿,￿￿-tetrahydrocyclohepta[b]indole-￿-carbox-
amide (￿￿￿).
N
Ts
Me
NO
I
￿￿￿
Note: The experimental part for this compound is described in one single
block, since all intermediates are highly instable and are directly used for
the next transformation, cf. Section ￿.￿.
Part I: Methyltriphenylphosphonium bromide (￿￿%, ￿￿￿ mg,
￿.￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous THF (￿.￿ml) and
cooled to –￿￿ °C under an argon atmosphere. NaHMDS (￿.￿ ￿
in THF, ￿.￿ ml, ￿.￿￿ mmol, ￿.￿ eq.) was added dropwise and the
￿￿￿
￿￿ Experimental
reaction mixture was stirred ￿￿min at –￿￿ °C, then additional ￿￿min at ￿ °C and then again
recooled to –￿￿ °C to yield an bright yellow suspension. A solution of aldehyde ￿￿￿ (￿￿￿.￿mg,
￿.￿￿mmol, ￿.￿ eq.) in anhydrous THF (￿.￿ml) was added and the reaction mixture was stirred
￿￿min at –￿￿ °C (monitored by TLC) and then additional ￿￿min at ￿ °C. The reaction mixture
was diluted with precooled ether and quenched by the addition of ice-cold ￿%HCl. The layers
were separated and the aqueous layer was quickly extracted twice with precooled ether. The
combined organic layers were dried over sodium sulfate and the solvent was removed under
reduced pressure (at ￿￿ °C or below, important) to yield crude Wittig intermediate ￿￿￿ as a yellow
foam which was quickly subjected to the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brown
with vanillin).
Part II: Crude ester ￿￿￿ (￿.￿￿mmol, ￿.￿ eq.) was dissolved in EtOH–H￿O (￿:￿, ￿￿ml) and
cooled to ￿ °C. Fine powdered potassium hydroxide (￿.￿￿ g, ￿￿.￿mmol, ￿￿.￿ eq.) was added in
portions and the resulting mixture was stirred ￿￿min at ￿ °C (monitored by TLC). Precooled
￿ ￿HCl was added until the acid precipitated (pH ￿), then the mixture was diluted with ether.
The layers were separated and the aqueous layer was quickly extracted once with ether. The
combined organic layers were dried over sodium sulfate and the solvent was removed under
reduced pressure (at ￿￿ °C or below, important) to obtain crude carboxylic acid ￿￿￿ as white foam.
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brown with vanillin).
Part III: Crude carboxylic acid ￿￿￿ (￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous DMF
(￿.￿ml) and cooled to ￿ °C. A solution of amine ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous
DMF (￿.￿ml) was added at ￿ °C, followed by the addition of HBTU (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.)
and DIPEA (￿.￿ml, ￿.￿￿mmol, ￿.￿ eq.). The resulting mixture was stirred ￿ h at ￿ °C (monitored
by TLC) at which point the solution turned dark orange. The reaction mixture was diluted with
ether and quenched by the addition of ￿￿% citric acid. The layers were separated and the organic
layer was extracted once with sat. aq. NaHCO￿ and brine, respectively. The aqueous layer
containing the ￿￿% citric acid was once again extracted with ether. The layers were separated
and the organic layer was extracted once with sat. aq. NaHCO￿ and brine, respectively. The
combined organic layers were dried over sodium sulfate and concentrated in vacuo to a￿ord
crude divinylcyclopropane ￿￿￿ as yellow oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brown with
vanillin).
Part IV: TLC analysis indicated, that partial rearrangement already took place during the
evaporation process. Therefore, crude divinylcyclopropane ￿￿￿ was taken up in benzene and
stirred ￿ h at ￿￿ °C (monitored by TLC). The solvent was evaporated in vacuo to obtain crude
cyclohepta[b]indoline ￿￿￿ which turned out to be unstable and was therefore directly used in the
next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brown with vanillin). HRMS (ESI): calcd. for
C￿￿H￿￿IN￿O￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
Part V: Crude cyclohepta[b]indoline ￿￿￿ (￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿.￿ml) and cooled to ￿ °C. Trimethylsilyl trifluoromethanesulfonate (￿￿￿ ￿l, ￿.￿￿mmol,
￿.￿ eq.) was added dropwise. The ice bath was removed and the reaction mixture was stirred
￿￿ h (monitored by NMR) at ambient temperature. The reaction mixture was quenched by the
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
addition of ￿ ￿HCl and the layers were separated. The aqueous layer was extracted twice with
CH￿Cl￿ and the combined organic layers were dried over K￿CO￿. The solvent was removed in
vacuo and the residue was subjected to flash column chromatography (hexanes–EtOAc, ￿.￿:￿)
to obtain pure cyclohepta[b]indole ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿% yield for the whole sequence
starting from aldehyde ￿￿￿). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brownwith vanillin).
￿HNMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿ Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm.￿ IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿IN￿NaO￿S
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿S,￿S,￿R)-￿-(((tert-Butyldimethylsilyl)oxy)methyl)-N-((Z)-￿-iodobut-￿-en-￿-yl)-N-methyl-￿-
(￿-tosyl-￿H-indol-￿-yl)cyclopropane-￿-carboxamide (￿￿￿).
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￿￿￿
Enantioenriched ester ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
EtOH–H￿O (￿:￿, ￿.￿ml) and cooled to ￿ °C. Fine powdered potassium
hydroxide (￿￿￿ mg, ￿.￿￿ mmol, ￿￿.￿ eq.) was added in portions and
the resulting mixture was stirred ￿￿min at ￿ °C (monitored by TLC).
Precooled ￿ ￿HCl was added until the acid precipitated (pH ￿), then
the mixture was diluted with ether. The layers were separated and the
aqueous layer was quickly extracted once with ether. The combined
organic layers were dried over sodium sulfate and the solvent was
removed under reduced pressure (at ￿￿ °C or below, important) to obtain crude carboxylic acid
as white foam which was directly taken up in anhydrous DMF (￿.￿ml) and cooled to ￿ °C. A
solution of amine ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) in anhydrous DMF (￿.￿ ml) was added
at ￿ °C, followed by the addition of HBTU (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) and DIPEA (￿￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿ eq.). The resulting mixture was stirred ￿￿ h at ￿ °C at which point the solution
turned dark orange. The reaction mixture was diluted with EtOAc and quenched by the addition
of ￿￿% citric acid. The layers were separated and the organic layer was extracted once with
sat. aq. NaHCO￿ and brine, respectively. The aqueous layer containing the ￿￿% citric acid
was once again extracted with EtOAc. The layers were separated and the organic layer was
extracted once with sat. aq. NaHCO￿ and brine, respectively. The combined organic layers were
dried over sodium sulfate and concentrated in vacuo to a￿ord crude amide ￿￿￿. Purification by
flash column chromatography (hexanes–EtOAc, ￿:￿) a￿orded pure title compound ￿￿￿ (￿￿￿mg,
￿ The compound appears as two rotamers in a ratio of ￿.￿:￿.￿.
￿￿￿
￿￿ Experimental
￿￿￿ ￿mol, ￿￿%) as pale yellow foam. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, carboxylic acid, stains
dark red with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, amide, stains dark orange with vanillin).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿.￿H), ￿.￿￿ (s, ￿.￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), -￿.￿￿ – -￿.￿￿
(m, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿,
–￿.￿ ppm.￿ HRMS (ESI): calcd. for C￿￿H￿￿IN￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(￿S,￿S,￿R)-￿-formyl-N-((Z)-￿-iodobut-￿-en-￿-yl)-N-methyl-￿-(￿-tosyl-￿H-indol-￿-yl)cyclopropane-
￿-carboxamide (￿￿￿).
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￿￿￿
Silyl alcohol ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in ￿.￿ml
of AcOH–THF–H￿O (￿:￿:￿, v/v) an was stirred ￿￿ h at ambient tem-
perature. The reaction mixture was diluted with CH￿Cl￿ and sat. aq.
NaHCO￿ was added carefully. The layers were separated and the aque-
ous layer was extracted twicewithCH￿Cl￿. The combined organic layers
were dried over magnesium sulfate and the solvent was removed under
reduced pressure to yield crude alcohol which was directly taken up in
CH￿Cl￿ (￿.￿ml). Dess–Martin periodinane (￿￿￿, ￿￿.￿mg, ￿￿￿ ￿mol,
￿.￿ eq.) and NaHCO￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿.￿ eq.) were added and the reaction mixture was
stirred ￿￿min at ambient temperature (monitored by TLC). The reaction mixture was diluted
with CH￿Cl￿ and quenched by the addition of sat. aq. NaHCO￿. The layers were separated and
the aqueous layer was extracted once with CH￿Cl￿. The combined organic layers were dried over
magnesium sulfate and the solvent was removed under reduced pressure. The resulting crude
was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain aldehyde ￿￿￿
(￿￿.￿ mg, ￿￿￿ ￿mol, ￿￿% over two steps) as white foam. ￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿
(dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿,
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿IN￿O￿S [M + H]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿ The compound appears as two rotamers in a ratio of ￿.￿:￿.￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿.￿
(￿aS,￿R)-N-((Z)-￿-Iodobut-￿-en-￿-yl)-￿-methoxy-N-methyl-￿-tosyl-￿,￿a,￿,￿-tetrahydrocyclo-
hepta[b]indole-￿-carboxamide (￿￿￿).
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Part I:KHMDS (￿.￿￿ in PhMe, ￿.￿ml, ￿.￿mmol, ￿.￿ eq.) was added
dropwise to a solution of (methoxymethyl)triphenylphosphonium
chloride (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous THF (￿.￿ml)
at –￿￿ °C. The resulting solution was stirred ￿￿min at –￿￿ °C and
additional ￿￿min at –￿ °C to obtain a dark red solution. A solution
of aldehyde ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF
(￿.￿ml) was added dropwise at –￿ °C and the reaction mixture was
stirred for ￿ h at this temperature (monitored by TLC). The reaction mixture was diluted with
ether and quenched by the addition of sat. aq. NH￿Cl/￿%HCl (￿:￿). The layers were separated
and the aqueous layer was extracted once with ether. The combined organic layers were extracted
once with brine and dried over sodium sulfate. The solvent was removed in vacuo. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, CAN).
Part II: The residue was directly taken up in EtOH–H￿O (￿.￿ml, ￿:￿). Fine powdered potas-
sium hydroxide (￿￿￿mg, ￿.￿￿mmol, ￿￿.￿ eq.) was added in portions and the resulting mixture
was stirred ￿￿min at ambient temperature (monitored by TLC). ￿ ￿HCl was added until the
acid precipitated (pH ￿), then the mixture was diluted with CH￿Cl￿. The layers were separated
and the aqueous layer was extracted once with CH￿Cl￿. The combined organic layers were
dried over sodium sulfate and the solvent was removed under reduced pressure to obtain crude
carboxylic acid as pale yellow foam. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains rose with vanillin).
Part III: The crude material was dissolved in anhydrous DMF (￿.￿ ml) and cooled to ￿ °C.
A solution of amine ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) in anhydrous DMF (￿.￿ml) was added
at ￿ °C, followed by the addition of HBTU (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) and DIPEA (￿￿￿ ￿l,
￿.￿￿mmol, ￿.￿ eq.). The resulting mixture was stirred ￿￿ h at ￿ °C at which point the solution
turned dark orange. The reaction mixture was diluted with EtOAc and quenched by the addition
of ￿￿% citric acid. The layers were separated and the organic layer was extracted once with sat.
aq. NaHCO￿ and brine, respectively. The aqueous layer containing the ￿￿% citric acid was once
again extracted with EtOAc. The layers were separated and the organic layer was extracted once
with sat. aq. NaHCO￿ and brine, respectively. The combined organic layers were dried over
sodium sulfate and concentrated in vacuo to a￿ord crude amide ￿￿￿. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, diastereomer I, stains pink with vanillin). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, diastereomer II,
stains light brown with vanillin).
Part IV: The crude material was taken up in anhydrous toluene and stirred ￿ h at ￿￿￿ °C. The
solvent was removed in vacuo and the residue was subjected to flash column chromatography
(hexanes–EtOAc, ￿:￿) to obtain title compound ￿￿￿ as diastereomers which were directly used
for the rearomatization step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, diastereomer I, CAN). Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, diastereomer II, CAN).HRMS (ESI): calcd. for C￿￿H￿￿IN￿NaO￿S [M +Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿￿
￿￿ Experimental
(Z)-N-(￿-Iodobut-￿-en-￿-yl)-N-methyl-￿-tosyl-￿,￿￿-dihydrocyclohepta[b]indole-￿-carbox-
amide (￿￿￿).
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To a solution of crude cyclohepta[b]indoline ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.)
in anhydrous CH￿Cl￿ (￿.￿ ml) was added trimethylsilyl trifluo-
romethanesulfonate (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) dropwise at ￿ °C.
The solution was stirred ￿￿ h at this temperature (monitored by
TLC) at which the solution turned dark red. ￿ ￿HCl was added, the
layers were separated and the aqueous layer was extracted twice with
CH￿Cl￿. The combined organic layers were dried over K￿CO￿ and
the solvent was evaporated in vacuo. The residue was subjected to flash column chromatography
(hexanes–EtOAc, ￿:￿) to a￿ord undesired cyclohepta[b]indole ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿% from
aldehyde ￿￿￿) as yellow oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿
(d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿
(q, J = ￿.￿Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d,
J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿IN￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿-tosyl-￿,￿,￿a,￿,￿￿,￿￿a-hexahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one (￿￿￿).
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￿￿￿
A flame-dried Schlenk tube was charged with vinyl iodide ￿￿￿ (￿￿￿mg,
￿￿￿ ￿mol, ￿.￿ eq.), phenol (￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿￿ eq.), and K￿PO￿
(￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.). The tube was evacuated and backfilled
with argon. This was repeated three times, then Pd(PPh￿)￿ (￿￿.￿ mg,
￿￿.￿ ￿mol, ￿￿ mol %) was added in the glovebox. Freeze-pump-thaw
degassed anhydrous toluene (￿￿.￿ml) was added and stirring was contin-
ued at ￿￿￿ °C. TLC indicated the full conversion after ￿.￿ h, the reaction
mixture was then cooled to ambient temperature. CH￿Cl￿ and sat. aq. NaHCO￿ were added, the
layers were separated and the aqueous layer was extracted thrice with CH￿Cl￿. The combined
organic layers were dried over magnesium sulfate and the solvent was removed under reduced
pressure. The residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to
obtain pure piperidine ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%) as white foam. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, stains bright orange with vanillin). ￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (qt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J =
￿￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿￿￿
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￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI):
calcd. for C￿￿H￿￿N￿O￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿.￿° (c = ￿.￿, CHCl￿).
NMR spectra on page ￿￿￿.
Note: (i) This procedure can also be carried out with Pd￿(dba)￿  CHCl￿ (￿￿ mol %) and
DavePhos®(￿￿mol %) instead of Pd(PPh￿)￿. (ii) This procedure was carried out with up to ￿￿￿￿mg
of starting material with ￿￿–￿￿% yield.
(￿S,￿aS,￿￿aR)-￿-ethyl-￿-methyl-￿-tosyl-￿,￿,￿a,￿,￿,￿,￿￿,￿￿a-octahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one (￿￿￿).
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￿￿￿
Olefine ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added to EtOH (￿.￿ ml,
almost no dissolution). Adams’s catalyst (￿.￿ mg, ￿￿ ￿mol, ￿.￿ eq.)
was added and the vigorous stirred reaction mixture was hydrogenated
(p(H￿) = ￿ atm) at ambient temperature for ￿ h. The mixture was filtered
over celite and the solvent was removed under reduced pressure to obtain
title compound ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%) as white solid (a:b = ￿:￿￿,
according to NMR analysis). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H),
￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J =
￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿S [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(￿S,￿aS,￿￿aR)-￿-Ethyl-￿-methyl-￿,￿,￿a,￿,￿,￿,￿￿,￿￿a-octahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one (￿￿￿).
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￿￿￿
Tosylated indole ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in an-
hydrous methanol (￿.￿ml) under argon atmosphere. Ammonium chlo-
ride (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) and magnesium turnings (￿￿.￿ mg,
￿.￿￿ mmol, ￿￿.￿ eq.) were added. The reaction mixture was irradiated
with ultrasonic at ambient temperature for ￿￿min (monitored by TLC).
The reaction mixture was diluted with ether and sat. aq. NH￿Cl was
added. The layers were separated and the aqueous layer was washed
thrice with ether, then the aqueous layer was basified with K￿CO￿ and backwashed once with
ether. The combined organic layers were dried over sodium sulfate and the solvent was removed
in vacuo to obtain a hardly soluble white solid which was dissolved in hot toluene and subjected to
￿￿￿
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flash column chromatography (hexanes–EtOAc, ￿:￿). This a￿orded title compound ￿￿￿ as white
solid (￿￿.￿ mg, ￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains excellent with KMnO￿,
stains dark red with Ehrlich’s reagent). HRMS (ESI): calcd. for C￿￿H￿￿N￿O [M + H]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿.
(￿S,￿aS,￿￿aR)-￿-Ethyl-￿-methyl-￿,￿,￿a,￿,￿￿,￿￿a-hexahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indole-￿,￿(￿H,￿H)-dione [ ￿-oxo-￿￿,￿￿-diepisilicine ] (￿￿￿).
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Indole ￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in THF–H￿O
(￿:￿, ￿.￿ ml) and I￿O￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added. The
resulting mixture was stirred ￿ h at ambient temperature (monitored
by TLC) at which point the reaction mixture became dark orange. The
solvent was evaporated in vacuo and the residue was partitioned between
EtOAc and water. The layers were separated and the organic layer was
additionally washed once with sat. aq. Na￿S￿O￿, sat. aq. NaHCO￿, and
brine, respectively. Drying over sodium sulfate followed by flash column chromatography (EtOAc,
pure) a￿orded ￿-oxo-cyclohepta[b]indole ￿￿￿ as yellow solid (￿￿.￿mg, ￿￿ ￿mol, ￿￿%). Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains bright yellow then brown with vanillin). ￿HNMR (￿￿￿MHz, CDCl￿)
d = ￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿ Hz,
￿H), ￿.￿￿ (q, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿)
d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿,￿,￿a,￿,￿￿,￿￿a-hexahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one (￿￿￿).
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￿￿￿
A solution of tosylated indole ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) in an-
hydrous degassed THF (￿.￿ ml) was added in one portion to a freshly
prepared solution of SmI￿ (￿.￿ ￿ in degassed THF, ￿￿￿ml, ￿￿.￿mmol,
￿￿.￿ eq.) at ambient temperature. After complete addition, the reaction
was stirred ￿ s, then H￿O (￿￿￿ ￿l, ￿￿.￿ mmol, ￿￿.￿ eq.) was added fol-
lowed by the addition of pyrrolidine (￿.￿￿ml, ￿￿.￿mmol, ￿￿.￿ eq.). The
reaction mixture immediately turned pale green and a white precipitate
was formed. The mixture was diluted with EtOAc (￿￿￿ ml) and ￿ ￿ HCl (￿￿￿ ml) was added.
The layers were separated and the aqueous layer was extracted twice with EtOAc. The aqueous
layer was basified with K￿CO￿ and checked for product residues. The combined organic layers
￿￿￿
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were dried over sodium sulfate and the solvent was removed under reduced pressure to obtain
crude indole ￿￿￿ as a pale yellow solid. The product turned out to be very sensitive towards
oxidation and therefore was directly used in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains
pale red with vanillin, stains immediately bright yellow with CAN). HRMS (ESI): calcd. for
C￿￿H￿￿N￿NaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿,￿,￿a,￿,￿,￿,￿￿,￿￿a-octahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one (￿￿￿).
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Crude indole ￿￿￿ (￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous CH￿Cl￿
(￿￿.￿ml) to yield a bright yellow solution. Trifluoroacetic acid (￿￿.￿ml)
was added after which the solution turned dark red. Triethylsilane (￿.￿ml,
￿￿.￿mml, ￿￿.￿ eq.) was added at ambient temperature and the resulting
solution was stirred ￿ h at this temperature (monitored by TLC) before it
was carefully quenched by the addition of sat. aq. K￿CO￿. The layers were
separated and the aqueous layer was extracted twice with CH￿Cl￿. The
combined organic layers were dried over sodium sulfate the solvent was removed under reduced
pressure. The residue was subjected to flash column chromatography (cyclohexane–EtOAc, ￿:￿)
to obtain pure indole ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿%) as white solid. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, stains bright pink with CAN). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (qt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd,
J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm.
IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿. HRMS (ESI):
calcd. for C￿￿H￿￿N￿NaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, CHCl￿).
NMR spectra on page ￿￿￿.
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿,￿,￿a,￿,￿￿,￿￿a-hexahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indole-￿,￿(￿H,￿H)-dione [ (+)-￿-Oxoisomethuenine ] (￿￿￿).
N
H
Me
N
H
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O
￿￿￿
Indole ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was dissolved in THF–H￿O (￿:￿,
￿.￿ml) and I￿O￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was added in one portion
at ambient temperature. The reaction mixture was stirred ￿ h at this
temperature (monitored by TLC), before the solvent was evaporated in
vacuo. The residue was dissolved in CH￿Cl￿ and methanol and silica was
added. The solvent was removed in vacuo and the residue was subjected
to flash column chromatography (CH￿Cl￿ –MeOH, ￿￿:￿, or alternatively
￿￿￿
￿￿ Experimental
hexanes–EtOAc, ￿:￿) to obtain pure title compound ￿￿￿ as pale yellow solid (￿￿.￿mg, ￿￿.￿ ￿mol,
￿￿%). Rf = ￿.￿￿ (EtOAc, pure, stains bright yellow with CAN).
￿H NMR (￿￿￿MHz, CDCl￿) d =
￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J =
￿￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm.
IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿.
HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c =
￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
￿￿.￿￿ Experimental Part for Section ￿.￿
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿,￿,￿,￿,￿a,￿,￿,￿,￿￿,￿￿a-decahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿-ol [ Isomethueninol ] (￿￿￿).
N
H
Me
N
H
H
OH
￿￿￿
A solution of ￿-oxoisomethuenine (￿￿￿, ￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in
anhydrous THF (￿￿.￿ml) was cooled to ￿ °C and LiAlH￿ (￿.￿ ￿ in THF,
￿.￿￿ml, ￿￿.￿ eq.) was added dropwise. The solution turned bright yellow
and stirring was continued for ￿ h at ambient temperature (monitored by
TLC) at which the solution was again colorless. The reaction mixture was
cooled to ￿ °C and benzene (￿￿ml) was added. To this solution was added
sodium fluoride (￿.￿ g) followed by the careful addition of H￿O (￿.￿ml,
exothermic!). The ice bath was removed and the mixture was stirred vigorously for ￿￿ min
at ambient temperature. The mixture was filtered through a medium porosity sintered-glass
funnel and the retentate was washed with an appropriate amount of chloroform. The solvent
was removed in vacuo to obtain crude alcohol ￿￿￿ as colorless foam which was directly used
in the next step. Rf = ￿.￿￿ (cyclohexane–CHCl￿–Et￿NH, ￿￿:￿:￿).
￿H NMR (￿￿￿ MHz, CDCl￿)
d = ￿.￿￿ (br s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br d,
J = ￿￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿￿.￿, ￿￿.￿Hz, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿O [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿￿ Experimental Part for Section ￿.￿
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿,￿,￿,￿a,￿,￿,￿￿,￿￿a-octahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one [ ￿￿-Epimethuenine ] (￿￿).
N
H
Me
N
H
H
O
￿￿
Crude alcohol ￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous chlo-
roform (￿￿.￿ ml) and MnO￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿￿.￿ eq.) was added.
The reaction mixture was stirred ￿ h at ambient temperature (monitored
by TLC) before it was filtered over celite. The retentate was washed with
an appropriate amount of chloroform and the solvent was removed in
vacuo to obtain crude title compound ￿￿ which was subjected to flash
column chromatography (cyclohexane–CHCl￿–Et￿NH, ￿￿:￿:￿) to a￿ord
isomethuenine (￿￿.￿ mg, ￿￿￿ ￿mol, ￿￿% over two steps) as pale yellow solid. Rf = ￿.￿￿
(cyclohexane–CHCl￿–Et￿NH, ￿￿:￿:￿, stains red with Ehrlich’s reagent, stains excellent with
KMnO￿).
￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. ￿H NMR (￿￿￿ MHz, DMSO) d = ￿￿.￿￿ (s, ￿H), ￿.￿￿ (d,
J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H) ppm.￿
￿￿C NMR (￿￿￿ MHz, DMSO) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿N￿O [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿S,￿aS,￿￿aR)-￿-Ethyl-￿-methyl-￿,￿,￿,￿a,￿,￿,￿￿,￿￿a-octahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one [ ￿￿,￿￿-Diepisilicine ] (￿￿).
N
H
Me
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￿￿
￿￿-Epimethuenine (￿￿, ￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhy-
drous ethanol (￿.￿ml) and Adams’s catalyst (￿.￿mg, ￿￿.￿ ￿mol, ￿.￿￿ eq.)
was added. The reaction mixture was hydrogenated (p(H￿) = ￿ atm) for
￿.￿ h at ambient temperature (monitored by TLC). The mixture was fil-
tered over celite and the solvent was removed in vacuo. The residue was
subjected to flash column chromatography (cyclohexane–CHCl￿–Et￿NH,
￿￿:￿:￿) to obtain ￿￿,￿￿-diepisilicine (￿￿, ￿￿.￿ mg, ￿￿.￿ ￿mol, ￿￿%) as
yellow solid. Rf = ￿.￿￿ (cyclohexane–CHCl￿–Et￿NH, ￿￿:￿:￿, stains with KMnO￿).
￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (br s, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H),
￿ Two signal are partially overlapped by the solvent signals.
￿￿￿
￿￿ Experimental
￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿ Hz, ￿H), ￿.￿￿ (dqd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿ Hz,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿N￿O [M + H]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿R,￿aS,￿￿aR)-￿-ethyl-￿-methyl-￿,￿,￿,￿a,￿,￿,￿￿,￿￿a-octahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indol-￿(￿H)-one [ ￿￿-Episilicine ] (￿￿).
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￿￿
In the previous step, the ￿￿-a-epimer ￿￿-episilicine (￿￿, ￿.￿mg, ￿.￿ ￿mol,
￿%) was also obtained as yellow solid. NMR analysis revealed a mix-
ture of at least three di￿erent compounds. Purification by prepara-
tive chromatography (cyclohexane–CHCl￿–Et￿NH, ￿￿:￿:￿) furnished ti-
tle compound ￿￿ (￿￿￿ ￿g, ￿.￿ ￿mol, ￿%) as pale yellow solid. Rf =
￿.￿￿ (cyclohexane–CHCl￿–Et￿NH, ￿￿:￿:￿, stains with KMnO￿).
￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿O
[M + H]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿° (c = ￿.￿￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿aR,￿￿aR,E)-￿-Ethylidene-￿-methyl-￿-oxo-￿,￿,￿,￿,￿a,￿,￿,￿,￿￿,￿￿a-decahydro-
pyrido[￿’,￿’:￿,￿]cyclo hepta[￿,￿-b]indole ￿-oxide [ ￿￿-epimethuenine-N-oxide ] (￿￿).
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￿￿
￿￿-Epimethuenine (￿￿, ￿.￿ g, ￿￿.￿ ￿mol, ￿.￿ eq.) was dissolved in CH￿Cl￿
(￿.￿ ml) and mCPBA (￿￿%, ￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was added in
one potion at ambient temperature and stirring was continued at this
temperature for ￿￿min (monitored by TLC). The reaction mixture was
quenched by the addition of sat. aq. K￿CO￿ and the layers were separated.
The aqueous layer was extracted thrice with CH￿Cl￿ and the combined
organic layers were dried over sodium sulfate. The solvent was removed
under reduced pressure to obtain a pale yellow residue (￿.￿mg, ￿￿%). Comparison of the crude
NMR data with literature revealed, that title compound ￿￿ has been formed. No optimization
or HPLC purification was carried out. Rf = ￿.￿￿ (EtOAc–iPrOH–Et￿NH, ￿￿:￿￿:￿). HRMS (ESI):
calcd. for C￿￿H￿￿N￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿° (c = ￿.￿, CHCl￿).
￿￿￿
￿￿.￿￿ Experimental Part for Section ￿.￿
(￿S,￿aS,￿￿aR)-￿-Ethyl-￿-methyl-￿,￿,￿,￿a,￿,￿￿a-hexahydropyrido[￿’,￿’:￿,￿]cyclo-
hepta[￿,￿-b]indole-￿,￿￿(￿H,￿H)-dione [ ￿-oxo-￿￿,￿￿-diepisilicine ] (￿￿).
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￿￿
￿￿,￿￿-Diepisilicine (￿￿, ￿.￿ mg, ￿￿.￿ ￿mol) was dissolved in acetone
(￿.￿ ml) and cooled to ￿ °C and treated with Jones reagent (￿￿￿). After
stirring ￿ min, the reaction mixture was diluted with CH￿Cl￿ and sat.
aq. K￿CO￿ was added. The layers were separated and the aqueous layer
was extracted twice with CH￿Cl￿. The solvent was evaporated and NMR
analysis of the crude (￿.￿mg, ￿.￿ ￿mol, ￿￿%) revealed after comparison
with literature, that ￿-oxo-￿￿,￿￿-diepisilicine has been formed. No opti-
mization or HPLC purification was carried out. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (br s, ￿H),
￿.￿￿ (dt, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿
(ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (q, J =
￿￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿Hz,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for
C￿￿H￿￿N￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿° (c = ￿.￿￿, CHCl￿).
￿￿￿
￿￿ Experimental
￿￿￿
Part III
The Isoschizogamine Project

￿￿Schizozyganes
￿￿.￿ Introduction
Schizozyganes represent a small group of hexacyclic N-acyl indoline alkaloids. These alkaloids
were isolated in ￿￿￿￿ from the twigs of Schizozygia co￿aeoides Bail. (Apocynaceae) growing in
tropical East Africa with schizozygine (￿￿￿) being the main alkaloid (Fig. ￿￿-￿).[￿￿￿] In Kenya
this plant is used to treat several ailments: (i) the leaf extracts are used to treat ringworm, (ii)
the steam from boiling the leaves is used to soothe inflamed eyes, (iii) the root extracts in
combination with coconut oil were used for the treatment of sores on the skin. In addition, it
was shown by R.M. Kariba and co-workers that theses extracts were fungitoxic to Trichophyton
mentagrophytes,Microsporum gypseum, Cladosporium cucumerinum, and Candida albicans.[￿￿￿]
Two pairs of minor alkaloids were also reported: schizogamine (￿￿￿), schizogaline (￿￿￿) and
isoschizogamine (￿￿￿), isoschizogaline (￿￿￿).[￿￿￿] The di￿erences in physico-chemical properties
between the pairs were ascribed to the epimeric stereochemistry at C-￿. However, this turned
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Figure ￿￿-￿. Schizozyganes from Schizozygia ca￿aeoides: (i) schizozygine (￿￿￿), schizogamine (￿￿￿), and schizogaline (￿￿￿), (ii)
originally proposed structures of isoschizogamine (￿￿￿) and isoschizogaline (￿￿￿),[￿￿￿,￿￿￿] (iii) revised structures of
isoschizogamine (￿￿￿) and isoschizogaline (￿￿￿).[￿￿￿]
￿￿￿
￿￿ Schizozyganes
out to be erroneous and a revised structure for isoschizogamine (￿￿￿) and isoschizogaline (￿￿￿)
was published by J. Hájícˇek and co-workers based on up-to-date NMR analyses.[￿￿￿] The absolute
configuration of the iso-schizozygane alkaloids isoschizogamine (￿￿￿) and isoschizogaline (￿￿￿)
was determined using vibrational circular dichroism (VCD) spectroscopy.[￿￿￿,￿￿￿]
￿￿.￿ Biosynthesis
It was anticipated that the skeleton of the schizozyganes could be biogenetically derived from
the Aspidosperma alkaloid family (for further information, the author refers to Section ￿.￿, p. ￿￿).
Indeed, both groups of alkaloids have been found in the same plant species.[￿￿￿]
J. Hájícˇek et al. reported a biosynthetic proposal[￿￿￿] starting from alkaloid ￿￿￿ (probably
originated from the same biogenetic sequence as Aspidosperma alkaloid tabersonine) which
undergoes rearrangement via indole iminium ion (Scheme ￿￿-￿). The newly formed azomethine
ion is trapped by the indole via C-￿ forming pentacycle ￿￿￿. This intermediate is the precursor
for schizogamine (￿￿￿). For the generation of its iso-derivative, dehydrogenation at C-￿￿ takes
place generating iminium ￿￿￿ which is trapped by indoline nitrogen addition. This leads to
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Scheme ￿￿-￿. Proposed biosynthesis of isoschizogamine (￿￿￿).[￿￿￿]
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￿￿.￿ Total Syntheses of Isoschizogamine (￿￿￿)
aziridine ￿￿￿. Subsequent reductive opening of the aziridine ring a￿ords tetrahydroquinoline ￿￿￿
which is finally transformed into hexacyclic isoschizogamine (￿￿￿) via lactam formation.
￿￿.￿ Total Syntheses of Isoschizogamine (￿￿￿)
The structure of isoschizogamine (￿￿￿) contains a unique [￿,￿,￿,￿]diazafenestrane system with
an additional C￿–C￿￿ bridged five-membered ring. Additionally, the hexacyclic skeleton has a
highly substituted tetrahydroquinoline unit with four contiguous stereogenic centers.
Isoschizogamine (￿￿￿) has been synthesized five times so far. The first total synthesis of
racemic ￿￿￿ was published in ￿￿￿￿ by Heathcock et al.[￿￿￿] (that was only one year, after the orig-
inally proposed structure has been revised by Hájícˇek and co-workers). The originally proposed
absolute configuration via vibrational circular dichroism spectroscopy was later confirmed by the
first asymmetric total synthesis of ￿￿￿ by Fukuyama et al. in ￿￿￿￿.[￿￿￿] Three additional asymmet-
ric total syntheses of ￿￿￿ have been published in ￿￿￿￿ by the groups of Qin,[￿￿￿] Tokuyama,[￿￿￿]
and Zhu.[￿￿￿]
In ￿￿￿￿, Heathcock et al. reported the first preparation of (±)-isoschizogamine (￿￿￿).[￿￿￿] The
synthesis required eight steps from a readily available ketone starting material. The key transfor-
mations are shown in Scheme ￿￿-￿. Imine ￿￿￿ underwent Michael addition to Meldrum’s acid
derivative ￿￿￿ at –￿￿ °C. This formed an intermediate which, upon heating in toluene, under-
went a cyclization with concomitant loss of acetone and carbon dioxide. Final dehydration with
Martin’s sulfurane furnished tetrahydroquinolizinone ￿￿￿ in ￿￿% overall yield. The aromatic
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Scheme ￿￿-￿. Key transformations in the total synthesis of (±)-isoschizogamine (Heathcock, ￿￿￿￿).[￿￿￿]
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Scheme ￿￿-￿. An Approach to the isoschizozygane alkaloid core (Padwa, ￿￿￿￿).[￿￿￿,￿￿￿]
nitro group was then reduced to the corresponding aniline and subsequent reduction of the
lactam carbonyl with lithium aluminium hydride gave aminal ￿￿￿ as single diastereomer. ￿￿￿
was transformed into (±)-isoschizogamine (￿￿￿) in three additional steps finishing a landmark
eight-step synthesis of this natural product.
Padwa and co-workers reported an approach to the isoschizozygane alkaloid core in ￿￿￿￿
(Scheme ￿￿-￿).[￿￿￿] Thioamide ￿￿￿ was reacted with carbon suboxide at ambient temperature to
give isolable betaine ￿￿￿ which, upon heating in toluene, underwent intramolecular ￿,￿-dipolar
cycloaddition reaction to yield intermediate ￿￿￿. The resulting cycloadduct underwent loss of
carbonyl sulfide followed by a hydrogen shift to give hexahydroquinolizinone ￿￿￿. Both the
aromatic nitro group and the lactam carbonyl were reduced and treatment with acid furnished
a ￿:￿-mixture of the diastereomeric aminals ￿￿￿ and ￿￿￿. Treatment of either isolated isomer
with acetic acid resulted in an equilibrated ￿:￿-mixture of ￿￿￿ and ￿￿￿ of which the latter
one possessing the correct core skeleton of the isoschizozygane family of alkaloids. Padwa
and co-workers reported a more detailed manuscript four years later[￿￿￿] but a complete total
synthesis of isoschizogamine (￿￿￿) has not been published until today.
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￿￿.￿ Total Syntheses of Isoschizogamine (￿￿￿)
In ￿￿￿￿, Zhou and co-workers were the first to report an asymmetric approach towards the
synthesis of (–)-isoschizogamine (￿￿￿, Scheme ￿￿-￿).[￿￿￿] #-Lactam ￿￿￿, which was synthesized
via an aza-Claisen rearrangement strategy,[￿￿￿] was reacted with ￿-aminoveratrole (￿￿￿) and a
catalytic amount of tosylic acid in refluxing toluene. This formed iminium ion ￿￿￿ which in
situ underwent a formal hetero Diels–Alder reaction to furnish highly functionalized tetrahydro-
quinoline product ￿￿￿ which can be an intermediate in the synthesis towards isoschizogamine
(￿￿￿). However, no further approaches towards the total synthesis of ￿￿￿ have been reported.
The first asymmetric total synthesis of isoschizogamine (￿￿￿) was published by Fukuyama
et al. in ￿￿￿￿ (Scheme ￿￿-￿).[￿￿￿] Transformation of (+)-exo-norborneol (￿￿￿) into bicyclic
compound ￿￿￿ was carried out by means of a Wagner–Meerwein rearrangement. Tandem
metathesis constructed bicyclic lactone ￿￿￿ which was transformed into ketone ￿￿￿ in three
steps. Acid-mediated cleavage of the TBDPS group, followed by treatment with PPTS in re-
fluxing toluene, a￿orded a hemiaminal ether and subsequent metathesis furnished hexahydro-
quinoline ￿￿￿ in ￿￿% overall yield. This intermediate was transformed into Heathcock’s key
intermediate ￿￿￿ in additional eight steps and (–)-isoschizogamine (￿￿￿) was completed similar
to Heathcock et al. in three steps.
In late ￿￿￿￿, three asymmetric total syntheses of isoschizogamine (￿￿￿) have been published.
The synthesis of Qin and co-workers[￿￿￿] employed two asymmetric Michael addition reactions
to establish the chiral centers at C-￿ and C-￿￿. A key intermediate is thioamide ￿￿￿ (a similarity
to Heathcock’s intermediate is once again obvious). The thioamide and amide functionalities
were converted to a methylthioiminium cation and a methoxyl imidate group, respectively, using
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￿￿.￿ Total Syntheses of Isoschizogamine (￿￿￿)
Meerwein salt. This in situ prepared intermediate was then treated with lithium aluminium
hydride at –￿￿ °C to provide hexacyclic intermediate ￿￿￿. This intermediate is already very close
to the natural product and was converted in several additional steps to (–)-isoschizogamine (￿￿￿)
and unnatural ￿-hydroxyisoschizogamine (￿￿￿).
In the synthesis of Tokuyama et al.,[￿￿￿] chiral aldehyde ￿￿￿ underwent an acid-mediated
diastereoselective triple cyclization cascade including an intramolecular aldol condensation,
aza–Michael addition, and lactamization in one-pot to provide the tetracyclic compound ￿￿￿ as a
single isomer (Scheme ￿￿-￿). ￿￿￿was then transformed into ￿￿￿ in several steps. Chemoselective
C–H oxidation at the position adjacent to the nitrogen atom a￿orded compound ￿￿￿ which was
heated to thermally remove the Boc group and subsequent treatment with bismuth triflate in
the presence of molecular sieves constructed the cyclic aminal ￿￿￿. (–)-Isoschizogamine (￿￿￿)
was synthesized in eight additional steps.
One of the most elegant and short total syntheses of isoschizogamine (￿￿￿) was reported by
Zhu and co-workers (Scheme ￿￿-￿).[￿￿￿] Carbamate ￿￿￿ (accessible in four steps from ￿-nitro-
veratraldehyde) was reacted with optically active selenoimine ￿￿￿ (accessible in four steps from
commercially available material) in acetonitrile at ￿￿￿ °C (microwave) to a￿ord iminium salt ￿￿￿.
Pivalic acid was added and the resulting solution was once again heated to ￿￿￿ °C for ￿￿minutes
under microwave irradiation to give desired hexacyclic compound ￿￿￿. Oxidation of ￿￿￿ to the
selenoxide followed by a syn elimination a￿orded (–)-isoschizogamine (￿￿￿) in ￿￿% overall yield.
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￿￿.￿ Strategy and Retrosynthetic Analysis
Isoschizogamine (￿￿￿) is a highly fused hexacyclic compound and contains a unique [￿,￿,￿,￿]di-
azafenestrane system, thus the two nitrogen atoms of these heterocycles form an aminal adjacent
to a quaternary carbon. with an additional C￿–C￿￿ bridged five-membered ring (Fig. ￿￿-￿). Ad-
ditionally, the hexacyclic skeleton has a highly substituted tetrahydroquinoline unit with four
contiguous stereogenic centers and a pyrrolidinone moiety.
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Figure ￿￿-￿. Analysis of the hexacyclic framework of isoschizogamine (￿￿￿).
The strategy for the synthesis of isoschizogamine (￿￿￿) is shown in Scheme ￿￿-￿. ￿￿￿ is
formed in an acid-mediated reaction from tetrahydroquinolizine ￿￿￿which in turns derives from
epithioquinolizinone ￿￿￿ via thioamide formation and desulfurization with Raney nickel. The
formation of epithioquinolizinone ￿￿￿ represents the key-step in this synthesis. It is planned to
form ￿￿￿ from a, a-disubstituted dihydropyridinethione ￿￿￿ via substituted thioisomünchnone
intermediate ￿￿￿. a, a-Disubstituted dihydropyridinethione ￿￿￿ itself can be formed (i) from
MeO
OMe
N
NO
H
N
MeO2C
H2N
OMe
OMe
N
MeO2C
O2N
OMe
OMe
S
O
NH
O2N
OMeS
N
S
O
O2N
OMe
OMeOMe
MeO2CMeO2C
isoschizogamine (￿￿￿) ￿￿￿ ￿￿￿
￿￿￿￿￿￿
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Scheme ￿￿-￿￿. Retrosynthetic analysis (part II).
amide ￿￿￿ (racemic variant), (ii) from (S)-￿-hydroxypiperidin-￿-one (￿￿￿, derived from ￿-￿￿￿),
or (iii) from g-butenolide ￿￿￿ (derived from glycidol ￿￿￿, Scheme ￿￿-￿￿). The first metathesis
approach was carried out in cooperation with a Russian group colleague (Konnichiwa).
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Figure ￿￿-￿. Thioisomünchnones.
The key intermediate of this synthesis is planned to be
the thioisomünchnone[￿￿￿,￿￿￿] derivative ￿￿￿. Thioisomünch-
none is a trivial name for derivatives of either mesoionic com-
pound thiazol-￿-ium-￿-olate (￿￿￿) or thiazol-￿-ium-￿-olate (￿￿￿,
Fig. ￿￿-￿). There are several general ways for the generation of
thioisomünchnones, all of them are based on thioamides. Potts
et al. described the synthesis of thioisomünchnones via the reaction of bromoalkenoyl chlorides
with thioamides (Scheme ￿￿-￿￿a).[￿￿￿] Another possibility is the reaction of thioamides with
diazo compounds, also first reported by Potts and co-workers (Scheme ￿￿-￿￿b).[￿￿￿] Modern
modifications of this procedure use metal catalysis (e.g. rhodium). A third option is the reaction
of thioamides with oxirane-￿,￿-dicarbonitrile derivatives like ￿￿￿. The double loss of hydrogen
cyanide forms ketene intermediate ￿￿￿ which generates thioisomünchnone ￿￿￿ as first reported
by Baudy and co-workers (Scheme ￿￿-￿￿c).[￿￿￿]
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Isomünchnones and its sulfur counterpart thioisomünchnones have been applied frequently
in diverse synthetic approaches and total syntheses[￿￿￿–￿￿￿] and several reviews have been pub-
lished.[￿￿￿–￿￿￿]
Thioisomünchnones possess a masked thiocarbonylylide dipol which is stabilized through
the nitrogen. This dipole allows this mesoionic compound to react remarkably with electron
poor olefins thus undergoing ￿,￿-dipolar cycloadditions. Palacios et al. have demonstrated
the general reactivity of ￿-methyl thioisomünchnone with several a,b-unsaturated compounds.
Thioisomünchnone ￿￿￿ is generated from the reaction of thioamide ￿￿￿ and chloroalkenoyl
chloride ￿￿￿ and reacts with the electron poor double bond of methyl vinyl ketone to furnish
￿-aza-￿-oxo-￿-thiabicycle ￿￿￿ (Scheme ￿￿-￿￿).[￿￿￿]
Padwa and co-workers demonstrated the feasibility of the ￿,￿-dipolar cycloaddition reac-
tion of thioisomünchnones with olefins in a short total synthesis of yohimbanoid alkaloid
(±)-alloyohimbane (￿￿￿, Scheme ￿￿-￿￿). Thioisomünchnone dipole ￿￿￿ was generated by the
reaction of bromoalkenoyl chloride ￿￿￿ with thioamide ￿￿￿. Subjection of thio-cycloadduct ￿￿￿
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Scheme ￿￿-￿￿. Reactivity of ￿-methyl thioisomünchnone.[￿￿￿]
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to Raney nickel followed by further reduction using lithium aluminium hydride yielded (±)-allo-
yohimbane (￿￿￿) in ￿￿% overall yield.
Previous work in our group demonstrated the transformation of thioamide ￿￿￿ into thioiso-
münchnone ￿￿￿ and its intramolecular ￿,￿-dipolar cycloaddition reaction for the generation
of cycloadduct ￿￿￿. This highly e￿cient method could be used for the synthesis of complex
polycyclic N-heterocycles and was therefore chosen as key-step in the synthesis of isoschizoga-
mine (￿￿￿).
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￿￿Approaches Towards theSynthesis of Isoschizogamine
These chapter describes three di￿erent approaches towards the synthesis of the thioisomünch-
none precursor for the synthesis of isoschizogamine (￿￿￿). This project was a side project on
which work was carried out simultaneously to the primary cyclohepta[b]indole project. Work
on this project found a more or less abrupt end when the cyclohepta[b]indole project began to
produce promising results. In favor of the completion of the total syntheses of diverse natural
products with the cyclohepta[b]indole motif, the work on this project was discontinued. The be-
ginning of the first approach was carried out in cooperation with my group colleague Konstantin.
Since the first approach found a quick end and was not relevant, the results of Konstantin have
not found its way into this section.
￿￿.￿ Preface: The ￿,￿-Dihydropyridin-￿-one Moiety
NH
O
Figure ￿￿-￿.
￿,￿-Dihyd-
ropyridin-￿-
one.
Although the ￿,￿-dihydropyridin-￿-one motif seems very simple, its synthesis and
the synthesis of its a,a-disubstituted derivatives should not be underestimated. The
b,g-unsaturated double bond turns this compound into a di￿cult to synthesize
intermediate and literature concerning its synthesis is scarce. The unsubstituted
dihydropyridinone is either synthesized by means of metathesis[￿￿￿,￿￿￿] or by the
reaction of ammonia with vinyl acrylic acid.[￿￿￿] However, the latter example pro-
duces the a,b-unsaturated compound as the major product. For the synthesis of
a,a-disubstituted dihydropyridinones only four examples are reported in literature of which two
are published in the context of isoschizogamine and use basically the same strategy.
Naito and co-workers reported the synthesis of furopyridone ￿￿￿ in six steps starting from
tryptamine (￿￿￿, Scheme ￿￿-￿). Treatment of ￿￿￿ with LDA (￿.￿ eq.) and ethyl iodide (￿￿.￿ eq.)
furnished a,a-disubstituted lactam ￿￿￿ in ￿￿% yield. However, the major product was a,b-unsa-
turated lactam ￿￿￿ (￿￿%).
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[￿￿￿]
Zhou and co-workers (cf. Section ￿￿.￿) reported the synthesis of vinyl N-acetylaziridine ￿￿￿
in five steps from diene ￿￿￿ (Scheme ￿￿-￿). Treatment of ￿￿￿ with LiHMDS followed by
heating in toluene furnished g,d-unsaturated #-lactam ￿￿￿ via [￿,￿]-sigmatropic rearrangement.
Ring-opening-ring-closing sequence a￿orded a,a-disubstituted dihydropyridinone ￿￿￿ in four
additional steps in ￿￿% overall yield. A similar strategy was also used by Padwa and co-workers
in ￿￿￿￿ (cf. Section ￿￿.￿).[￿￿￿]
En route to (+)-vincadi￿ormine (￿￿￿), Pandey et al. reported the synthesis of optically active
a,a-disubstituted dihydropyridinone ￿￿￿. ￿-chloronicotinic acid (￿￿￿) was transformed into
nicotinic acid derivative ￿￿￿. Birch reduction-alkylation of ￿￿￿ was only possible with the strong
electrophillic allyl bromide and ￿,￿-dihydropyridine derivative ￿￿￿ was obtained in moderate
￿￿% yield. Acid-mediated ring opening followed by copper-mediated removal of the auxiliary
furnished a,a-disubstituted dihydropyridinone ￿￿￿ in two additional steps.
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Scheme ￿￿-￿. Synthesis of a,a-disubstituted dihydropyridinone ￿￿￿ (Pandey, ￿￿￿￿).[￿￿￿]
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￿￿.￿ The Metathesis Approach
The target compound in this approach is a,a-disubstituted amide ￿￿￿ (Scheme ￿￿-￿). It was
planned to form dihydropyridinone ￿￿￿ via ring-closing metathesis. For this purpose, one allyl
group can be selectively cleaved with either a catalytic amount of tetrakis(triphenylphosphine)pal-
ladium(￿) in the presence of N,N-dimethylbarbituric acid[￿￿￿] or a catalytic amount of Pd￿(dba)￿
and a phosphine ligand (dppb) in the presence of thiosalicylic acid.[￿￿￿] Both methodologies
are known to remove selectively one allyl group from diallylamines. After the ring closure,
the internal alkyne has to be reduced to the corresponding (Z)-alkene which is not trivial
in the presence of an aromatic nitro group. However, according to Trost et al. this can be
achieved once again with Pd￿(dba)￿ and a phosphine ligand (tri-o-tolylphosphine) with ￿,￿,￿,￿-
tetramethyldisiloxane as the hydride donor.[￿￿￿] a,a-Disubstituted amide ￿￿￿ is the required
precursor for the desired formation of the thioisomünchnone intermediate (Section ￿￿.￿).
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Scheme ￿￿-￿. Planned transformation of target compound ￿￿￿ into key intermediate ￿￿￿.
A variety of electrophiles and veratrol derivatives which are required for upcoming synthetic
sequences have been synthesized. These are discussed at first (Scheme ￿￿-￿). ￿-Bromoveratrole
(￿￿￿) was reacted with ￿￿% aqueous nitric acid at –￿ °C for ￿￿min to a￿ord ￿-bromo-￿-nitro-
veratrole (￿￿￿) in ￿￿% yield. Sonogashira coupling with but-￿-yn-￿-ol a￿orded alkyne ￿￿￿ in
very good yield (￿￿%). Alcohol ￿￿￿ was then transformed into its corresponding bromide ￿￿￿,
iodide ￿￿￿, and triflate ￿￿￿ using standard procedures.
In a further sequence, veratraldehyde (￿￿￿) was transformed into ￿-nitroveratraldehyde (￿￿￿)
with ￿￿% aqueous nitric acid. Conversion of the aldehyde into the ￿,￿-dibromoolefine ￿￿￿
followed by Fritsch–Buttenberg–Wiechell rearrangement a￿orded terminal alkyne ￿￿￿ in mod-
erate yield (￿￿%). In an alternative sequence, Sonogashira reaction of ￿-bromo-￿-nitroveratrole
(￿￿￿) with trimethylsilylacetylene a￿orded trimethylsilyl alkyne ￿￿￿ in quantitative yield. The
deprotection of the alkyne moiety was carried out with potassium carbonate in methanol and
a￿orded terminal alkyne ￿￿￿ in almost quantitative yield.
With electrophiles ￿￿￿, ￿￿￿, and ￿￿￿ in hands attention next turned to the alkylation of
crotonoyl diallylamide ￿￿￿ (Scheme ￿￿-￿). ￿￿￿ was synthesized from the reaction of crotonoyl
chloride (￿￿￿) with diallyl amine in toluene at ￿￿ °C. The a-alkylation of amide ￿￿￿ turned out
to be quite cumbersome. Reaction of the lithium enolate of ￿￿￿ (generated with either LiHMDS,
LDA, or LiTMP) with aryl bromide ￿￿￿, aryl iodide ￿￿￿, or aryl triflate ￿￿￿ at –￿￿ °C did not
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Scheme ￿￿-￿. Synthesis of crotonoyl diallylamide ￿￿￿ and its reaction with various electrophiles.
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form a-alkylated amide ￿￿￿. Instead, E￿ elimination reaction took place
and transformed the electrophiles into the corresponding aryl butenyne
derivatives (cf. Scheme ￿￿-￿). Neither the addition of either DMPU or
HMPA, nor the lowering of the reaction temperature to –￿￿￿ °C did a￿ect
this result. Therefore, the a-alkylation of allyl but-￿-enoate (￿￿￿), which is
easy accessible from vinylacetic acid, was investigated (Scheme ￿￿-￿) but
similar results were obtained.
As a result, compounds ￿￿￿, ￿￿￿, and ￿￿￿ turned out to be great sub-
strates for an elimination reaction but weak substrates for an SN￿ reaction.
Therefore, the electrophiles have been modified and the aryl rest was
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Scheme ￿￿-￿. Synthesis of allyl but-￿-enoate (￿￿￿) and its reaction with various electrophiles.
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replaced by a trimethylsilyl group. Starting from but-￿-yn-￿-ol (￿￿￿), a variety of electrophiles
has been synthesized (Scheme ￿￿-￿). Treatment of ￿￿￿ with an excess of nBuLi followed by the
addition of an excess of chlorotrimethylsilane and subsequent work-up with ￿￿HCl a￿orded
protected alkyne ￿￿￿ in ￿￿% yield. The alcohol moiety was then converted into the correspond-
ing iodide ￿￿￿ and triflate ￿￿￿ using standard procedures. Reaction of alcohol ￿￿￿ with diethyl
chlorophosphate led to decomposition and phosphate ￿￿￿ was not obtained. In an alternative
sequence, but-￿-yn-￿-ol (￿￿￿) was converted into its corresponding tosylate ￿￿￿ which was then
subjected to nBuLi and chlorotrimethylsilane to furnish protected alkyne ￿￿￿ in ￿￿% yield. This
compound was converted both to the corresponding bromide ￿￿￿ with lithium bromide and to
the cobalt-substituted alkyne ￿￿￿ by the reaction with dicobalt octacarbonyl.
With this variety of electophiles in hands, attention next turned to the alkylation of dially-
lamide ￿￿￿ (own work) and of ester ￿￿￿ (group colleague, Scheme ￿￿-￿￿). Once again, lithium
enolate of ￿￿￿ (generated with either LiHMDS, LDA, or LiTMP) was reacted with bromide ￿￿￿,
tosylate ￿￿￿, or iodide ￿￿￿ but no reaction could be observed and only small amounts of the
corresponding E￿ product has been formed. To evaluate this result, the lithium enolate of ￿￿￿
was generated with LiTMP and quenched by the addition of water (Scheme ￿￿-￿￿) to a￿ord
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Scheme ￿￿-￿￿. Alkylation of amide ￿￿￿ and ester ￿￿￿.
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Scheme ￿￿-￿￿. Formation of the anion of ￿￿￿ and subsequent quench by H￿O.
N,N-diallylbut-￿-enamide (￿￿￿) thus proving the formation of the anion. Alkylation product ￿￿￿
could finally be generated with triflate ￿￿￿ and the addition of HMPA (￿.￿ eq.). However, the
yield was very low (<￿￿%) thus making this transformation not feasible. Same was true for the
alkylation of ester ￿￿￿ (group colleague).
In summary, the alkylation of both the amide ￿￿￿ and the ester ￿￿￿ turned out to be very
cumbersome. On the one hand, ethynylaryl compounds ￿￿￿, ￿￿￿, and ￿￿￿ turned out to be
unfavorable SN￿ substrates and were not suitable for an alkylation reaction due to the domination
of the E￿ elimination reaction. On the other hand, ethynylsilyl compounds ￿￿￿, ￿￿￿, and ￿￿￿
were also not suitable for an alkylation reaction since no reaction with these substrates took
place. Only the reaction with triflate ￿￿￿ could generate traces of the desired compounds but
this transformations were not feasible due to the low yield.
￿￿.￿ The Hydroxypiperidinone Approach
The second approach is based on a completely di￿erent strategy than the metathesis approach.
The target compound in this approach is a,a-disubstituted amide ￿￿￿ (Scheme ￿￿-￿￿). This
compound can be easily transformed into amide ￿￿￿ which is the required precursor for the
desired formation of the thioisomünchnone intermediate (Section ￿￿.￿). However, in this
approach a,a-disubstituted amide ￿￿￿ derives from a ￿-hydroxy-￿,￿-dihydropyridinone derivative
(e.g. ￿￿￿) via a Johnson–Claisen rearrangement reaction. This leads to precursor ￿￿￿: TBS-
protected (S)-￿-hydroxypiperidin-￿-one, a compound which can be synthesized in an enantiopure
fashion from glutamic acid.
The synthesis of optically active lactam ￿￿￿ is shown in Scheme ￿￿-￿￿ and is based on (S)-￿-oxo-
tetrahydrofuran-￿-carboxylic acid (￿￿￿)—a readily available and popular building block. First
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Scheme ￿￿-￿￿. Synthesis of TBS-protected (S)-￿-hydroxypiperidin-￿-one.
introduced by K. Mori in ￿￿￿￿ in the synthesis of sulcatol[￿￿￿] it has been used over ￿￿ times in var-
ious syntheses.[￿￿￿] Starting from ￿-glutamic acid, reaction with sodium nitrite in acidic medium
at ￿ °C for six hours smoothly furnished g-carboxyl-g-butyrolactone ￿￿￿ in ￿￿% yield.[￿￿￿,￿￿￿,￿￿￿]
This reaction can be carried out on large scales without di￿culty (in this case ￿.￿mol/￿￿￿ g).
The deamination of ￿-￿￿￿ proceeds via a diazonium ion. The choice of pathway, however, is not
obvious and has been discussed.[￿￿￿] Next in line was the generation of alcohol ￿￿￿ via reduction
of the carboxylic acid. There are many possibilities for this transformation. Originally obtained
by reduction of the corresponding methyl ester, it was found out that the more convenient
direct reduction of ￿￿￿ with borane dimethyl sulfide gave almost quantitative distilled yields
of alcohol ￿￿￿ with full retention of configuration. ￿￿￿ was then transformed into azide ￿￿￿
in a two-step sequence via formation of tosylate ￿￿￿ and subsequent displacement of the sul-
fonate group with sodium azide in N,N-dimethyl formamide.[￿￿￿] Hydrogenation of azide ￿￿￿
was then used for the generation (S)-(–)-piperidinol (￿￿￿) which was directly converted into its
TBS-protected counterpart ￿￿￿ in ￿￿% overall yield.[￿￿￿]
With TBS-protected (S)-(–)-piperidinol ￿￿￿ in hands, attention next turned to the a-alkylation of
this compound. Although some protocols for the a-alkylation of unprotected d-valerolactam have
been reported,[￿￿￿] the a-alkylation of ￿￿￿ remains a terra incognita and attempts for this alkylation
are shown in Scheme ￿￿-￿￿. Once again, the alkylation turned out to be very cumbersome and
can be summarized briefly. Several attempts for the reaction of optically active amide ￿￿￿ with
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Scheme ￿￿-￿￿. Several attempts for the alkylation of TBS-protected (S)-(–)-piperidinol (￿￿￿).
at least two equivalents of either nBuLi, LiHMDS, LDA, or LiTMP followed by the addition of
either electrophile ￿￿￿ or ￿￿￿ did not a￿ord homopropargylic amide ￿￿￿. The addition of either
HMPA or DMPU did not change this result. For this reason, the free amide was protected with
a Boc group and alkylations of ￿￿￿ were investigated. Reactions with either electrophile ￿￿￿
or ￿￿￿ were not successful and homopropargylic amide ￿￿￿ was not formed. Only the reaction
with electrophile ￿￿￿ have generated alkylation product ￿￿￿—but only in trace amounts, thus
making this route unfavorable.
On this account, it was planned to bring the sulfenylation step forward, thus changing the
order of steps. Therefore, lactam ￿￿￿ was transformed into di￿erent ￿-(arylthio)piperidinones
(Scheme ￿￿-￿￿, cf. Tab. ￿￿-￿). However, these transformations often produced the monosulfide
compound ￿￿￿ as the minor product and the formation of the bissulfide adduct ￿￿￿ dominated.
Addition of HMPA and prolonged reaction times below –￿￿ °C finally a￿orded monosulfide
compound ￿￿￿ as the major product in ￿￿% yield. Notwithstanding this, two protocols for
the desulfenylation either by a Grignard reagent or by LDA/HMPA have been reported.[￿￿￿,￿￿￿]
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Table ￿￿-￿. Conditions for Scheme ￿￿-￿￿.
# Conditions ￿￿￿ ￿￿￿ ￿￿￿
￿ nBuLi (￿.￿ eq.), THF, –￿￿ °C  ￿ °C, ￿￿min, then PhSSPh, ￿ h ￿￿% ￿￿% —
￿ nBuLi (￿.￿ eq.), THF, –￿￿ °C to ￿ °C, ￿￿min, then TMSCl, ￿ °C, ￿￿￿min, then
–￿￿ °C, addition of N-phenylthiophthalimide (￿￿￿), KHMDS, –￿￿ °C, ￿￿min,
then rt., ￿￿min, then ￿% HCl
￿￿% — —
￿ PhSSPh, KOtBu, THF, ￿￿ °C, ￿￿ h ￿￿% — —
￿ nBuLi (￿.￿ eq.), THF, –￿￿ °C to ￿ °C, ￿￿min, then –￿￿ °C, HMPA (￿.￿ eq.),
PhSSPh, –￿￿ °C, ￿￿ h
￿￿% ￿￿% —
￿ nBuLi (￿.￿ eq.), THF, –￿￿ °C to ￿ °C, ￿￿min, then –￿￿ °C,
￿-nitrobenzenesulfenyl chloride, –￿￿ °C, ￿￿ h
— — ￿￿%
Based on these protocosl, reaction of bissulfide adduct ￿￿￿ with ethylmagnesium bromide
in THF at –￿￿ °C furnished the monosulfide compound ￿￿￿ in ￿￿% yield after two hours.
In addition, lactam ￿￿￿ was reacted with ￿-nitrobenzenesulfenyl chloride. This furnished
monosulfide compound ￿￿￿ in ￿￿% yield along with some decomposition products. With sulfide
compounds ￿￿￿ and ￿￿￿ in hands, attention next turned to their alkylation and the formation
of ￿￿￿ or ￿￿￿, respectively. But once again, neither the generation of ￿￿￿ nor ￿￿￿ could be
accomplished, thus bringing the attempts of the alkylation of lactam ￿￿￿ to an end.
Since several attempts for the alkylation of lactam ￿￿￿ and its derivatives failed, the ret-
rosynthetic strategy was revised and the alkylation step was brought forward. Therefore, the
a-alkylation of optically active azide ￿￿￿ (Scheme ￿￿-￿￿, cf. Scheme ￿￿-￿￿) was investigated.
However, this investigations were aborted as it turned out that azide ￿￿￿ was not stable to strong
basic conditions and decomposed very rapidly.
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￿￿.￿ The g-Butenolide Approach
As a result from previous approaches, the synthesis of substituted dihydropyridinone ￿￿￿
required a modified retrosynthetic strategy (Scheme ￿￿-￿￿). Therefore, ￿￿￿ is synthesized from
azide ￿￿￿￿ via reduction of the azide moiety and concomitant lactam formation. Compared
to previous approaches, this reduction cannot be carried out via hydrogenation due to the
present alkyne moiety. However, several other methodologies for the reduction of an azide to
the corresponding amine are known:[￿￿￿] this transformation can be carried out in the presence
of thiols,[￿￿￿–￿￿￿] complex hydrides (e.g. butyltriphenylphosphonium tetrahydroborate ￿￿￿￿ as a
selective reducing agent for reduction of organic azides),[￿￿￿] boranes,[￿￿￿–￿￿￿] borohydrides[￿￿￿,￿￿￿]
and phosphanes (Staudinger reaction),[￿￿￿–￿￿￿] to name but a few. Azide ￿￿￿￿ is planned to
be synthesized from g-butenolide ￿￿￿￿. Two di￿erent approaches were envisioned for its
synthesis: on the one hand ￿￿￿￿ can be synthesized from vinyl bromide ￿￿￿ viaNegishi coupling
(this transition metal catalyzed cross-coupling reaction has been chosen since this reaction
allows for the coupling of sp￿, sp￿, and sp carbons),[￿￿￿,￿￿￿] on the other hand it is available via
alkylation/selenoxide elimination sequence from optically active lactone ￿￿￿￿. Vinyl bromide ￿￿￿
can be synthesized from glycidol derivative ￿￿￿￿ using a modified protocol of Movassaghi
and Jacobsen who reported a direct method for the conversion of terminal epoxides into g-
butanolides.[￿￿￿,￿￿￿] Both stereoisomers of glycidol are commercially available, thus making
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this approach enantioselective, too. Optically active lactone ￿￿￿￿ in turn is available from
g-carboxyl-g-butyrolactone ￿￿￿ (cf. Section ￿￿.￿) via reduction/silyl protection sequence.
￿￿.￿.￿ g-Butenolides from Terminal Epoxides
In ￿￿￿￿, Movassaghi and Jacobsen reported a straightforward methodology for the generation
of g-butanolides from terminal epoxides.[￿￿￿] By reason of the simple access to enantioen-
riched epoxides, this methodology found broad application in the synthesis of optically active
g-butanolides. The strategy is based on the use of ￿-morpholino-￿- trimethylsilyl acetylene
(￿￿￿￿). The synthesis of this ynamine is shown in Scheme ￿￿-￿￿. Trichloroacetyl chloride (￿￿￿￿)
was transformed into N-trichloroacetyl morpholine amide via the reaction with morpholine.
This intermediate was then subjected to triphenylphosphine in refluxing o-xylene which led to a
formal deoxygenation and the formation of desired N-trichlorovinyl morpholine (￿￿￿￿) in ￿￿%
yield. The suggested mechanism for this step is shown in Scheme ￿￿-￿￿ and is proposed to
proceed via the attack of the keteniminium salt ￿￿￿￿. Subjection of morpholine derivative ￿￿￿￿
to an excess of nBuLi followed by the addition of chlorotrimethylsilane furnished ynamine ￿￿￿￿
in ￿￿% yield. The mechanism is proposed to proceed via a Fritsch–Buttenberg–Wiechell re-
arrangement followed by lithium-halogen exchange. Ynamine ￿￿￿￿ was then reacted with
(R)-(+)-glycidol (￿￿￿￿), which was activated by boron trifluoride diethyl etherate, and an excess
of N-bromosuccinimide followed by the treatment with lithium carbonate in DMF at ￿￿ °C.
This furnished g-butenolide ￿￿￿ in ￿￿% yield.[￿￿￿]
The mechanism for this reaction might not be obvious and the proposed mechanism is
shown in Scheme ￿￿-￿￿. The reaction of ynamine ￿￿￿￿ and boron trifluoride diethyl etherate
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allows the rapid and e￿cient conversion of terminal epoxide ￿￿￿￿ to the corresponding cyclic
keteneaminal ￿￿￿￿ via the intramolecular attack of the keteniminium salt ￿￿￿￿. Reaction with
an excess of N-bromosuccinimide a￿ords dibromo g-butanolide ￿￿￿￿ which is then subjected
to elimination conditions to yield g-butenolide ￿￿￿.
With g-butenolide ￿￿￿ in hands, attention next turned to the Negishi coupling of homopropar-
gylic zinc species ￿￿￿￿ or ￿￿￿￿, respectively, to vinyl bromide ￿￿￿ (Scheme ￿￿-￿￿). Negishi
coupling reactions on similarg-butenolide substrates have not been reported until today. Notwith-
standing this, ￿￿￿ was subjected to a variety of typical Negishi coupling conditions (Tab. ￿￿-￿).
Unfortunately, coupling product ￿￿￿￿ has not been formed in any case. Therefore, attention next
turned to the C–C-bond formation via Suzuki coupling which is also suitable for the coupling of
sp￿ and sp￿ carbons.[￿￿￿–￿￿￿]
For this purpose, a variety of di￿erent precursors for a Suzuki coupling reaction have been
synthesized (Scheme ￿￿-￿￿). The fact, that homopropargylic iodide ￿￿￿ and especially aryl
homopropargylic iodide ￿￿￿ were poor SN￿ substrates (cf. Section ￿￿.￿) was utilized and both
compounds were subjected to ￿,￿-diazabicyclo(￿.￿.￿)undec-￿-ene at elevated temperatures in
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Scheme ￿￿-￿￿. Transformation of vinyl bromide ￿￿￿ into g-butenolide ￿￿￿￿ via Negishi coupling failed.
Table ￿￿-￿. Conditions for Scheme ￿￿-￿￿.
# Conditions
￿ ￿￿￿￿, PdCl￿(dppf)  CH￿Cl￿ (￿mol %), CuI (￿mol %), DMAc, ￿￿ °C
￿ ￿￿￿￿, PdCl￿(dppf)  CH￿Cl￿ (￿mol %), DMF, rt., ￿￿ h
￿ ￿￿￿￿, PdCl￿(dppf)  CH￿Cl￿ (￿mol %), THF, ￿ °C  rt., ￿￿ h
￿ ￿￿￿￿, PdCl￿(dppf)  CH￿Cl￿ (￿mol %), DMF, rt., absence of light, ￿￿ h
￿ ￿￿￿￿, Pd(PPh￿)￿ (￿mol %), Et￿O, rt., ￿￿ h
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Scheme ￿￿-￿￿. Syntheses of various precursors for a Suzuki coupling reaction.
toluene. Enynes ￿￿￿ and ￿￿￿￿, respectively, were formed in less than ten minutes in quantitative
yield. First prepared in ￿￿￿￿ by C. J. Willis,[￿￿￿] organotrifluoroborate salts turned out to be
versatile compounds in organic synthesis. They can be conveniently prepared from boronic
acids and in general are air and moisture stable crystalline solids which can be synthesized
on a multigram scale and purified by simple recrystallization.[￿￿￿] Molander and co-workers
demonstrated their use in metal-catalyzed cross-coupling reactions.[￿￿￿,￿￿￿] For this reason,
organotrifluoroborate salt ￿￿￿￿ was prepared from TBS-protected allyl alcohol (￿￿￿￿) via boronic
acid pinacol ester ￿￿￿￿ in ￿￿% overall yield (unoptimized).
Although some unsuccessful trials concerning the Suzuki coupling of vinyl bromide ￿￿￿ and
precursors ￿￿￿, ￿￿￿￿, and ￿￿￿￿ were carried out, this approach found an abrupt end based on
results from a di￿erent approach towards g-butenolide ￿￿￿￿ (cf. Section ￿￿.￿.￿). It was found
that upcoming transformations of g-butenolide ￿￿￿￿ are not compatible with the existing double
bond and therefore required its installation at a later stage of the synthesis, thus making this
approach redundant.
￿￿.￿.￿ g-Carboxyl-g-Butyrolactone Approach
As shown in Scheme ￿￿-￿￿, this retrosynthetic approach was designed to install the side chain
in an alkylation reaction followed by the dehydrogenation via selenoxide elimination. Optically
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Scheme ￿￿-￿￿. Retrosynthetic analysis for the synthesis of g-butenolide ￿￿￿￿.
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Scheme ￿￿-￿￿. Synthesis of optically active g-butenolide ￿￿￿￿.
active lactone ￿￿￿￿ in turn is available from g-carboxyl-g-butyrolactone ￿￿￿ (cf. Section ￿￿.￿) via
reduction/silyl protection sequence.
Reduction of g-carboxyl-g-butyrolactone ￿￿￿ with borane dimethyl sulfide gave almost quan-
titative distilled yields of alcohol ￿￿￿ which was transformed into its silyl counterpart ￿￿￿￿ in
￿￿% yield using standard conditions (Scheme ￿￿-￿￿). Next in line was the a-alkylation with
electrophile ￿￿￿ which failed so many times in previous attempts. Notwithstanding this, depro-
tonation of lactone ￿￿￿￿ with LDA at –￿￿ °C followed by the addition of HMPA (￿.￿ eq.) and
electrophile ￿￿￿ furnished product ￿￿￿￿ in ￿￿% yield (￿￿% brsm).[￿￿￿] It should be noted that no
reaction took place in the absence of HMPA. Also the substitution of either HMPA with DMPU
or triflate ￿￿￿ with its corresponding iodide (￿￿￿) or bromide (￿￿￿) did not generate desired
compound ￿￿￿￿. With ￿￿￿￿ in hands, attention next turned to the dehydrogenation of the ketone.
Several methodologies are known for this transformation which can be achieved via sulfoxide
elimination,[￿￿￿,￿￿￿] selenoxide elimination,[￿￿￿] DDQ dehydrogenation,[￿￿￿] dehydrogenation
with methyl phenylsulfinate,[￿￿￿] or Saegusa–Ito oxidation[￿￿￿] to name but a few. Although many
methodologies have been reported, this transformation still attracts researcher and leads to the
design of new reagents particularly for this transformation, e.g. N-tert-butylbenzenesulfinimidoyl
chloride[￿￿￿] or a Pd(TFA)￿/￿,￿-diazafluorenone catalyst.
[￿￿￿] This approach focused on the se-
lenoxide elimination. For this reason, lactone ￿￿￿￿ was reacted with LiHMDS at –￿￿ °C followed
by the addition of chlorotrimethylsilane. The in situ generated ketene silyl acetal was then reacted
with phenylselenyl bromide to a￿ord organoselenium species ￿￿￿￿ which was directly subjected
to oxidative conditions (H￿O￿, cat. pyridine) to furnish a,b-unsaturated lactone ￿￿￿￿ in ￿￿%
combined yield. Finally, the silyl ether was cleaved with hydrogen fluoride in pyridine–THF to
obtain alcohol ￿￿￿￿ in ￿￿% yield, the alkyne protecting group remained untouched under these
conditions.
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Scheme ￿￿-￿￿. Attempts to the synthesis of azide ￿￿￿￿.
Table ￿￿-￿. Conditions for Scheme ￿￿-￿￿.
# Conditions Product Yield [%] Reference
￿ TsCl, Et￿N, DMAP, CH￿Cl￿, rt., ￿￿min ￿￿￿￿ ￿￿ —
￿ Tf￿O, pyridine, CH￿Cl￿, ￿ °C , ￿￿min ￿￿￿￿ —
￿) —
￿ DPPA, DBU, PhH, ￿ °C, ￿￿ h ￿￿￿￿ ￿￿ [￿￿￿]
￿ PPh￿, DEAD, DPPA, THF, ￿ °C ￿￿￿￿ —
￿) [￿￿￿]
￿ PPh￿, DIAD, DPPA, PhMe, ￿ °C ￿￿￿￿ —
￿) [￿￿￿,￿￿￿]
￿ PPh￿, DTBAD, DPPA, THF, ￿ °C ￿￿￿￿ —
￿) [￿￿￿]
￿) not determined
With alcohol ￿￿￿￿ in hands, attention next turned to its conversion to the corresponding
azide ￿￿￿￿ (Scheme ￿￿-￿￿). For this reason, ￿￿￿￿ was converted into mesylate ￿￿￿￿ which was
subjected to usual displacement conditions with sodium azide in N,N-dimethylformamide.
However, the obtained product turned out to be UV active and analysis revealed, that desired
azide ￿￿￿￿ was not formed; elimination product ￿￿￿￿ was generated instead as the single
product. Alcohol ￿￿￿￿ was therefore converted into di￿erent leaving groups (tosyl and triflate,
cf. Tab. ￿￿-￿, Entries ￿–￿) but under these conditions once again the elimination product ￿￿￿￿
was obtained as the single product in approximately ￿￿% yield. Since approximately ￿￿% of the
starting material have been recovered, the reaction rate for the competitive elimination reaction
seems to be much higher than for the deprotonation of the alcohol. Therefore, several direct
conversions of alcohol ￿￿￿￿ into azide ￿￿￿￿ via Mitsunobu reaction[￿￿￿] were carried out (cf.
Tab. ￿￿-￿, Entries ￿–￿) but the generation of azide ￿￿￿￿ could be never observed and elimination
product ￿￿￿￿ was formed in each case. Based on this results, the previous described approach
with the generation of g-butenolides from terminal epoxides was discontinued.
Since the transformation to the corresponding azide was not successful, it was planned to
install the troublesome double bond after the formation of the azide. For this reason, organose-
lenium species ￿￿￿￿ was subjected to aqueous acidic tetrahydrofuran for ￿￿ h which led to the
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Scheme ￿￿-￿￿. New synthesis of azide ￿￿￿￿.
cleavage of the TBS ether (Scheme ￿￿-￿￿). The liberated alcohol ￿￿￿￿ was then converted into
the corresponding tosylate ￿￿￿￿ which was subjected to usual displacement conditions with
sodium azide inN,N-dimethylformamide at ￿￿ °C. Azide ￿￿￿￿ was formed after ￿￿min as single
product which was taken up in dichloromethane and subjected to oxidative conditions (H￿O￿,
cat. pyridine) to furnish a,b-unsaturated lactone ￿￿￿￿ in ￿￿% overall yield (from alcohol ￿￿￿￿).
A small amount of azide ￿￿￿￿ was then subjected to Staudinger conditions (PPh￿, THF–H￿O
￿￿:￿) to obtain lactam ￿￿￿￿ thus demonstrating the general feasibility of this synthetic sequence.
Based on this results, the scope was extended by the additional installation of the required
aryl moiety (Scheme ￿￿-￿￿). Silyl protected alkyne ￿￿￿￿ was subjected to potassium carbonate
in methanol to liberate the terminal alkyne. Subsequent Sonogashira reaction of alkyne ￿￿￿￿
with ￿-bromo-￿-nitroveratrole (￿￿￿) in diethylamine as solvent at ￿￿ °C furnished lactone ￿￿￿￿
in ￿￿% combined yield. Lactone ￿￿￿￿ was then reacted with LiHMDS at –￿￿ °C followed by
the addition of chlorotrimethylsilane. The in situ generated ketene silyl acetal was then reacted
with phenylselenyl bromide to a￿ord an organoselenium species which was directly subjected
to aqueous acidic tetrahydrofuran for ￿￿ h to cleave the TBS ether to a￿ord alcohol ￿￿￿￿. The
alcohol was transformed into the corresponding tosylate and usual displacement conditions
with sodium azide in N,N-dimethylformamide at ￿￿ °C furnished azide ￿￿￿￿ in ￿￿% overall
yield. Finally, g-butenolide ￿￿￿￿ was obtained after oxidation of the organoselenium species
with ￿￿￿￿ and concomitant elimination.
The work on the these approaches was undertaken contemporaneously with the work on the
synthesis of cyclohepta[b]indoles which finally led to the the syntheses of Ervatamia alkaloids
(cf. Part II). In favor of the completion of the total syntheses of diverse natural products with
the cyclohepta[b]indole motif, the work on this project was discontinued at this point. However,
the general feasibility of the last approach has been demonstrated thus providing a synthetic
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Scheme ￿￿-￿￿. Synthesis of g-butenolide ￿￿￿￿.
sequence for the generation of optically active lactam ￿￿￿￿ and g-butenolide ￿￿￿￿ (Schemes ￿￿-￿￿
and ￿￿-￿￿) starting from enantiopure g-carboxyl-g-butyrolactone (￿￿￿) which is accessible from
￿-glutamic acid.
￿￿.￿ Summary and Outlook
This part of the thesis dealt with three di￿erent approaches towards the synthesis of the key inter-
mediate for the synthesis of isoschizogamine (￿￿￿). The global catchword for these approaches
seems to be elimination; some parts read like a textbook example for competitive reactions.
Since this project was a side-project, this part was recapped not as detailed as the part about
the cyclohepta[b]indoles on purpose although it turned out that this project required way more
investigations than originally anticipated; only the most important results and dead-ends have
been presented.
It was pointed out, that the synthesis of a,a-disubstituted ￿,￿-dihydropyridin-￿-ones is not
trivial and should not be underestimated. The first approach (“The Metathesis Approach”,
Scheme ￿￿-￿￿) found a quick end since the enolates formed from amides turned out to be
moderate nucleophiles and in combination with the required electrophiles the E￿ elimination
reaction dominated over SN￿ displacement. Therefore, attention next turned to the second
approach (“The Hydroxypiperidinone Approach”, Scheme ￿￿-￿￿).
The target compound of this approach was dihydropyridinone ￿￿￿￿ which was planned to be
transformed to key intermediate ￿￿￿ via Johnson–Claisen rearrangement. TBS-Protected (S)-(–)-
piperidinol ￿￿￿ was synthesized in six steps from ￿-glutamic acid (￿￿￿). This is a very robust
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Scheme ￿￿-￿￿. Combined approaches towards dihydropyridinones ￿￿￿￿ and ￿￿￿￿.
sequence and enantiopure ￿￿￿ can be synthesized in multidecagram amounts in a short period
of time. Since both enantiomers of glutamic acid are commercially available, this approach would
allow the synthesis of either natural (–)-isoschizogamine (￿￿￿￿) or its unnatural antipode. How-
ever, the transformation of TBS-protected (S)-(–)-piperidinol ￿￿￿ into dihydropyridinone ￿￿￿￿
was not successful. Therefore, ￿-glutamic acid (￿￿￿) was converted into enantiopure lactone ￿￿￿￿
which could be converted into g-butenolide ￿￿￿￿ in four additional steps. An additional approach
towards g-butenolide ￿￿￿￿ was envisioned via the sp￿–sp￿ cross-coupling of vinyl bromide ￿￿￿
which is available from (almost) enantiopure glycidol derivative ￿￿￿￿ in one single step. Attempts
for the cross-coupling were ine￿ective, but it turned out the transformation of alcohol ￿￿￿￿
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into the corresponding azide ￿￿￿￿ was not feasible anyway since elimination product ￿￿￿￿ has
been formed in every case. Finally, azide ￿￿￿￿ was synthesized through the postponed oxidative
elimination of organoselenium species ￿￿￿￿. This sequence was alsomodified to the synthesis of
organoselenium species ￿￿￿￿ (the aryl moiety is already installed) and its oxidative elimination to
yield azide ￿￿￿￿. Azide ￿￿￿￿ was shown to be transformed into desired dihydropyridinone ￿￿￿￿
via Staudinger reaction.
The work on the these approaches was undertaken contemporaneously with the work on the
synthesis of cyclohepta[b]indoles which finally led to the the syntheses of Ervatamia alkaloids
(cf. Part II). In favor of the completion of the total syntheses of diverse natural products with
the cyclohepta[b]indole motif, the work on this project was discontinued at this point. However,
the general feasibility of the last approach has been demonstrated thus providing a synthetic
sequence for the generation of enantiopure lactam ￿￿￿￿ and g-butenolide ￿￿￿￿ which are
accessible from ￿-glutamic acid. Both enantiomers of glutamic acid are commercially available,
thus allowing the synthesis of either natural (–)-isoschizogamine (￿￿￿￿) or its unnatural antipode.
￿￿.￿.￿ Optimizations and Alternatives
The final approach described a reliable synthesis of dihydropyridinone ￿￿￿￿, but there is always
room for improvement or coequal alternatives. Two proposals are discussed briefly.
It was shown, that g-butenolide ￿￿￿￿ could be synthesized from azide ￿￿￿￿ which was shown
to be available from lactone ￿￿￿￿ in seven steps. An alternative synthesis of azide ￿￿￿￿ is shown
in Scheme ￿￿-￿￿ and was already partially carried out. Hex-￿-ynoic acid (￿￿￿￿) was transformed
into methyl hex-￿-ynoate (￿￿￿￿) with methyl iodide and potassium carbonate. The terminal
alkyne was then subjected to Sonogashira coupling conditions with aryl bromide ￿￿￿ to obtain
acetylene ￿￿￿￿ in ￿￿% yield. Deprotonation with LDA followed by the addition of allyl bromide
a￿orded g,d-unsaturated compound ￿￿￿￿ inmoderate yield (this compound is also available from
the reaction of allyl alcohol with the appropriate orthoester via Johnson–Claisen rearrangement).
Either an Upjohn dihydroxylation[￿￿￿] or a Sharpless asymmetric dihydroxylation[￿￿￿] would lead
to g-hydroxymethyl-g-butyrolactone ￿￿￿￿. This compound is already an advanced intermediate
and would require only a few transformations to a￿ord azide ￿￿￿￿. The asymmetric variant can
be carried out either with commercially available AD-mix a or AD-mix b, thus allowing once
again the synthesis of either natural (–)-isoschizogamine (￿￿￿￿) or its unnatural antipode.
In addition, an optimization for the cross-coupling of aryl bromide ￿￿￿ with diverse terminal
alkynes is proposed. In ￿￿￿￿, Oshima and co-workers reported a triethylborane-mediated hydro-
gallation and hydroindation.[￿￿￿] They also described a one-pot hydroindation/cross-coupling
reaction (Scheme ￿￿-￿￿). It was shown, that the triethylborane-mediated hydroindation of
alkynes proceeds in an antimanner to a￿ord the corresponding (Z)-alkenylindium species (a
rational explanation for this outcome is shown in Scheme ￿￿-￿￿). This method was used to
employ unprotected alkynes as (Z)-alkenylmetal precursors and to synthesize either functional-
ized (Z)-alkenyl iodides or arylalkenes in a one-pot operation. This methodology can be applied
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Scheme ￿￿-￿￿. One-pot hydroindation/cross-coupling reaction for the selective synthesis of (Z)-olefins from terminal alkynes and aryl
halides (Oshima, ￿￿￿￿).[￿￿￿]
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to a variety of alkynes and aromatic rings (electron-rich and electron-deficient). Although it
was shown, that according to Trost et al. the reduction of the alkyne moiety in presence of an
nitroarene can be achieved with Pd￿(dba)￿ and a phosphine ligand (tri-o-tolylphosphine) with
￿,￿,￿,￿-tetramethyldisiloxane as the hydride donor (cf. Section ￿￿.￿),[￿￿￿] the method of Oshima
and co-workers would simplify the synthesis and allow a more rapid access to the desired target
compound.
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￿￿￿
￿￿Experimental
The experimental part follows the order of the particular sections and compounds are ordered
by appearance. The general methods are described in Section A.￿ on p. ￿￿￿ and are valid for all
other experimental parts in this thesis.
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￿-Bromo-￿,￿-dimethoxy-￿-nitrobenzene [ ￿-Bromo-￿-nitroveratrole ] (￿￿￿).[￿￿￿]
Br
NO2
MeO
MeO
￿￿￿
Nitric acid (￿￿% aq., ￿￿￿ ml) was cooled to –￿ °C and ￿-bromoveratrole
(￿￿.￿ ml, ￿￿￿ mmol) was added dropwise over ￿￿ min. After complete
addition, the mixture was stirred additional ￿￿ min below –￿ °C at which
point a large amount of yellow precipitate has been formed. The reaction
mixture was dilutedwith ￿￿￿￿ml of ice-cold water and themixture was filtered through amedium
porosity sintered-glass funnel. The retentate was washed with an appropriate amount of water
and collected. Recrystallization from ethanol furnished title compound ￿￿￿ as yellow solid
(￿￿.￿ g, ￿￿mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains yellow with CAN).M.p. ￿￿￿ °C.
￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm.
￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS
(ESI): calcd. for C￿H￿BrNO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
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￿-(￿,￿-dimethoxy-￿-nitrophenyl)but-￿-yn-￿-ol (￿￿￿).
NO2
MeO
MeO
OH
￿￿￿
Aryl bromide ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in di-
ethylamine (￿.￿ml) and the resulting suspension was degassed us-
ing ultrasonication. Copper(I) iodide (￿￿.￿mg, ￿￿￿ ￿mol, ￿mol %)
and bis(triphenylphosphine)palladium(II) dichloride (￿￿.￿ mg,
￿￿ ￿mol, ￿mol %) were added under argon followed by the addi-
tion of but-￿-yn-￿-ol (￿￿￿ ￿l, ￿.￿￿ ￿mol, ￿.￿ eq.). The resultingmixture was stirred ￿￿min at ￿￿ °C
(monitored by TLC), then silica was added and the solvent was removed in vacuo. The residue was
subjected to flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) and title compound ￿￿￿
was obtained as pale yellow solid (￿.￿￿ g, ￿.￿￿ mmol, ￿￿%). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿,
stains with CAN). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz,
CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿-Bromobut-￿-yn-￿-yl)-￿,￿-dimethoxy-￿-nitrobenzene (￿￿￿).
NO2
MeO
MeO
Br
￿￿￿
Alcohol ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿.￿ ml) and cooled to ￿ °C. Phosphorus tribromide (￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise and the reaction mixture
was stirred over night with the cooling bath slowly warming up to
ambient temperature. The reaction was quenched by the addition
of sat. aq. K￿CO￿ and extracted thrice with ether. The combined organic layers were dried over
sodium sulfate and the solvent was removed under reduced pressure to obtain bromide ￿￿￿ as
yellow oil (￿￿.￿mg, ￿￿.￿ ￿mol, ￿￿%) which was directly used in the next steps without further
purification.
￿-(￿-Iodobut-￿-yn-￿-yl)-￿,￿-dimethoxy-￿-nitrobenzene (￿￿￿).
NO2
MeO
MeO
I
￿￿￿
Alcohol ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
benzene (￿.￿ ml). To this solution was added imidazole (￿￿.￿ mg,
￿￿￿ ￿mol, ￿.￿ eq.) and PPh￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.). Themixture
was stirred until full dissolution of all components (slightly heating
or ultrasonic may be necessary). Iodine (￿￿￿mg, ￿￿￿ ￿mol ￿.￿ eq.)
was dissolved in benzene (￿￿￿ ￿l) to obtain a dark purple solution which was added dropwise to
the reaction mixture. After complete addition, the reaction mixture was diluted with EtOAc and
sat. aq. sodium thiosulfate was added. The layers were separated and the aqueous layer was
extracted once with EtOAc. The combined organic layers were dried over magnesium sulfate
and the solvent was then removed under reduced pressure. This a￿orded iodide ￿￿￿ as orange
solid which was directly used in the next steps due to its instability. ￿H NMR (￿￿￿MHz, CDCl￿,
￿￿￿
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crude) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿INNaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿,￿-Dimethoxy-￿-nitrophenyl)but-￿-yn-￿-yl trifluoromethanesulfonate (￿￿￿).
NO2
MeO
MeO
OTf
￿￿￿
Alcohol ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ and cooled to –￿￿ °C. Pyridine (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.)
was added followed by the addition of trifluoromethanesulfonic
anhydride (￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.). The reaction mixture was
stirred for ￿￿ min at –￿￿ °C before quenched by the addition of
￿% HCl. The layers were separated and the aqueous layer was extracted twice with CH￿Cl￿.
The combined organic layers were dried over magnesium sulfate and the solvent was removed
in vacuo to obtain crude triflate ￿￿￿ which was purified via filtration over a plug of silica (hex-
anes–EtOAc, ￿:￿) to a￿ord triflate ￿￿￿ as colorless oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%). The compound
was directly used in the next steps due to its instability. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS
(ESI): calcd. for C￿￿H￿￿F￿NO￿S [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿,￿-dimethoxy-￿-nitrobenzaldehyde (￿￿￿).[￿￿￿]
CHO
NO2
MeO
MeO
￿￿￿
Nitric acid (￿￿% aq., ￿￿￿ml) was cooled to ￿ °C and ￿,￿-dimethoxybenzalde-
hyde (￿￿.￿ g, ￿￿￿mmol) was added in portions over ￿￿min, keeping the
temperature at ￿ °C. After complete addition, the reactionmixture was stirred
additional ￿￿min at ￿ °C, then additional ￿￿min at ambient temperature.
The reaction mixture was poured into ￿￿￿￿ml of ice-cold water to precipitate the product which
was collected by filtration through a medium porosity sintered-glass funnel. The retentate was
washed with additional ice-cold water (￿￿￿￿ml) and collected. Recrystallization from ethanol
furnished title compound ￿￿￿ as yellow solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿%). M.p. ￿￿￿ °C. ￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm.
￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm.
HRMS (ESI): calcd. for C￿H￿￿NO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿,￿-Dibromovinyl)-￿,￿-dimethoxy-￿-nitrobenzene (￿￿￿).
NO2
MeO
MeO
BrBr
￿￿￿
Tetrabromomethane (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) and triphenylphosphine
(￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) were dissolved in anhydrous CH￿Cl￿ (￿￿￿ml)
to yield a bright dark red solution. ￿-Nitro-￿,￿-dimethoxybenzaldehyd (￿￿￿,
￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added in portions at ambient temperature
and stirring was continued for additional ￿￿min (monitored by TLC) after
complete addition at this temperature. Water was added and the layers were separated. The
aqueous layer was extracted twice with CH￿Cl￿, the combined organic layers were once extracted
￿￿￿
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with brine and dried over sodium sulfate. The solvent was removed under reduced pressure
and the residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿ 
￿:￿  ￿:￿) to obtain ￿,￿-dibromoolefin ￿￿￿ as pale red solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿%). ￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿Br￿NNaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
((￿,￿-Dimethoxy-￿-nitrophenyl)ethynyl)trimethylsilane (￿￿￿).
NO2
MeO
MeO
TMS
￿￿￿
Aryl bromide ￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in diethy-
lamine (￿￿.￿ ml) and the resulting suspension was degassed using
ultrasonication. Copper(I) iodide (￿￿￿ mg, ￿￿￿ ￿mol, ￿ mol %) and
bis(triphenylphosphine)palladium(II) dichloride (￿￿￿mg, ￿￿￿ ￿mol,
￿mol %) were added under argon followed by the addition of ethynyl-
trimethylsilane (￿.￿ml, ￿￿.￿mmol, ￿.￿￿ eq.). The resulting mixture was stirred ￿￿min at ￿￿ °C
(monitored by TLC) before it was diluted with EtOAc and quenched by the addition of ￿%HCl.
The layers were separated and the aqueous layer was washed once with EtOAc. The combined
organic layers were dried over magnesium sulfate and then filtered over a plug of celite to obtain
crude title compound ￿￿￿ as brown solid in quantitative yield which was directly used in the
next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brown with vanillin). HRMS (ESI): calcd. for
C￿￿H￿￿NO￿Si [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿-Ethynyl-￿,￿-dimethoxy-￿-nitrobenzene (￿￿￿).
NO2
MeO
MeO
￿￿￿
Variant ￿: ￿,￿-dibromoolefin ￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved
in anhydrous THF (￿￿￿ml) and cooled to –￿￿ °C. nBuLi (￿.￿ ￿ in hexanes,
￿￿.￿ ml, ￿￿.￿ mmol, ￿.￿￿ eq.) was added dropwise and after complete
addition the dark green solution was stirred ￿￿min at –￿￿ °C and additional
￿￿￿min at ambient temperature. The reaction mixture was cooled down to –￿￿ °C and quenched
by the addition of sat. aq. NH￿Cl. The reaction mixture was diluted with ether and the layers
were separated. The aqueous layer was extracted twice with ether and the combined organic
layers were dried over magnesium sulfate. The solvent was removed under reduced pressure
and the residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain
pure acetylene ￿￿￿ as o￿-white solid (￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield)
Variant ￿: Crude silyl acetylene ￿￿￿ (￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous methanol
(￿￿ml) and potassium carbonate (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added at ambient temperature.
The reaction mixture was stirred at ￿￿ min at this temperature (monitored by TLC) before
it was diluted with ether and quenched by the addition of water. The layers were separated
and the aqueous layer was extracted twice with ether. The combined organic layers were dried
￿￿￿
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over sodium sulfate and the solvent was removed in vacuo. The residue was subjected to flash
column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to obtain acetylene ￿￿￿ as o￿-white solid
(￿.￿￿ g, ￿￿.￿ mmol, ￿￿% over two steps). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains light brown
with vanillin). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(s, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(E)-N,N-Diallylbut-￿-enamide (￿￿￿).[￿￿￿]
O
N
￿￿￿
Triethylamine (￿￿.￿ml, ￿￿￿mmol, ￿.￿ eq.) in anhydrous toluene (￿￿ml)
was added to a solution of diallylamine (￿￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.) in
anhydrous toluene (￿￿￿ml) at ￿ °C followed by the addition of a solution
of crotonoyl chloride (￿￿.￿ml, ￿￿￿mmol, ￿.￿ eq.) in anhydrous toluene
(￿￿￿ ml) over ￿￿ min. The resulting mixture was stirred ￿￿ min at ￿ °C
and then filtered to remove the triethylamine hydrochloride. The filtrate was concentrated
to approximately ￿￿% and chloroform was added and then filtered once again to remove the
residual triethylamine hydrochloride. The filtrate was concentrated in vacuo and the residue was
distilled (p = ￿.￿ Torr, ￿￿–￿￿ °C) to obtain amide ￿￿￿ as colorless oil (￿￿.￿ g, ￿￿￿mmol, ￿￿%).
Rf = ￿.￿￿ (CH￿Cl￿ –EtOAc, ￿￿:￿, stains with KMnO￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dq,
J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (br d, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NO [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Allyl but-￿-enoate (￿￿￿).
O
O
￿￿￿
A mixture of vinylacetic acid (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.), allyl alcohol
(￿￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.), and tosylic acid monohydrate (￿￿.￿ g,
￿￿.￿ mmol, ￿.￿ eq.) was heated in anhydrous benzene (￿￿￿ ml) with
azeotropic removal of water (Dean–Stark technique) for six hours. The reaction flask was at-
tached to a distillation apparatus and ester ￿￿￿ was obtained (p = ￿￿￿ Torr, ￿￿ °C) as colorless
liquid (￿￿.￿ g, ￿￿￿mmol, ￿￿%). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd.
for C￿H￿￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(Trimethylsilyl)but-￿-yn-￿-ol (￿￿￿).
OH
TMS
￿￿￿
￿-butyn-￿-ol (￿.￿￿ g, ￿￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous THF
(￿￿￿ml) and cooled to –￿￿ °C. A solution of nBuLi (￿.￿￿ in hexanes, ￿￿ml,
￿￿￿ mmol, ￿.￿ eq.) was added dropwise over ￿￿ min and stirring was
continued for ￿￿min at –￿￿ °C. Chlorotrimethylsilane (￿￿.￿ml, ￿￿￿mmol, ￿.￿ eq.) was added
￿￿￿
￿￿ Experimental
dropwise at –￿￿ °C and stirring was continued at this temperature for additional ￿￿min, then
additional ￿￿min at –￿￿ °C, and additional ￿￿min at ambient temperature (monitored by TLC).
The reaction mixture was diluted with ether and quenched by the addition of ￿ ￿ HCl. The
layers were separated and the aqueous layer was extracted thrice with ether. The combined
organic layers were dried over magnesium sulfate and the solvent was removed under reduced
pressure to obtain alcohol ￿￿￿ as colorless oil (￿￿.￿ g, ￿￿.￿mmol, ￿￿%) which was analytically
pure according to NMR analysis. ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t,
J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ ppm. HRMS (ESI): calcd. for C￿H￿￿OSi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(￿-Iodobut-￿-yn-￿-yl)trimethylsilane (￿￿￿).[￿￿￿]
I
TMS
￿￿￿
Alcohol ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.), imidazole (￿￿￿mg, ￿￿.￿mmol,
￿.￿￿ eq.), and triphenylphosphine (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿￿ eq.) were dis-
solved in anhydrous CH￿Cl￿ (￿￿ ml) and cooled to ￿ °C. Iodine (￿.￿￿ g,
￿.￿￿mmol, ￿.￿￿ eq.) was added in portions and stirring was continued for ￿￿ h at ￿ °C (moni-
tored by TLC). The reaction mixture was diluted with water and extracted twice with pentane.
The combined organic layers were dried over magnesium sulfate and the solvent was removed
under reduced pressure. The residue was subjected to flash column chromatography (pure
pentane) to obtain iodide ￿￿￿ as colorless oil (￿.￿￿ g, ￿.￿￿mmol, ￿￿%). Rf = ￿.￿￿ (pentane, pure).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(s, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿, ￿.￿ ppm. HRMS (ESI):
calcd. for C￿H￿￿ISi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(Trimethylsilyl)but-￿-yn-￿-yl trifluoromethanesulfonate (￿￿￿).
OTf
TMS
￿￿￿
Alcohol ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ and cooled to ￿ °C. Pyridine (￿￿￿ ￿l, ￿.￿￿ mmol, ￿.￿￿ eq.) was
added followed by the addition of trifluoromethanesulfonic anhydride
(￿.￿￿ ml, ￿.￿￿ mmol, ￿.￿￿ eq.). The reaction mixture was stirred for ￿￿ min at ￿ °C before
quenched by the addition of ￿% HCl. The layers were separated and the aqueous layer was
extracted twice with CH￿Cl￿. The combined organic layers were dried over magnesium sulfate
and the solvent was removed in vacuo to obtain crude triflate ￿￿￿ which was purified via filtration
over a plug of silica (pentane–ether, ￿￿:￿) to a￿ord triflate ￿￿￿ as colorless oil (￿.￿￿ g, ￿.￿￿mmol,
￿￿%). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿
(s, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿F￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿￿.￿
But-￿-yn-￿-yl ￿-methylbenzenesulfonate (￿￿￿).
OTs
￿￿￿
To ￿-butyn-￿-ol (￿.￿￿ g, ￿￿￿mmol, ￿.￿ eq.) in anhydrous CH￿Cl￿ (￿￿￿ml) was
added triethylamine (￿￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.) and tosyl chloride (￿￿.￿ g,
￿￿￿mmol, ￿.￿￿ eq.) at ￿ °C. The resulting mixture was stirred ￿￿min at ￿ °C,
then ￿￿ h at ambient temperature before it was quenched by the addition of ice-cold water. The
layers were separated and the aqueous layer was extracted twice with CH￿Cl￿. The combined
organic layers were dried over magnesium sulfate and the solvent was removed in vacuo to
obtain crude tosylate ￿￿￿ which was directly used in the next step.
￿-(Trimethylsilyl)but-￿-yn-￿-yl ￿-methylbenzenesulfonate (￿￿￿).
OTs
TMS
￿￿￿
Crude tosylate ￿￿￿ (￿￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous THF
(￿￿￿ ml) and cooled to –￿￿ °C. A solution of nBuLi (￿.￿ ￿ in hexanes,
￿￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.) was added dropwise and stirring was con-
tinued for additional ￿￿ min at –￿￿ °C. Chlorotrimethylsilane (￿￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.)
was added dropwise over ￿￿min at –￿￿ °C and stirring was continued for additional ￿￿ h with
the cooling bath slowly warming up to ￿ °C. The reaction mixture was diluted with ether and
quenched by the addition of sat. aq. NH￿Cl. The layers were separated and the aqueous layer
was extracted once with ether. The combined organic layers were dried and the solvent was
removed in vacuo to obtain crude tosylate ￿￿￿ as brown oil which solidified below ￿ °C after
￿￿ h. Recrystallization from hexanes furnished title compound ￿￿￿ as o￿-white solid (￿￿.￿ g,
￿￿￿mmol, ￿￿% over two steps). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS
(ESI): calcd. for C￿￿H￿￿O￿SSi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Bis(tricarbonylcobalt) complex of ￿-(Trimethylsilyl)but-￿-yn-￿-yl ￿-methylbenzenesulfonate (￿￿￿).
TMS
OTs
(OC)3Co Co(CO)3
￿￿￿
To a solution of tosylate ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in CH￿Cl￿ (￿.￿ml)
was added dicobalt octacarbonyl (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in one portion
at ambient temperature. After stirring for ￿￿ min at that temperature,
the reaction mixture was evaporated to dryness in vacuo. The crude prod-
uct was purified by silica gel column chromatography (pentane–ether, ￿￿:￿) to obtain pure
bis(tricarbonylcobalt) complex ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%) as brown solid. ￿HNMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t,
J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿Co￿NaO￿SSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
(￿-Bromobut-￿-yn-￿-yl)trimethylsilane (￿￿￿).
Br
TMS
￿￿￿
A mixture of tosylate ￿￿￿ (￿￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.), lithium bromide
(￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) and TBAI (￿￿￿ mg, ￿.￿￿ mmol, ￿ mol %) in
acetone (￿￿ml) was stirred at ambient temperature for ￿￿ h. The mixture
was diluted with pentane and water was added. The layers were separated and the aqueous layer
was extracted twice with pentane. The combined organic layers were dried over magnesium
sulfate and concentrated in vacuo. The crude product was purified by silica gel column chro-
matography (pure pentane) to obtain bromide ￿￿￿ as colorless oil (￿￿.￿ g, ￿￿.￿mmol, ￿￿%). Rf =
￿.￿￿ (pentane, pure). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz,
￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ ppm. HRMS
(ESI): calcd. for C￿H￿￿BrNaSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿.￿ Experimental Part for Section ￿￿.￿
(S)-￿-Oxotetrahydrofuran-￿-carboxylic acid (￿￿￿).
O
O
COOH
￿￿￿
￿-Glutamic acid (￿￿￿ g, ￿.￿￿ mol, ￿.￿ eq.) was dissolved in H￿O (￿￿￿ ml),
cooled to ￿ °C and conc. HCl (￿￿￿ml) was added to yield a white suspension.
A solution of NaNO￿ (￿￿￿ g, ￿.￿￿mol) in H￿O (￿￿￿ml) was added dropwise
at ￿–￿ °C under vigorous stirring over six hours. The pale yellow solution was
stirred at ambient temperature overnight. Water was evaporated in vacuo to obtain a pale-yellow
oil together with colorless crystals. This residue was stirred vigorously for ￿ h with ethyl acetate
(￿￿￿ml) and anhydrous sodium sulfate. The mixture was filtered through a medium porosity
sintered-glass funnel and the filtrate was concentrated in vacuo to obtain a yellow oil which was
kept below ￿ °C overnight to induce solidification. The product was warmed up to ambient
temperature and ether was added. The mixture was stirred ￿￿ min at ambient temperature
and additional five hours at ￿￿ °C. The crystalline product was isolated by suction. The latter
sequence was repeated two more times to furnish three batches of white crystalline product
which were identical according to NMR analysis (￿￿￿ g, ￿￿￿mmol, ￿￿%). M.p. ￿￿ °C. ￿H NMR
(￿￿￿MHz, MeOD) d = ￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, MeOD) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿H￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, MeOH). NMR spectra on page ￿￿￿.
￿￿￿
￿￿.￿ Experimental Part for Section ￿￿.￿
(S)-￿-(Hydroxymethyl)dihydrofuran-￿(￿H)-one (￿￿￿).
O
O
OH
￿￿￿
(S)-(+)-carboxylic acid (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿￿ml). BH￿  SMe￿ (￿.￿ml, ￿￿.￿mmol, ￿.￿￿ eq.) was added dropwise
over ￿￿ min at ambient temperature. After complete addition, the reaction
mixture was stirred additional ￿ h at this temperature (monitored by TLC).
The mixture was cooled to ￿ °C and methanol (￿￿ml) was carefully added. The solvents were
removed in vacuo and the residue was redissolved in methanol. The solvent was again removed
in vacuo and title compound ￿￿￿ was obtained by Kugelrohr distillation as colorless oil (￿.￿￿ g,
￿￿.￿mmol, ￿￿%). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dddd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H) ppm. HRMS
(ESI): calcd. for C￿H￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, EtOH).
NMR spectra on page ￿￿￿.
(S)-(￿-Oxotetrahydrofuran-￿-yl)methyl ￿-methylbenzenesulfonate (￿￿￿).
O
O
OTs
￿￿￿
(S)-Alcohol ￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous pyridine
(￿￿ml) and cooled to ￿ °C. Tosyl chloride (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added
in portions followed by the addition of DMAP (￿￿￿mg, ￿.￿￿mmol, ￿￿mol %).
The reaction mixture was stirred ￿￿￿ min at this temperature, then diluted
with EtOAc and quenched by the addition of ice-cold ￿%HCl. The layers were separated and
the aqueous layer was extracted once with EtOAc. The combined organic layers were dried over
magnesium sulfate and the solvent was removed in vacuo. Recrystallization from EtOAc–Et￿O
(￿:￿.￿) a￿orded tosylate ￿￿￿ as bright white powder (￿.￿￿ g, ￿￿.￿mmol, ￿￿%). Rf = ￿.￿￿ (EtOAc,
pure). M.p. ￿￿ °C. ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dddd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿,
￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dddd, J = ￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿O￿S [M + H]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(S)-￿-(Azidomethyl)dihydrofuran-￿(￿H)-one (￿￿￿).
O
O
N3
￿￿￿
Amixture of tosylate ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) and sodium azide (￿￿￿mg,
￿￿.￿mmol, ￿.￿ eq.) was stirred ￿.￿ h at ￿￿ °C (monitored by TLC). The solvent
was removed under reduced pressure, the residue triturated with chloroform
and filtered through a celite pad. The filtrate was concentrated to give crude ￿￿￿
which was purified by silica gel column chromatography to obtain pure azide ￿￿￿ (￿￿￿mg, ￿.￿￿
mmol, ￿￿%) as colorless oil. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
￿￿￿
￿￿ Experimental
(m, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿N￿NaO￿
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(S)-￿-Hydroxypiperidin-￿-one (￿￿￿).
NH
O
OH
￿￿￿
Azide ￿￿￿ (￿.￿￿ g, ￿￿.￿ mmol) was dissolved in anhydrous methanol (￿￿￿ ml) and
Pd/C (￿￿%, ￿￿￿ mg) was added. The mixture was hydrogenated (p = ￿￿￿ psi) at
ambient temperature for ￿.￿ h. The mixture was filtered through a celite pad and
the filtrate was concentrated in vacuo. The obtained product was usually used crude
for the next step. In case of a purification, crude ￿￿￿ was purified by alumina gel
chromatography (chloroform–MeOH, ￿:￿) followed by a recrystallization from acetonitrile to
yield pure ￿￿￿ a bright white powder. ￿H NMR (￿￿￿ MHz, DMSO) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (dq,
J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (qt, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿,
￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm.
HRMS (ESI): calcd. for C￿H￿￿NO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿.￿° (c = ￿.￿,
MeOH). NMR spectra on page ￿￿￿.
(S)-￿-((tert-Butyldimethylsilyl)oxy)piperidin-￿-one (￿￿￿).
NH
O
OTBS
￿￿￿
Crude (S)-hydroxypiperidone ￿￿￿ (￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous
N,N-dimethylformamide (￿￿￿ml) and cooled to ￿ °C. tert-Butyldimethylsilyl chloride
(￿￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) and imidazole (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) were added
and the resulting mixture was stirred ￿￿ min at this temperature, then additional
￿￿ h at ambient temperature. The solvent was removed under reduced pressure. The
residue was dissolved in EtOAc and silica was added. The solvent was removed in vacuo and the
residue was subjected to flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure
piperidinone ￿￿￿ as colorless crystals (￿￿.￿ g, ￿￿.￿ mmol, ￿￿% over two steps). M.p. ￿￿ °C.
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (br s, ￿H), ￿.￿￿ (p, J = ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J =
￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NO￿Si [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿.￿° (c = ￿.￿, CHCl￿).
NMR spectra on page ￿￿￿.
tert-Butyl (S)-￿-((tert-butyldimethylsilyl)oxy)-￿-oxopiperidine-￿-carboxylate (￿￿￿).
NBoc
O
OTBS
￿￿￿
(S)-Lactame ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous THF
(￿￿.￿ml) and DABCO (￿￿￿mg, ￿.￿￿mmol, ￿.￿￿ eq.) was added. The mixture was
cooled down to –￿￿ °C and nBuLi (￿.￿ ￿ in hexanes, ￿.￿￿ ml, ￿.￿￿ mmol, ￿.￿ eq.)
was added dropwise. The mixture was stirred ￿￿ min at this temperature, then a
solution of Boc￿O (￿￿￿mg, ￿.￿￿mmol, ￿.￿￿mmol) in anhydrous THF (￿.￿ml) was
added in one portion at –￿￿ °C. The reaction mixture was stirred additional three hours at this
￿￿￿
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temperature. The reaction was quenched by the addition of sat. aq. NaHCO￿ at –￿￿ °C, then
ether was added and the layers were separated. The aqueous layer was extracted once and the
combined organic layers were extracted thrice with sat. aq. NH￿Cl. The organic layer was dried
over magnesium sulfate and the solvent w as removed in vacuo. The crude was subjected to
flash column chromatography (hexanes–EtOAc, ￿:￿) to obtain pure title compound ￿￿￿ as white
solid. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br d, J = ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
[a]￿￿D = +￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿S,￿S)-￿-((tert-Butyldimethylsilyl)oxy)-￿-(phenylthio)piperidin-￿-one (￿￿￿).
NH
O
OTBS
PhS
￿￿￿
Variant ￿: Amide ￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous
THF (￿￿.￿ ml) and cooled to –￿￿ °C. A solution of nBuLi (￿.￿ ￿ in hexanes,
￿.￿ml, ￿￿.￿mmol, ￿.￿ eq.) was added dropwise and stirring was continued for
additional ￿￿ min at ￿￿ °C, then ￿￿ min at ￿ °C. The mixture was recooled to
–￿￿ °C and HMPA (￿.￿ml, ￿￿.￿mmol, ￿.￿ eq.) was added in one portion. The
mixture was stirred ￿￿min at this temperature, then a solution of diphenyl disulfide (￿￿￿mg,
￿.￿￿mmol, ￿.￿￿ eq.) in anhydrous THF (￿.￿ml) was added dropwise and stirring was continued
at –￿￿ °C for ￿￿ h. The reaction was quenched at –￿￿ °C by the addition of ￿ ￿HCl and diluted
with EtOAc. The layers were separated and the aqueous layer was extracted twice with EtOAc.
The combined organic layers were extracted once with brine, dried over sodium sulfate and the
solvent was removed under reduced pressure. The crude residue was subjected to flash column
chromatography (hexanes–EtOAc, ￿.￿:￿  ￿:￿) to obtain both monothio compound ￿￿￿ (￿￿￿mg,
￿.￿￿mmol, ￿￿%) and bisthio compound ￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿￿%) as white and yellow solid,
respectively.
Variant ￿: To a solution of bisthio compound ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol, ￿.￿ eq.) in anhydrous
THF (￿.￿ml) was added a solution of ethylmagnesium bromide (￿.￿ ￿ in Et￿O, ￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿￿ eq.) at –￿￿ °C. After ￿ h of stirring in the cold, the reaction mixture was quenched by the
dropwise addition of ￿% HCl and extracted thrice with ether. The combined organic layers were
dried over sodium sulfate and concentrated in vacuo to leave a residue that was purified by flash
column chromatography on silica gel (hexanes–EtOAc, ￿:￿) to furnish monothio compound ￿￿￿
(￿￿.￿mg, ￿￿.￿ ￿mol, ￿￿%) as white solid. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (ddt, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz,
￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NNaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿.￿° (c = ￿.￿, MeOH).
NMR spectra on page ￿￿￿.
￿￿￿
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(S)-￿-((tert-Butyldimethylsilyl)oxy)-￿,￿-bis(phenylthio)piperidin-￿-one (￿￿￿).
NH
O
OTBS
PhS
PhS
￿￿￿
To a solution of lactam ￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous
THF (￿.￿ ml) was added a solution of nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l,
￿￿￿ ￿mol, ￿.￿￿ eq.) at –￿￿ °C. After complete addition the resulting solution
was stirred ￿￿ min at ￿ °C. Chlorotrimethylsilane (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.)
was added dropwise and the mixture was stirred additional ￿￿￿ min at ￿ °C.
N-Phenylthiophthalimide (￿￿￿, ￿￿￿mg, ￿.￿￿mmol, ￿.￿￿ eq.) was added in one portion and the
solution was cooled down to –￿￿ °C. A solution of KHMDS (￿.￿ ￿ in toluene, ￿.￿ml, ￿.￿￿mmol,
￿.￿￿ eq.) was added dropwise and the mixture was stirred ￿￿ min at –￿￿ °C, then additional
￿￿min at ambient temperature (monitored by TLC). The reaction was then quenched by the
dropwise addition of ￿%HCl and extracted thrice with EtOAc. The combined organic layers were
dried over sodium sulfate and concentrated in vacuo to leave a residue that was purified by flash
column chromatography on silica gel (hexanes–EtOAc, ￿.￿:￿) to furnish bisthio compound ￿￿￿
(￿￿￿mg, ￿￿￿ ￿mol, quant.) as yellow solid. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br d, J = ￿.￿Hz, ￿H), ￿.￿￿ (tt, J = ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), –￿.￿￿ (d, J = ￿￿.￿ Hz, ￿H) ppm. HRMS (ESI):
calcd. for C￿￿H￿￿NNaO￿S￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿S,￿S)-￿-((tert-Butyldimethylsilyl)oxy)-￿-((￿-nitrophenyl)thio)piperidin-￿-one (￿￿￿).
NH
O
OTBS
S
NO2
￿￿￿
To a solution of lactam ￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF
(￿.￿ml) was added a solution of nBuLi (￿.￿ ￿ in hexanes, ￿￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿ eq.) at –￿￿ °C. The solution was stirred ￿￿min at this temperature and
then additional ￿￿ min at ￿ °C. The solution was recooled to –￿￿ °C and
a solution of ￿-nitrobenzenesulfenyl chloride (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿￿ eq.)
in anhydrous THF (￿.￿ml) was added. The resulting mixture was stirred ￿￿ h at –￿￿ °C, then
quenched by the dropwise addition of ￿ ￿HCl and extracted twice with EtOAc. The combined
organic layers were dried over sodium sulfate and concentrated in vacuo to leave a residue that
was purified by flash column chromatography on silica gel (hexanes–EtOAc, ￿:￿  ￿:￿) to furnish
title compound ￿￿￿ (￿￿.￿mg, ￿￿.￿ ￿mol, ￿￿%) as bright yellow solid. Rf = ￿.￿￿ (hexanes–EtOAc,
￿.￿:￿). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (p, J = ￿.￿ Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddt, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d,
J = ￿￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿SSi [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Note: This compound has been synthesized only once. Based on the results, the use of nBuLi is not
recommended, since the formation of butyl(￿-nitrophenyl)sulfane has been observed. The use of LDA
or an equal base should avoid the formation of this product and raise the yield.
￿￿￿
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￿,￿,￿-Trichloro-￿-morpholinoethan-￿-one (￿￿￿￿).
O
N
Cl
Cl
Cl
O
￿￿￿￿
Morpholine (￿￿￿ ml, ￿.￿￿ mol, ￿.￿￿ eq.) was dissolved in anhydrous THF
(￿￿￿ ml) and cooled to ￿ °C. A solution of trichloroacetyl chloride (￿￿￿ g,
￿￿￿ mmol, ￿.￿ eq.) in anhydrous THF (￿￿ ml) was added dropwise over
￿￿ min at ￿ °C. The resulting milky white suspension was warmed up to
ambient temperature for additional ￿ h, then diluted with ether (￿￿￿ml) and
quenched by the addition of ￿ ￿ HCl (￿￿￿ ml). The layers were separated and the aqueous
layer was extracted once with ￿ ￿ HCl, twice with sat. aq. NaHCO￿, and finally once with
brine. The organic layer was dried over sodium sulfate and concentrated in vacuo to provide
title compound ￿￿￿￿ (￿￿￿ g, ￿￿￿mmol, ￿￿%) as white solid which was directly used for the next
step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains with KMnO￿).
￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ –
￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿Cl￿NNaO￿ [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
N-Trichlorovinyl morpholine (￿￿￿￿).
Cl
N
Cl
Cl
O
￿￿￿￿
Amide ￿￿￿￿ (￿￿￿ g, ￿￿￿mmol, ￿.￿ eq.) was dissolved in o-xylene and triph-
enylphosphine (￿￿￿ g, ￿￿￿mmol, ￿.￿ eq.) was added. The resulting solution
was heated to ￿￿￿ °C for ￿.￿ h. The reaction mixture was cooled to ￿￿￿ °C,
the reaction flask was equipped with a distillation apparatus and the solvent
was removed under reduced pressure (￿￿￿ Torr). The pressure was further
reduced to ￿￿ Torr to collect title compound ￿￿￿￿ as pale yellow oil (￿￿.￿ g, ￿￿￿mmol, ￿￿% over
two steps). ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS
(ESI): calcd. for C￿H￿Cl￿NNaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-((Trimethylsilyl)ethynyl)morpholine (￿￿￿￿).
N OTMS
￿￿￿￿
N-Trichlorovinyl morpholine (￿￿￿￿, ￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) was dis-
solved in anhydrous ether (￿￿￿ ml) and cooled to –￿￿ °C. A solution of
nBuLi (￿.￿￿ in hexanes, ￿￿￿ml, ￿￿￿mmol, ￿.￿ eq.) was added over ￿￿min
and the resulting o￿-white suspension was gradually warmed to ambient temperature over ￿ h.
The solution was recooled to –￿￿ °C and chlorotrimethylsilane (￿￿.￿ ml, ￿￿￿ mmol, ￿.￿ eq.)
was added dropwise and the mixture was allowed to warm to ￿￿ °C. After ￿￿ h, the suspension
was diluted with hexanes and the solids were removed by filtration through a medium porosity
sintered-glass funnel. The filtrate was concentrated and title compound ￿￿￿￿ was obtained by
Kugelrohr distillation (￿￿.￿ g, ￿￿.￿ mmol, ￿￿%) as colorless oil which solidified below ￿ °C.
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿.￿ ppm. HRMS (ESI): calcd.
￿￿￿
￿￿ Experimental
for C￿H￿￿NOSi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Note: Storage in the freezer under an atmosphere of argon is possible for an indefinite period of time.
(S)-tert-Butyldimethyl(oxiran-￿-ylmethoxy)silane (￿￿￿￿).
O
OTBS
￿￿￿￿
A mixture of (S)-Glycidol (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.), tert-butyldimethylsilyl
chloride (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.), and imidazole (￿.￿￿ g, ￿￿￿mmol, ￿.￿ eq.)
in anhydrous N,N-dimethylformamide (￿￿ ml) was stirred at ￿ °C for ￿￿ min,
then additional ￿￿￿min at ambient temperature. Pentane–ether (￿:￿) and brine were added and
the layers were separated. The aqueous layer was extracted once with pentane–ether (￿:￿) and
the combined organic layers were dried over sodium sulfate. Evaporation of the solvent under
reduced pressure and purification of the residue by flash column chromatography (pentane–ether,
￿￿:￿   ￿￿:￿) provided pure title compound ￿￿￿￿ as colorless oil (￿￿.￿ g, ￿￿.￿ mmol, ￿￿%).
Alternatively, title compound ￿￿￿￿ can be purified via Kugelrohr distillation. ￿HNMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿NaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(S)-￿-Bromo-￿-(((tert-butyldimethylsilyl)oxy)methyl)furan-￿(￿H)-one (￿￿￿).
O
Br
O
OTBS
￿￿￿
Ynamine ￿￿￿￿ (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
CH￿Cl￿ (￿￿￿ml) and cooled to ￿ °C. Boron trifluoride diethyl etherate (￿.￿ml,
￿￿.￿ mmol, ￿.￿ eq.) was added dropwise followed by the addition of ￿￿￿￿
(￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) at ￿ °C. The dark orange solution was stirred
￿￿min at this temperature (monitored by TLC), then N-bromosuccinimide
(￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added at ￿ °C and the reaction mixture was stirred additional
￿￿ min at this temperature before it was diluted with CH￿Cl￿ and quenched by the addition
of ￿%HCl. The resulting mixture was stirred vigorously for ￿￿min at ambient temperature,
then the layers were separated and the aqueous layer was extracted once with CH￿Cl￿. The
combined organic layers were extracted once with brine and dried over sodium sulfate. The
solvent was removed under reduced pressure and the residue was dissolved in anhydrous N,N-
dimethylformamide (￿￿ml). Lithium chloride (dried at ￿￿￿ °C under vacuum, ￿.￿￿ g, ￿￿￿mmol,
￿.￿ eq.) and lithium carbonate (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) were added and the resulting mixture
was heated to ￿￿ °C for ￿￿min (monitored by TLC). The mixture was diluted with water and
pentane–ether (￿:￿) was added. The layers were separated and the aqueous layer was extracted
once with pentane–ether (￿:￿). The combined organic layers were extracted once with brine,
dried over sodium sulfate and concentrated in vacuo. The residue was subjected to flash column
chromatography (hexanes–EtOAc, ￿:￿) to obtain pure g-butenolide ￿￿￿ as pale yellow solid
(￿.￿￿ g, ￿￿.￿mmol, ￿￿%). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (ddd,
￿￿￿
￿￿.￿ Experimental Part for Section ￿￿.￿.￿
J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿BrNaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. [a]￿￿D = –￿￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
￿-(But-￿-en-￿-yn-￿-yl)-￿,￿-dimethoxy-￿-nitrobenzene (￿￿￿).
NO2
MeO
MeO
￿￿￿
Iodide ￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous
toluene (￿￿.￿ml) and DBU (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) was added in
one portion. The resulting solution was heated to ￿￿ °C for ￿￿ min
(monitored by TLC). The reactionmixture was quenched by the addition
of ￿%HCl and diluted with EtOAc. The layers were separated and the
aqueous layer was extracted once with EtOAc. The combined organic layers were dried over
magnesium sulfate and concentrated in vacuo. The residue was subjected to flash column
chromatography (hexanes–EtOAc, ￿:￿) to provide enyne ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, quant.) as pale
olive solid. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿￿.￿Hz,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
Note: Similar procedure was used for the generation of enyne ￿￿￿￿ from iodide ￿￿￿.
(Allyloxy)(tert-butyl)dimethylsilane (￿￿￿￿).
OTBS
￿￿￿￿
A mixture of ally alcohol (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.), tert-butyldimethylsilyl chlo-
ride (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.), and imidazole (￿.￿￿ g, ￿￿￿ mmol, ￿.￿ eq.) in
anhydrous N,N-dimethylformamide (￿￿ml) was stirred ￿￿ h at ambient temper-
ature. The reaction mixture was then diluted with pentane–ether (￿:￿) and water was added.
The layers were separated and the aqueous layer was extracted once with pentane–ether (￿:￿).
The combined organic layers were washed once with brine and dried over sodium sulfate. The
solvent was removed under reduced pressure and the residue was subjected to flash column
chromatography (pentane–ether, ￿￿:￿) to provide silyl alcohol ￿￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿￿%)
as colorless oil. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (ddt, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq,
J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿NaOSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
￿￿￿
￿￿ Experimental
tert-Butyldimethyl(￿-(￿,￿,￿,￿-tetramethyl-￿,￿,￿-dioxaborolan-￿-yl)propoxy)silane (￿￿￿￿).
TBSO B
O
O
￿￿￿￿
Borane dimethyl sulfide (￿.￿￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) was added
dropwise to a solution of pinacol (￿.￿￿ g, ￿￿.￿ mmol ￿.￿ eq.) in
anhydrous CH￿Cl￿ (￿.￿ ml) at ￿ °C and the resulting solution was
stirred for additional ￿￿ min at this temperature. The cooling bath
was removed and stirring was continued for additional ￿￿￿ min at ambient temperature.
The reaction mixture was recooled to ￿ °C and a solution of silyl alcohol ￿￿￿￿ (￿.￿ g,
￿￿.￿ mmol, ￿.￿ eq.) in anhydrous CH￿Cl￿ (￿.￿ ml) was added followed by the addition of
chloridotris(triphenylphosphane)rhodium(I) (￿￿.￿mg, ￿￿.￿ ￿mol, ￿.￿￿mol %). The reaction
mixture was stirred ￿￿min at ￿ °C and then ￿￿ h at ambient temperature. The reaction mixture
was diluted with water and the layer were separated. The aqueous layer was extracted twice with
ether and the combined organic layers were dried over magnesium sulfate. The solvent was
removed in vacuo and the residue was subjected to flash column chromatography (pentane–ether,
￿￿:￿) to obtain boronate ester ￿￿￿￿ as colorless oil (￿.￿￿ g, ￿.￿￿mmol, ￿￿%) which was directly
used for the next transformation. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿
(dq, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H) ppm.
NMR spectra on page ￿￿￿.
Potassium ￿-trifluoroboratopropan-￿-ol (￿￿￿￿).
HO BF3K
￿￿￿￿
Boronate ester ￿￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in anhy-
drous acetonitrile (￿￿ml) and cooled to ￿ °C. Potassium bifluoride (￿.￿￿ g,
￿￿.￿ mmol, ￿.￿ eq.) was added in one portion followed by the dropwise
addition of water (￿.￿ml) over a period of ￿￿min at ￿ °C. The cooling bath was removed and
the reaction mixture was stirred for ￿.￿ h at ambient temperature. Acetone was added and the
suspension allowed to settle, then the solution decanted into a conical flask. The reaction flask
was rinsed twice with MeOH and similarly decanted. The combined organics were filtered
through a cotton plug and evaporated. The residue was taken up in water and washed four
times with ethyl acetate. The aqueous layer was concentrated in vacuo and the residue was taken
up in methanol and once again concentrated in vacuo to provide trifluoroborate salt ￿￿￿￿ as
bright white solid (￿￿￿mg, ￿.￿￿mmol, ￿￿%) after drying for several hours under high vacuum.
￿H NMR (￿￿￿MHz, MeOD) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (p, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H) ppm. NMR spectra on page ￿￿￿.
Note: (i) Storage under argon at –￿￿ °C. (ii) Caution! In this context, potassium bifluoride is a
potential hydrogen fluoride source and should be handled with care.
￿￿￿
￿￿.￿ Experimental Part for Section ￿￿.￿.￿
￿￿.￿ Experimental Part for Section ￿￿.￿.￿
(S)-￿-(((tert-Butyldimethylsilyl)oxy)methyl)dihydrofuran-￿(￿H)-one (￿￿￿￿).
O
O
OTBS
￿￿￿￿
Crude alcohol ￿￿￿ (￿￿￿ mmol, ￿.￿ eq.) was dissolved in anhydrous DMF
(￿￿￿ml) and cooled to ￿ °C. tert-Butyldimethylsilyl chloride (￿￿.￿ g, ￿￿￿mmol,
￿.￿ eq.) and imidazole (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) were added in portions
at ￿ °C and stirring was continued for additional six hours (monitored by
TLC). The reaction mixture was concentrated in vacuo to approximately ￿￿%, then diluted with
pentane–ether (￿:￿) and brine–H￿O (￿:￿). The layers were separated and the aqueous layer
was extracted twice with pentane–ether (￿:￿). The organic layer was dried over magnesium
sulfate and concentrated under reduced pressure to yield crude title compound ￿￿￿￿ which was
subjected to flash column chromatography (pentane–ether, ￿￿:￿  ￿￿:￿) to provide pure title
compound ￿￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿￿% over two steps) as colorless oil. ￿H NMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (ddt, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm.
￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿, –￿.￿ ppm. HRMS
(ESI): calcd. for C￿￿H￿￿NaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. [a]￿￿D = +￿￿.￿° (c = ￿.￿,
CHCl￿). NMR spectra on page ￿￿￿.
(￿S)-￿-(((tert-Butyldimethylsilyl)oxy)methyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)dihydrofuran-
￿(￿H)-one (￿￿￿￿).
O
O
OTBSTMS
￿￿￿￿
nBuLi (￿.￿ ￿ in hexanes, ￿.￿￿ ml, ￿.￿￿ mmol, ￿.￿ eq) was added to a
solution of diisopropylamine (￿￿￿ ￿l, ￿.￿￿mmol, ￿.￿ eq.) in anhydrous
THF (￿￿.￿ml) at –￿￿ °C and the solution was stirred ￿￿min at –￿￿ °C. A
solution of lactone ￿￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) and HMPA (￿.￿ml,
￿.￿￿mmol ￿.￿￿ eq.) in anhydrous THF (￿.￿ml) was added over ￿￿min
via syringe pump at –￿￿ °C and the resulting solution was stirred for additional ￿ h at this
temperature. A solution of freshly prepared triflate ￿￿￿ (￿.￿￿ g, ￿.￿￿mmol, ￿.￿￿ eq.) in anhydrous
THF (￿.￿ ml) was added dropwise at –￿￿ °C and stirring was continued for ￿￿ min at this
temperature. The mixture was diluted with ether and quenched by the addition of ￿% HCl.
The layers were separated and the aqueous layer was extracted once with ether. The combined
organic layers were dried over magnesium sulfate and concentrated in vacuo to obtain crude
title compound ￿￿￿￿ which was subjected to flash column chromatography (hexanes–EtOAc,
￿￿:￿  ￿:￿) to provide recovered starting material (￿￿￿ mg, ￿.￿￿ mmol) along with pure title
compound ￿￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿%, ￿￿% brsm, diastereomeric ratio = ￿:￿) as colorless
oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains with KMnO￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿
(dq, J = ￿.￿, ￿.￿Hz, ￿.￿￿H, major diastereomer), ￿.￿￿ (ddt, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿.￿￿H, minor
diastereomer), ￿.￿￿ (ddd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
￿￿￿
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(qd, J = ￿.￿, ￿.￿Hz, ￿.￿￿H, major diastereomer), ￿.￿￿ – ￿.￿￿ (m, ￿.￿￿H, minor diastereomer),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿.￿, ￿.￿, –￿.￿, –￿.￿, –￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿O￿Si￿ [M + H]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Note: The yield was not significantly higher when stirring was carried out for longer than ￿￿ min after
the addition of triflate ￿￿￿, e.g. ￿￿ h at –￿￿ °C provided title compound ￿￿￿￿ in ￿￿% yield (￿￿%
brsm).
(￿S)-￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(phenylselanyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)
dihydrofuran-￿(￿H)-one (￿￿￿￿).
O
O
OTBSTMS
PhSe
￿￿￿￿
LiHMDS (￿.￿ ￿ in THF, ￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise
to a solution of lactone ￿￿￿￿ (￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous
THF (￿.￿ml) at –￿￿ °C. The resulting mixture was stirred ￿￿min at this
temperature, then chlorotrimethylsilane (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) was
added in one portion at –￿￿ °C and the cooling bath was removed. The
mixture was stirred ￿￿ min at ambient temperature, then recooled to –￿￿ °C. A solution of
phenylselenyl bromide (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) in anhydrous THF (￿.￿ ml) was added
at this temperature and stirring was continued for additional ￿min (monitored by TLC). The
dark orange reaction mixture was diluted with ether and water was added. The mixture was
stirred vigorously at ambient temperature until the etheral layer became light yellow. Brine was
added and the layers were separated. The aqueous layer was extracted twice with ether and the
combined organic layers were dried over magnesium sulfate. The solvent was evaporated under
reduced pressure to obtain crude organoselenium compound ￿￿￿￿ as yellow oil which was
directly subjected to the oxidative elimination. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains intensely
with KMnO￿, stains dark purple with vanillin).
(S)-￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)furan-
￿(￿H)-one (￿￿￿￿).
O
O
OTBSTMS
￿￿￿￿
Crude organoselenium species ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
anhydrous CH￿Cl￿ (￿.￿ml) and cooled to ￿ °C. A solution of H￿O￿ (￿￿%,
￿.￿ml) in H￿O (￿.￿ml) was added dropwise at this temperature followed
by the addition of pyridine (one drop). The reaction mixture was stirred
vigorously at ￿ °C for ￿￿ min (monitored by TLC) to obtain a colorless
suspension. The reaction mixture was diluted with ether and quenched by the addition of sat.
aq. NaHCO￿. The layers were separated and the aqueous layer was extracted twice with ether.
The combined organic layers were dried over sodium sulfate and the solvent was removed under
￿￿￿
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reduced pressure. The residue was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿) to obtain pure g-butenolide ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿% over two steps) as colorless oil.
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark olive with vanillin).
￿H NMR (￿￿￿MHz, CDCl￿) d =
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J =
￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz,
￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿.￿, –￿.￿, –￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿O￿Si￿ [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(S)-￿-(Hydroxymethyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)furan-￿(￿H)-one (￿￿￿￿).
O
O
OHTMS
￿￿￿￿
A solution of silyl alcohol ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous
THF (￿.￿ml) was added to a solution of hydrogen fluoride pyridine (￿￿%
wt, ￿.￿ ml) at ￿ °C and stirring was continued for three hours at this
temperature (monitored by TLC). The reaction mixture was diluted with
EtOAc and carefully quenched by the addition of sat. aq. NaHCO￿. The
layers were separated and the aqueous layer was extracted twice with EtOAc. The combined
organic layers were extracted with ￿ ￿HCl to remove pyridine and dried over magnesium sulfate.
The solvent was removed in vacuo to obtain title compound ￿￿￿￿ as colorless oil in quantitative
yield which was directly subjected to the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains brown
with vanillin). HRMS (ESI): calcd. for C￿￿H￿￿NaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(S)-(￿-Oxo-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)-￿,￿-dihydrofuran-￿-yl)methyl
methanesulfonate (￿￿￿￿).
O
O
OMsTMS
￿￿￿￿
Crude alcohol ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrousCH￿Cl￿
(￿.￿ ml) and cooled to ￿ °C. Freshly distilled methanesulfonyl chloride
(￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) and triethylamine (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) were
added and stirring was continued for ￿￿min at this temperature (moni-
tored by TLC). The reaction as quenched by the addition of sat. aq. NH￿Cl
and diluted with CH￿Cl￿. The layers were separated and the aqueous layer was extracted twice
with CH￿Cl￿. The combined organic layers were dried over sodium sulfate and concentrated
in vacuo to provide crude mesylate ￿￿￿￿ as pale yellow oil which was directly subjected to the
next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd. for C￿￿H￿￿NaO￿SSi [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿￿
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￿-Methylene-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)furan-￿(￿H)-one (￿￿￿￿).
O
O
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￿￿￿￿
A mixture of crude mesylate ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) and sodium azide
(￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous DMF (￿.￿ml) was heated to ￿￿ °C
for ￿￿min (monitored by TLC). The reaction mixture was diluted with ether
and brine and the layers were separated. The aqueous layer was extracted twice
with ether and the combined organic layers were extracted once with brine.
Drying over magnesium sulfate followed by the removal of the solvent under reduced pressure
furnished crude title compound ￿￿￿￿ which was purified by flash column chromatography
(hexanes–EtOAc, ￿:￿) to provide pure g-butenolide ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿% over three
steps) as colorless oil. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿ (dt,
J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿O￿Si [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(￿S)-￿-(Hydroxymethyl)-￿-(phenylselanyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)dihydrofuran-
￿(￿H)-one (￿￿￿￿).
O
O
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PhSe
￿￿￿￿
Crude silyl alcohol ￿￿￿￿ (￿￿￿ ￿mol) was stirred in AcOH–THF–H￿O (￿:￿:￿,
￿￿.￿ml) for ￿￿ h at ambient temperature. The reaction was quenched by
the careful addition of sat. aq. NaHCO￿ and diluted with CH￿Cl￿. The lay-
ers were separated and the aqueous layer was extracted once with CH￿Cl￿.
The combined organic layers were dried over magnesium sulfate and con-
centrated in vacuo. The residue was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿  ￿:￿) to obtain pure title compound ￿￿￿￿ as yellow oil (￿￿￿mg, ￿￿￿ ￿mol, ￿￿% over two
steps). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (d, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dddd, J = ￿￿.￿, ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿,
￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿O￿SeSi [M + H]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
((￿S)-￿-Oxo-￿-(phenylselanyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)tetrahydrofuran-￿-yl)methyl
￿-methylbenzenesulfonate (￿￿￿￿).
O
O
OTsTMS
PhSe
￿￿￿￿
Alcohol ￿￿￿￿ (￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhydrous
pyridine (￿.￿ml) and cooled to ￿ °C. DMAP (￿.￿mg, ￿￿ ￿mol, ￿￿mol%) and
tosyl chloride (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) were added and the resulting
mixture was stirred at ￿ °C for ￿ h, then additional ￿ h at ￿￿ °C (monitored
by TLC). The reaction mixture was diluted with ether and quenched by
the addition of ￿ ￿HCl. The layers were separated and the aqueous layer was extracted once
with ether. The combined organic layers were dried over magnesium sulfate and concentrated
￿￿￿
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in vacuo. The crude residue was directly subjected to the next step. HRMS (ESI): calcd. for
C￿￿H￿￿NaO￿SSeSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿S)-￿-(Azidomethyl)-￿-(phenylselanyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)dihydrofuran-
￿(￿H)-one (￿￿￿￿).
O
O
N3TMS
PhSe
￿￿￿￿
A mixture of crude tosylate ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) and sodium azide
(￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous DMF (￿.￿ml) was heated to ￿￿ °C
for ￿￿min (monitored by TLC). The reaction mixture was cooled to ambient
temperature and diluted with ether and water. The layers were separated
and the aqueous layer was extracted once with ether. The combined organic
layers were dried over magnesium sulfate and concentrated in vacuo. The crude residue was
directly subjected to the next step. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿SeSi [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(S)-￿-(Azidomethyl)-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)furan-￿(￿H)-one (￿￿￿￿).
O
O
N3TMS
￿￿￿￿
Crude organoselenium species ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
anhydrous CH￿Cl￿ (￿.￿ml) and cooled to ￿ °C. A solution of H￿O￿ (￿￿%,
￿￿￿ ￿l) in H￿O (￿.￿ml) was added dropwise at this temperature followed
by the addition of pyridine (one drop). The reaction mixture was stirred
vigorously at ￿ °C for ￿￿ min (monitored by TLC) to obtain a colorless
suspension. The reaction mixture was diluted with ether and quenched by the addition of sat.
aq. NaHCO￿. The layers were separated and the aqueous layer was extracted twice with ether.
The combined organic layers were dried over sodium sulfate and the solvent was removed under
reduced pressure. The residue was subjected to flash column chromatography (hexanes–EtOAc,
￿:￿) to obtain pure g-butenolide ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿% over three steps) as colorless
oil. ￿H NMR (￿￿￿ MHz, C￿D￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿
(s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(S)-￿-Hydroxy-￿-(￿-(trimethylsilyl)but-￿-yn-￿-yl)-￿,￿-dihydropyridin-￿(￿H)-one (￿￿￿￿).
NH
O
OH
TMS
￿￿￿￿
Azide ￿￿￿￿ (￿￿.￿ mg, ￿￿.￿ ￿mol, ￿.￿ eq.) was dissolved in THF (technical,
￿.￿ml), H￿O (￿￿ ￿l) was added followed by the addition of triphenylphosphine
(￿￿.￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.). The reaction mixture was stirred at ambient
temperature for ￿ h (monitored by TLC). Triethylamine (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.)
was added at this temperature and stirring was continued for additional ￿ h.
Volatile components were evaporated in vacuo and by azeotropic distillation
with benzene to obtain title compound ￿￿￿￿ as colorless oil along with trace amounts of the
￿￿￿
￿￿ Experimental
imino-phosphorane adduct. The ￿H NMR spectrum of amide ￿￿￿￿ was determined from the
crude mixture. ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NO￿Si [M +H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
HRMS (ESI): calcd. for C￿￿H￿￿NO￿PSi [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿ (imino-phosphorane
adduct). [a]￿￿D = –￿￿.￿° (c = ￿.￿, CHCl￿). NMR spectra on page ￿￿￿.
(￿S)-￿-(But-￿-yn-￿-yl)-￿-(((tert-butyldimethylsilyl)oxy)methyl)dihydrofuran-￿(￿H)-one (￿￿￿￿).
O
O
OTBS
￿￿￿￿
Silyl protected alkyne ￿￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in
anhydrous methanol (￿.￿ml). Potassium carbonate (￿￿￿mg, ￿.￿￿mmol,
￿.￿ eq.) was added at ambient temperature and stirring was continued
for ￿￿min at this temperature (monitored by TLC). The reaction mixture
was diluted with ether and sat. aq. NH￿Cl. The layers were separated and
the aqueous layer was extracted once with ether. The combined organic layers were dried over
magnesium sulfate and concentrated in vacuo. The obtained residue was directly used in the next
step without purification. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). HRMS (ESI): calcd. for C￿￿H￿￿NaO￿Si
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿S)-￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-(￿,￿-dimethoxy-￿-nitrophenyl)but-￿-yn-￿-yl)-
dihydrofuran-￿(￿H)-one (￿￿￿￿).
MeO
MeO NO2 O
O
OTBS
￿￿￿￿
Crude alkyne ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) and aryl bromide ￿￿￿ were
dissolved in diethylamine (￿.￿ml) and the resulting solution was
degassed (ultrasonication plus argon). Pd(PPh￿)￿Cl￿ (￿￿.￿ mg,
￿￿ ￿mol, ￿mol%) and copper(I) iodide (￿.￿mg, ￿￿ ￿mol, ￿mol%)
were added and the reaction mixture was heated to ￿￿ °C for
￿￿min (monitored by TLC). The mixture was diluted with ether
and quenched by the addition of ￿ ￿ HCl. The layers were separated and the aqueous layer was
extracted twice with ether. The combined organic layers were dried over sodium sulfate and
concentration in vacuo provided crude title compound ￿￿￿￿ which was purified by flash column
chromatography (hexanes–EtOAc, ￿:￿   ￿:￿) to furnish pure ￿￿￿￿ (￿￿￿ mg, ￿￿￿ ￿mol, ￿￿%
over to steps) as diastereomeric mixture (diastereomeric ratio = ￿:￿) as yellow oil. The ￿H NMR
spectra of both diastereomers were determined from the mixture. ￿H NMR (￿￿￿MHz, C￿D￿,
major diastereomer) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dq, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(dtd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H) ppm. ￿HNMR (￿￿￿MHz, C￿D￿, minor diastereomer)
d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddt, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿,
￿￿￿
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￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, C￿D￿, diastereomeric mixture) d = ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, -￿.￿, -￿.￿,
-￿.￿, -￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿Si [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(￿S)-￿-(((tert-butyldimethylsilyl)oxy)methyl)-￿-(￿-(￿,￿-dimethoxy-￿-nitrophenyl)but-￿-yn-￿-yl)-
￿-(phenylselanyl)dihydrofuran-￿(￿H)-one (￿￿￿￿).
MeO
MeO NO2 O
O
OTBS
SePh
￿￿￿￿
Lactone ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) was dissolved in anhy-
drous THF (￿.￿ml) and cooled to –￿￿ °C. LiHMDS (￿.￿￿ in THF,
￿￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿ eq.) was added dropwise and the result-
ing solution was stirred ￿￿min at –￿￿ °C. Chlorotrimethylsilane
(￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) was added in one portion at –￿￿ °C
and stirring was continued at ambient temperature for ￿￿min.
The mixture was recooled to –￿￿ °C and a solution of phenylselenyl bromide (￿￿.￿mg, ￿￿￿ ￿mol,
￿.￿￿ eq.) in anhydrous THF (￿.￿ ml) was added dropwise. The mixture was stirred ￿￿ min
at –￿￿ °C, then the dark orange reaction mixture was diluted with ether and water was added.
The mixture was stirred vigorously at ambient temperature until the etheral layer became light
yellow. Brine was added and the layers were separated. The aqueous layer was extracted twice
with ether and the combined organic layers were dried over magnesium sulfate. The solvent
was evaporated under reduced pressure to obtain crude organoselenium compound ￿￿￿￿ as
yellow oil which was directly subjected to the next step without purification. HRMS (ESI): calcd.
for C￿￿H￿￿NNaO￿SeSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿S)-￿-(￿-(￿,￿-dimethoxy-￿-nitrophenyl)but-￿-yn-￿-yl)-￿-(hydroxymethyl)-￿-(phenylselanyl)-
dihydrofuran-￿(￿H)-one (￿￿￿￿).
MeO
MeO NO2 O
O
OH
SePh
￿￿￿￿
Crude organoselenium silyl alcohol ￿￿￿￿ (￿￿￿ ￿mol) was stirred
in AcOH–THF–H￿O (￿:￿:￿, ￿.￿ml) for ￿￿ h at ambient temper-
ature. The reaction was quenched by the careful addition of sat.
aq. NaHCO￿ and diluted with CH￿Cl￿. The layers were sepa-
rated and the aqueous layer was extracted once with CH￿Cl￿.
The combined organic layers were dried over magnesium sulfate
and concentrated in vacuo. The crude residue was subjected to the next step without further
purification. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿Se [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
￿￿￿
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((￿S)-￿-(￿-(￿,￿-dimethoxy-￿-nitrophenyl)but-￿-yn-￿-yl)-￿-oxo-￿-(phenylselanyl)tetrahydrofuran-
￿-yl)methyl ￿-methylbenzenesulfonate (￿￿￿￿).
MeO
MeO NO2 O
O
OTs
SePh
￿￿￿￿
Crude alcohol ￿￿￿￿ (￿￿￿ ￿mol) was dissolved in anhydrous pyri-
dine (￿.￿ ml) and cooled to ￿ °C. DMAP (￿.￿ mg, ￿￿ ￿mol,
￿￿mol %) and tosyl chloride (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿￿ eq.) were
added and the resulting mixture was stirred ￿￿ h at ambient
temperature. The reaction mixture was diluted with ether and
quenched by the addition of ￿ ￿ HCl. The layers were separated
and the aqueous layer was extracted once with ether. The combined organic layers were dried
over magnesium sulfate and concentrated in vacuo. The crude residue was directly subjected to
the next step without further purification. HRMS (ESI): calcd. for C￿￿H￿￿NNaO￿SSe [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
(￿S)-￿-(Azidomethyl)-￿-(￿-(￿,￿-dimethoxy-￿-nitrophenyl)but-￿-yn-￿-yl)-￿-(phenylselanyl)-
dihydrofuran-￿(￿H)-one (￿￿￿￿).
MeO
MeO NO2 O
O
N3
SePh
￿￿￿￿
A mixture of crude tosylate ￿￿￿￿ (￿￿￿ ￿mol, ￿.￿ eq.) and sodium
azide (￿￿.￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was heated to ￿￿ °C for
￿￿￿min (monitored by TLC). The reaction mixture was diluted
with ether and brine and the layers were separated. The aqueous
layer was extracted twice with ether and the combined organic
layers were extracted once with brine. Drying over magnesium
sulfate followed by the removal of the solvent under reduced pressure furnished crude title
compound ￿￿￿￿ which was purified by flash column chromatography (hexanes–EtOAc, ￿:￿) to
provide pure azide ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿% over four steps) as diastereomeric mixture
(diastereomeric ratio =￿:￿) as yellow oil. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (td, J =
￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS
(ESI): calcd. for C￿￿H￿￿N￿O￿Se [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
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Methyl hex-￿-ynoate (￿￿￿￿).
O
OMe
￿￿￿￿
Hex-￿-ynoic acid (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous
N,N-dimethylformamide (￿￿.￿ ml). Methyl iodide (￿.￿ ml, ￿￿.￿ mmol,
￿.￿ eq.) and potassium carbonate (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) were added
and the mixture was stirred for ￿￿ h at ambient temperature. The mixture was diluted with
ether and brine was added. The layers were separated and the aqueous layer was extracted twice
with ether. The combined organic layers were dried over sodium sulfate and concentrated in
￿￿￿
￿￿.￿ Experimental Part for Section ￿￿.￿
vacuo to provide methyl ester ￿￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿￿%) as colorless oil. ￿HNMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (tdd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (t, J =
￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Methyl ￿-(￿,￿-dimethoxy-￿-nitrophenyl)hex-￿-ynoate (￿￿￿￿).
MeO
MeO NO2
O
OMe
￿￿￿￿
Aryl bromide ￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was dis-
solved in diethylamine (￿.￿ ml) and the resulting bright
yellow solution was degassed (ultrasonication plus argon).
Pd(PPh￿)￿Cl￿ (￿￿.￿ mg, ￿￿ ￿mol, ￿ mol %) and copper(I)
iodide (￿￿.￿ mg, ￿￿ ￿mol, ￿ mol %) were added and the
reaction mixture was heated to ￿￿ °C. A solution of alkyne ￿￿￿￿ in diethylamine (￿.￿ml) was
added in one portion and stirring was continued at ￿￿ °C for additional ￿￿ min (monitored
by TLC). The mixture was diluted with EtOAc and quenched by the addition of ￿ ￿HCl. The
layers were separated and the aqueous layer was extracted twice with EtOAc. The combined
organic layers were dried over magnesium sulfate and concentration in vacuo provided crude
title compound ￿￿￿￿ which was purified by flash column chromatography (hexanes–EtOAc,
￿:￿) to furnish pure ￿￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿￿%, ￿￿% brsm) as dark orange oil. Rf = ￿.￿￿
(hexanes–EtOAc, ￿:￿, stains bright orange with vanillin). ￿H NMR (￿￿￿MHz, C￿D￿) d = ￿.￿￿
(s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J =
￿.￿Hz, ￿H), ￿.￿￿ (p, J = ￿.￿Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd.
for C￿￿H￿￿NNaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Methyl ￿-allyl-￿-(￿,￿-dimethoxy-￿-nitrophenyl)hex-￿-ynoate (￿￿￿￿).
MeO
MeO NO2
O
OMe
￿￿￿￿
A solution of nBuLi (￿.￿￿ in hexanes, ￿￿￿ ￿l, ￿￿￿ ￿mol) was
added to a solution of diisopropylamine (￿￿ ￿l, ￿￿￿ ￿mol,
￿.￿￿ eq.) in anhydrous THF (￿.￿ ml) at –￿￿ °C and was
stirred ￿￿min at this temperature. A solution of ester ￿￿￿￿
(￿￿￿mg, ￿￿￿ ￿mol, ￿.￿ eq.) in anhydrous THF (￿.￿ml) was
added dropwise at –￿￿ °C and the resulting solution was
stirred ￿￿min at this temperature. Allyl bromide (￿￿ ￿l, ￿￿￿ ￿mol, ￿.￿￿ eq.) was added dropwise
and the stirring was continued at –￿￿ °C for ￿ h. The reaction was then diluted with ether and
quenched by the addition of sat. aq. NH￿Cl. The layers were separated and the aqueous layer
was extracted twice with ether. The combined organic layers were dried over magnesium sulfate
and concentrated in vacuo. The crude residue was subjected to flash column chromatography
(hexanes–EtOAc, ￿:￿) to furnish title compound ￿￿￿￿ (￿￿.￿mg, ￿￿￿ ￿mol, ￿￿%) as colorless oil.
Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
￿￿￿
￿￿ Experimental
(ddt, J = ￿￿.￿, ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (q,
J = ￿.￿Hz, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dq, J = ￿￿.￿, ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for
C￿￿H￿￿NO￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
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￿￿Cycloaplysinopsin A
￿￿.￿ Marine Dimeric Bisindole Alkaloids
The bisindoles tubastrindoles A–C (￿￿￿￿–￿￿￿￿) with an hitherto unprecedented skeleton were
isolated from the Japanese Tubastraea sp. stony coral collected in the Odomari area, Kagoshima
Prefecture (Fig. ￿￿-￿).[￿￿￿] The skeleton possesses a tetrahydrocarbazole core which is function-
alized with two modified hydantoin (also known as glycolylurea) moieties and a second indole
moiety. After further investigation of Tubastraea sp. the authors reported five new tubastrindoles
D–H (￿￿￿￿–￿￿￿￿).[￿￿￿] The authors primarily assumed that compounds ￿￿￿￿–￿￿￿￿ are biogenet-
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Figure ￿￿-￿. Aplysinopsin dimers tubastrindoles A–H (￿￿￿￿–￿￿￿￿) and dictazolines A–E (￿￿￿￿–￿￿￿￿).
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ically formed from an enzymatic Diels–Alder cycloadditon of two molecules of aplysinopsin
(￿￿￿￿, Fig. ￿￿-￿), a natural product which also has been isolated from the same stony coral.
However, all tubastrindoles have a very low optical purity; the absolute values of their optical
rotations ranging from ￿.￿ to ￿￿. This suggested that the dimers might be either artifacts formed
during isolation or a naturally occurring mixture of enantiomers in almost equal ratios.
Shortly after the report of tubastrindoles A–C (￿￿￿￿–￿￿￿￿), Mancini and co-workers published
two additional quasi-racemic bisindoles cycloaplysinopsin A (￿￿￿￿) and cycloaplysinopsin B
(￿￿￿￿, Fig. ￿￿-￿), isolated from tropical Indo-Pacific (Comoros, Philippines) scleractinian corals
of the family Dendrophylliidae.[￿￿￿] HR-EI-MS data showed an intense retro-Diels–Alder frag-
mentation signal, corresponding to the molecular ion of ￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿,
Fig. ￿￿-￿). This led again to the proposition, ￿￿￿￿ is derived from the Diels–Alder reaction
between two molecules of (E)-￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿), followed by a double bond
shift to establish the fused indole unit. However, attempts to form ￿￿￿￿ from synthetic (E)-￿￿￿￿
under non-enzymatic conditions were not successful. Therefore, the authors concluded that
a ‘Diels–Alderase’ enzyme an adventitious Diels–Alder catalyst present in the coral extracts
triggers the dimerization. ‘Diels–Alderase’ enzymes are discussed controversially about whether
nature uses the famous reaction to produce its own useful molecules. Some candidate natural
‘Diels–Alderases’ have been identified, but these have either been shown not to perform the
reaction, or the evidence that they catalyze a Diels–Alder reaction is ambiguous. Quite recently
Race and co-workers may have found the first real ‘Diels–Alderase’ enzyme in a bacterium called
Verrucosispora mari originated from the Pacific seabed.[￿￿￿]
Cycloaplysinopsin C (￿￿￿￿), a third aplysinopsin dimer, has been isolated from Tubastraea sp.
collected from the archipelago of the Hanish Islands in Yemen together with the known alkaloids
aplysinopsin (￿￿￿￿) and ￿-bromo-￿’oxo-aplysinopsin (￿￿￿￿) by Meyer and co-workers.[￿￿￿]
The study of the secondary metabolites produced by the marine sponge Smenospongia cere-
briformis has led to the isolation of two new bisindoles, dictazolines A (￿￿￿￿) and B (￿￿￿￿,
Fig. ￿￿-￿).[￿￿￿] Once again, the HR-EI-MS data of ￿￿￿￿ showed an intense signal corresponding
to a retro-Diels–Alder aplysinopsin unit similar to the results of Mancini et al.[￿￿￿]
In early ￿￿￿￿, the proposed biosynthetic origins of the aplysinopsin dimers took another twist.
Further investigation of the extract of Smenospongia cerebriformis yielded three more bisindoles
dictazolines C–E (￿￿￿￿–￿￿￿￿), along with the structurally unique cyclobutyl-containing bisin-
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doles dictazoles A and B, ￿￿￿￿ and ￿￿￿￿, respectively.[￿￿￿] Using Baran’s pioneering biomimetic
total synthesis of ageliferin from the cyclobutane sceptrin as a guide,[￿￿￿] Williams et al. suggested
that the dictazoles are possible precursors to the corresponding dictazolines.[￿￿￿] Specifically, it is
assumed that dictazole A (￿￿￿￿) can be converted to dictazoline C (￿￿￿￿) via the vinylcyclobutane
rearrangement,[￿￿￿] as outlined in Scheme ￿￿-￿. Based on the work of Baran et al., pure dictazole
A (￿￿￿￿) was exposed to microwave irradiation at ￿￿￿ °C in water for ￿min. A significant amount
of dictazoline C (￿￿￿￿) was detected by LC-MS along with three monomeric aplysinopsins, which
presumably arose from a retro-Diels–Alder reaction of ￿￿￿￿. Due to the limited isolated amount
of ￿￿￿￿, the yield of this transformation has not been optimized, and the products have not been
characterized by NMR.
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￿￿.￿ Investigations on the Synthesis of Cycloaplysinopsin A
Although the conclusions of Williams and co-workers are quite remarkable, they have led to
even more unanswered questions. No work has been done for the conversion of the monomeric
aplysinopsins to the corresponding cyclobutane dimer in a [￿+￿]-process. In addition, it is still
unclear if the proposed vinylcyclobutane rearrangement to the cyclohexenyl dimer renders the
Diels–Alder proposal obsolete, or if there is a biosynthetic cycle which includes more than one
defined pathway (Scheme ￿￿-￿).
This work focuses on the attempts to the synthesis of cycloaplysinopsin A (￿￿￿￿) since it is one
of the most simple aplysinopsin dimers: the indole core is not halogenated and it possesses two
identical spiro-￿,￿-dimethylhydantoin moieties. The handling of hydantoin derivatives is more
facilely than their diimino derivatives which possess a guanidine moiety. Careful consideration
leads to the result that in the case of a potential Diels–Alder pathway as well as in the case of a
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potential [￿+￿]-pathway the product should derive from the same two identical (E)-configured
aplysinopsin monomers (Schemes ￿￿-￿ and ￿￿-￿). In this case the aplysinopsin derivative is the
known isolated alkaloid ￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿, Fig. ￿￿-￿).
￿￿.￿.￿ Synthetic Work
The crucial compound which is required for an examination of both compelling biosynthetic
pathways (Scheme ￿￿-￿) through chemical synthesis is ￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿). In
the first retrosynthetic approach ￿￿￿￿ derives from ￿-acylindole ￿￿￿￿ via reduction–elimination
sequence. The formation of the ￿-acylindole ￿￿￿￿ should be achieved via photochemically
induced Wol￿ rearrangement of ￿-diazo-￿,￿-dimethylbarbituric acid (￿￿￿￿).
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Cyclic diazo compound ￿￿￿￿ was readily prepared by the diazotransfer reaction of N,N-dime-
thylbarbituric acid (￿￿￿￿) withmethanesulfonyl azide in acetonitrile in ￿￿%yield (Scheme ￿￿-￿).[￿￿￿]
Irradiation of ￿￿￿￿ in ethanol at l = ￿￿￿ nm did not induce a Wol￿ rearrangement and only
starting material was recovered. However, irradiation of ￿￿￿￿ in ethanol at l = ￿￿￿ nm for
￿.￿ h under aerobic conditions yielded hydantoin ￿￿￿￿ via ketene ￿￿￿￿ in ￿￿% yield.[￿￿￿] But
the repetition of this sequence with ethyl mercaptan instead of ethanol reduced the yield of
hydantoin ￿￿￿￿ drastically and the use of diethylamine furnished hydantoin ￿￿￿￿ only in traces.
Finally, the use of indole as a nucleophile was not successful at all; neither an irradiation at l =
￿￿￿ nm in aprotic solvents (acetonitrile, diethyl ether, dioxane) nor the use of metal catalysis
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(silver benzoate and/or silver trifluoroacetate, with ultrasonic or in the presence of a weak base)
furnished ￿-acylindole ￿￿￿￿. Since the route via the Wol￿ rearrangement was not prosperous, a
di￿erent strategy for the synthesis of aplysinopsin derivative ￿￿￿￿ was taken into account.
The new approach allows a quick access to aplysinopsin derivatives like ￿￿￿￿ or the known
aplysinopsin monomer ￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿). For this, ￿-methylhydantoin (￿￿￿￿)
was transformed with N,N-dimethylformamide dimethyl acetal into (E)-￿-((dimethylamino)me-
thylene)-￿-methylhydantoin (￿￿￿￿) in ￿￿% yield (Scheme ￿￿-￿). This compound was then
coupled with indole under acidic conditions to furnish aplysinopsin derivative ￿￿￿￿ in ￿￿%
yield. In addition, ￿-methylhydantoin (￿￿￿￿) was transformed to ￿,￿-dimethylhydantoin (￿￿￿￿)
with iodomethane in the presence of K￿CO￿ in DMF at ￿￿ °C for ￿￿ h.
[￿￿￿] Repetition of the
reaction sequence using N,N-dimethylformamide dimethyl acetal followed by indole led to
￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿) in ￿￿% overall yield. No attempts to optimize the overall
yields of this sequence were made. Both ￿￿￿￿ and ￿￿￿￿ are characteristically bright yellow solids.
With aplysinopsin derivatives ￿￿￿￿ and ￿￿￿￿ in hand, several experiments concerning the
[￿+￿]-products ￿￿￿￿ and ￿￿￿￿, respectively, or the [￿+￿]-products ￿￿￿￿ and ￿￿￿￿, respectively,
have been conducted (Tab. ￿￿-￿). In no case a [￿+￿]-product was obtained, not even in slight
amounts. No Diels–Alder product has been observed neither in refluxing toluene nor in refluxing
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Table ￿￿-￿. Conditions for the conversion of ￿￿￿￿ and ￿￿￿￿ into the [￿+￿]-products ￿￿￿￿ and ￿￿￿￿, respectively, or the [￿+￿]-
products ￿￿￿￿ and ￿￿￿￿, respectively.
# Compound Type Conditions Result
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] PhMe, ￿￿￿ °C, ￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] bromobenzene, ￿￿￿ °C, ￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] DMSO, ￿￿￿ °C, ￿￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] BnOH, ￿￿￿ °C, ￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] diethylene glycol, ￿￿￿ °C, ￿￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] hv (￿￿￿ nm), PhH, ￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] hv (￿￿￿ nm), PhH, ￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] hv (￿￿￿ nm), acetone, ￿ h —
￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] Ledwith–Weitz salt (￿￿mol-%), CH￿Cl￿, ￿ °C ￿￿￿￿: decomp., ￿￿￿￿: —
￿￿ ￿￿￿￿, ￿￿￿￿ [￿+￿] Ledwith–Weitz salt (￿￿mol-%), DMSO, ￿ °C ￿￿￿￿: decomp., ￿￿￿￿: —
bromobenzene nor in refluxing DMSO nor in refluxing benzyl alcohol. Even after treatment of
compound ￿￿￿￿ for ￿￿ h in refluxing diethylene glycol (￿￿￿°C !) quantitative amounts of starting
material have been recovered. The [￿+￿] experiments merely proved the high stability of these
compounds.
For the construction of [￿+￿]-products ￿￿￿￿ and ￿￿￿￿ the aplysinopsin derivatives ￿￿￿￿ and
￿￿￿￿ were irradiated at di￿erent wavelengths (￿￿￿ nm, ￿￿￿ nm) and in di￿erent solvents
(benzene, acetone). However, no formation of any [￿+￿]-product could be observed under these
conditions and starting materials were completely recovered in all cases.
N
Br
BrBr
SbCl6
Ledwith–Weitz salt (￿￿￿￿)
Final attempts for the formation of the cyclobutane included
radical-cation cycloadditions using the Ledwith–Weitz salt (￿￿￿￿).[￿￿￿]
Stable cation radical salts were first isolated in ￿￿￿￿ (Wurster’s Red
and Blue).[￿￿￿] However, it took some decades to descry the true na-
ture of these salts asmonomeric species possessing both an unpaired
electron and a single unit of positive charge.[￿￿￿] These reagents are
often used for radical-cation cyclodimerizations of electron-rich di-
enes and radical-cation Diels–Alder reactions of these dienes with electron-rich olefins.[￿￿￿] A
reactivity umpolung of the electron-rich diene via cation radical formation provides an e￿ective
and direct remedy for the absence of electron deficiency in these dienic systems. Despite the
beneficial characteristics of these cation radical salts, the application in total synthesis is very rare.
A recent use was in the total syntheses of kingianins A and D by the group of M. S. Sherburn.[￿￿￿]
Reaction of aplysinopsin derivative ￿￿￿￿ with ￿￿￿￿ (￿￿ mol-%) at ￿ °C led to decomposition
both in CH￿Cl￿ and DMSO. Repetition with ￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿) was also not
successful; no reaction took place and the starting material was completely recovered. No further
attempts were made to achieve the dimer formation of aplysinopsin derivatives.
￿￿￿
￿￿ Cycloaplysinopsin A
￿￿.￿ Experimental
￿-Diazo-￿,￿-dimethylpyrimidine-￿,￿,￿(￿H,￿H,￿H)-trione (￿￿￿￿).
MeN NMe
OO
O
N2
￿￿￿￿
￿,￿-dimethylbarbituric acid (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was added to a flame-
dried Schlenk tube. The reaction vessel was evacuated and flushed with argon.
MeCN (￿￿.￿ml) was added and after complete dissolution of the starting material
MsN￿ (￿.￿ml, ￿￿.￿mmol, ￿.￿ eq.) was added dropwise followed by Et￿N (￿.￿ml,
￿￿.￿ mmol, ￿.￿ eq.) and stirring was continued under Argon atmosphere for
￿ h at ambient temperature (monitored by TLC). The mixture was diluted with
￿￿% aq. NaOH and extracted thrice with CH￿Cl￿ (￿￿￿ ml). The combined organic extracts
were dried over MgSO￿ and concentrated in vacuo to yield crude diazo compound ￿￿￿￿. After
recrystallization from benzene diazo compound ￿￿￿￿ was obtained as yellow solid (￿.￿￿ g,
￿.￿￿ mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿, UV active).
￿H NMR (￿￿￿ MHz,
CDCl￿) d = ￿.￿￿ (s, ￿H) ppm.
￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm.
HRMS (ESI): calcd. for C￿H￿N￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Notes: (i) Caution! Although I have never had any trouble with mesyl azide, it is potentially explosive!
(ii) This reaction can also be done using p-ABSA instead of MsN￿ yielding the same product over night
with slightly diminished yield (￿￿%).
Ethyl ￿,￿-dimethyl-￿,￿-dioxoimidazolidine-￿-carboxylate (￿￿￿￿).
MeN
NMe
O
CO2Et
O
￿￿￿￿
A flame dried quartz vessel was charged with a solution of diazo compound ￿￿￿￿
(￿￿.￿mg, ￿￿.￿ ￿mol) in dry EtOH (￿￿ml). The vessel was flushed with air and
then suspended horizontally under a UV lamp (Benda, ￿ × ￿ W, ￿￿￿ nm). The
mixture was irradiated for ￿￿￿min at room temperature and turned pale yellow
in the course of time. TLC analysis showed complete consumption of starting
material. The solvent was removed in vacuo to yield dioxoimidazolidine ￿￿￿￿ as a pale yellow
oil (￿￿.￿ mg, ￿￿.￿ ￿mol, ￿￿% yield) which was analytically pure according to NMR. Rf = ￿.￿￿
(hexanes–EtOAc, ￿.￿:￿). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (t, J = ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿N￿O￿ [M + H]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(E)-￿-((Dimethylamino)methylene)-￿-methylimidazolidine-￿,￿-dione (￿￿￿￿).
Me
N O
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￿￿￿￿
A mixture of ￿-methylhydantoin (￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.), N,N-
dimethylformamide dimethyl acetal (￿￿%, ￿.￿￿ g, ￿.￿ ml, ￿￿.￿ mmol,
￿.￿ eq.), and dry acetonitrile (￿￿￿ml) was heated under reflux for ￿.￿ h. The
mixture was cooled down to ambient temperature and volatile components
were evaporated in vacuo to obtain a yellow oil which was triturated with
chloroform–hexanes (￿:￿, ￿￿￿ml). The precipitate was collected by filtration and washed with
￿￿￿
￿￿.￿ Experimental
chloroform–hexanes (￿:￿). Final drying under high vacuum yielded title compound ￿￿￿￿ as
white solid (￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿.￿:￿).
￿HNMR (￿￿￿MHz,
DMSO–d￿) d = ￿￿.￿￿ (br s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. IR (neat): ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿H￿￿N￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(E)-￿-((￿H-Indol-￿-yl)methylene)-￿-methylimidazolidine-￿,￿-dione (￿￿￿￿).
Me
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H
￿￿￿￿
Hydantoin ￿￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) and indole (￿￿￿ mg,
￿.￿￿mmol, ￿.￿ eq.) were dissolved in acetic acid (￿￿ml) and heated
under reflux for ￿.￿ h. The mixture was cooled down to ambient
temperature and volatile components were evaporated in vacuo. The
residue was triturated with ethanol and the precipitate was collected
by filtration. Final drying under high vacuum yielded aplysinopsin derivative ￿￿￿￿ as yellow
solid (￿￿￿.￿mg, ￿.￿￿mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark blue with
Ehrlich’s reagent). ￿H NMR (￿￿￿ MHz, DMSO) d = ￿￿.￿￿ (s, ￿H), ￿￿.￿￿ (s, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (dtd, J = ￿￿.￿, ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, DMSO–d￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿￿H￿￿N￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿,￿-Dimethylimidazolidine-￿,￿-dione (￿￿￿￿).
Me
N O
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O
￿￿￿￿
To a suspension of ￿-methylhydantoin (￿.￿￿ g, ￿￿mmol, ￿.￿ eq.) and K￿CO￿ (￿.￿￿ g,
￿￿mmol, ￿.￿ eq.) in abs. DMF (￿￿ml) was added MeI (￿.￿ml, ￿￿mmol, ￿.￿ eq.)
and the resulting mixture was stirred at ￿￿ °C for ￿￿ h. The reaction was quenched
by the addition of ￿.￿ ￿ HCl (￿￿￿ ml) and extracted thrice with EtOAc (￿￿￿ ml).
The combined organic layers were washed once with brine, dried over MgSO￿
and concentrated in vacuo. Purification by flash column chromatography (hexanes–EtOAc,
￿:￿) furnished ￿,￿-dimethylimidazolidine-￿,￿-dione (￿￿￿￿) as yellow oil (￿￿￿ mg, ￿.￿ mmol,
￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (s, ￿H),
￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿N￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
(E)-￿-((Dimethylamino)methylene)-￿,￿-dimethylimidazolidine-￿,￿-dione (￿￿￿￿).
Me
N O
NMe
O
Me2N
￿￿￿￿
￿,￿-Dimethylhydantoin (￿￿￿￿, ￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in
absolute MeCN (￿.￿ml), N,N-dimethylformamide dimethyl acetal (￿.￿ml,
￿.￿￿mmol, ￿.￿ eq.) was added and the resulting mixture was heated under
reflux for ￿.￿ h and then additional ￿￿.￿ h at ￿￿ °C. The mixture was cooled
down to ambient temperature and volatile components were evaporated
￿￿￿
￿￿ Cycloaplysinopsin A
in vacuo to obtain a yellow oil (￿￿￿mg, ￿.￿￿mmol, ￿￿% crude yield) which was used without
purification in the next step. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
(E)-￿-((￿H-Indol-￿-yl)methylene)-￿,￿-dimethylimidazolidine-￿,￿-dione (￿￿￿￿).
Me
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￿￿￿￿
Crude hydantoin ￿￿￿￿ (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was dissolved in
glacial acetic acid (￿￿.￿ml) and indole (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.)
was added in one portion. The resulting mixture was heated under
reflux for ￿.￿ h. The mixture was cooled down to ambient tempera-
ture and volatile components were evaporated in vacuo. The residue
was triturated with ethanol and the precipitate was collected by filtration. Final drying under
high vacuum yielded ￿’-deimino-￿’-oxaplysinopsin (￿￿￿￿, ￿￿￿ mg, ￿￿￿ ￿mol, ￿￿% yield) as a
characteristic bright yellow solid. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿, stains dark blue with Ehrlich’s
reagent). ￿H NMR (￿￿￿ MHz, DMSO) d = ￿￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm.
￿￿C NMR (￿￿￿MHz, DMSO–d￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿￿￿
￿￿Dihydroarcyriacyanin A
￿￿.￿ Bisindolylmaleimide Alkaloids
Arcyriacyanin A (￿￿) is a bisindolylmaleimide alkaloid from Arcyria nutans.[￿￿] It is a cytotoxic
compound and inhibits protein kinase C and protein tyrosine kinase.[￿￿,￿￿] The green-blue
bisindolylmaleimide is both a cyclohepta[b]indole and a cyclohepta[cd]indole and its structure
can be formally derived from arcyriarubin A (￿￿￿￿) by connecting the two indoles at C-￿ • and C-￿’
• (Scheme ￿￿-￿). It is isomeric to arcyriaflavin A (￿￿￿￿). The possible biosynthetic relationships
of the Arcyria compounds are pretty apparent: it can be assumed that arcyriarubin A (￿￿￿￿) may
be oxidatively cyclized either to arcyriaflavin A (￿￿￿￿) or to arcyriacyanin A (￿￿), depending on the
conformation of the starting compound (Scheme ￿￿-￿). The precursor of all Arcyria compounds
is dihydroarcyriarubin A (￿￿￿￿) which is initially formed from two molecules of tryptophan.
Double dehydrogenation would lead to either the intermediate ￿￿￿￿ or intermediate ￿￿￿￿ via
arcyriarubin A (￿￿￿￿) and subsequently via electrocyclic ring closure followed by sigmatropic
￿,￿-hydrogen shifts to either the arcyriaflavins or the arcyriacyanin pigments ￿￿ and ￿￿￿￿.
The cis-dihydro modification dihydroarcyriacyanin A (￿￿) has been found in the yellow spo-
rangia of Arcyria nutans[￿￿] and recently in the fruiting bodies of Arcyria denudate and Arcyria
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Scheme ￿￿-￿. u bisindolylmaleimide alkaloids: arcyriacyanin A (￿￿), dihydroarcyriacyanin A (￿￿), arcyriarubin A (￿￿￿￿), and arcyri-
aflavin A (￿￿￿￿).
￿￿￿
￿￿ Dihydroarcyriacyanin A
N
H
N
H
H
N OO
N N
H
N OO
N
N
H
N OO
N
H
N
H
H
N OO
HH
N N
H
N OO
H H
N
N
HN
O
O
H
H
– 2H
– 2H
– 
2H
[1,5] H
[1,5] H
￿￿￿￿
￿￿￿￿ ￿￿￿￿ ￿￿￿￿
￿￿
￿￿￿￿ ￿￿￿￿
￿￿￿￿
Scheme ￿￿-￿. Biosynthesis of the Arcyria compounds.
obvelata collected at Ko¯chi Prefecture, Japan.[￿￿] It exhibits cytotoxic activity against Jurkat cells
with an IC￿￿ value of ￿.￿ ￿g/ml.
Arcyriacyanin A (￿￿) has been synthesized twice in the late ￿￿￿￿s by the groups of Steglich
and Tobinaga, respectively.[￿￿,￿￿] Both strategies rely on palladium catalyzed cross-coupling
reactions. In the synthesis of the Steglich group, N-Boc-indole is stannylated at C￿ to yield ￿￿￿
(Scheme ￿￿-￿). ￿,￿’-Bisindole ￿￿￿ is obtained via Stille coupling of the generated stannylindole
￿￿￿ with N-tosyl-￿-bromoindole followed by removal of the N-protecting groups. Finally, ￿,￿-
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Scheme ￿￿-￿. Synthesis of arcyriacyanin A (Steglich, ￿￿￿￿). Reagents and conditions: a) LDA, THF, –￿￿ °C, ￿ h, then Me￿SnCl,
–￿￿ °C  rt, ￿￿%. b) N-tosyl-￿-bromoindole, PhMe, ￿￿ °C, Pd(PPh￿)￿, ￿￿ h, ￿￿% c) EtOH, ￿￿ °C, ￿￿% NaOH, ￿ h,
￿￿%. d) EtMgBr (￿.￿ eq.), THF, rt., then PhMe, ￿￿￿ °C, ￿,￿-dibromomaleimide, ￿ h, ￿￿%.
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￿￿￿ ￿￿￿ ￿￿￿ arcyriacyanin A (￿￿)
Scheme ￿￿-￿. Synthesis of arcyriacyanin A (Tobinaga, ￿￿￿￿). Reagents and conditions: a) nBuLi, THF, –￿￿ °C, ￿￿ min, then Et￿B,
–￿￿ °C, ￿￿ min, then PdCl￿(PPh￿)￿ (￿ mol %), N-(tert-butyldimethylsilyl)-￿-iodoindole, D, ￿ h, ￿￿%. b) TBAF, THF,
￿ h, rt., ￿￿%. c) Pd/C, MeOH, H￿ (￿ atm), ￿ h, ￿￿%. d) MeMgBr, PhH, rt., ￿￿ min, N-(tert-butyldimethylsilyl)-￿,￿-
dibromomaleimide, D, ￿ h, ￿￿%. e) TBAF, THF, rt., ￿ h, quant.
￿￿￿
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dibromomaleimide reacts with the bisbromomagnesium salt of ￿￿￿ under refluxing conditions
to furnish arcyriacyanin A (￿￿) in ￿￿% overall yield. The synthesis of Tobinaga et al. has basically
the same final step but ￿,￿’-bisindole ￿￿￿ is built up in a di￿erent fashion (Scheme ￿￿-￿). N-
Methoxyindole is converted into triethyl-(￿-methoxyindole-￿-yl)borate and undergoes a Suzuki
coupling with N-(tert-butyldimethylsilyl)-￿-iodoindole to yield bis-N-protected ￿,￿’-bisindole ￿￿￿
which in turn is converted into ￿,￿’-bisindole ￿￿￿ in two additional steps.
￿￿.￿ Aims
A small amount of time was spent on the total synthesis of dihydroarcyriacyanin A (￿￿). Techni-
cally, this molecule is not very challenging in a chemical point of view. Especially since already
two groups have synthesized arcyriacyanin A (￿￿) using the obvious synthons which were cou-
pled via palladium catalyzed cross-coupling reactions (Section ￿￿.￿). At the beginning of my
work towards the synthesis of cyclohepta[b]indoles an interesting reactivity was observed in
our group by my co-workers. Oxindole ￿￿￿ could be transformed into Fischer’s base derivative
￿￿￿ which in turn is a divinylcyclopropane system (Scheme ￿￿-￿). Although the yields were
exceedingly low for this transformation, upon heating ￿￿￿ underwent smoothly a divinylcyclo-
propane rearrangement to yield cyclohepta[b]indole ￿￿￿. By reason of very low yields the work
towards the cyclohepta[b]indoles via Fischer’s base derivatives was discontinued. However, when
oxindole ￿￿￿ was refluxed in high-boiling-point solvents, stereochemical scrambling at the cyclo-
propane moiety occurred (equilibrium between ￿￿￿ and ￿￿￿). As a result the vinyl moiety has
the correct geometry for a potential Cope rearrangement with the aromatic indole core. Indeed,
the divinylcyclopropane rearrangement took place yielding cyclohepta[cd]indolone ￿￿￿. This
transformation provided both the first experimental evidence for a possible enzyme-catalyzed
sigmatropic process in the C-￿ prenylation of indole alkaloids and the first direct C-C-bond
forming cyclization which functionalizes the very unreactive C-￿ indole position .[￿￿￿]
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Scheme ￿￿-￿. Intended synthesis of dihydroarcyriacyanin A (￿￿): simultaneous construction of both a cyclohepta[b]indole and a
cyclohepta[cd]indole via the divinylcyclopropane rearrangement.
To cut a long story short, depending on the stereochemistry of the vinyl group at the cyclopropyl
moiety it is possible to construct both cyclohepta[b]indoles and cyclohepta[cd]indoles. The
ultimate proof of concept would be the short total synthesis of dihydroarcyriacyanin A (￿￿) as
outlined in Scheme ￿￿-￿.
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Figure ￿￿-￿. Di￿erent view of divinylcyclopropane
￿￿￿￿: ￿￿￿￿a yields in a cyclohepta[b]indole and
￿￿￿￿b furnishes a cyclohepta[[cd]indole.
It was planned to cyclopropanate the double bond
of the maleimide moiety of ￿￿￿￿. For this purpose,
a carbene equivalent like ￿￿￿￿ is required. Once
the cyclopropanation took place the two diastere-
omers ￿￿￿￿ and ￿￿￿￿ are expected to be formed of
which only cis-configured divinylcyclopropane ￿￿￿￿
is suitable for a [￿,￿] sigmatropic rearrangement.
As depicted in Fig. ￿￿-￿, two di￿erent seven mem-
bered rings are formed simultaneously; whereas
the labeled divinylcyclopropane ￿￿￿￿a leads to a cyclohepta[b]indole the labeled divinylcyclo-
propane ￿￿￿￿b furnishes the cyclohepta[cd]indole. The success of this reaction would be a great
proof of concept of the methodologies which were developed by myself and co-workers.
￿￿.￿ Synthetic Work
￿￿.￿.￿ Synthesis of the Cyclopropanation Precursor
Building block ￿￿￿￿ is pretty simple and requires no explanation in extenso. It is simple ac-
cessible via the reaction of indole with maleimide followed by dehydrogenation with DDQ
(Scheme ￿￿-￿).[￿￿￿–￿￿￿] The reaction rate could be increased enormously by changing the solvent
from ￿,￿-dioxane to ethyl acetate (￿￿ h vs. ￿￿min) in the latter reaction.[￿￿￿]
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Scheme ￿￿-￿. Synthesis of ￿-(￿-indolyl)maleimide (￿￿￿￿).
￿￿.￿.￿ Synthesis of the Carbene Precursor
Diazo compounds are used as precursors to carbenes, which are generated by thermolysis,
photolysis, or transformation into the corresponding metal-carbenoids. For this reason several
diazo compounds have been prepared (Scheme ￿￿-￿). Diazoisatin (￿￿￿￿) is a popular building
block and has been employed in several syntheses as carbene precursor viametal carbenoids.[￿￿￿]
It is easy accessible from isatin in a short two-step procedure via the isatin-￿-N-tosylhydrazone
in ￿￿% yield.[￿￿￿] The N-Boc derivative of ￿￿￿￿ has also been prepared (￿￿￿￿). In addition, it
was assumed that ￿-diazo-￿H-indole-￿-carboxylate (￿￿￿￿) could also act as a substrate since it is
isoelectronic with a-diazocarbonyl compounds.[￿￿￿] It is easily prepared by dropwise addition of
glacial acetic acid to a mixture of ethyl indole-￿-carboxylate (￿￿￿￿) and sodium nitrite. Although
diazoisatin (￿￿￿￿) is known for its great stability,[￿￿￿] diazo compound ￿￿￿￿ is known to decom-
pose considerable exothermically when heated over ￿￿￿ °C. Albeit the frequent use of diazo
compounds in cyclopropanation reactions these reaction works best with electron-rich olefins.
The cyclopropanation of electron-deficient double bonds usually requires di￿erent reagents, i.e.,
sulfur ylides. For this reason it was tried to synthesize sulfoxonium compounds ￿￿￿￿ and ￿￿￿￿,
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Scheme ￿￿-￿. Syntheses of di￿erent carbene precursors and sulfur ylides, respectively.
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￿￿ Dihydroarcyriacyanin A
and sulfonium compound ￿￿￿￿. Apparently, ￿-sulfoxonium-oxindoles or ￿-sulfonium-oxindoles
are not literature known since no data was found to be available by a SciFinder® search. And
indeed, although the synthesis of sulfoxonium ylides from a-diazo compounds is known under
photochemical or metal catalysis conditions,[￿￿￿,￿￿￿] no reaction took place in the case of dia-
zoisatins ￿￿￿￿ and ￿￿￿￿. Also the synthesis of sulfonium ylide ￿￿￿￿ from a-bromo amide ￿￿￿￿
(accessible from indole-￿-carbaldehyde with two equivalents of NBS in tert-butanol along with
its dibromo compound in a ￿:￿ ratio) was not successful using several di￿erent conditions
which were also used before for the generation of other sulfonium and sulfoxonium compounds
starting from a-bromo carbonyl compounds. Therefore, only diazo compounds were used for
further work.
￿￿.￿.￿ Cyclopropanation of Maleimide ￿￿￿￿
The cyclopropanation of arylmaleimide derivatives is known and is especially used in the pharma-
ceutical area.[￿￿￿,￿￿￿] In almost all cases the cyclopropanation is based on the Johnson–Corey–Chay-
kovsky reaction and cyclopropanation of maleimide derivatives using diazo compounds is very
rare and only two examples are known.[￿￿￿f,￿￿￿a] In both cases metal carbenoid complexes are
avoided and a Kishner cyclopropane synthesis[￿￿￿b] is used instead. Having this literature results
in hands, diazoisatins ￿￿￿￿ and ￿￿￿￿ were refluxed in toluene with maleimide derivative ￿￿￿￿
but no reaction took place even after ￿￿ h (Scheme ￿￿-￿). Changing the solvent to xylene did
not change this result; cyclopropanation products ￿￿￿￿ or ￿￿￿￿ could never be observed. Using
the N-Boc derivative ￿￿￿￿ led to formation of remarkable amounts of ￿￿￿￿ by loss of the Boc
group. The attempt to form a copper carbenoid with anhydrous cupric sulfate in refluxing
hexanes yielded only in the formation of little amounts of the corresponding dimers of the
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￿￿￿
￿￿.￿ Experimental
diazo compounds. However, cyclopropanation products ￿￿￿￿ or ￿￿￿￿ could never be observed.
The same results were obtained when diazo compound ￿￿￿￿ was used instead. In addition,
cyclopropanation via a rhodium carbenoid was also not successful so that any further attempts
were discontinued at that point.
￿￿.￿ Experimental
￿-(￿H-Indol-￿-yl)pyrrolidine-￿,￿-dione (￿￿￿￿).
N
H
H
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O
O
￿￿￿￿
A mixture of indole (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) and maleimide (￿.￿￿ g,
￿￿.￿ mmol, ￿.￿ eq.) was dissolved in glacial acetic acid (￿￿ ml) and stirred
at ￿￿￿ °C for ￿ d in a sealed tube (monitored by TLC). The reaction mixture
was allowed to cool down to ambient temperature and the volatile compo-
nents were evaporated in vacuo. The crude residue was purified by flash
column chromatography (hexanes–EtOAc, ￿:￿   ￿:￿) to obtain pure title
compound ￿￿￿￿ as an orange solid (￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿). ￿HNMR (￿￿￿MHz, DMSO) d = ￿￿.￿￿ (s, ￿H), ￿￿.￿￿ (s, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (dd, J = ￿￿.￿, ￿.￿Hz, ￿H) ppm.
HRMS (ESI): calcd. for C￿￿H￿￿N￿O￿ [M +H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-(￿H-Indol-￿-yl)-￿H-pyrrole-￿,￿-dione (￿￿￿￿).
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￿￿￿￿
Pyrrolidinedione ￿￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in anhydrous
ethyl acetate (￿￿￿ ml). ￿,￿-Dichloro-￿,￿-dicyano-￿,￿-benzoquinone (￿.￿￿ g,
￿￿.￿mmol, ￿.￿ eq.) was added in one portion at ambient temperature and
stirring was continued at this temperature for ￿￿min (monitored by TLC). The
reaction was extracted twice with aq. sodium sulfite (￿￿%, ￿￿￿ml) and once
with brine (￿￿￿ ml). The combined organic layers were dried over Na￿SO￿
and volatile components were evaporated in vacuo. Purification by flash column chromatography
furnished title compound ￿￿￿￿ as a bright red solid (￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield) which yields
a bright yellow solution when dissolved in DMSO or chloroform. Rf = ￿.￿￿ (hexanes–EtOAc,
￿:￿, bright yellow spot on TLC, visible without stain or UV light). ￿H NMR (￿￿￿MHz, DMSO)
d = ￿￿.￿￿ (s, ￿H), ￿￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (d, J =
￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, DMSO–d￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿N￿NaO￿ [M + Na]
+
￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
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￿￿ Dihydroarcyriacyanin A
￿-Diazoindolin-￿-one (￿￿￿￿).
N
H
O
N2
￿￿￿￿
Isatin (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in abs. THF (￿￿ ml). Tosyl
hydrazide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added and the reaction mixture was
stirred ￿￿min at ￿￿ °C, then it was allowed to cool down to ambient temperature
and was filtered through a medium porosity sintered-glass funnel. The solid
was repeatedly rinsed with THF, then taken up in ￿.￿ ￿ NaOH (￿￿￿ml), and
stirred ￿￿min at ￿￿ °C. The reaction mixture was extracted thrice with EtOAc and the combined
organic layers were dried over MgSO￿. Volatile components were evaporated in vacuo and
the residue was recrystallized from acetone to give diazo compound ￿￿￿￿ as red solid (￿.￿￿ g,
￿.￿￿mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿
(s, ￿H), ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿ Hz, ￿H),
￿.￿￿ (d, J = ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿.￿ (C––N￿, very weak) ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿ (C––N￿), ￿￿￿￿, ￿￿￿￿,
￿￿￿￿, ￿￿￿￿ cm–￿. HRMS (ESI): calcd. for C￿H￿N￿NaO [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
tert-Butyl ￿-diazo-￿-oxoindoline-￿-carboxylate (￿￿￿￿).
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O
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￿￿￿￿
Diazoisatin ￿￿￿￿ (￿￿￿ mg, ￿.￿￿ mmol, ￿.￿ eq.) was dissolved in abs. THF
(￿￿.￿ml) and cooled to ￿ °C. Boc￿O (￿￿￿mg, ￿.￿￿mmol, ￿.￿ eq.) was added in
one portion followed by the addition of DMAP (￿￿.￿mg, ￿￿￿ ￿mol, ￿.￿ eq.). The
reaction was stirred ￿min at ￿ °C, then the ice bath was removed and stirring
was continued at ambient temperature for additional ￿￿ min (monitored by
TLC). Volatile components were evaporated in vacuo and the crude residue was purified by flash
column chromatography (hexanes–EtOAc, ￿:￿) to furnish N-Boc protected diazoisatin ￿￿￿￿
as a brown solid (￿￿￿ mg, ￿.￿￿ mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿ MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm.
￿￿C NMR
(￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿ (C––N￿,
very weak), ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found
￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Ethyl ￿-diazo-￿H-indole-￿-carboxylate (￿￿￿￿).
N
CO2Et
N2
￿￿￿￿
Ethyl indole-￿-carboxylate (￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in
anhydrous CH￿Cl￿ (￿￿￿ ml) and cooled to ￿ °C. Sodium nitrite (￿￿.￿ g,
￿￿￿mmol, ￿.￿ eq.) was added in portions followed by dropwise addition
of glacial acetic acid over ￿￿ min (inner temp. < ￿ °C). After complete
addition the ice bath was removed and stirring was continued at ambient temperature. Although
lots of precipitate has been already formed after ￿￿min, the reaction was stirred ￿￿ h in total
(monitored by TLC). After ￿￿ h, two additional equivalents of sodiumnitrite and glacial acetic acid,
￿￿￿
.￿ Experimental
respectively, were added to the reactionmixture. The reaction was poured into water (￿￿￿ml) and
the layers were separated. The aqueous layer was extracted two additional times with CH￿Cl￿
(￿￿ml). The combined organic layers were extracted once with bicarb (￿￿￿ml) and dried over
Na￿SO￿. Volatile components were evaporated in vacuo and the crude residue was purified by
flash column chromatography (hexanes–EtOAc, ￿:￿  ￿:￿) to yield diazo compound ￿￿￿￿ as
a pale yellow solid (￿.￿￿ g, ￿￿.￿ mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿ MHz, C￿D￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J =
￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t, J =
￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, C￿D￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. ￿H NMR
(￿￿￿MHz, DMSO) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (t,
J = ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿N￿O￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
Note: Caution! Studies indicate considerable exothermic decomposition when the pale yellow crystalline
solid ￿￿￿￿ is heated over ￿￿￿ °C.
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AExperimental Part for Reagents
A.￿ General Methods
The general methods described in this section are also valid for all other experimental parts in
this thesis (Section ￿￿.￿, Section ￿￿.￿, Section ￿￿.￿, and Section ￿￿.￿).
All reactions were carried out in oven-dried glassware under an argon atmosphere, unless
otherwise stated. All reagents were obtained from commercial suppliers and were used without
further purification unless otherwise stated. Butyl refers to n-butyl and ether refers to diethyl
ether unless otherwise stated. The terms hexanes and petroleum ether are used equally unless
otherwise stated. Solvent mixtures were generally prepared in terms of volume ratios (v/v)
unless otherwise stated. In the context of work-up, NH￿Cl, NaCl, Na￿S￿O￿, and NaHCO￿ refer
to NH￿Cl (aq., sat.), NaCl (aq., sat.), Na￿S￿O￿ (aq., sat.) and NaHCO￿ (aq., sat.), respectively,
unless otherwise stated.
All solvents were distilled and/or dried prior to use by standard methodology except for those,
which were reagent grade. The applied petroleum ether fraction had a boiling point of ￿￿–￿￿ °C.
Anhydrous solvents were obtained as follows: THF, diethyl ether and toluene by distillation
from sodium and benzophenone; dichloromethane and chloroform by distillation from calcium
hydride. Absolute triethylamine and pyridine and diisopropylethylamine were distilled over
calcium hydride prior to use. Only tap water was used and aqueous solutions were prepared on
site. All other solvents were HPLC grade unless otherwise stated.
Reactions were stirred magnetically or mechanically and monitored by thin layer chromatogra-
phy with silica gelMerck® ￿￿-F￿￿￿ plates and visualized with ultraviolet radiation and by staining
with either aqueous acidic potassium permanganate, aqueous acidic ceriummolybdate, aqueous
acidic vanillin, aqueous acidic dinitrophenylhydrazine, ninhydrin or aqueous acetic dimethy-
laminobenzaldehyde solutions. Flash column chromatography was performed with silica gel
(￿.￿￿ – ￿.￿￿￿mm, ￿￿￿ – ￿￿￿mesh) under pressure. In some cases, alumina was used instead of
￿￿￿
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silica. Preparative thin layer chromatography was carried out using Macherey-Nagel, ADAMANT
UV￿￿￿, Glass plates, silica ￿￿. Yields refer to chromatographically and spectroscopically pure
compounds, unless otherwise stated.
Concerning the work-up, no volumina for the solvents and aqueous solutions are stated in
most cases unless it is important.
￿H, ￿￿C, DEPT, ￿H–￿H COSY, HMBC, HMQC, NOE, and NOESY NMR experiments were
recorded in CDCl￿, C￿D￿, MeOD, DMSO–d￿, pyridine–d￿, toluene–d￿, or acetone–d￿ using
either a Bruker Avance DPX-￿￿￿ (￿￿￿MHz), AV-￿￿￿ (￿￿￿MHz), DPX ￿￿￿ (￿￿￿MHz), Ascend
￿￿￿ Avance III HD (￿￿￿ MHz), or DPX ￿￿￿ (￿￿￿ MHz) using the residual CDCl￿ peak (dH =
￿.￿￿ ppm, dC = ￿￿.￿￿ ppm), C￿H￿ peak (dH = ￿.￿￿ ppm, dC = ￿￿￿.￿￿ ppm), (CD￿)￿CO peak (dH =
￿.￿￿ ppm, dC = ￿￿.￿, ￿￿￿.￿ ppm), MeCN peak (dH = ￿.￿￿ ppm, dC = ￿.￿, ￿￿￿.￿ ppm), and MeOH
peak (dH = ￿.￿￿ ppm, dC = ￿￿.￿￿ ppm) as an internal standard.
[￿￿￿] Chemical shift, d, is given
in parts per million (ppm) and coupling constants, J, are given in Hertz (Hz) (s = singlet, d =
doublet, t = triplet, q = quadruplet, p = pentett, m = multiplet, br = broad signal, or combination
of these acronyms). Assignments of proton resonances were confirmed, when possible, by
correlated spectroscopy.
NMR spectra were processed with Mestrelab Mnova ￿￿ and ￿￿. The baseline have been often
corrected or smoothed viaWhittaker Smoothing.[￿￿￿]
High-performance liquid chromatography, HPLC, was run on either AlphaChrom using an
AGILENT Prep SIL Scalat (￿.￿ ✓ ￿￿￿ mm, ￿ ￿m or ￿￿.￿ ✓ ￿￿￿ mm, ￿￿ ￿m) column or on a
Merck-Hitachi HPLC System (L-￿￿￿￿ pump, L-￿￿￿￿ autosampler, L-￿￿￿￿ UV-detector, D-￿￿￿￿
Interface), with HPLC grade solvents and using UV detection (l = ￿￿￿, ￿￿￿ nm) at ambient
temperature.
High Resolution Mass Spectra, HRMS, were recorded on a Waters Micromass LCT Premier
spectrometer (ESI).
IR measurements were carried out using Bruker Vector ￿￿.
Melting points were determined on OptiMelt MPA ￿￿￿ (Stanford Research Systems).
Compound names were either generated using ChemDraw®or looked up at catalogues of
chemical suppliers.￿
￿ In some cases the naming is not strict according to IUPAC and more friendly but still correct names were used,
e.g., “￿-iodoxybenzoic acid” instead of “￿-hydroxy-￿-oxo-￿l￿-benzo[d][￿,￿]iodaoxol-￿(￿H)-one”.
￿￿￿
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A.￿.￿ Sulfur Ylides and Precursors
(Ethoxycarbonylmethyl)dimethylsulfonium bromide (￿￿￿￿).[￿￿￿,￿￿￿]
Me2S OEt
OBr
￿￿￿￿
A mixture of ethyl bromoacetate (￿￿.￿ g, ￿￿.￿mmol ￿.￿￿ eq.) and dimethyl sul-
fide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) were stirred in ￿￿ml of anhydrous acetone for
￿￿ h at ambient temperature in the absence of light. The resultant precipitate
was filtered through a medium porosity sintered-glass funnel, washed with an
appropriate amount of cold acetone, and dried in vacuo for ￿￿ h to furnish sulfonium salt ￿￿￿￿
as white solid in quantitative yield. Rf = ￿.￿￿ (DCM–MeOH, ￿￿:￿). M.p. ￿￿ °C.
Note: Storage in the absence of light.
Ethyl ￿-(dimethyl-l￿-sulfaneylidene)acetate [ EDSA ] (￿￿￿￿).
Me2S
OEt
O
￿￿￿￿
Variant ￿: The sulfur ylide ￿￿￿￿ was prepared by stirring a suspension of sul-
fonium salt ￿￿￿￿ (￿.￿ eq.) and sodium hydride (￿￿% dispersion in mineral oil,
￿.￿ eq.) in anhydrous THF under an argon atmosphere at ambient temperature
for ￿.￿ h. The voluminous white precipitate (sodium bromide) was removed
by filtration using a Schlenk-frit and the filtrate was transferred to the relevant reaction mixture.
Variant ￿ (according to Payne): [￿￿￿] Sulfonium salt ￿￿￿￿ (￿.￿￿ g, ￿.￿￿ mmol) was dissolved in
￿.￿ml of anhydrous CH￿Cl￿ and the suspension was stirred at ￿ °C. Saturated aqueous potassium
carbonate solution (￿.￿ml) was added followed by ￿￿ ￿NaOH (￿.￿ml). The ice bath was removed
and the reaction mixture was stirred at ambient temperature for additional ￿￿min. The phases
were separated and the aqueous layer was extracted thrice with CH￿Cl￿. The combined organic
layers were dried over K￿CO￿ (￿￿min), filtered, and concentrated in vacuo to furnish ylide ￿￿￿￿
as a pale yellow solid (￿￿% crude yield) which usually was directly used in the next step. Rf =
￿.￿￿ (DCM–MeOH, ￿￿:￿).
Note: Storage is possible at –￿￿ °C in a sealed bottle under an argon atmosphere.
(Ethoxycarbonylmethyl)tetrahydrothiophenium bromide (￿￿￿￿).
S
OEt
O
Br
￿￿￿￿
A mixture of ethyl bromoacetate (￿￿.￿ g, ￿￿.￿mmol ￿.￿ eq.) and tetrahydro-
tiophene (￿￿.￿ml, ￿￿￿mmol, ￿.￿￿ eq.) were stirred in ￿￿ml of anhydrous
acetone for ￿￿ h at ambient temperature in the absence of light. The resultant
precipitate was filtered through a medium porosity sintered-glass funnel and
dried in vacuo for ￿￿ h to furnish sulfonium salt ￿￿￿￿ as white solid in almost quantitative yield.
Rf = ￿.￿￿ (DCM–MeOH, ￿￿:￿). M.p. ￿￿￿ °C (decomp.).
Note: Storage in the absence of light.
￿ The experimental procedures for the reagents have no strict order of listing but are grouped by similarity where
possible.
￿￿￿
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Ethyl ￿-(tetrahydro-￿l￿-thiophen-￿-ylidene)acetate (￿￿￿￿).
S
OEt
O
￿￿￿￿
Sulfonium salt ￿￿￿￿ (￿.￿￿ g, ￿.￿￿mmol) was dissolved in ￿.￿ml of anhydrous
CH￿Cl￿ and the suspension was stirred at ￿ °C. Saturated aqueous potassium
carbonate solution (￿.￿ml) was added followed by ￿￿￿NaOH (￿.￿ml). The ice
bath was removed and the reactionmixture was stirred at ambient temperature
for additional ￿￿min. The phases were separated and the aqueous layer was extracted thrice
with CH￿Cl￿. The combined organic layers were dried over K￿CO￿ (￿￿ min), filtered, and
concentrated in vacuo to furnish ylide ￿￿￿￿ as a white solid in quantitative yield which usually
was directly used in the next step. Rf = ￿.￿￿ (DCM–MeOH, ￿￿:￿). M.p. ￿￿ °C (decomp.).
￿HNMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (q, J = ￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. NMR spectra on page ￿￿￿.
Note: Storage is possible at –￿￿ °C in a sealed bottle under an argon atmosphere.
(tert-Butoxycarbonylmethyl)tetrahydrothiophenium bromide (￿￿￿￿).
S
OtBu
O
Br
￿￿￿￿
A mixture of ethyl bromoacetate (￿￿.￿ g, ￿￿.￿mmol ￿.￿ eq.) and tetrahydro-
tiophene (￿.￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) were stirred in ￿￿ ml of anhydrous
acetone for ￿￿ h at ambient temperature in the absence of light. The resultant
precipitate was filtered through a medium porosity sintered-glass funnel,
washed with an appropriate amount of cold acetone, and dried in vacuo for ￿￿ h to furnish sulfo-
nium salt ￿￿￿￿ as white solid in quantitative yield. Rf = ￿.￿￿ (DCM–MeOH, ￿￿:￿). M.p. ￿￿￿ °C
(decomp.). ￿H NMR (￿￿￿ MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Note: Storage in the absence of light.
tert-Butyl ￿-(tetrahydro-￿l￿-thiophen-￿-ylidene)acetate (￿￿￿￿).
S
OtBu
O
￿￿￿￿
Sulfonium salt ￿￿￿￿ (￿.￿￿ g, ￿.￿￿mmol) was dissolved in ￿.￿ml of anhydrous
CH￿Cl￿ and the suspension was stirred at ￿ °C. Saturated aqueous potassium
carbonate solution (￿.￿ ml) was added followed by ￿￿ ￿ NaOH (￿.￿ ml).
The ice bath was removed and the reaction mixture was stirred at ambient
temperature for additional ￿￿ min. The phases were separated and the aqueous layer was
extracted thrice with CH￿Cl￿. The combined organic layers were dried over K￿CO￿ (￿￿ min),
filtered, and concentrated in vacuo to furnish ylide ￿￿￿￿ as a pale yellow solid in quantitative
yield which usually was directly used in the next step. Rf = ￿.￿￿ (DCM–MeOH, ￿￿:￿). M.p. ￿￿ °C.
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Note: Storage is possible at –￿￿ °C in a sealed bottle under an argon atmosphere.
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A.￿.￿ Olefination Reagents and Precursors
Ethyl (Diphenylphosphono)acetate [ Ando Reagent ] (￿￿￿).
O
OEt
P
O
O
O
￿￿￿
Variant ￿ (according to Brückner): [￿￿￿] A ￿-L flame dried Schlenk flask
was charged with sodium hydride (￿￿% dispersion in mineral oil, ￿￿.￿
g, ￿￿￿mmol, ￿.￿ eq.), the flask was evacuated and flushed with argon.
Anhydrous THF (￿￿￿ml) was added and the mixture was cooled down
to ￿ °C. Diphenyl phosphite (￿￿.￿ ml, ￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) was
added via syringe pump over a period of ￿.￿ h at ￿ °C. After complete
addition the reaction mixture was stirred an additional hour at ￿ °C after which the reaction
mixture became a clear orange solution. Subsequently ethyl bromoacetate (￿￿.￿ ml, ￿￿.￿ g,
￿￿￿mmol, ￿.￿ eq.) was added via syringe pump over a period of ￿￿￿min at ￿ °C. The ice bath
was removed and the reaction mixture was stirred for additional ￿￿ h at ambient temp. The
reaction mixture was diluted with ether and quenched by the addition sat. aq. NH￿Cl–H￿O
(￿:￿, ￿￿￿ml). The layers were separated and the aqueous layer was extracted twice with ether
(￿￿￿ml). The combined organic layers were dried over MgSO￿ and volatile components were
evaporated in vacuo. The remaining orange oil was purified via flash column chromatography
using hexanes–EtOAc (￿:￿  ￿:￿  ￿:￿  ￿:￿.￿) as eluent. Phosphonate ￿￿￿ was obtained as a
clear viscous oil (￿￿.￿ g, ￿￿￿mmol, ￿￿% yield).
Variant ￿: A ￿￿￿-ml flame dried Schlenk tube was charged with a solution of diphenyl phosphite
(￿￿.￿ ml, ￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) in absolute CH￿Cl￿ (￿￿￿ ml) and cooled to ￿ °C. Ethyl
bromoacetate (￿￿.￿ml, ￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was added followed by the addition of Et￿N
(￿￿.￿ml, ￿￿.￿ g, ￿￿￿mmol, ￿.￿￿ eq.) over ￿￿min at ￿ °C. After complete addition the reaction
mixture was stirred additional ￿￿min at this temperature (formation of white precipitate), then
the ice bath was removed and the reaction mixture was stirred additional ￿.￿ h at ambient
temperature (monitored by TLC). The reaction was quenched by the addition of H￿O (￿￿￿ml),
the layers were separated and the aqueous layer was extracted twice with ether (￿￿￿ml). The
combined organic layers were dried over Na￿SO￿ and volatile components were evaporated
in vacuo. The remaining orange oil was purified via flash column chromatography using
hexanes–EtOAc (￿:￿   ￿:￿   ￿:￿   ￿:￿.￿) as eluent. Phosphonate ￿￿￿ was obtained as a
clear viscous oil (￿￿.￿ g, ￿￿￿mmol, ￿￿% yield). Rf = ￿.￿￿–￿.￿ (hexanes–EtOAc, ￿:￿).
￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿￿H), ￿.￿￿ (qd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (d, J = ￿￿.￿Hz,
￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿￿H￿￿NaO￿P [M + Na]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
Note: (i) The own developed conditions seemed to be more convenient, even for the preparation of large
amounts of phosphonate ￿￿￿. (ii)Storage under argon at –￿￿ °C.
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(Dimethoxymethyl)diphenylphosphine oxide (￿￿￿).
P
OMeMeO
O
￿￿￿
Chlorodiphenylphosphine (￿.￿ml, ￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added
dropwise to trimethyl orthoformate (￿.￿ ml, ￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.,
neat, caution: very exothermic) under an argon atmosphere at ambient
temperature. The reaction mixture solidified and was then heated for
￿￿￿min at ￿￿￿ °C (caution: large volumes of gas [MeCl] are produced). The
reaction mixture was allowed to cool down to ambient temperature and the yellow solid was
recrystallized from cyclohexane–toluene (￿:￿) to obtain title compound ￿￿￿ as a white solid (￿￿.￿
g, ￿￿.￿mmol, ￿￿% yield). M.p. ￿￿ °C. ￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ –
￿.￿￿ (m, ￿H), ￿.￿￿ (d, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Diethyl (￿,￿-dithian-￿-yl)phosphonate (￿￿￿).
SS
P(OEt)2O
￿￿￿
￿,￿-Dithiane (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in ￿￿￿ ml of anhydrous
benzene in a ￿￿￿ml flame dried Schlenk tube. NCS (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was
added in small portions at ambient temperature after which the reactionmixture was
stirred for ￿￿ h at this temperature under an argon atmosphere. Triethyl phosphite
(￿￿.￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) was then added dropwise at ambient temperature
and the reaction mixture was stirred additional ￿.￿ h at ￿￿ °C (monitored by TLC). The reaction
mixture was allowed to cool down to ambient temperature and was filtered through a medium
porosity sintered-glass funnel. The filtride was washed with an appropriate amount of cold ether
and the filtrate was then concentrated under reduced pressure. The residue was triturated with
cold ether to precipitate residues of succinimide which were again removed by filtration. Volatile
components were evaporated in vacuo to obtain a yellow oil which was purified by flash column
chromatography using cyclohexane–EtOAc (￿:￿) as eluent. Title compound ￿￿￿ was obtained
as colorless viscous oil (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield) which solidified below ￿￿ °C. Rf = ￿.￿￿
(cyclohexane–EtOAc, ￿:￿). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (pd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿
(d, J = ￿￿.￿Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (td, J =
￿.￿, ￿.￿ Hz, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿O￿PS￿ [M + H]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
Note: Phosphonate ￿￿￿ is also accessible via the deprotonation of ￿,￿-dithiane followed by the addition of
diethyl chlorophosphate, but the yields were low. In addition, diethyl chlorophosphate is a cholinesterase
inhibitor and therefore highly toxic.
(Iodomethyl)triphenylphosphonium iodide [ Stork-Zhao Reagent ] (￿￿￿).
I PPh3I
￿￿￿
Triphenylphosphine (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) and diiodomethane (￿.￿ ml,
￿￿.￿mmol, ￿.￿ eq.) were refluxed in anhydrous benzene (￿￿ml) in the absence of
light under an argon atmosphere for ￿￿.￿ h. The reaction mixture was allowed to
cool down to ambient temperature and the resultant precipitate was filtered through a medium
￿￿￿
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porosity sintered-glass funnel. The white solid was washed four times with anhydrous cold
benzene (￿￿ ml). The collected solid was dried under high vacuum for ￿￿ h in the absence
of light to obtain title compound ￿￿￿ as a white solid (￿￿.￿ g, ￿￿.￿ mmol, quantitative yield).
M.p. ￿￿￿ °C (lit. ￿￿￿ °C).
Note: The solid was transferred to an argon flushed amber-glass bottle and stored in a freezer.
(￿-Bromoethoxy)(tert-butyl)dimethylsilane (￿￿￿￿).
OTBS
Br
￿￿￿￿
To a solution of ￿-bromoethanol (￿.￿ml, ￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) in anhydrous
CH￿Cl￿ (￿￿ml) was added tert-butyldimethylsilyl chloride (￿.￿￿ g, ￿￿.￿mmol,
￿.￿ eq.) followed by the addition of Et￿N (￿￿.￿ml, ￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.)
and DMAP (￿￿.￿mg, ￿￿￿ ￿mol, ￿mol %) at ambient temperature. The reaction mixture was
stirred at this temperature for ￿￿ h before it was diluted with pentane–ether (￿:￿) and quenched
by the addition of H￿O. The layers were separated and the aqueous layer was extracted twice
with pentane–ether (￿:￿, ￿￿ml). The combined organic layers were extracted once with brine,
dried over MgSO￿ and volatile components were evaporated in vacuo. The residue was purified
by flash column chromatography using pentane–ether (￿￿:￿) as eluent to obtain silane ￿￿￿￿ as
clear colorless oil (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield). Rf = ￿.￿￿ (hexanes–EtOAc, ￿￿:￿, stains with
KMnO￿).
￿HNMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (s,
￿H), ￿.￿￿ (s, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, –￿.￿ ppm. HRMS
(ESI): calcd. for C￿H￿￿BrNaOSi [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿-((tert-Butyldimethylsilyl)oxy)ethyl)triphenylphosphonium bromide (￿￿￿￿).
OTBS
BrPh3P
￿￿￿￿
Bromide ￿￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was refluxed with triphenylphos-
phine (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) in anhydrous benzene (￿￿ml) for ￿.￿ h
(monitored by TLC). The reaction mixture was allowed to cool down to
ambient temperature and the resultant precipitate was filtered through a medium porosity
sintered-glass funnel. The white solid was washed four times with anhydrous cold benzene
(￿￿ml). The collected solid was dried under high vacuum for ￿￿ h to obtain title compound ￿￿￿￿
as a white solid (￿￿.￿ g, ￿￿.￿mmol, quantitative yield). ￿H NMR (￿￿￿MHz, MeOD) d = ￿.￿￿ –
￿.￿￿ (m, ￿￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿Hz, ￿H),
￿.￿￿ (s, ￿H), –￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
(￿-Bromopropoxy)(tert-butyl)dimethylsilane (￿￿￿￿).
Br OTBS
￿￿￿￿
￿-bromopropan-￿-ol (￿￿%, ￿.￿ ml, ￿￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dis-
solved in anhydrous CH￿Cl￿ (￿￿￿ml). tert-Butyldimethylsilyl chloride (￿￿.￿ g,
￿￿￿ mmol ￿.￿￿ eq.) was added in portions followed by addition of DMAP
(￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) and Et￿N (￿￿.￿ml, ￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) at ambient temperature.
The reaction mixture was stirred at this temperature for ￿￿ h before it was diluted with CH￿Cl￿
￿￿￿
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and quenched by the addition of ￿ ￿H￿SO￿. The layers were separated and the organic layer
was washed once with sat. aq. NaHCO￿, sat. aq. NH￿Cl, and brine, respectively. The organic
layer was dried over MgSO￿ and volatile components were evaporated in vacuo. Purification
by flash column chromatography (pentane–ether, ￿:￿) furnished silane ￿￿￿￿ as clear colorless
oil (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield). Rf = ￿.￿￿ (pentane–ether, ￿:￿).
￿H NMR (￿￿￿MHz, CDCl￿)
d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (p, J = ￿.￿Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿
(s, ￿H) ppm. ￿H NMR (￿￿￿MHz, DMSO) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿BrNaOSi
[M + Na]+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
tert-Butyl(￿-iodopropoxy)dimethylsilane (￿￿￿￿).
I OTBS
￿￿￿￿
Crude bromide ￿￿￿￿ (￿￿.￿ mmol, ￿.￿ eq.) was dissolved in anhydrous ace-
tone (￿￿ ml). Sodium iodide (￿.￿￿ g, ￿￿￿ mmol, ￿.￿ eq.) was added in one
portion and the reaction mixture was refluxed for ￿￿min (monitored by TLC,
iodide ￿￿￿￿ is slightly more polar than bromide ￿￿￿￿). The reaction mixture was allowed to cool
down to ambient temperature, ether (￿￿￿ml) was added, and solids were removed by filtration
through a medium porosity sintered-glass funnel. The filtrate was concentrated in vacuo and
the residue was purified by flash column chromatography (pentane–ether, ￿￿:￿   ￿￿:￿￿) to
yield iodide ￿￿￿￿ as light rose oil (￿￿.￿ g, ￿￿.￿ mmol, ￿￿% yield over two steps). ￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (t, J = ￿.￿Hz, ￿H), ￿.￿￿ (tt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. HRMS (ESI): calcd. for C￿H￿￿IOSi [M + H]
+ ￿￿￿.￿￿￿￿,
found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
(￿-((tert-Butyldimethylsilyl)oxy)propyl)triphenylphosphonium bromide (￿￿￿).
BrPh3P OTBS
￿￿￿
Silane ￿￿￿￿ (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) was heated with triphenylphos-
phine (￿￿%, ￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) in anhydrous benzene (￿￿.￿ml)
to ￿￿￿ °C in a sealed tube for ￿ d. Volatile components were evaporated in
vacuo and the resultant solid was dried under high vacuum for ￿￿ h to obtain title compound ￿￿￿
as a white solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m,
￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm.
NMR spectra on page ￿￿￿.
(￿-Carboxyethyl)triphenylphosphonium bromide (￿￿￿￿).
O
OHBrPh3P
￿￿￿￿
Triphenylphosphine (￿￿%, ￿￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) and ￿-bromopro-
pionic acid (￿￿%, ￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) were refluxed in MeCN
(￿￿.￿ml) for ￿ d (reaction progress was controlled by ￿HNMR). The solvent
was removed in vacuo and the remained solid was recrystallized fromMeCN
to obtain carboxylic acid ￿￿￿￿ as white solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield). ￿HNMR (￿￿￿MHz,
￿￿￿
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CDCl￿) d = ￿￿.￿￿ (br s, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿￿H), ￿.￿￿ (dt, J = ￿￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dt, J =
￿￿.￿, ￿.￿ Hz, ￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿ (d, J = ￿￿.￿ Hz), ￿￿￿.￿ (d, J =
￿.￿ Hz), ￿￿￿.￿ (d, J = ￿￿.￿ Hz), ￿￿￿.￿ (d, J = ￿￿.￿ Hz), ￿￿￿.￿ (d, J = ￿￿.￿ Hz), ￿￿.￿ (d, J = ￿.￿ Hz),
￿￿.￿ (d, J = ￿￿.￿Hz) ppm. NMR spectra on page ￿￿￿.
A.￿.￿ Hypervalent Iodine Compounds
Iodosobenzene (￿￿￿￿).[￿￿￿]
I
O
￿￿￿￿
A ￿￿￿ ml flask was charged with (diacetoxyiodo)benzene (￿.￿￿ g, ￿￿.￿ mmol,
￿.￿ eq.) and ￿ ￿ NaOH (￿￿.￿ ml) was added dropwise over a period of ￿￿ min
with vigorous stirring. Stirring was continued for another ￿￿min after complete
addition followed by standing for additional ￿￿ min to complete the reaction.
￿￿ml of H￿O was added and the solid was filtered through a medium porosity sintered-glass
funnel. The solid was collected and again dissolved in ￿￿ml of H￿O, was shaken properly and
filtered through a medium porosity sintered-glass funnel. The latter sequence was repeated
one more time. The collected white solid was dried under high vacuum for ￿￿ h to obtain title
compound ￿￿￿￿ as a fine-grained powder (￿.￿￿ g, ￿.￿￿mmol, ￿￿% yield). M.p. ￿￿￿ °C (decomp.).
Note: Caution! Iodosobenzene explodes quite impressively when heated to ￿￿￿ °C.
￿-Iodoxybenzoic acid [ IBX ] (￿￿￿).[￿￿￿]
I
O
O
O OH
￿￿￿
A ￿-L two-neck round-bottom flasks was charged with Oxone® (￿￿￿ g, ￿￿￿mmol,
￿.￿￿ eq.) and equipped with a mechanical stirrer. Water (￿￿￿ml) was added and
after complete dissolution of Oxone®, ￿-iodobenzoic acid (￿￿.￿ g, ￿￿￿ mmol,
￿.￿ eq.) was added in one portion. The reaction mixture was heated until the
inner temperature has reached ￿￿ °C and from this point stirring was continued
at this inner temperature for ￿.￿ h. The oil bath was removed, the reactionmixture allowed to cool
down to ambient temperature, and was then stirred for ￿￿min at ￿ °C. The resultant precipitate
was filtered through a medium porosity sintered-glass funnel, the white solid was washed six
times with H￿O (￿￿￿ml), and subsequently two additional times with acetone (￿￿￿ml). The
collected white solid was dried under high vacuum for ￿￿ h to obtain title compound ￿￿￿ as a
fine-grained powder (￿￿.￿ g, ￿￿￿mmol, ￿￿% yield). M.p. ￿￿￿ °C (decomp.). ￿H NMR (￿￿￿MHz,
DMSO) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. ￿￿C NMR (￿￿￿MHz, DMSO–d￿) d =
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿ (d, J = ￿.￿Hz), ￿￿￿.￿, ￿￿￿.￿ ppm. NMR spectra on page ￿￿￿.
Notes: (i) Caution! Although I could not observe any explosions while handling with IBX, even not when
measuring the melting point, IBX is known to be explosive under impact or heating to >￿￿￿ °C.[￿￿￿] (ii)
This procedure was also reproducible on twice the scale (￿￿￿ g of ￿-iodobenzoic acid) yielding ￿￿.￿ g of
IBX (￿￿% yield).
￿￿￿
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￿,￿,￿-Triacetoxy-￿,￿-dihydro-￿,￿-benziodoxol-￿(￿H)-one [ Dess–Martin Periodinane ] (￿￿￿).[￿￿￿]
I
O
O
OAc
OAc
AcO
￿￿￿
To a suspension of IBX (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) in Ac￿O (￿￿￿ml) was added
a catalytic amount of TsOH  H￿O (￿￿￿mg, ￿.￿￿mmol, ￿.￿￿mol %) and the
reaction mixture was stirred at ￿￿ °C for ￿.￿ h. The heating bath was then
replaced with an ice bath and stirring was continued for additional ￿￿ min.
The resultant precipitate was filtered through a medium porosity sintered-glass
funnel and the white solid was washed four times with anhydrous cold ether (￿￿ ml). The
collected white solid was dried under high vacuum for ￿￿ h to obtain title compound ￿￿￿ as a
fine-grained powder (￿￿.￿ g, ￿￿￿mmol, ￿￿% yield). M.p. ￿￿￿ °C. ￿H NMR (￿￿￿MHz, CDCl￿)
d = ￿.￿￿ (dd, J = ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (ddd, J = ￿.￿, ￿.￿, ￿.￿Hz, ￿H), ￿.￿￿ (td, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
A.￿.￿ Diazo Compounds and Precursors
Diazomethane (￿￿￿).[￿￿￿]
AL-180 Diazald® and Diazomethane Generators AL-180 Diazald® and Diazomethane Generators AL-180 Diazald® and Diazomethane Generators
Diazoketone formation from carboxylic acid halides
21
Pyrazoline formation
22
2. Generation and use of diazomethane-d2
The Diazald® Glassware Set or the Mini Diazald® Apparatus
may be used. WARNING: All safety precautions empha-
sized for  diazomethane (Section III) apply to diazo -
methane-d2 also.
2-(2-Ethoxyethoxy)ethan(ol-d) (carbitol-d, 50 g) and anhydrous
ether (20 mL) are added to a solution of 30% sodium deuterox-
ide in D2O (20 g). This mixture is placed in a 250 mL distilling flask
equipped with a dropping funnel, an efficient condenser, a mag-
netic stirring bar, and a water bath at 70 °C. The condenser is
connected to two receiving flasks in series, the second of which
contains 20 to 30 mL of anhydrous ether. The inlet tube of the
second receiver dips below the surface of the ether and both
receivers are cooled to 0 °C. The solution (occasionally a second
layer forms without detriment) in the distilling flask is stirred vig-
orously and a solution of Diazald® in anhydrous ether (10 mL per
gram of Diazald®) is added through the dropping funnel over 
a period of 20 minutes. When the dropping funnel is empty,
anhydrous ether is added slowly until the distillate is colorless
(~60 mL).
The combined ethereal distillates contain about 2.5 mmol of
deuterated diazomethane per gram of Diazald® used. They 
also contain some HOD-D2O. Drying over solid KOH should be
avoided, as drying for 1 hour leads to ca. 15% exchange.
Reaction of the wet ethereal deuterated diazomethane with a
deuterated carboxylic acid (RCOOD-see Table III on page 5) gives
deuterated methyl esters containing 90% of the deuterium
present in the deuterated diazomethane. 
Deuterated carboxylic acids (RCOOD) are prepared by washing
an ethereal solution of the acid (RCOOD, 50 mmol) with four
5 g portions of deuterium oxide. The isotopic purity of the
deuterated methyl ester is improved to >95% (using 97% D
deuterated diazomethane)  if 5 g of D2O is added to the ethe-
real deuterated diazomethane solution, followed by vigorous
stirring during addition of the deuterated carboxylic acid.
The quantities of 2-(2-ethoxyethoxy)ethan(ol-d) and 30%
NaOD in D2O supplied in the kit may be used to generate
deuterated diazomethane of higher isotopic purity by using
less Diazald® (see Table III on page 5).
V. DIAZOMETHANE PRECURSORS 
AND RELATED PRODUCTS
Description Cat. No.
Diazald® D28000
Diazald®-N-methyl-13C, 99 atom % 13C 277614
Diazald®-N-methyl-13C-N-methyl-d3, 295981
99 atom % 13C, 99.5 atom % D
Diazald®-N-methyl-d3, 98 atom % D 329908
S
O O
Ph
S
O O
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CD2N2
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NN
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Cl CD2N2
Et2O, rt
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C. Accessories for the Mini Diazald® Apparatus
Aldrich lists several sizes of separatory funnels and receivers
with C19/22 Clear-Seal® joints.
3. iazald® Glassware Set with System 45® connections
A. Description and use
This glassware set (Fig. 3) incor-
porates System 45® connections
that eliminate glass joints,
clamps, and grease, and permits
the safe preparation of dia-
zomethane (~100 mmol) from
Diazald®. The unique, one-piece
distillation head features a 
highly efficient coiled condenser. 
The method of diazomethane
generation is essentially a scale-
up of the procedure outlined for
the Mini Diazald® Apparatus.
4. The Macro Diazald® Kit
A. Description and use
Designed by M. Hudlicky,14 this kit 
(Fig. 4) enables the preparation of 200
to 300 mmol of diazomethane from
Diazald®. Like the Mini Diazald®
Apparatus, it features a dry ice cold-
finger condenser which quantitatively
condenses all the diazomethane/ether
vapor. It also includes a U-tube vapor
trap and PTFE stopcock to ensure trap-
ping of all vapors. The stopcock is
closed at the start of distillation. As the
distillate drips off the condenser, the
stopcock is opened and the first por-
tions fill the trap, allowing the conden-
sate to collect in the Erlenmeyer flask,
but preventing the escape of uncondensed vapors into the
receiver.
Hudlicky
15
has proposed a modification employing a cold trap
(such as that used in vacuum systems) as the receiver vessel.
B. Replacement Parts
IV. DEUTERATED DIAZOMETHANE
1. Applications
Diazomethane-d2 (CD2N2)
16
is a useful reagent for the simple
preparation of a wide variety of deuterated compounds 
widely used in NMR spectroscopy. Deuterated compounds are
also important stereochemical and mechanistic tools in iso-
tope effect studies and as "cold-labeled" materials for biolog-
ical investigations.
Methyl esters from carboxylic acids
17
Ring expansion of ketones
18-20
O
CD2N2
O
D
D
CO2D CO2CD3
CD2N2
Et2O
Description Cat. No.
PTFE stopper, ST/NS 24/40 Z115584
Dropping funnel, 500 mL Z115541
Round-bottom flask, 2-neck, 500 mL Z115576
Cold-finger condenser assembly Z115592
Erlenmeyer flask, 500 mL Z115568
Description Cat. No.
Diazald® Glassware Set, complete Z419761
Replacement parts
Addition funnel, 60 mL, with PTFE valve Z419850
Distillation head Z419788
Solid-top cap, with PTFE liner, 32 mm Z416983
Quick-disconnect fittings, with I in. Z417432
hose fitting
O-rings, Viton®, size 2-011, for use with Z418439
quick-disconnect fittings
Description Cat. No.
Round-bottom flask, 50 L Z100331
Round-bottom flask, 100 mL Z100358
Round-bottom flask, 250 mL Z100366
Separatory funnel, with PTFE Z100382
stopcock, 125 mL
PTFE stopper Z100390
III. DIAZOMETHANE GENERATORS
Aldrich carries several apparatuses for
the preparation of diazomethane
from Diazald® (see Table I on page 5).
These apparatuses feature Clear-Seal®
joints or System 45® connections.
1. The Aldrich Diazomethane
Generator with System 45®
connection
This apparatus (Fig. 1) affects the gen-
eration of diazomethane without the
need for co-distillation with ether. This
apparatus is mainly used for small
scale GC work and preparative analysis
of samples no larger than 0.3 mmol. A
representative procedure follows:
To the outside tube of the Aldrich dia-
zomethane generation apparatus add 4-methoxybenzoic acid
(0.465 g, 0.300 mmol) and ether (3.0 mL). To the inside tube
add Diazald® (0.367 g, 1.71 mmol) and carbitol (1.0 mL).
Assemble the two parts and place the lower part of the outer
tube in an ice bath. After equilibrating to the cooling bath
temperature, slowly inject drop-wise through the septum via
a syringe, aqueous KOH (37%, ~1.5 mL). Gently shake the
apparatus by hand to ensure mixing of reactants within the
inner tube, while being careful not to allow these reactants to
spill into the outer tube. The solution in the outer tube may
become yellow in color and persist, indicating an excess of dia-
zomethane. After 50 min, open the apparatus. Carefully add
solid silicic acid (0.151 g) to the inner tube to destroy unre -
acted diazomethane. Evaporate the yellow ether solution in the
outside tube under a gentle stream of nitrogen affording
methyl 4-methoxybenoate as a white solid product (0.490 g,
98.4%). GC/MS analysis should indicate the material to be ana-
lytically pure. 
2. The Aldrich Mini Diazald® Apparatus
A. Description
This unit (Fig. 2) is designed for the preparation of 1 to 
50 mmol of diazomethane from Diazald® or a 25 wt. % solution
of Diazald® in 2-Methoxyethyl ether (diglyme), and consists of
a reaction vessel and condenser in one compact piece (with
19/22 Clear-Seal® joints). The only additional equipment needed
consists of an addition funnel and receiver (both of which
must have Clear-Seal® joints). The major feature of this appa-
ratus is the “cold-finger” in
place of a water-jacketed
condenser. When filled
with dry ice/isopropanol
slush, the condenser very
efficiently prevents dia-
zomethane/ether vapor
from escaping into the
atmosphere. A typical
experimental procedure
employing this apparatus
follows.
B. Procedure
(i)  For an alcohol-
containing ethereal solu-
tion
Fill the condenser with dry ice, then add isopropanol slowly
until the cold-finger is about one-third full. Add ethanol
(95%, 10 mL) to a solution of potassium hydroxide (5 g) in
water (8 mL) in the reaction vessel. Attach a 100 mL  receiving
flask (with Clear-Seal® joint) to the condenser and cool the
receiver in dry ice/isopropanol bath. Provide an ether trap at
the side-arm (the glass tube must have firepolished ends). The
trap should be cooled in a dry ice/isopropanol bath.
Place a separatory funnel (with Clear-Seal® joint) over the
reaction vessel and charge the funnel with a solution of
Diazald® (5.0 g, 23 mmol) in ether (45 mL) or 20 mL of 25 
wt. % Diazald® in diglyme (5 g, 23.3 mmol) and 30 mL of ether.
Warm the reaction vessel to 65 °C with a water bath and add
the Diazald® solution over a period of 20 minutes. The rate of
distillation should be approximately the rate of addition.
Replenish the cold-finger with dry ice as necessary. When 
all the Diazald® has been used up, slowly add 10 mL of ether
and continue the distillation until the distillate is colorless. 
If the distillate is still yellow, add another 10 mL of ether and
continue the distillation. The ether will contain 700 mg to 900
mg (16.6 mmol to 21.4 mmol) of diazomethane depending on
whether Diazald® or Diazald® in diglyme is used respectively.
(ii) For an alcohol-free ethereal solution
If an alcohol-free ethereal solution of diazomethane is
required, add 2-(2-ethoxyethoxy)ethanol (14 mL) and ether 
(8 mL) to a solution of potassium hydroxide (2.5 g) in water (4
mL) in the reaction vessel. Distill diazomethane as above (a sim-
ilar yield is obtained). 
CO2H CO2CH3CH2N2
Etrt 2O
CO3H CO3H
98% isolated yield
(0.3 mmol scale)
to seperatory funnel
dry ice condenser
to receiver
to ether 
trap
Fig. 1 Apparatus for 
preparing diazomethane 
(cooling bath not shown).
Fig. 4.  Macro Diazald® Kit
set-up (heating and cooling
baths are not shown).Fig. 2 Aldrich Mini Diazald
® apparatus
Fig. 3 Typical set-up with Diazald®
Glassware Set (heating and cooling 
baths are not included).
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Figure ￿-￿. Apparatus for the safe generation
of diazomethane.
Using an apparatus similar to Fig. ￿-￿, a solution of N-methyl-N-
nitroso-p-toluenesulfonamid (￿￿.￿ g, also known as Diazald®) in
ether (￿￿￿ ml) is slowly added over ￿￿ min to a stirred solution
of KOH (￿.￿ g) in ￿￿ml of water and ￿￿ml of ￿-methoxyethanol
which is heated to ￿￿ °C. The solution turned yellow almost im-
mediately and a solution of diazomethane in ether began to distill.
The receiving flask which is attached to the distillation apparatus
was cooled in an dry ice bath. After complete addition of Diazald®,
additional ether (￿￿ml) was added dropwise and distillation was
continued until the distillate was colorless. Using this procedure,
diazomethane is btained as approx. ￿.￿ ￿ yellow solution i ether.
Notes: (i) Caution! Diazomethane is highly toxic and highly explosive.
The operation must be carried out in a good hood with an adequate
shield! The utmost care is essential in the preparation and use of this
material! (ii) It is highly recommended that ground joints and sharp sur-
faces be avoided. Thus all glass tubes should be carefully fire-polished, connections should be made with
rubber stoppers, and separatory funnels should be avoided, as should etched or scratched flasks. Diazald®
set with System ￿￿™ compatible connections glassware kit from Sigma-Aldrich (Z￿￿￿￿￿￿) was
used.￿
￿ www.sigmaaldrich.com/catalog/product/aldrich/z￿￿￿￿￿￿, Fig. ￿-￿ has also been copied from this source.
￿￿￿
A.￿ Experimental
￿-Diazoacetonitrile (￿￿￿).[￿￿￿]
N2
CN
￿￿￿
A two-necked round-bottom flask was charged with a-aminoacetonitrile bisulfite (￿.￿￿ g
￿￿.￿mmol, ￿.￿ eq.), CH￿Cl￿ (￿￿.￿ml) was added and the suspension was cooled down
to –￿￿ °C under an argon atmosphere. A solution of NaNO￿ (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.)
in water (￿.￿ml) was added dropwise. After complete addition, the organic layer turned
bright yellow and the suspension was stirred additional ￿￿min at –￿￿ °C. The reaction mixture
was transferred to a separatory funnel and the layers were separated. The organic layer was
washed once with ￿% aq. K￿CO￿ (￿￿ml) and the aqueous layers were backwashed with CH￿Cl￿
(￿￿ml). The combined organic layers were dried over K￿CO￿ and the volume was reduced to
approx. ￿￿ ml under reduced pressure (T = ￿￿ °C). IR analysis confirmed the existence of a
diazo group (n = ￿￿￿￿ cm–￿). The bright yellow solution of ￿-diazoacetonitrile in CH￿Cl￿ was
used directly in subsequent reactions.
Note: Caution! ￿-Diazacetonitrile (￿￿￿) has been reported to be highly explosive at high concentrations.
The ￿￿ wt% solution of ￿￿￿ in CH￿Cl￿ is not so dangerous. It is important, that ￿￿￿ can be used only
in dilute solution: additionally, it must be avoided concentration and isolation of ￿￿￿, especially on a
large scale.[￿￿￿]
Methanesulfonyl azide (￿￿￿).[￿￿￿]
MsN3
￿￿￿
Sodium azide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added in small portions over a period of
￿￿min to a solution of methanesulfonyl chloride (￿.￿ml, ￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) in
absolute acetone (￿￿.￿ml) at ambient temperature under argon. After complete addition,
the suspension was stirred additional ￿￿ min at this temperature. The mixture was filtered
through a medium porosity sintered-glass funnel, and the salt (NaCl) was repeatedly rinsed
with absolute acetone. Careful rotary evaporation of the filtrate followed by high vacuum for
￿.￿ h furnished azide ￿￿￿ as colorless oil which solidified below ￿￿ °C in ￿￿% yield. ￿H NMR
(￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Notes: (i) Caution! Like all sulfonyl azide derivaties, azide ￿￿￿ is potentially explosive and should be
handled with care. Especially never crack the solid but wait until the compound liquidates. (ii) Storage
in the freezer is possible for an indefinite period of time.
￿-Nitrobenzenesulfonyl azide (￿￿￿￿).
O2N S
O
O
N3
￿￿￿￿
Sodium azide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in H￿O–acetone
(￿:￿.￿, ￿￿ ml) and the resulting suspension was stirred vigorously. A
solution of ￿-nitrobenzenesulfonyl chloride (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.)
in acetone (￿￿ ml) was added slowly at ambient temperature. After
complete addition the resulting suspension was stirred additional ￿.￿ h at this temperature.
Acetone was removed under reduced pressure (T = ￿￿ °C) and the residue was extracted twice
with CH￿Cl￿ (￿￿ ml). The organic layers were combined, washed once with brine, and dried
￿￿￿
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over Na￿SO￿. Volatiles were removed in vacuo (T = ￿￿ °C) and the residue was dried under high
vacuum for ￿￿ h to obtain azide ￿￿￿￿ as pale yellow solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield) which
was stored under argon below –￿￿ °C. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz,
￿H), ￿.￿￿ (dt, J = ￿.￿, ￿.￿Hz, ￿H) ppm. NMR spectra on page ￿￿￿.
Note: Caution! Like all sulfonyl azide derivaties, azide ￿￿￿￿ is potentially explosive and should be
handled with care.
￿,￿-di-tert-Butyl-￿-methylphenyl ￿-oxobutanoate (￿￿￿￿).
O O
O
￿￿￿￿
In an opened round-bottom flask, ￿,￿,￿-Trimethyl-￿H-￿,￿-dioxin-￿-one
(￿￿%, ￿.￿ml, ￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) and dibutylhydroxytoluene
(￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) were heated in xylenes (￿.￿ml) at ￿￿￿ °C.
The evolution of acetone became apparent within several minutes.
After ￿￿￿min the oil bath was removed and volatile components were
evaporated in vacuo. The residue was recrystallized from benzene
to yield ￿,￿-dicarbonyl ￿￿￿￿ as white powder (￿.￿￿ g, ￿￿.￿ mmol, ￿￿% yield). Rf = ￿.￿￿ (hex-
anes–EtOAc, ￿:￿, stains intensely dark blue with CAN). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿￿.￿￿
(s, ￿.￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿.￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿.￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿.￿H),
￿.￿￿ (d, J = ￿.￿ Hz, ￿￿H) ppm. ￿￿C NMR (￿￿￿ MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿,
￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿, ￿￿.￿,
￿￿.￿, ￿￿.￿, ￿￿.￿ ppm. HRMS (ESI): calcd. for C￿￿H￿￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿.
NMR spectra on page ￿￿￿.
Note: ￿￿￿￿ appears as keto–enol tautomers, approx. ￿:￿ ratio.
￿,￿-di-tert-Butyl-￿-methylphenyl ￿-diazo-￿-oxobutanoate (￿￿￿￿).
O O
O
N2
￿￿￿￿
Dibutylhydroxytoluene[￿￿￿] (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.), NaOAc (￿￿￿
mg, ￿.￿mmol, ￿.￿ eq.) and p-ABSA (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) were
dissolved in anhydrous acetonitrile (￿￿ml). The reaction mixture was
refluxed and a solution of ￿,￿,￿-trimethyl-￿H-￿,￿-dioxin-￿-one (￿￿%,
￿.￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) in anhydrous acetonitrile (￿.￿ ml) was
added dropwise over a period of ￿￿min to the reaction mixture. After
complete addition, the reaction mixture was refluxed for additional ￿￿ h and then stirring was
continued for additional two days at ambient temperature. The diazoacetoacetate product was
isolated by adding NaOH (￿￿% aq. solution) and extracting with ether, washing the ether extract
with water and then drying the extract over MgSO￿. Evaporation of the ether left a brown oil
that was subjected to acetyl cleavage. Rf = ￿.￿￿ (hexanes–EtOAc, ￿￿:￿).
￿￿￿
A.￿ Experimental
￿,￿-di-tert-Butyl-￿-methylphenyl ￿-diazoacetate (￿￿￿).
O
O
N2
￿￿￿
The crude diazo compound ￿￿￿￿ was dissolved in ￿￿ml of acetonitrile and
KOH (￿% aq. solution, ￿￿ ml) was added to the solution. The resulting
mixture was stirred for ￿ h at ambient temperature at which a yellow solid
precipitated. The mixture was filtered through a medium porosity sintered-
glass funnel, and the solid was repeatedly rinsed with water. The solid
was dried in vacuo to obtain title compound ￿￿￿ as a yellow solid. The
yield can by increased by storage of the residual filtrate at –￿￿ °C for several days (additional
precipitation of deacetylated product). It was observed, that the yield varies between ￿￿% and
￿￿% (over two steps) and highly depends on the quality of ￿,￿,￿-trimethyl-￿H-￿,￿-dioxin-￿-one.
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (d, J = ￿.￿ Hz, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s,
￿￿H) ppm. ￿￿C NMR (￿￿￿MHz, CDCl￿) d = ￿￿￿.￿, ￿￿￿.￿, ￿￿￿.￿, ￿￿.￿ (C––N￿, very weak), ￿￿.￿,
￿￿.￿, ￿￿.￿ ppm. IR (neat): ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿, ￿￿￿ cm–￿. HRMS (ESI):
calcd. for C￿￿H￿￿N￿NaO￿ [M + Na]
+ ￿￿￿.￿￿￿￿, found ￿￿￿.￿￿￿￿. NMR spectra on page ￿￿￿.
￿-Diazopentane-￿,￿-dione (￿￿￿￿).
O O
N2
￿￿￿￿
Acetylacetone (￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was dissolved in absolute acetonitrile
(￿￿￿ ml) and p-ABSA (￿.￿￿ g, ￿￿.￿ mmol. ￿.￿ eq.) was added in one portion at
ambient temperature. The reaction mixture was cooled down to ￿ °C and Et￿N
(￿.￿ ml, ￿￿.￿ mmol, ￿.￿ eq.) was added over ￿￿ min at ￿ °C. After complete
addition the reaction mixture was stirred ￿￿ min at ￿ °C, then additional ￿￿ min at ambient
temperature (monitored by TLC). The white precipitate was removed via filtration and the filtrate
were triturated with pentane–ether (￿:￿) and the precipitated white solids were again removed
via filtration. Volatile components were removed in vacuo and the residue was purified via
flash column chromatography (pentane–ether, ￿:￿) to obtain diazo ￿￿￿￿ as yellow oil (￿.￿￿ g,
￿￿.￿mmol, quantitative yield). Rf = ￿.￿￿ (pentane–ether, ￿:￿).
￿H NMR (￿￿￿MHz, C￿D￿) d =
￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
￿-Diazopropan-￿-one (￿￿￿).
O
N2
￿￿￿
Diazo ￿￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was stirred in ￿ ￿ NaOH–ether (￿:￿, ￿￿￿ml)
at ambient temperature for ￿￿min (monitored by TLC). The layers were separated and
the aqueous layer was washed four times with CH￿Cl￿ (￿￿ml). The combined organic
layers were dried over Na￿SO￿. The solvent was evaporated under reduced pressure
(T = ￿￿ °C, p = ￿￿￿mbar) to obtain diazo ￿￿￿ as yellow oil. IR analysis confirmed the existence
of a diazo group (n = ￿￿￿￿ cm–￿). Rf = ￿.￿￿ (pentane–ether, ￿:￿). ￿H NMR (￿￿￿MHz, CDCl￿)
d = ￿.￿￿ (br s, ￿H), ￿.￿￿ (s, ￿H) ppm.
Note: Caution! If possible, avoid glass apparatus with ground joints and sharp surfaces.
￿￿￿
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A.￿.￿ Other Reagents
Samarium(II) iodide [ Kagan’s Reagent ] (￿￿￿￿).[￿￿￿]
SmI2
￿￿￿￿
Preliminary work: in the absence of light, commercial ￿,￿-diiodoethane was dissolved in
ether and washed four times sat. aq. Na￿S￿O￿ and then once with brine. The solution
was dried over Na￿SO￿, transferred into an amber round-bottom flask, and the solvent
was removed in vacuo. The resulting bright white needles/plates were dried additional ￿￿min
under high vacuum prior to use.
A flame-dried Schlenk tube was charged with samarium (￿￿￿mg, ￿.￿mmol, ￿.￿ eq.) and freshly
washed ￿,￿-diiodoethane (￿￿￿ mg, ￿.￿ mmol, ￿.￿ eq.). The Schlenk tube was wrapped in tin
foil and was evacuated and backfilled with argon (three times). Under an argon atmosphere,
absolute THF (￿￿.￿ml) was added at ambient temperature. After stirring for two minutes, the
Schlenk tube was evacuated (carefully) one more time, backfilled with argon and stirred at least
￿￿ h at ambient temperature. This procedure yields in an approx. ￿.￿ ￿ deep blue solution of
SmI￿. To get the exact concentration, the SmI￿ solution can be titrated following the procedure
of Hilmersson[￿￿￿] (reduction of ￿-heptanone using mixtures of SmI￿, triethylamine, and water).
Note: Storage is possible for several days under argon in the absence of light. Re-titration is recommended.
￿,￿,￿-Trifluoroethyl ￿,￿,￿-trifluoroacetate (￿￿￿).[￿￿￿]
F3C
O
O CF3
￿￿￿
Trifluoroacetic anhydride (￿￿.￿ ml, ￿￿.￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was mixed
with ￿,￿,￿-trifluoroethanol (￿.￿ml, ￿.￿￿ g, ￿￿.￿mmol, ￿.￿￿ eq.) at ￿ °C under
argon atmosphere. The clear reaction mixture was then refluxed for ￿ h and
left standing for additional ￿￿ h at ambient temperature. CaCO￿ (￿.￿￿ g,
￿￿.￿mmol, ￿.￿ eq.) was added at ambient temperature and the reaction mixture was stirred at
this temperature for additional ￿￿min. The condenser was removed and a distillation apparatus
was placed on the flask. Distillation (￿￿ °C, ￿ atm; distillation under argon atmosphere; collection
of the product in a Schlenk tube) a￿orded ester ￿￿￿ as colorless oil (￿￿.￿ g, ￿￿.￿ mmol, ￿￿%
yield) which was stored in a Schlenk tube under argon in a glove box. ￿H NMR (￿￿￿ MHz,
CDCl￿) d = ￿.￿￿ (q, J = ￿.￿Hz, ￿H) ppm. NMR spectra on page ￿￿￿.
CrO￿, aq. H￿SO￿ [ Jones Reagent ] (￿￿￿).
CrO3
aq. H2SO4
￿￿￿
A typical procedure for the generation of Jones reagent is as follows: ￿.￿ g of CrO￿
were dissolved in ￿￿.￿ ml of H￿O. Using water cooling, ￿.￿ ml of conc. H￿SO￿
was added under stirring. The precipitate was dissolved by addition of a minimum
amount of water. This yields in a dark red solution which was stored in the fridge.
￿￿￿
A.￿ Experimental
Diethyl ￿,￿-dihydro-￿,￿-dimethyl-￿,￿-pyridinedicarboxylate [ Hantzsch Ester ] (￿￿￿￿).
N
H
CO2Et
Me Me
EtO2C
￿￿￿￿
A ￿￿￿ml round-bottom flask was charged with ethyl acetoacetate (￿￿.￿ g,
￿￿￿ mol, ￿.￿ eq.), urotropine (￿￿.￿ g, ￿￿.￿ mmol, ￿/￿ eq.) and ethanol
(￿￿￿ ml, undenaturated). The reaction mixture was stirred at ambient
temperature and a solution of ammonium phosphate (￿￿.￿ g, ￿￿￿mmol,
￿.￿ eq.) in H￿O (￿￿ml) was added dropwise. After complete addition, the reaction mixture was
stirred at ￿￿ °C for ￿.￿ h. After cooling down to ambient temperature, the resultant precipitate
was filtered through a medium porosity sintered-glass funnel, washed with an appropriate
amount of cold water and then cold ethanol. The collected solid was dried under high vacuum
for ￿￿ h to obtain title compound ￿￿￿￿ as light orange solid (￿￿.￿ g, ￿￿.￿ mmol, ￿￿% yield).
￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (q, J = ￿.￿ Hz, ￿H), ￿.￿￿ (s, ￿H), ￿.￿￿ (s, ￿H),
￿.￿￿ (t, J = ￿.￿Hz, ￿H) ppm. NMR spectra on page ￿￿￿.
￿,￿,￿,￿￿,￿￿,￿￿-Hexaoxacyclooctadecane [ ￿￿-crown-￿ ] (￿￿￿￿).
O
O
O
O
O
O
￿￿￿￿
￿￿-crown-￿ is commercially available and was never prepared. However, it
often requires purification.
A round-bottom flask is charged with commercially available ￿￿-crown-￿
(￿￿.￿ g). Anhydrous acetonitrile (￿￿ml) is added and the flask is equipped
with a calcium chloride drying tube. The resulting slurry is warmed up
to ￿￿ °C and stirred vigorously until all material was dissolved and a clear
colorless solution is obtained. The oil bath was removed and the solution allowed to cool down
to ambient temperature. The flask was flushed with argon and stored for ￿￿ h in the freezer.
The resultant precipitate was filtered through a medium porosity sintered-glass funnel under
argon. The white solid was washed with anhydrous dry ice cold acetonitrile. The collected solid
was dried under high vacuum with gentle heating (￿￿ °C) for several hours to obtain ￿￿-crown-￿
as white powder (approx. ￿￿% yield).
Note: Storage under argon below –￿￿ °C.
tert-Butyl methylcarbamate (￿￿￿).[￿￿￿]
MeNHBoc
￿￿￿
A ￿￿￿ ml round-bottom flask was charged with di-tert-butyl dicarbonate (￿￿.￿ g,
￿￿.￿mmol, ￿.￿ eq) and Amberlyst® ￿￿ (hydrogen form, dry; ￿.￿ g). The mixture was
cooled down to ￿ °C and methylamine (￿￿ wt. % in H￿O, ￿.￿ml, ￿￿.￿mmol, ￿.￿￿ eq.) was added
dropwise (strongly exothermic, large amounts of gas are produced). After complete addition, the
cooling bath was removed and the reaction mixture was stirred additional ￿ min at ambient
temperature. The mixture was filtered through a medium porosity sintered-glass funnel, and
the solid was repeatedly rinsed with MeOH. Rotary evaporation of the filtrate followed by high
vacuum for ￿.￿ h furnished carbamate ￿￿￿ (￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield) as clear colorless oil
￿￿￿
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which solidified below ￿￿ °C. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ (s, ￿H), ￿.￿￿ (d, J = ￿.￿Hz,
￿H), ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Potassium (E)-diazene-￿,￿-dicarboxylate (￿￿￿￿).[￿￿￿]
N
N
O
KO
O
OK
￿￿￿￿
Potassium hydroxide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in H￿O and
cooled to ￿ °C. Azodicarbonamide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was added
in small portions at this temperature and vigorous stirring was continued
for ￿￿min. A yellow solid precipitated. The mixture was filtered through
a medium porosity sintered-glass funnel, and the solid was repeatedly rinsed with cold water,
then with cold MeOH, and finally with cold ether. After short drying under high vacuum
dicarboxylate ￿￿￿￿ was obtained as bright yellow solid (￿.￿￿ g, ￿￿.￿mmol ￿￿% yield).
Note: This reagent is used for the in situ generation of diimide (NH)￿.
Bromodimethylsulfonium bromide (￿￿￿￿).
Me
S
Br
Me
Br
￿￿￿￿
A solution of bromine (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) in absolute CH￿Cl￿ (￿￿.￿ml)
was added to a solution of dimethyl sulfide (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) in absolute
CH￿Cl￿ (￿￿.￿ml). A yellow solid precipitated and the suspension was stirred for
additional ￿￿min. The mixture was filtered through a medium porosity sintered-
glass funnel, and the solid was repeatedly rinsed with cold ether. The collected solid was dried
under high vacuum for ￿.￿ h to obtain bromide ￿￿￿￿ as yellow solid (￿￿.￿ g, ￿￿￿ mmol ￿￿%
yield). M.p. ￿￿ °C. ￿H NMR (￿￿￿MHz, DMSO) d = ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
N,N-Dichloro-tert-butylamine (￿￿￿￿).[￿￿￿]
N
Cl
Cl
￿￿￿￿
A ￿-L round-bottom flask equipped with a mechanical stirrer was charged with
tert-butylamine (￿￿.￿ml, ￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) which was dissolved in CH￿Cl￿
(￿￿￿ml). Calcium hypochlorite (￿￿%, ￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was added and the
reaction mixture was cooled down to ￿ °C. ￿ ￿HCl (￿￿￿ml) was added over a period
of ￿￿min at ￿ °C and stirring at this temperature was continued for addition ￿ h. Both layers
became bright yellow. The layers were separated and the aqueous layer was extracted twice with
CH￿Cl￿ (￿￿￿ml). The combined organic layers were extracted once with water and once with
brine. Drying over Na￿SO￿ followed by solvent removal under reduced pressure (p > ￿￿￿mbar)
yielded amine ￿￿￿￿ (￿￿.￿ g, ￿￿￿ mmol, ￿￿% yield) as bright yellow oil. ￿H NMR (￿￿￿ MHz,
CDCl￿) d = ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Note: Caution: a large amount of chlorine gas is produced during this reaction. The operation must be
carried out in a good hood with adequate ventilation.
￿￿￿
A.￿ Experimental
N-tert-Butylbenzenesulfinimidoyl chloride (￿￿￿￿).
N
S
Cl
Ph
￿￿￿￿
A solution of S-phenyl thioacetate (￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) in anhydrous
benzene (￿￿ml) was added to a solution of N,N-Dichloro-tert-butylamine (￿￿.￿ g,
￿￿￿ mmol, ￿.￿￿ eq.) in anhydrous benzene (￿￿ ml). The reaction mixture
was refluxed for ￿￿ min and cooled down to ambient temperature. Volatile
components were evaporated in vacuo and by azeotropic distillation with benzene (￿ times) to
obtain title compound ￿￿￿￿ as orange oil (￿￿.￿ g, ￿￿￿mmol, ￿￿% yield) which partially solidified
to a yellow solid by keeping it still or by cooling it below ￿ °C. The product was used crude
for follow-up reactions. If necessary, purification can be done via careful distillation (￿￿￿ °C,
￿.￿mmHg).[￿￿￿] ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(s, ￿H) ppm. NMR spectra on page ￿￿￿.
Note: N-tert-Butylbenzenesulfinimidoyl chloride (￿￿￿￿) is a useful reagent for the oxidation of various
alcohols to the corresponding carbonyl compounds and for the synthesis of a,b-unsaturated carbonyl
compounds.
Methyl benzenesulfinate (￿￿￿￿).[￿￿￿]
Ph
S
O
OMe
￿￿￿￿
Diphenyl disulfide (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) was dissolved in absolute MeOH
(￿￿￿ml) and cooled to ￿ °C. NBS (￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) is added in portions
at ￿ °C and stirring was continued for additional ￿min at this temperature. The
cooling bath was removed and the reaction mixture was stirred addition ￿￿min at
ambient temperature. ￿￿￿ml of CH￿Cl￿ were added and the reaction mixture was washed twice
with bicarb (￿￿￿ml) and once with water (￿￿￿ml). The organic layer was dried over Na￿SO￿,
volatiles were removed under reduced pressure, and the residue was purified via flash column
chromatography using hexanes–EtOAc (￿:￿) as eluent. Sulfinate ￿￿￿￿ was obtained as yellow oil
(￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield). ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿
(m, ￿H), ￿.￿￿ (s, ￿H) ppm. NMR spectra on page ￿￿￿.
Butyltriphenylphosphonium tetraborate [ BTPPTB ] (￿￿￿￿).[￿￿￿]
PPh3 PPh3
O
B
O B
O
B
OB O
O
O
￿￿￿￿
To a solution of Butyltriphenylphosphonium bromide
(￿￿.￿ g, ￿￿.￿mmol, ￿.￿ eq.) in absolute MeOH (￿￿.￿ml)
was added NaBH￿ (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) in portions
at ambient temperature. The mixture was stirred at this
temperature for ￿￿ h, very strong evolution of gas during
the first ￿￿min was observed. The solvent was removed in
vacuo which yielded a white sticky solid which was washed
with H￿O (￿￿￿ml). The collected solid was dried under high vacuum for ￿￿ h to yield tetrab-
orate ￿￿￿￿ as white flu￿y powder (￿￿.￿ g, ￿￿.￿ mmol, ￿￿% yield). M.p. ( °C.￿￿￿) ￿H NMR
￿￿￿
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(￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (t, J =
￿.￿Hz, ￿H) ppm.￿ NMR spectra on page ￿￿￿.
￿-Chloro-￿H-benzo[d][￿,￿,￿]triazole (￿￿￿￿).[￿￿￿]
N
N
N
Cl
￿￿￿￿
Commercial bleach (￿￿%NaOCl, ￿￿ml, ￿￿.￿mmol, ￿.￿ eq.) was added dropwise to
a solution of benzotriazole (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.) in ￿￿% aqueous acetic acid
(￿￿ml) at ambient temperature. After complete addition the reaction mixture was
stirred additional ￿￿￿min at this temperature at which a white solid precipitated.
The mixture was filtered through a medium porosity sintered-glass funnel, and the solid was
repeatedly rinsed with water until the filtrate was neutral (approx. ￿￿￿ml). The collected solid
was dried under high vacuum in the absence of light for ￿￿ h to obtain title compound ￿￿￿￿ as
white solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield) which was transferred to an argon flushed amber-glass
bottle and stored in a freezer. M.p. ￿￿￿ °C.
(￿H-Benzo[d][￿,￿,￿]triazol-￿-yl)methanol (￿￿￿￿).[￿￿￿]
N
N
N
OH
￿￿￿￿
Amixture of benzotriazole (￿.￿￿ g, ￿￿.￿mmol, ￿.￿ eq.), formalin (￿￿% in H￿O,
￿.￿￿ g, ￿.￿ml, ￿.￿ eq.), glacial acetic acid (￿￿ml) and H￿O (￿￿￿ml) was slowly
stirred at ambient temperature for ￿￿￿min. Themixture was filtered through a
medium porosity sintered-glass funnel, and the solid was washed with ice-cold
water. The collected solid was recrystallized from H￿O and dried ￿￿ h in vacuo
to obtain title compound ￿￿￿￿ as white solid (￿.￿￿ g, ￿￿.￿mmol, ￿￿% yield). M.p. ￿￿￿ °C.
Note: Benzotriazolylmethanol (￿￿￿￿) has proved to be a useful and versatile tool in synthesis since it
generates in situ formaldehyde under anionic conditions.[￿￿￿]
￿-(Phenylthio)isoindoline-￿,￿-dione (￿￿￿).
N
O
O
SPh
￿￿￿
Phthalimide (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was dissolved in anhydrous pyridine
(￿￿.￿ ml) and diphenyl disulfide (￿￿.￿ g, ￿￿.￿ mmol, ￿.￿￿ eq.) was added.
The reaction mixture was heated until complete dissolution of all materials.
After cooling down to ambient temperature (small amounts of materials
re-precipitated) a solution of bromine (￿.￿ g, ￿.￿ml, ￿￿.￿mmol, ￿.￿ eq.) in
acetonitrile (￿￿.￿ml) was added over a period of ￿￿min at ambient temperature. After complete
addition, the reactionmixture was stirred ￿.￿ h at this temperature. H￿O (￿￿￿ml) was added over
a period of ￿￿min which started the precipitation of the product. After complete addition, the
reaction mixture was cooled down to ￿ °C and stirred additional ￿￿min for full precipitation. The
mixture was filtered through a medium porosity sintered-glass funnel, and the solid was washed
with a minimum amount of ice-cold water. The collected solid was dried in vacuo and complete
removal of H￿O residues was achieved by azeotropic distillation with benzene (￿ times). Drying
￿ CH￿–P signals diminished
￿￿￿
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under high vacuum for ￿￿ h in the absence of light furnished phthalimide derivative ￿￿￿ as a
pale yellow flu￿y solid (￿￿.￿ g, ￿￿.￿mmol, ￿￿% yield) which was transferred to an argon flushed
amber-glass bottle and stored in a freezer. M.p. ￿￿￿ °C (lit. ￿￿￿ °C).[￿￿￿] ￿H NMR (￿￿￿ MHz,
CDCl￿) d = ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ (dd, J = ￿.￿, ￿.￿ Hz, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H),
￿.￿￿ – ￿.￿￿ (m, ￿H) ppm. NMR spectra on page ￿￿￿.
￿-Nitrobenzenesulfonohydrazide [ NBSH ] (￿￿￿￿).[￿￿￿]
NO2
S
N
H
NH2
OO
￿￿￿￿
￿-Nitrobenzenesulfonyl chloride (￿￿.￿ g, ￿￿￿mmol, ￿.￿ eq.) was dissolved
in anhydrous THF (￿￿￿ ml) and cooled down to –￿￿ °C under an argon
atmosphere. N￿H￿  H￿O (￿￿.￿ ml, ￿￿.￿ g, ￿￿￿ mmol, ￿.￿ eq.) was added
dropwise to this solution. After complete addition, the dropping funnel was
rinsed with anhydrous THF (￿ ml) and the reaction mixture was stirred
￿￿min at –￿￿ °C. EtOAc (￿￿￿ml) was added at –￿￿ °C and the mixture was washed quickly five
times with ￿￿% ice-cold aqueous NaCl (￿￿￿ml). The organic layer was dried over Na￿SO￿ at
￿ °C and filtered. The filtrate was added slowly (over ￿min) to hexanes (￿￿￿￿ml) at ambient
temperature. White solid precipitated immediately. After additional ￿￿min the mixture was
filtered through a medium porosity sintered-glass funnel, and the solid was repeatedly rinsed
with hexanes. The collected solid was dried in vacuo for ￿￿ h to obtain hydrazide ￿￿￿￿ as a
pale yellow solid (￿￿.￿ g, ￿￿.￿ mmol, ￿￿% yield) which was transferred to an argon flushed
amber-glass bottle and stored in a freezer. Rf = ￿.￿￿ (hexanes–EtOAc, ￿:￿). M.p. ￿￿ °C (lit. ￿￿￿ °C).
￿H NMR (￿￿￿MHz, CD￿CN) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ (br s, ￿H), ￿.￿￿
(br s, ￿H) ppm. ￿H NMR (￿￿￿MHz, CDCl￿) d = ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿ – ￿.￿￿ (m, ￿H), ￿.￿￿
(br s, ￿H) ppm. NMR spectra on page ￿￿￿.
Chloridobis(h￿-cyclopentadienyl)hydridozirconium [ Schwartz’s reagent ] (￿￿￿￿).[￿￿￿]
Zr ClH
￿￿￿￿
To zirconocene dichloride (￿.￿￿ g, ￿.￿￿mmol, ￿.￿ eq.) in THF (￿￿ml) in a flame-dried
Schlenk tube was added dropwise DIBAL (￿.￿ ￿ in THF, ￿.￿￿ml, ￿.￿￿mmol, ￿.￿ eq.)
at ￿ °C. The resultant suspension was stirred for ￿￿min before the supernatant liquid
was removed with a syringe. The white solid remaining in the tube was washed thrice
with THF (￿ml). Solvent residues were removed in vacuo and the remaining solid was dried
under high vacuum to provide Cp￿Zr(H)Cl (￿￿￿￿) as white powder which was stored under
argon atmosphere and below ￿ °C.
Bis(triphenylphosphine)palladium(II) dichloride (￿￿￿￿).
Pd(PPh3)2Cl2
￿￿￿￿
Triphenylphosphine (￿.￿￿ g, ￿￿.￿ mmol, ￿.￿ eq.) was added to a solution of pal-
ladium(II) chloride (￿.￿￿ g, ￿.￿￿ mmol, ￿.￿ eq.) in ￿￿ ml of benzonitrile and the
reaction mixture was stirred at ￿￿￿ °C under argon atmosphere. After ￿￿min, the heat source
was removed and the reaction mixture was allowed to cool down slowly to room temperature.
￿￿￿
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The precipitated yellow solid was filtered o￿ under argon atmosphere using a Schlenk frit
and washed twice with ether. Extensive drying under high vacuum in the absence of light
provided bis(triphenylphosphine)palladium(II) dichloride (￿￿￿￿) as a bright yellow solid (￿.￿￿ g,
￿.￿￿mmol, ￿￿%), which was stored in the glove box for use.
Dimethyl (￿-Diazo-￿-oxopropyl)phosphonate [ Bestmann-Ohira Reagent ] (￿￿￿￿).[￿￿￿,￿￿￿]
(MeO)2P
O O
N2
￿￿￿￿
General procedure: Stirring of a mixture of chloroacetone (￿.￿ eq.), potassium io-
dide (￿.￿ eq.), and trimethyl phosphite (￿.￿ eq.) in acetone–acetonitrile (￿:￿, ￿.￿￿)
for ￿ h at ￿￿ °C and for ￿ h at ￿￿ °C in the air followed by simple filtration and
distillation (￿￿ °C, ￿.￿￿mmHg) furnished dimethyl (￿-oxopropyl)phosphonate
as colorless liquid.
To an ice-cold solution of NaH (￿￿% dispersion in mineral oil, ￿.￿ eq.) in anhydrous ben-
zene–THF (￿:￿, ￿.￿ ￿) was added a solution of dimethyl (￿-oxopropyl)-phosphonate (￿.￿ eq) in
anhydrous benzene (￿.￿￿). The white suspension was stirred for ￿ h at room temperature before
a solution of ￿-methylbenzenesulfonyl azide (￿￿￿, ￿.￿￿ eq.) in anhydrous benzene (￿.￿ ￿) was
added. The reaction mixture was stirred overnight at room temperature, then filtered over a plug
of celite and concentrated in vacuo to obtain diazo ￿￿￿￿ as an orange oil. ￿H NMR (￿￿￿MHz,
CDCl￿) d = ￿.￿￿ (d, ￿H), ￿.￿￿ (s, ￿H) ppm. NMR data matches the reported.
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Spectrum B-￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
￿￿￿
N
Ts
H Me
Me
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
Stempel	ES	263	~20mg	in	CDCl3	at	298.0K,	22.03.2013	Koertje
1H-1d
CDCl3
298.0	K
3
.0
5
3
.1
1
3
.0
6
1
.0
2
1
.0
2
0
.9
9
2
.0
3
1
.0
0
2
.9
9
1
.0
6
1
.1
1
2
.0
0
0
.9
9
0
.7
5
1
.3
7
2
.2
9
2
.5
5
2
.5
7
2
.5
7
2
.5
9
2
.6
0
2
.6
2
2
.6
2
2
.6
4
2
.9
4
2
.9
5
2
.9
5
2
.9
6
2
.9
6
3
.0
0
3
.0
0
3
.0
1
3
.0
1
5
.0
5
5
.0
6
5
.0
6
5
.3
5
5
.3
6
5
.3
8
5
.3
9
5
.4
0
5
.4
0
5
.4
0
5
.4
0
5
.4
1
5
.4
1
5
.4
2
5
.4
2
5
.4
3
5
.4
3
5
.4
3
5
.4
4
5
.4
4
5
.4
5
5
.4
5
6
.0
5
6
.0
5
6
.0
6
6
.0
6
6
.0
6
6
.0
6
6
.0
7
6
.0
7
6
.0
7
6
.0
8
6
.0
8
6
.0
8
6
.0
8
6
.0
8
6
.0
9
7
.0
1
7
.0
1
7
.0
3
7
.0
3
7
.0
4
7
.0
4
7
.0
4
7
.0
4
7
.0
5
7
.0
5
7
.0
6
7
.0
6
7
.0
6
7
.0
6
7
.0
6
7
.1
2
7
.1
2
7
.1
3
7
.1
4
7
.1
4
7
.1
5
7
.1
8
7
.1
8
7
.2
0
7
.2
0
7
.2
0
7
.2
2
7
.2
2
7
.3
4
7
.3
4
7
.3
5
7
.3
6
7
.3
6
7
.3
7
7
.6
6
7
.6
6
7
.6
6
7
.6
8
7
.6
8
7
.6
8
Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
N
Ts
H CO2Et
Me
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
Stempel	ES	262	42mg	in	CDCl3	at	298.0K,	22.03.2013	Koertje
1H-1d
CDCl3
298.0	K
3
.0
2
3
.1
8
3
.1
5
1
.0
2
1
.0
2
1
.0
2
1
.0
8
1
.0
1
1
.0
0
1
.0
2
1
.0
0
1
.0
6
2
.0
8
1
.0
7
1
.1
2
2
.0
6
1
.0
5
0
.6
5
0
.6
7
0
.6
9
1
.7
4
2
.2
9
2
.8
4
2
.8
6
2
.8
7
2
.9
0
2
.9
1
2
.9
3
3
.0
1
3
.0
1
3
.0
2
3
.0
3
3
.0
3
3
.0
6
3
.0
7
3
.0
8
3
.0
8
3
.0
9
3
.4
2
3
.4
4
3
.4
5
3
.4
6
3
.4
7
3
.4
7
3
.4
8
3
.5
0
3
.6
2
3
.6
4
3
.6
4
3
.6
5
3
.6
6
3
.6
7
3
.6
8
3
.6
9
3
.7
0
4
.9
3
4
.9
5
4
.9
6
4
.9
6
4
.9
6
4
.9
7
5
.6
0
5
.6
1
5
.6
1
5
.6
3
5
.6
4
5
.6
4
5
.6
8
5
.6
8
5
.6
9
5
.6
9
5
.6
9
5
.7
0
5
.7
0
5
.7
0
5
.7
1
5
.7
1
5
.7
2
5
.7
2
5
.7
2
5
.7
3
5
.7
3
5
.7
3
5
.9
4
5
.9
5
5
.9
5
5
.9
6
5
.9
6
5
.9
6
5
.9
7
6
.9
8
6
.9
8
7
.0
0
7
.0
0
7
.0
2
7
.0
2
7
.0
4
7
.0
6
7
.0
9
7
.1
1
7
.1
7
7
.1
8
7
.1
9
7
.2
0
7
.2
1
7
.2
2
7
.2
6
	C
D
C
l3
7
.3
4
7
.3
6
7
.6
6
7
.6
8
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. HSQC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. HMBC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. HSQC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. HSQC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. HMBC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
￿￿￿
N
Ts
OH
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
ES872:	CHB-indoline	aromatization
C6D6
296.6	K
3
.0
7
1
.8
5
0
.9
9
0
.9
2
0
.8
7
0
.9
5
0
.9
5
0
.9
6
0
.9
7
2
.0
9
0
.9
6
2
.2
6
2
.0
1
1
.0
0
1
.6
1
2
.3
4
2
.3
5
2
.3
6
2
.3
7
2
.3
7
2
.3
8
2
.3
8
2
.3
9
2
.3
9
2
.4
0
2
.4
1
2
.4
1
2
.4
1
2
.4
3
2
.4
4
2
.4
4
2
.4
5
2
.4
5
2
.4
7
2
.4
7
2
.4
8
2
.6
3
2
.6
4
2
.6
5
2
.6
7
2
.6
8
2
.6
8
3
.0
5
3
.0
7
3
.0
7
3
.0
9
3
.1
6
3
.1
7
3
.1
8
3
.2
0
3
.8
6
3
.8
6
3
.8
7
3
.8
7
3
.8
8
3
.9
1
3
.9
1
3
.9
2
3
.9
2
3
.9
3
4
.1
5
4
.1
6
4
.2
0
4
.2
1
5
.5
1
5
.5
1
5
.5
2
5
.5
3
5
.5
4
5
.5
4
5
.5
5
5
.5
5
5
.5
9
5
.5
9
5
.6
0
5
.6
0
5
.6
1
5
.6
1
5
.6
2
5
.6
2
5
.6
3
5
.6
3
5
.6
4
5
.6
5
6
.4
3
6
.4
5
7
.0
8
7
.0
8
7
.1
0
7
.1
0
7
.1
2
7
.1
2
7
.1
5
7
.1
6
	C
6
D
6
7
.1
8
7
.1
8
7
.1
9
7
.1
9
7
.2
0
7
.2
0
7
.2
0
7
.2
1
7
.2
1
7
.2
2
7
.2
2
7
.5
2
7
.5
4
8
.6
0
8
.6
0
8
.6
2
8
.6
2
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￿￿￿
N
H
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
Stempel	ES	066	>15mg	in	C6D6	at	298.0K	20.07.16,	Rettstadt
Es	1066
1d-1H
C6D6
298.0	K
2
.1
9
4
.4
1
2
.0
4
2
.0
5
0
.8
9
0
.9
7
2
.0
1
1
.0
0
1
.5
3
1
.5
4
1
.5
4
1
.5
5
1
.5
5
1
.5
5
1
.5
6
1
.5
6
1
.5
7
1
.5
7
1
.5
7
1
.5
8
1
.5
8
1
.5
8
1
.5
9
1
.5
9
1
.6
2
1
.6
2
1
.6
3
1
.6
3
1
.6
3
1
.6
3
1
.6
4
1
.6
5
1
.6
5
1
.6
5
1
.6
6
1
.6
6
1
.6
6
1
.6
6
1
.6
7
1
.6
7
1
.6
8
1
.6
8
1
.6
8
1
.6
9
1
.6
9
1
.7
0
1
.7
0
1
.7
1
1
.7
1
1
.7
1
1
.7
2
1
.7
2
1
.7
2
1
.7
3
1
.7
3
1
.7
4
2
.3
4
2
.3
5
2
.3
7
2
.7
5
2
.7
7
2
.7
8
6
.4
5
7
.0
5
7
.0
5
7
.0
6
7
.0
6
7
.0
7
7
.0
7
7
.0
7
7
.0
8
7
.0
8
7
.0
9
7
.1
6
	C
₆D
₆
7
.2
2
7
.2
2
7
.2
3
7
.2
3
7
.2
4
7
.2
4
7
.2
4
7
.2
5
7
.2
6
7
.2
6
7
.5
7
7
.5
8
7
.5
8
7
.5
8
7
.5
8
7
.5
9
7
.5
9
7
.5
9
7
.5
9
7
.6
0
7
.6
0
7
.6
0
Spectrum B-￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
N
H
￿￿￿
0102030405060708090100110120130140150160170180190200
f1	(ppm)
Stempel	ES	066	>15mg	in	C6D6	at	298.0K	20.07.16,	Rettstadt
Es	1066
13C-BB
C6D6
298.0	K
2
5
.0
8
2
7
.8
7
2
9
.1
8
2
9
.4
9
3
2
.1
9
1
1
0
.6
0
1
1
3
.7
6
1
1
8
.1
8
1
1
9
.4
1
1
2
0
.9
2
1
2
8
.0
6
	C
6
D
6
1
3
0
.0
7
1
3
4
.9
0
1
3
6
.8
8
Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
￿￿￿
B NMR Spectra
N
H
O
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
Stempel	ES	067	>15mg	in	C6D6	at	298.0K	20.07.16,	Rettstadt
ES	1067
1d-1H
C6D6
298.0	K
2
.0
1
2
.0
2
2
.0
4
2
.0
3
2
.0
3
1
.0
4
1
.0
0
1
.0
1
1
.4
0
1
.4
2
1
.4
2
1
.4
3
1
.4
3
1
.4
4
1
.4
5
1
.4
6
1
.4
6
1
.4
7
1
.5
0
1
.5
0
1
.5
1
1
.5
2
1
.5
3
1
.5
4
1
.5
5
1
.5
5
1
.5
6
2
.5
4
2
.5
5
2
.5
5
2
.5
6
2
.5
7
2
.6
7
2
.6
9
2
.7
0
7
.0
5
7
.0
5
7
.0
6
7
.0
7
7
.0
7
7
.0
8
7
.0
8
7
.0
9
7
.1
6
7
.1
6
	C
6
D
6
7
.1
6
7
.2
1
7
.2
1
7
.2
3
7
.2
3
7
.2
3
7
.2
5
7
.2
5
7
.5
0
7
.5
0
7
.5
2
7
.5
2
9
.1
2
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HSQC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HSQC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HMBC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HSQC ￿D-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
￿￿￿
B NMR Spectra
N
H
Me
N
H
H
OH
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
ES1011:	amino	alcohol,	crude
CDCl3
295.5	K
3
.0
7
2
.0
5
0
.8
0
1
.7
9
2
.7
3
1
.2
1
1
.8
4
1
.0
5
0
.8
2
0
.7
0
0
.9
0
0
.9
9
2
.0
6
1
.0
8
1
.0
0
0
.7
9
1
.6
8
1
.7
0
1
.8
7
1
.8
9
1
.9
2
1
.9
4
1
.9
7
1
.9
9
2
.1
3
2
.1
4
2
.1
6
2
.1
7
2
.2
1
2
.2
3
2
.2
4
2
.2
7
2
.2
8
2
.3
2
2
.3
6
2
.3
8
2
.3
9
2
.4
2
2
.4
5
2
.7
5
2
.7
6
2
.7
9
2
.8
7
2
.8
8
2
.8
9
2
.9
1
2
.9
2
2
.9
3
2
.9
3
3
.4
0
3
.4
3
3
.6
7
3
.6
9
3
.7
0
5
.0
2
5
.0
3
5
.0
5
5
.0
6
5
.3
8
5
.4
0
5
.4
2
5
.4
4
7
.0
7
7
.0
8
7
.1
0
7
.1
2
7
.1
4
7
.1
6
7
.2
6
	C
D
C
l3
7
.3
1
7
.3
3
7
.4
2
7
.4
4
8
.7
1
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HSQC ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HMBC ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HSQC ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. HMBC ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
N
H
Me
N
H
H
O
￿￿
1.01.52.02.53.03.54.04.55.05.56.06.57.07.5
f2	(ppm)
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
f1
	(
p
p
m
)
ES1048:	16,20-diepisilicine,	full
CDCl3
296.3	K
Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿ (experimental on page ￿￿￿).
Br
NO2
MeO
MeO
￿￿￿
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1	(ppm)
Stempel	ES	064	>15mg	in	CDCl3	at	298.0K	18.07.16,	Rettstadt
ES	1064
1d-1H
CDCl3
298.0	K
2
.9
8
3
.0
1
1
.0
0
1
.0
0
3
.9
1
3
.9
4
7
.0
9
7
.2
6
	C
D
C
l3
7
.5
4
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
NO2
MeO
MeO
￿￿￿
0102030405060708090100110120130140150160170180190200
f1	(ppm)
Stempel	ES	063	>15mg	in	CDCl3	at	298.0K	19.07.16,	Rettstadt
ES	1063
13C-BB
CDCl3
298.0	K
5
6
.5
8
5
6
.6
6
7
7
.1
6
	C
D
C
l3
7
9
.4
9
8
3
.9
2
1
0
7
.6
5
1
1
1
.5
0
1
1
6
.1
7
1
4
3
.4
4
1
4
9
.3
4
1
5
2
.8
1
Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
￿￿￿
B NMR Spectra
HO BF3K
￿￿￿￿
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1	(ppm)
ES827:	BF3K	salt
MeOD
297.0	K
2
.0
2
2
.0
4
0
.0
0
2
.0
0
0
.1
4
0
.1
5
0
.1
7
0
.1
9
0
.1
9
0
.2
1
0
.2
3
1
.4
8
1
.5
0
1
.5
2
1
.5
4
1
.5
6
3
.3
1
	C
D
3
O
D
3
.4
7
3
.4
9
3
.5
0
4
.9
1
	H
D
O
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
O
O
OTBSTMS
￿￿￿￿
-100102030405060708090100110120130140150160170180190
f1	(ppm)
ES837
CDCl3
297.5	K
-5
.4
0
-5
.3
3
-5
.2
7
-5
.1
9
0
.2
1
0
.2
1
1
8
.1
8
1
8
.2
0
1
8
.4
1
1
8
.4
5
2
5
.7
9
2
5
.9
7
2
5
.9
8
2
9
.6
6
3
0
.0
6
3
0
.3
6
3
0
.5
8
3
8
.7
3
3
9
.7
7
6
4
.0
6
6
5
.1
6
7
7
.1
6
	C
D
C
l3
7
8
.0
3
7
8
.6
4
8
5
.7
3
8
5
.9
4
1
0
5
.6
2
1
0
5
.6
5
1
7
8
.5
9
1
7
9
.4
1
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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ES468: 1H,	1,3-dimethylbarbituric-diazo,	Wolff	rearr.,	254	nm	—	CDCl3	—	296.4	K
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. COSY￿￿ ￿D-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
￿￿￿
B NMR Spectra
N
H
O
N2
￿￿￿￿
0102030405060708090100110120130140150160170180190200
f1	(ppm)
ES552:	diazoisatine
CDCl3
298.0	K
6
1
.6
0
7
7
.1
6
	C
D
C
l3
1
1
0
.8
1
1
1
7
.3
9
1
1
8
.5
1
1
2
2
.3
5
1
2
5
.7
0
1
3
1
.9
2
1
6
9
.1
5
Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
OTBS
BrPh3P
￿￿￿￿
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1	(ppm)
ES352:	TBS-ethanol	Wittig	salt
MeOD
300.0	K
5
.7
2
8
.6
7
1
.9
7
1
.0
0
0
.9
7
1
5
.0
2
-0
.1
0
0
.7
1
0
.7
3
0
.7
4
1
.0
0
3
.3
1
	C
D
3
O
D
3
.7
1
3
.7
4
3
.7
7
3
.8
0
3
.8
3
3
.9
9
4
.0
1
4
.0
4
4
.1
0
4
.1
2
4
.1
5
4
.8
6
	H
D
O
7
.6
9
7
.7
1
7
.7
2
7
.7
3
7
.7
3
7
.7
4
7
.7
4
7
.7
5
7
.7
5
7
.7
6
7
.7
6
7
.7
7
7
.7
8
7
.7
8
7
.7
8
7
.7
9
7
.7
9
7
.8
0
7
.8
1
7
.8
2
7
.8
2
7
.8
3
7
.8
3
7
.8
4
7
.8
4
7
.8
4
7
.8
5
7
.8
5
7
.8
5
7
.8
6
7
.8
6
7
.8
7
7
.8
7
7
.8
8
7
.8
8
7
.8
9
7
.8
9
7
.9
0
7
.9
1
7
.9
2
7
.9
2
7
.9
2
Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿￿C-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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Spectrum B-￿￿￿. ￿H-NMR spectrum for compound ￿￿￿￿ (experimental on page ￿￿￿).
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DList of Abbreviations
#
# entry
— no reaction (in tables)
D reflux
￿w microwave
￿￿-c-￿ ￿￿-crown-￿
A
abs. absolute
Ac acetyl
acac acetylacetone
A-FABP adipocyte fatty-acid binding protein
AIBN azobisisobutyronitrile
Alloc allyloxycarbonyl
aq. aqueous
Ar aryl
B
BArF￿￿ tetrakis(￿,￿-bis(trifluoromethyl)phenyl)-
borate
BHT butylated hydroxytoluene
BINAP ￿,￿’-bis(diphenylphosphino)-
￿,￿’-binaphthyl
BINOL ￿,￿’-bi-￿-naphthol
Bn benzyl
Boc tert-butyloxycarbonyl
BOX bisoxazoline
brsm based on recovered starting material
Bu butyl
BTAC benzyltriethylammonium chloride
BTEAC   BTAC
BTMAP benzyltrimethylammonium bromide
Bz benzoyl
C
CAN ceric ammonium nitrate
cat. catalyst
cat. catalytic (in terms of amounts)
cf. confer (compare to)
Cp cyclopentadienyl
COD ￿,￿-cyclooctadiene
cond. conditions
CSA camphorsulfonic acid
cy cyclohexyl
D
dn deuteration degree
DABCO ￿,￿-diazabicyclo[￿.￿.￿]octan
DavePhos ￿-dicyclohexylphosphino-￿’-
(N,N-dimethylamino)biphenyl
dba dibenzylideneacetone
DTBAD di-tert-butyl azodicarboxylate
DBU ￿,￿-diazabicycloundec-￿-ene
DCC N,N’-dicyclohexylcarbodiimide
DCE dichloroethane
DCH-￿￿-c-￿ dicyclohexano-￿￿-crown-￿
DCM dichloromethane
DDQ ￿,￿-dichloro-￿,￿-dicyano-￿,￿-benzo-
quinone
DEAD diethyl azodicarboxylate
￿￿￿
D List of Abbreviations
decomp. decomposition
DIAD diisopropyl azodicarboxylate
DiBAL diisobutylaluminium hydride
DMAP ￿-dimethylaminopyridine
DMAPP dimethylallyl pyrophosphate
DMDO dimethyldioxirane
DMF N,N-dimethylformamide
DMFDMA N,N-dimethylformamide dimethyl acetal
DMI ￿,￿-dimethyl-￿-imidazolidinone
DMP Dess–Martin periodinane
DMPU ￿,￿-dimethyl-￿,￿,￿,￿-tetrahydro-￿(￿H)-
pyrimidinone
DMSO dimethyl sulfoxide
DNsOH ￿,￿-dinitrobenzenesulfonic acid
DOSP N-(p-dodecylphenylsulfonyl)prolinato
dpephos (oxydi-￿,￿-phenylene)bis(diphenyl-
phosphine)
DPPA diphenylphosphoryl azide
dppb ￿,￿-bis(diphenylphosphino)butane
dppp ￿,￿-bis(diphenylphosphino)propane
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E
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HEH Hantzsch ester
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IUPAC International Union of Pure and Applied
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L
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LUMO lowest unoccupied molecular orbital
M
￿ molar
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Me methyl
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MIRC Michael initiated ring closure
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MS molecular sieves
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MVK methyl vinyl ketone
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n normal- (descriptor)
￿ normal (concentration)
NBS N-bromosuccinimide
NCS N-chlorosuccinimide
NDMBA N,N-dimethylbarbituric acid
NMO N-methylmorpholine N-oxide
NMR nuclear magnetic resonance
Ns nosyl (￿-nitrobenzenesulfonyl)
Nu nucleophile
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O octyl
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Ph phenyl
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quant. quantitative
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R rest
Ra–Ni Raney nickel
Rf retardation factor
rt. room temperature
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TBDMS   TBS
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TEBAC   BTAC
TES triethylsilyl
Tf triflyl (trifluoromethanesulfonyl)
TFA trifluoroacetic acid
THP tetrahydropyranyl
THF tetrahydrofuran
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TLC thin-layer chromatography
TMDS ￿,￿,￿,￿-tetramethyldisiloxane
TMP ￿,￿,￿,￿-tetramethylpiperidine
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w/u work-up
X
xs excess
XPhos ￿-dicyclohexylphosphino-￿’,￿’,￿’-
triisopropylbiphenyl
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